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The United Kingdom Focal Point on Drugs 
 
The United Kingdom (UK) Focal Point on Drugs is based at the Department of Health 
and the North West Public Health Observatory at the Centre for Public Health, 
Liverpool John Moores University.  It is the national partner of the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and provides 
comprehensive information to the Centre on the drug situation in England, Northern 
Ireland, Scotland and Wales.   
 
The Focal Point works closely with the Home Office, other Government Departments 
and the devolved administrations.  In addition to this annual report, it collates an 
extensive range of data in the form of standard tables and responses to structured 
questionnaires, which are submitted regularly to the EMCDDA.  It also contributes to 
other elements of the EMCDDA’s work such as the development and implementation 
of its five key epidemiological indicators, the Exchange on Drug Demand Reduction 
Action (EDDRA) and the implementation of the Council Decision on New 
Psychoactive Substances. 
 
Further information about the United Kingdom Focal Point, including previous annual 
reports and data submitted to the EMCDDA, can be found on the Focal Point website 
at www.ukfocalpoint.org.uk  
 
The EMCDDA's website is www.emcdda.europa.eu 
 
The Head of the United Kingdom Focal Point on Drugs is Alan Lodwick at the 
Department of Health (alan.lodwick@dh.gsi.gov.uk).  
 
 
The structure and content of this report 
 
The structure and content of this annual report are pre-determined by the EMCDDA 
to facilitate comparison with similar reports produced by the other European Focal 
Points.  Ten chapters cover the same subjects each year, and one further chapter 
gives in-depth information on a selected issue, which changes from year to year.  
 
Each of the first ten chapters begins with an Overview.  This sets the context for the 
remainder of the chapter, describing the main features of the topic under 
consideration within the United Kingdom.  This may include information about the 
main legislative and organisational frameworks, sources of data and definitions used, 
the broad picture shown by the data and recent trends. 
 
The remainder of each chapter is concerned with New Developments and Trends 
that have not been included in previous annual reports. Generally, this covers 
developments that have occurred in the second half of 2007 or the first half of 2008. 
Relevant data that have become available during this period will also be discussed 
although these will often refer to earlier time periods. 
 
This report, and the reports from the other European countries, will be used in the 
compilation of the EMCDDA’s annual report of the drug situation in the European 
Union and Norway to be published in 2009. 
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Summary 
1. National policy and context  
Drug strategies  
Three new drug strategies were published in the United Kingdom in 2008, each 
accompanied by an action or implementation plan.  In the 2008 United Kingdom Drug 
Strategy, Drugs: protecting families and communities, policies concerning health, 
education, housing and social care are confined to England; those relating to policing 
and the criminal justice system cover England and Wales.  The Scottish Government 
launched, The Road to Recovery. A New Approach to Tackling Scotland’s Drug 
Problem.  The Welsh Assembly Government launched Working Together to Reduce 
Harm – the Substance Misuse Strategy for Wales 2008-2018, a combined approach 
to the misuse of drugs, alcohol and other substances.   
 
All aim to make further progress on reducing harm but look to a greater focus on 
recovery, the latter seen as requiring a change in the culture of service providers to 
effect it and greater co-ordination between a wide range of wraparound services.  A 
further aim is that service provision should be more focused on the particular needs 
of the individual, as well as on new approaches to drug treatment and social re-
integration.  In all strategies, a stronger emphasis is placed on preventing harm to 
children and young people and to provision of support to families affected by drug 
misuse. 
 
All recent drug strategies have undergone a process of public consultation or debate. 
Drug classification  
ACMD recommend that gamma-butyrolactone (GBL) and 1,4 butanediol (1,4-BD), 
precursors for GHB, and 24 steroids and 2 non-steroid agents, come under the 
control of the Misuse of Drugs Act 1971 as Class C drugs.  Cannabis is to be 
reclassified as a Class B drug although the Advisory Council on the Misuse of Drugs 
(ACMD) recommended it remain as Class C.   
Implementation of strategies  
In England, and across the United Kingdom where powers are not devolved, 30 
new Public Service Agreements (PSAs) set out the key priorities for Government, 
each underpinned by a Delivery Agreement.  One such agreement is to reduce the 
harm caused by alcohol and drugs.  A new National Performance Framework 
supports delivery in Scotland, one indicator is “reducing the estimated number of 
problem drug users in Scotland by 2011”.  In Wales, a new National Substance 
Misuse Strategy Implementation Board will oversee delivery of the strategy. 
The Drug Harm Index  
The final report on the Drug Harm Index, developed to measure a previous PSA 
target to reduce the harm caused by illegal drugs, shows a fall from 89.1 points in 
2004 to 83.8 points in 2005.   
Public expenditure 
Annual public expenditure on drugs in the United Kingdom is estimated to be around 
€1,418 million (£970m). 
 Public perception of drug misuse 
In the United Kingdom, amongst the population, drug misuse is seen as both a 
consequence and cause of many social problems, such as family breakdown and 
poverty, and is one of the two factors most commonly identified as the main causes 
of crime (lack of parental discipline was the second factor). 
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Initiatives in civil society  
The independent United Kingdom Drug Policy Commission is seeking to develop a 
consensus statement on the meaning of the term recovery. 
2. Drug use in the population 
Population surveys  
Latest survey data for England and Wales, from the 2007/08 British Crime Survey 
(BCS), show that prevalence of drug use amongst the general population continues 
to fall, largely due to a decrease in cannabis use.  Recent increases in cocaine use 
have stabilised while reported use of crack cocaine remains low (0.1%).  Recent use 
of ecstasy and magic mushrooms is at its lowest level since the BCS started asking 
drug use questions.  Similar trends can be seen among young adults. 
 
Two surveys in Northern Ireland, the Northern Ireland Crime Survey for 2006/07 and 
the 2006/07 Drug Prevalence Survey, while reporting similar prevalence indicate 
conflicting trends.  The former survey, similar in methodology to the BCS, shows a 
decrease in recent and current drug use, with stability in lifetime use.  The latter 
suggests an increase in both lifetime and recent use since the previous survey in 
2002/03, but a decrease in current use.  However, there have been changes in 
methodology that could affect trends.  In both surveys, similar trends seen for all 
adults can be seen among young adults.  
Drug use amongst school children 
Two school surveys have been published this year, the 2007 school survey in 
England and the 2007 Young Person’s Behaviour and Attitudes Survey in Northern 
Ireland.  In England, recent and current drug use has fluctuated in recent years but 
the overall trend since 2001 is downwards.  As in previous surveys, recent drug use 
sees the greatest increase between the age of 13 and 14 and continues to increase 
at age 15.  Also, as with the adult population, recent use of cannabis continues to fall 
driving the overall reduction in drug use since 2003.  In Northern Ireland, prevalence 
of any drug use is lower than in England, largely due to lower levels of cannabis and 
volatile substance use.  
Other groups 
Amongst the Armed Forces, around 85 per cent of service men and women are 
tested for drugs annually.  Positive tests are extremely low, but increasing; 0.62 per 
cent in 2003 to 0.98 per cent in 2007.  The Army accounts for 92.6 per cent of 
positive tests.  There has been a decrease in the proportion of positive tests involving 
cannabis (from 50% in 2006 to 31% in 2007) and a large increase in those involving 
cocaine (from 22% to 47%). 
 
Amongst truants and school excludees there has been a decrease in the proportion 
reporting regular drug use from 21 per cent in 2003 to 14 per cent in 2007. 
 
A survey of lesbian and bisexual women’s health found them to be five times more 
likely to report recent drug use than women in general. 
 
Data show that, in 2007, 5.4 per cent of young people in care have a substance 
misuse problem.  This is a slight increase from 5.1 per cent in 2006. 
3. Prevention  
Drug strategies  
Prevention continues to be a prime focus in all the new drug strategies in the United 
Kingdom. 
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Drugs: protecting families and communities states that its communications will 
highlight the consequences and damage that can result from substance use, with the 
message that drug use is “unacceptable”.  
 
In England the Government campaign FRANK produced a series of information 
materials for mentors and befrienders.  
 
A key aim of the Scottish Government strategy is that no one should be ignorant of 
the consequences of drug use.   
Drug education in schools 
All strategies are committed to strengthening the role of drugs education in schools.  
A review of drugs education is in progress in England, and in Scotland a programme 
of reform of the curriculum, which includes drugs education, is on-going. 
 
In Wales, an evaluation of the All Wales Schools Core Liaison Programme, delivered 
by teachers in partnership with the police, found that pupils’ knowledge and 
understanding of drugs issues had increased and that in general they enjoyed the 
lessons.   
Selective prevention 
In England, integrated drug prevention initiatives with vulnerable young people 
through targeted youth support activities such as Positive Futures are to continue.  
€19 million (£13m) in funding will help deliver early interventions to stop potential 
future offenders at the first sign of problems such as truancy, bad behaviour in school 
or contact with the police.   
 
The Scottish Government has proposed that monies from the Proceeds of Crime Act 
2002 are used to fund positive opportunities for young people in communities with 
high levels of crime.  
Indicated prevention  
All strategies look towards a whole family approach to drug prevention with early 
identification of children at risk and families and interventions providing a more 
focused approach to meeting their needs. 
 
The National Institute for Health and Clinical Excellence (NICE) is developing clinical 
practice guidelines for pharmacological and psychological interventions in children, 
young people and adults affected by attention deficit hyperactivity disorder.   
4. Problem drug use  
Estimate of problem drug users  
The second of a three year sweep of estimates of problem drug users aged 15 to 64 
in England suggests that, in 2005/06, there were: 
• 332,090 problem drug users (PDUs), using opiates and/or crack, a rate of 9.97 
per thousand population;  
• 286,566 opiate users, a rate of 8.60 per thousand population;  
• 197,568 crack cocaine users, a rate of 5.93 per thousand population; and 
• 129,977 injectors who use opiates and/or crack cocaine, a rate of 3.90 per 
thousand population.   
 
These estimates suggest that problem drug use has remained stable across the two 
sweeps.  However, there was a statistically significant reduction in injectors; the rate 
per thousand falling from 4.16 to 3.90.  
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The male to female ratio of problem drug users has not changed; 3.3:1.  Highest 
prevalence of problem drug use was amongst those aged 25 to 34.  
 
Based on the latest research (Northern Ireland for 2004, Scotland 2003, England 
2005/06, and an estimate for Wales extrapolated from England) it is estimated that in 
the United Kingdom there are:  
• 403,547 problem drug users; and  
• 156,398 injecting drug users (primarily of opiates or crack cocaine).  
The Treatment Demand Indicator  
Numbers presenting for treatment as measured through the Treatment Demand 
Indicator (TDI), having increased substantially over the previous few years, appear to 
have stabilised in 2006/07, with 128,208 new presentations for treatment (128,446 in 
2005/06).  The vast majority of treatments are reported through outpatient services 
(94%).  Forty-four per cent (47,165) concerned drug users who sought treatment for 
the first time ever, a slight reduction from 2005/06 (49,625). 
 
Forty-one per cent of treatment presentations were for those aged between 25 and 
34.   
 
Opiates, mostly heroin, were the main primary drug reported (64%).  Cannabis was 
the second most reported primary drug (16%), and crack cocaine and cocaine 
powder accounted for seven per cent and six per cent respectively.  However, when 
any use of crack cocaine use is considered, not only as primary drug, there has been 
a much steeper rise in presentations, with 24 per cent of new presentations reporting 
use.  Similarly, with cocaine powder, there has been continued rise in presentations 
with 13 per cent reporting any use of it in 2006/07. 
 
The actual number of presentations for opiates as primary drug stabilised in 2006/07, 
having increased in the previous year.  The same trend can be seen in presentations 
for crack cocaine as primary drug of use.  Presentations for cannabis have increased 
over time, and continue to do so, now representing nearly a quarter of first ever 
presentations (24%); over half of those presenting with cannabis as primary drug 
were under 20 years of age and three quarters under 35.  
 
Current injecting was reported by 25 per cent; 50 per cent report having never 
injected.   
Treatment penetration  
Information on those in treatment is available for England only.  The National Drug 
Treatment Monitoring System data show that, of those in treatment in 2006/07: 
• 148,866 were problem opiate and/or crack cocaine users (either using these as 
primary drug or as a secondary or tertiary drug); that is 45 per cent of the PDU 
estimate, this compares with 42 per cent in 2005/06;  
• there were 140,357 opiate users, 49 per cent of the PDU estimate (46% in 
2005/06); and 
• there were 46,415 crack cocaine users in treatment, 24 per cent of the PDU 
estimates (21% in 2005/06). 
Problem users identified outside treatment services  
The Arrestees Survey provides information on drug use by those arrested.  The third 
annual sweep (2005/06) found that 26 per cent of arrestees had taken heroin, crack 
cocaine and/or cocaine powder in the month prior to arrest; 13 per cent having used 
heroin; 13 per cent cocaine powder; and 11 per cent crack cocaine.  
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‘Topping up’ 
In surveys of drug users in treatment over two-thirds reported using on top of 
substitute drugs.   
5. Drug-Related Treatment  
Drug strategies  
All new drug strategies continue to focus on providing better access to treatment and 
encouraging retention in treatment, particularly for vulnerable and excluded groups.  
However, there are some important changes in emphasis; throughout the United 
Kingdom it is expected that there will be a shift in treatment services towards a 
greater emphasis on recovery and on more personalised treatment. 
Numbers in treatment: England  
Only England provides information on the overall numbers in treatment.  In 2007/08 
202,666 individuals were in contact with structured drug treatment services, a much 
smaller increase in numbers (4%) than seen in previous years.  Eighty-three per cent 
(168,464) either completed treatment or were retained in treatment at the end of the 
year.  New presentations also increased by four per cent from 104,062 in 2006/07 to 
107,812 in 2007/08. 
Quality 
An improvement review of drug services in England led by the Healthcare 
Commission suggested that improvements could be made across all areas of 
community prescribing services, care planning and care coordination.  Following on 
from Drug Misuse and Dependence: UK Guidelines on Clinical Management, 
guidelines on ethical prescribing have since been issued.  These state that it is 
inappropriate for medications to be used as a reward or sanction.  In addition, a 
briefing on naltrexone implants has been prepared, suggesting that there is no sound 
evidence for this treatment.  A consultation on guidance on clinical governance in 
drug treatment is underway in England.   
 
New National Quality Standards for Substance Misuse Services in Scotland were 
published in 2008. 
 
Pilot projects to consider whether contingency management works are on-going in 
England. 
 
In England, the Treatment Outcome Profile (TOP), developed for use at the start of 
treatment and in care plan reviews, and reported through the National Drug 
Treatment Monitoring System, is now operational.  The new Scottish Drug Misuse 
Database Follow-up Reporting System has been introduced, providing outcome 
information to enable assessment of treatment effectiveness. 
6. Health correlates and consequences 
Drug-related deaths  
Based on the EMCDDA definition latest data on drug-related deaths across the 
United Kingdom are for 2006, when there were 1,785 deaths, a fall from the previous 
year (1,812).  The rate per 100,000 population was 2.95.  However, in Scotland drug-
related deaths increased from the previous year, from 352 to 416, a rate of 8.13 per 
100,000 population. 
 
Males continue be more likely to die than females, by a ratio of over 4:1, with the 
difference reducing over the last decade.  The average age of death continues to 
rise; in 2006 it was 36.5 years. 
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Data based on the United Kingdom ‘Drug Strategy’ definition are available for 2006 
and 2007.  Based on this definition, deaths in the United Kingdom rose slightly (by 
2%) in 2007, from 2,025 to 2,069, this rise being seen in England and Wales (from 
1,573 to 1,604) and in Scotland (from 421 to 455), but there was a fall in deaths in 
Northern Ireland, from 31 to 10.  
 
Mentions of heroin/morphine on death certificates increased by 14 per cent in 2007 
(1,119), having fallen by seven per cent in 2006 (978).  There was also an increase 
in mentions of cocaine in both years (by 2% to 225 in 2006, and 8% to 243 in 2007.  
Mentions of methadone also increased substantially (by 15% in 2006 to 338, and 
30% in 2007 to 440).   
 
Data from the Special Mortality Register (np-SAD) database are broadly consistent 
with those from the General Mortality Registers.  In 2007 there was a 13 per cent 
increase in recorded deaths from 1,366 in 2006 to 1,539 in 2007.  Opioids alone, or 
in combination with other drugs, accounted for the majority (71%) of deaths.  The 
proportion of cases involving cocaine increased from 11 per cent (174) in 2006 to 16 
per cent (239) in 2007.  
 
There were six cases in both 2006 and 2007 where methamphetamine was found 
and 12 deaths up to the end of 2007 where piperazines have been found.  The first 
death in the United Kingdom from cocaine powder toxicity was reported in 2007. 
 
Forty-nine deaths associated with the abuse of volatile substances were recorded in 
2006 (45 in 2005).  This compares with the all-time peak of 152 in 1990. 
 
There were 51 deaths of injecting drug users (IDUs) (including IDUs who have sex 
between men) with AIDS in 2006, a fall from the previous year (79).   
 
Forty-nine deaths associated with the abuse of volatile substances were recorded in 
2006 (45 in 2005).  This compares with the all-time peak of 152 in 1990. 
Drug-related infectious disease 
Data for 2007 suggests that prevalence of infectious disease amongst injecting drug 
users remains stable.  However, HIV prevalence remains higher than it was in 2000, 
at around one per cent, although in London it is higher, at or near, four per cent.  
There is emerging evidence suggesting a possible increase in transmission in recent 
years.  
 
Prevalence of hepatitis C (HCV) is much higher than that for HIV, at around 40 per 
cent of IDUs. 
 
Outbreaks of other infections among IDUs have been identified following reported 
increases in injecting risk behaviour. 
Comorbidity 
Prevalence and attribution of co-morbidity remain difficult to estimate.  Latest 
research suggests prevalence differs between treatment settings.  
Drug use and the neonate 
Hospital Episode Statistics show that in England and Wales during 2006/07, there 
were 178 episodes of “foetus and newborn affected by maternal drugs of addiction” 
and 1,326 episodes of babies with “neonatal withdrawal symptoms from maternal use 
of drugs of addiction”.  In Northern Ireland there were fewer than five inpatient 
episodes in 2006/07 with a diagnosis of foetus and newborn affected by maternal use 
of drugs of addiction.  There are no new data for Scotland.  
UNITED KINGDOM FOCAL POINT REPORT 2008  
 7
7. Responses to health correlates and consequences  
Drug-related death 
As part of the Action Plan on Reducing Drug-related Harm, a campaign to reduce 
drug-related deaths (and infectious disease) was launched in October 2008.  
 
In Scotland, a national database of drug-related deaths and an examination of the 
circumstances behind them is to be developed. 
 
A second edition of guidance designed to promote good practice in bars and 
nightclubs has been published.   
Drug-related infectious disease 
There has been a ten-fold increase between 2002 and 2006 in the number of tests 
for infectious disease carried out by drug services, reportedly due to oral fluid 
screening.  This is in addition to a high number of tests carried out by GPs at their 
surgeries. 
 
While uptake of hepatitis B vaccination has increased markedly over time, rising to 
66 per cent of IDUs in much of the United Kingdom in 2007, a Healthcare 
Commission review of harm reduction services in England found existing provision to 
be in need of improvement.  The Commission also found weaknesses in the 
provision of syringe exchange services, particularly in terms of out of hours provision. 
 
As part of the implementation of the Action Plan on Reducing Drug-related Harm in 
England, in October 2007 new data was provided to local partnerships about 
hepatitis C prevalence for their local area.  A new national web based system to 
collect information from local needle exchange services in England was introduced in 
2008 and a campaign to reduce infectious disease was launched. 
 
NICE is due to publish guidance on the provision of needle exchange services in 
February 2009. 
 
The ACMD Prevention Working Group on hepatitis C prevention is to consider: the 
epidemiology of hepatitis C; evidence on the effectiveness of interventions against 
hepatitis C; and effective interventions and delivery in the United Kingdom. 
 
In Scotland, phase two of the Hepatitis C Action Plan for Scotland, which aims to 
raise awareness of the disease, reduce the number of new infections and increase 
numbers in treatment, is to be supported by a budget of €63 million (£43m). 
Standards for hepatitis C testing and the treatment, care and social support of 
individuals infected with hepatitis C are to be developed in Scotland, as well as a 
surveillance system to monitor hepatitis C testing practice.   
 
In Scotland, a data collection system on needle exchange services is being 
developed. 
 
 An Action Plan for the Prevention, Management and Control of Hepatitis C in 
Northern Ireland was launched in 2007, with objectives to increase awareness and 
understanding and improve treatment.  Actions include a review of surveillance 
arrangements for hepatitis C.   
 
The Welsh Assembly Government suggests that there may be a case for using 
contingency management to increase the percentage of injecting drug users 
completing vaccination courses against hepatitis B.   
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A study to assess whether an uptake in hepatitis C testing among IDUs would follow 
on from the introduction of dried blood spot testing in drug treatment and prison 
settings found some preliminary evidence to support its use. 
 
The treatment of hepatitis C is also becoming a major concern, following evidence 
that a large majority of those infected has not received treatment.  The ACMD 
Prevention Working Group is to consider this issue and, as mentioned earlier, action 
plans in both Scotland and Northern Ireland aim to bring about improvements in 
treatment. 
Co-morbidity 
NICE have commissioned the National Collaborating Centre for Mental Health to 
develop clinical guidelines for the assessment and management of severe mental 
illness in conjunction with problematic substance misuse.   
 
The Scottish Government has published a series of recommendations for change 
and improvement in the provision of services for individuals with co-occurring 
substance use and mental health problems including increased awareness of co-
morbidity and improved support and service provision for individuals and their carers.   
Drug driving  
The Sentencing Guidelines Council (SGC) has published guidelines on sentencing 
and associated issues around death caused by dangerous driving, including while 
under the influence of drugs.  A specification for a drug testing device is currently 
being developed. 
8. Social correlates and consequences 
Housing  
New research suggests that 40 per cent of drug users seeking treatment had not 
been in stable accommodation in the four weeks prior to the treatment. 
Unemployment  
A feasibility study intended to estimate the number of problem drug users accessing 
state benefits estimated that 81 per cent (266,798) of problem drug users in England 
were in receipt of benefit, representing 6.6 per cent of all those receiving benefit.   
Education  
New research suggests that 38 per cent of clients seeking drug treatment had left 
school before the statutory minimum age of 16. 
Prostitution  
Research evidence from the Drug Treatment Outcomes Research Study (DTORS) 
found that ten per cent of female clients seeking drug treatment and one per cent of 
males reported being engaged in prostitution in the four weeks prior to treatment; all 
used heroin and/or crack. 
Children of drug using parents 
Research suggests that nearly half of those seeking treatment have children under 
the age of 16, although in three-quarters of cases these children lived apart from 
them; half were living with the other parent, 20 per cent living with other family 
members, eight per cent were in care; the rest (5%) lived elsewhere. 
Drug offences  
In England and Wales in 2006/07, 89,200 persons were arrested for drug offences, 
an increase of less than one per cent from 2005/06.  In Northern Ireland in 2007/08 
1,896 persons were arrested for drug offences, an increase of 9.8 per cent from the 
previous year.  In England and Wales arrests for possession have reduced 
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considerably since 2004 with the introduction of a ‘cannabis warning’, rather than an 
arrest for possession of cannabis for personal use.  In 2006/07 there were 22,900 
cannabis warnings, an increase of 28 per cent from 2005/06. 
 
Data presented to the EMCDDA over the last few years has been for persons found 
guilty, cautioned or dealt with by compounding for drug offences, which is recorded in 
such a way as to be able to be broken down by drug.  Latest data is on an all offence 
basis rather than a principal offence basis; data provided in previous Focal Point 
reports was based on principal drug offence.  New information reported this year for 
the United Kingdom as a whole is for both 2005 and 2006.  There were 118,706 
offences in 2005 increasing by 4.5 per cent to 124,344 in 2006.  There were 55,984 
convictions for cannabis-related offences in 2006, an increase of 2.1 per cent since 
2005 (54,813).  There were 15,471 convictions for heroin offences, a marginal 
increase since 2005 (15,629).  There were 7,422 offences concerning amphetamines 
in 2006, an increase of 8.1 per cent since 2005 (6,864); 6,233 offences concerned 
ecstasy in 2006, a small decrease of 1.6 per cent since the previous year (6,337).  
The largest increase was for cocaine powder, there were 12,028 offences in 2005, 
increasing by 28.6 per cent to 15,470 in 2006. 
Acquisitive crime 
New research supports the already well documented evidence that problem drug 
users, particularly those using opiates and crack cocaine, commit a considerable 
amount of acquisitive crime to support their drug use.  
Drug use in custody  
Drug testing in prison suggests that 9.1 per cent of the prison population use drugs 
while in custody in England and Wales.  However, survey data suggests the 
proportion in Scottish prisons to be 51 per cent in 2007.   
Economic and social costs  
Based on research into the social and economic costs of problem drug use in 
England, estimated costs in Scotland are in the region of €3.9 billion (£2.6bn) and in 
Wales around €1,140 million (£780m).  
9. Responses to social correlates and consequences  
Drug strategies 
All new drug strategies in the United Kingdom are concerned with recovery, and seek 
to align strategies on social exclusion and poverty, housing, education and training.  
Review of unemployment benefit for drug misusers  
A major initiative in 2008 is a Government Green Paper (consultation document) on 
the welfare system, No one written off: reforming welfare to reward responsibility, 
which proposes that problem drug users in receipt of benefits should take action to 
stabilise their habit and to take steps towards employment in return for receiving 
benefits. 
Initiatives for children of drug using parents 
In both Scotland and Wales the impact of parental substance misuse upon children 
has been of major concern in previous strategies, and now Drugs: protecting families 
and communities also places an increased priority on children and families affected 
by substance misuse.  Drug Courts, focused on drug using parents, already available 
in Scotland, are to be established in England following a process evaluation of two 
pilot courts. 
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Prisons 
There has been increased concern about the ability of prisons to cope with the health 
care needs of a rising prison population.  In England and Wales a review of the 
prison system suggested that as well as an expansion of prison capacity, changes 
are needed in existing sentencing legislation to modify the use of custody for certain 
types of low risk offenders and offences, reserving custody for the most serious and 
dangerous offenders.  Following this review, the Ministry of Justice suggests that 
community sentences, including drug rehabilitation programmes, can be a more 
effective punishment than short prison sentences for drug using offenders.  To this 
end the probation service in England and Wales is to receive an additional €58.8 
million (£40m) to pilot intensive alternatives to custody (see the Drugs Interventions 
Programme referred to below). 
 
In Scotland, the Scottish Prison Service is to publish a new Substance Misuse 
Strategy, which will complement the Scottish Government’s drugs strategy. 
 
Reviews of measures to disrupt the supply of drugs into prison in England and 
Wales, and in Northern Ireland, recommend the further introduction of mobile phone 
blocking technology.  In England and Wales it is recommended that body orifice 
security scanners (BOSS) also be introduced, and in Northern Ireland that the 
introduction of mandatory drug tests, currently only undertaken in England and 
Wales, be considered.  
 
In 2008, the Scottish Prison Service implemented the provision of harm reduction 
packs for prisoners engaged in injecting behaviour.  The packs consist of water 
ampoules, citric acid, Sterispoons, swabs, filter and foil.  Plans for a syringe 
exchange pilot in prisons in Scotland reported in the previous Focal Point report are 
yet to be finalised.  Disinfectant tablets are now provided in all adult prisons in 
England and Wales. 
 
A review of prison-based drug treatment funding in England suggests the need for a 
more strategic and evidence-based approach to service delivery.  Following this, a 
Prison Drug Treatment Review Group has been established to foster the 
development of prison drug treatment.  As of April 2008, 29 prisons had received 
funding to introduce an Integrated Drug Treatment System (IDTS), which aims to 
integrate clinical and psychological treatment in prison into one system. To allow for 
the full introduction of IDTS in all adult prisons in England by 2011, funding for clinical 
treatment in prisons is planned to increase from €18.57 (£12.7m) in 2007/08 to €62.9 
(£43m) by 2010/11. 
 
The Scottish Government is to review the feasibility of the transfer of primary health 
care in prison to the National Health Service; this has already occurred in England 
and Wales. 
 
In Scotland, there is to be a review of a pilot project to improve the integration of 
medical treatment with wider ‘wraparound’ therapeutic support.  
 
A new package of measures aimed at helping prisoners in England and Wales 
become drug free and access employment on release has been announced, 
including a drive to involve more employers in training offenders and offering them 
employment, and the drawing up of contracts with prisoners in return for 
opportunities to learn new skills.  
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Criminal justice interventions  
The Drug Interventions Programme (DIP) continues to be the main focus of action in 
England and Wales to reduce drug-related crime, with continued work to engage 
those identified though the criminal justice system in treatment.  Major interventions 
continue to be drug testing on arrest or charge, required assessment and restriction 
on bail, while conditional cautions have now been introduced.  The new United 
Kingdom Drug Strategy seeks to increase the number of conditional cautions with a 
DIP condition to 2,000 by March 2009, which means doubling current usage.  Drug 
Rehabilitation Requirements (DRRs) are also to be extended with plans for 1,000 
such orders by 2009.  As mentioned previously, to this end the probation service is to 
receive additional funding to pilot intensive alternatives to custody.  
 
Drug Treatment and Testing Orders continue to be the main community sentence 
imposed on drug using offenders in Scotland although, until recently, they were used 
only with high tariff offenders.  In June 2008, two pilots extending them to lower tariff 
offenders began.  Also, in Scotland, following an evaluation, there are plans to 
extend the Structured Deferred Sentence which has been piloted in five courts.  This 
is a low-tariff intervention providing structured social work for offenders post-
conviction, but prior to final sentencing, primarily aimed at offenders with underlying 
substance misuse problems, mental health or learning difficulties.  The purpose is to 
match, more effectively, intensity of intervention/supervision, as well as building 
offender motivation for positive change.  
 
Research suggests that 22 per cent of employers test employees for drug and 
alcohol use, with manufacturing and production organisations more likely to do so, 
and safety-critical organisations the most likely (53%).  Testing is most commonly 
carried out on suspicion of misuse; the next most common reasons are post-incident 
testing and pre-employment testing.  
10. Drug markets 
Availability 
Cannabis continues to be imported into the United Kingdom in significant quantities 
but domestic cultivation is rising, particularly of sinsemilla (skunk).  In late 2007 it was 
reported that 1,564 farms/factories had been found in England and Wales and in 
Scotland in 2006/07, 70.  Many are run by Vietnamese and are located in residential 
properties.  The market share of sinsemilla has increased markedly over recent years 
from 15 per cent in 2002 to 81 per cent in 2008. 
Seizures 
There were 209,566 seizures of drugs in the United Kingdom in 2006/07, an 11 per 
cent increase from 2005.  Increases are reported for herbal cannabis (44%) and 
cannabis plants (36%) but numbers of cannabis resin seizures have fallen by 27 per 
cent.  The quantity of cannabis plants seized increased substantially (72%).  Cocaine 
powder seizures continue to increase, a 36 per cent rise from 2005 although the 
quantity of cocaine seized has decreased by 14 per cent.  The quantity of heroin 
seized has fallen by 44 per cent but the number of seizures has remained stable.  
Crack cocaine and ecstasy seizures have increased both in number and quantity.  
Price  
The price of heroin and cocaine powder at street level has again fallen.  Prices for 
other drugs remain stable while an apparent rise in cannabis prices can be explained 
by a change in methodology.   
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Purity  
Heroin purity has continued to increase since 2003 although there have been reports 
in 2008 of a lack of ‘good’ quality heroin at street level.  The mean MDMA tablet 
content of ecstasy seized in 2007 was slightly higher than in 2006.  Purity of 
amphetamines has remained stable since 2003.  The average purity of cocaine 
powder seized by Revenue and Customs has remained stable, but that seized by the 
police continues to fall suggesting increased adulteration within the United Kingdom.  
There has also been a fall in the purity of crack cocaine.  The potency of traditional 
imported herbal cannabis and cannabis resin has fallen since the late 1990s with 
potency of sinsemilla increasing.   
 
Selected Issue  
11. Sentencing statistics  
Options available to law enforcement agencies 
Law enforcement agencies have a number of measures available to them when 
dealing with drug offenders.  These include out-of-court disposals such as cautions in 
England, Wales and Northern Ireland and fiscal fines in Scotland.  In addition, there 
are a wide range of measures that can be used after a finding of guilt by a court 
including custodial sentence, community sentence, fine, and confiscation order. 
Data collection systems 
Police forces and courts are required to submit data centrally for the collection of 
criminal justice data.  Different legal and data collection systems in England and 
Wales, in Scotland, and in Northern Ireland mean that it is not possible to provide 
data on the outcome of drug offences on a United Kingdom basis.   
England and Wales 
In England and Wales in 2006 there were 200,270 drug possession offences 
recorded by police and 37,913 drug trafficking offences.  There were a total of 90,926 
arrests for drug offences.  Forty-two per cent of all stop and searches carried out 
were under suspicion of drug offences.  Of these, eight per cent resulted in an arrest 
for Class A drugs. 
Drug possession offences 
In 2006, just over half of drug possession offences were for cannabis (this does not 
include cannabis warnings).  For drug possession offences (excluding cannabis 
warnings) the most common disposal was a caution (57%) followed by a fine (19%) 
with only two per cent receiving immediate custody.  Offences involving heroin and 
crack cocaine were more likely to receive immediate custody or a community 
sentence and less likely to be cautioned than offences involving other drugs.  
Cocaine powder offenders were more likely to receive a caution or fine and less likely 
to receive a community sentence or immediate custody than crack cocaine offenders. 
Drug trafficking offences 
A third of offenders found guilty at court or cautioned for drug trafficking were found 
guilty of cannabis offences with a fifth guilty of heroin trafficking offences.  The most 
common disposal was immediate custody (44%) followed by a caution (21%) and 
community sentence (18%).  Around 70 per cent of heroin, crack cocaine and 
cocaine powder trafficking offenders received a custodial sentence.  Cannabis and 
LSD trafficking offences were the only offences where a custodial sentence was not 
the most common disposal. 
Average sentence length 
Average sentence length was less than a year for possession and around three 
years for trafficking.  Cannabis offences received the shortest sentence. 
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Scotland 
2006 data for Scotland are for court outcomes only.  Three-quarters of those found 
guilty at court of drug possession offences received a fine with four per cent receiving 
immediate custody.  Almost half of those found guilty of drug trafficking offences 
received immediate custody, a further 19 per cent received a community sentence, 
and 16 per cent a fine.   
Northern Ireland 
In Northern Ireland, 58 per cent of all drug possession offences were dealt with by a 
caution and only one per cent by immediate custody.  Forty-five per cent of drug 
trafficking offences received immediate custody.  Penalties were proportionally higher 
for drugs in higher classes.   
 
Most relevant developments and trends  
New drugs strategies  
In 2008 three new drug strategies were launched in the United Kingdom, 
accompanied by an action or implementation plan.  All aim to make further progress 
on reducing the harms associated with drug use, to have a greater focus on 
personalised treatment and to promote recovery, and all give priority to the needs of 
the children of drug using parents.  
Reclassification of cannabis  
The independent Advisory Council on the Misuse of Drugs (ACMD) undertook an 
extensive review of cannabis and recommended that it remain a Class C drug.  
However, Government has decided that cannabis should be reclassified as a Class B 
drug, ACMD has recommended that gamma-butyrolactone (GBL) and 1,4 butanediol 
(1,4-BD), precursors for GHB, and 24 steroids and 2 non-steroid agents come under 
the control of the Misuse of Drugs Act 1971 as Class C drugs. 
Continued decline in drug use in the population  
Prevalence of drug use in the general population continues to decline and the trend 
amongst school children also continues to be downwards.  These trends continue to 
be associated with falls in cannabis use.  The increase in use of cocaine powder, 
seen amongst both school children and adults over recent years, appears to be 
stabilising in England and Wales.   
Early intervention projects 
Momentum is gaining on establishing early intervention projects and parenting 
programmes.  
Stability of problem prevalence  
Problem prevalence in England appears to be stable, with the latest estimates for 
2005/06 showing no significant change, however there is a decrease in injecting.  
Stability in presentations to treatment services  
Presentations to treatment services appear to be reaching a plateau.  This is seen 
amongst both all new presentations and first ever presentations in 2006/07.  It is also 
of note that numbers in treatment in England (such information is not available 
elsewhere) increased by four per cent in 2007/08, a smaller increase than in previous 
years. 
Interventions for the prevention and treatment of hepatitis C  
There has been a continued focus on the prevention of drug-related infectious 
disease over the last year, with further action around prevention and surveillance, 
syringe exchange monitoring, vaccination and counselling and testing.  Also, there is 
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renewed focus on providing treatment for hepatitis C across much of the United 
Kingdom.  
New proposals for problem drug users receiving benefits 
The Department of Work and Pensions, with a remit across the United Kingdom, 
proposes new legislation requiring problem drug users in receipt of out-of-work 
benefits to take action to stabilise their drug habit and to take steps towards 
employment in return for benefits.  
Rise in cultivation of cannabis in the United Kingdom  
Domestic cultivation of cannabis within the United Kingdom is rising, particularly 
sinsemilla (skunk). 
 
Consistency between indicators   
Opiates 
Opiate use, difficult to estimate by population based surveys, remains very low, 
reported by less than 0.1 per cent.  However, it is estimated that there were 286,566 
problem opiate users in England alone in 2005/06, a rate of 8.60 per thousand 
population aged 15 to 64.  This latest estimate is not a significant increase since the 
previous estimate for 2004/05.  Opiates also remain the most reported primary drug 
amongst those presenting to treatment (63.7%) and, although as a proportion of all 
presentations this has steadily reduced over time, the number actually reporting 
opiates as main drug has remained stable over the last two reporting periods (77,580 
in 2005/06 and 77,849 in 2006/07), having previously increased.  For first ever 
presentations to treatment there was a slight decrease in numbers in 2006/07 
(21,561) compared to 2005/06 (23,021), having previously steadily increased. 
Opiates continue to be associated with injecting drug use, and the spread of 
infectious disease, though there is no real change in the prevalence of HIV or 
hepatitis C in the United Kingdom.  Opiates continue to account for the most 
mentions on death certificates.  There were around 1,000 heroin/morphine mentions 
per year over the last four years, with 1,119 in 2007.  In 2006 there was a very small 
increase in drug law offences concerning heroin (from 15,629 to 15,741) and a 
similar marginal increase in the number of heroin seizures (from 16,402 to 16,553), 
although the quantity of seized heroin decreased. It has been reported that there has 
been a significant increase in the quantity of opium seized entering the United 
Kingdom with more than 500kg of opium seized since the beginning of 2006/07 and 
three seizures each in excess of 150kg.  The price of heroin at street level has 
continued to fall, but purity has continued to increase although there have been 
reports in 2008 of a lack of ‘good’ quality heroin at street level. 
Crack cocaine 
There is no indication of increased use of crack cocaine in general population 
surveys, reported use remaining at less than one per cent.  However, problem drug 
use estimates for England suggest that, in 2005/06, there were 197,568 problem 
crack cocaine users aged 15 to 64, 5.9 per thousand population; this is not a 
significant increase since the previous estimate for 2004/05.  The proportion of 
presentations to treatment for crack cocaine as primary drug has hardly changed 
over the last four reporting periods (from 5.4% to 5.8%), although the numbers 
presenting have steadily increased from 4,980 to 7,096.  First ever presentations for 
crack cocaine as primary drug, accounting for six per cent of presentations in 
2006/07, showed a slight decrease from the previous year in actual numbers 
presenting (from 3,116 to 2,900), having increased over the previous three reporting 
periods from 1,722 to 3,116.  However, when any use of crack cocaine is considered 
(not only as primary drug) there has been a much steeper rise in presentations and 
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the total number reporting such use is four times those reporting crack cocaine as 
primary drug, with 29,086 presentations (24% of the total) reporting use in 2006/07 
compared to 17,110 (18.5%) in 2003/04.  Convictions for drug law offences involving 
crack cocaine continue to rise, rising over the last year by nine per cent (from 3,734 
in 2006 to 4,076 in 2006). Seizures increased by five per cent in 2006/07 with the 
quantity of seized crack cocaine increasing by 16 per cent.  Price has remained 
stable, however, purity has fallen, reflecting the trend in cocaine powder. 
Cocaine powder 
There has been increased use of cocaine powder reported within the general 
population in the United Kingdom over the previous few years.  However, the most 
recent survey data, for England and Wales in 2007/08, show a decrease in last year 
use amongst 16 to 59 year olds from 2.6 to 2.3 per cent, and amongst young adults 
aged 16 to 24 the fall was from 6.0 per cent to 5.0 per cent.  Amongst school 
children, last year use was 1.6 per cent in 2006 and 1.8 per cent in 2007.  Treatment 
presentations for primary cocaine powder use have risen steadily over the previous 
four reporting periods, from 3,739 in 2003/04 to 8,372, with a 22 per cent rise from 
the previous year’s figure (6,890).  First ever presentations for cocaine powder have 
also increased over the last four years, the actual number of presentations increasing 
from 1,683 in 2003/04 (5.8% of all presentations) to 4,951 in 2006/07 (10.5% of all 
presentations).  Thirteen per cent (8,372) of those presenting to treatment in 2006/07 
reported use of cocaine powder as either primary or other drug used, a number 
steadily increasing over time.  Deaths associated with cocaine have also increased 
steadily over time, with 158 in 2003 and 243 in 2007.  However, without being able to 
distinguish between crack cocaine and cocaine powder in autopsies, deaths could 
involve the former.  The largest increase in convictions for drug offences in 2006 was 
for cocaine with 15,470 convictions, an increase of 28.6 per cent from 12,028 in 
2005.  Seizures increased by 36 per cent in 2006/07 although the quantity seized fell 
by 14 per cent.  The price of cocaine powder at street level continues to fall, as does 
purity.  
Cannabis  
Cannabis remains the most widely used drug across all age groups, but there has 
been a downward trend in use over the last five reporting years.  Latest survey data 
for England and Wales show that, in 2007/08, 30 per cent of adults aged 16 to 59 
had used cannabis in their lifetime, 7.4 per cent had used recently and 4.2 per cent 
were current users.  Amongst young adults aged 16 to 34, a downward trend has 
been seen since 2002/03.  Amongst younger people (16 to 24), the downward trend 
in recent use has been apparent over the last decade.  Amongst school children in 
England there has also been a downward trend in use of cannabis since 2004.  
Cannabis use is not included in problem drug use estimates, but it is the second 
most common drug for which treatment is sought, representing 15.6 per cent of 
treatment demands in 2006/07. This proportion has increased over recent years, 
although no increase was seen in 2006/07.  Numbers presenting have also 
increased; doubling from 9,847 in 2003/04 to 19,108 in 2006/07.  First ever treatment 
presentations for cannabis accounted for 42 per cent of all such presentations in 
2006/07, not a significant change from the previous year, but again numbers have 
doubled over the four years of reporting, from 5,289 to 11,325.  Cannabis offences 
continued to account for the majority of offences in 2006 (55,984), an increase of 2.1 
per cent from 2005. Cannabis also accounted for the majority of seizures with herbal 
cannabis seizures and cannabis plants seizures increasing in both number and 
quantity in 2006/07.  Cannabis resin seizures fell, however, as did the quantity 
seized. The price of cannabis has remained stable.  The potency of traditional 
imported herbal cannabis and cannabis resin has fallen since the late 1990s with 
potency of sinsemilla increasing.   
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Amphetamines  
Recent and current amphetamine use in the general population remains very low and 
continues to fall, recent use reported by one per cent in 2007/08 in England and 
Wales and current use by 0.4 per cent.  Amongst school children recent use has 
remained steady at around one per cent over the last seven years.  The proportion of 
treatment presentations has also remained stable at between 3.5 per cent and 3.8 
per cent over the last four reporting periods, although actual numbers of demands 
have increased from 3,474 in 2003/04 to 4,622 in 2006/07.  First ever treatments 
accounted for 4.3 per cent of all such presentations in 2006/07; while this is an 
increase since the previous year (3.9%), the overall trend appears to be downward.  
However, there were 7,422 offences concerning amphetamines in 2006, an increase 
of 8.1 per cent from 2005.  There was also a seven per cent increase in the number 
of amphetamines seizures in 2006/07 although the quantity seized decreased by 29 
per cent.  Price has remained stable, as has purity. 
Ecstasy 
Ecstasy is the third most commonly used drug after cannabis and cocaine powder for 
recent and current use.  In 2007/08, recent use in England and Wales was reported 
by 1.5 per cent, the lowest level since the British Crime Survey began measurement 
of self-reported drug use.  Prevalence of recent use by young adults aged 16 to 34 
was 3.1 per cent and for those aged between 16 and 24, 3.9 per cent.   Recent use 
of ecstasy amongst school children in England and Wales has remained stable over 
the last seven years at around 1.5 per cent although the figure for 2007 (1.3%) is 
lower than in any year since 2001.  Treatment demands are extremely low.  There 
were 6,233 offences concerning ecstasy in 2006, a small decrease of 1.6 per cent 
since the previous year (6,337).  However, in 2006/07, there was a 28 per cent 
increase in ecstasy seizures and the quantity of tablets seized more than doubled.  
The price of ecstasy has decreased since 2003 and the mean MDMA content has 
also decreased.  
Magic mushrooms 
In 2007/08 recent use of magic mushrooms in England and Wales was at its lowest 
level for 10 years at 0.5 per cent.  Recent use of magic mushrooms by young adults 
aged 16 to 34 had increased to 2.2 per cent in 2004/05 but then fell steadily to 1.0 
per cent in 2007/08.  Recent use by those aged 16 to 24 was 1.2 per cent, again 
having decreased in recent years.  Amongst school children in England there has 
been a steady decline in recent use from 2.1 per cent in 2001 to 1.2 per cent in 2007.  
There is no information on treatment demands or on price. 
LSD  
Within the general population, recent and current use of LSD is low, 0.3 per cent and 
0.1 per cent respectively and, for last year use among young adults aged 16 to 34, 
0.6 per cent and those aged 16 to 24, 0.7 per cent.  LSD use amongst school 
children has remained at between 0.6 per cent and 0.7 per cent since 2001. There is 
no information on treatment demands.  The number and quantity of LSD seizures 
decreased in 2006/07. Prices appear to be remaining stable.  
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The United Kingdom and its constituent countries 
 
 
The United Kingdom population was estimated to be 61 million in the middle of 2007 
83.8 per cent (51.1 million) live in England, 8.4 per cent (5.1 million) in Scotland, 4.9 












































































New developments and trends 
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1. National policy and context  
1.1 Overview 
The United Kingdom comprises four countries, England, Wales, Scotland and 
Northern Ireland.  England is the largest country with 84 per cent of the population.1   
A number of powers have been devolved from the United Kingdom Parliament to 
Wales, Scotland and Northern Ireland, but there are different levels of devolved 
responsibilities in each country.   
 
The Misuse of Drugs Act 1971 is the principal legislation in the United Kingdom with 
respect to the control and supply of drugs that are considered dangerous or 
otherwise harmful when misused.  This Act divides such drugs into three classes (A, 
B and C) to reflect their relative harms and sets maximum criminal penalties for 
possession, supply and production in relation to each class.  Drugs in Class A 
include cocaine based drugs, ecstasy, LSD, magic mushrooms, heroin, methadone 
and injectable amphetamines.  In addition, methamphetamine was reclassified from 
Class B to Class A in January 2007.  Class B drugs include amphetamines. Class C 
drugs include anabolic steroids and tranquillisers, and since January 2006, ketamine.  
Cannabis was reclassified from Class B to Class C in 2004, but the Home Secretary 
has asked Parliament to consider reclassifying the drug back to Class B.  The Drugs 
Act 2005 amended sections of The Misuse of Drugs Act 1971 and The Police and 
Criminal Evidence Act 1984, strengthening police powers in relation to the supply of 
drugs. 
 
In 1998 the first United Kingdom drug strategy was launched, setting four principal 
aims: prevention of drug use amongst young people, safeguarding communities, 
providing expanded treatment and reducing availability (UKADCU 1998).  Following 
devolution, each administration produced its own strategy, reflecting the United 
Kingdom drug strategy but tailored to its individual circumstances and deciding upon 
policy in areas where responsibility is devolved (NIO 1999; Scottish Office 1999; 
National Assembly for Wales 2000).  Northern Ireland updated its strategy in 2006, 
combining drug misuse with alcohol (DHSSPSNI 2006).  
 
The United Kingdom Government is responsible for setting the overall strategy and 
for its delivery in the devolved administrations only in the areas where is has 
reserved power.  A new United Kingdom Drug Strategy was launched in February 
2008; within it, policies concerning health, education, housing and social care are 
confined to England; policing and the criminal justice system, cover England and 
Wales.  The Scottish Government and the Welsh Assembly Government also 
launched new strategies in 2008, the latter combining drugs, alcohol and prescription 
drugs.  All aim to make further progress on reducing the harms and each looks 
towards a greater focus on recovery.  All three strategy documents are accompanied 
by an action or implementation plan. 
 
Annual public expenditure on drugs in the United Kingdom is estimated to be around 
€1,418 million (£970m2). 
                                                
1 For more information see: http://www.statistics.gov.uk/statbase/Product.asp?vlnk=15106  
2 The conversion rate used throughout is the December 2007 monthly average spot exchange 
rate quoted by the Bank of England unless stated otherwise.  
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1.2 Legal Framework  
1.2.1 Laws, regulations, directives or guidelines 
Classification of cannabis  
In July 2007, the Home Secretary asked the Advisory Council on the Misuse of Drugs 
(ACMD) to review the classification of cannabis.  The ACMD reported back in May 
2008, advising that after scrutiny of the available evidence, it considered that, based 
on its harmfulness to individuals and society, cannabis should remain a Class C 
substance (ACMD 2008a).  It was, however, acknowledged that use of cannabis is a 
significant public health issue, that it can unquestionably cause harm to individuals 
and society and that there is clear evidence that its use may worsen the symptoms of 
schizophrenia and lead to relapse.  Whilst it concluded that, in the population as a 
whole, cannabis most likely plays a modest role in the development of psychotic 
illness, it also accepted that the possibility that the greater use of higher potency 
cannabis may increase the harmfulness to mental health, more so if young people 
start to use at an early age or “binge smoke”.  
 
The Council made a total of 21 recommendations, including that given the 
widespread use of cannabis, a concerted public health response is needed to 
drastically reduce its use and that special emphasis should be placed on developing 
effective primary prevention programmes, directed at young people.  It also 
suggested that the scale and public health significance of cannabis use in the United 
Kingdom requires further research; with the British Crime Survey extended to include 
young people under the age of 16.  Publication of the ACMD report was 
accompanied by a report on the potency of cannabis (Hardwick and King 2008) (See 
Chapter 10). 
 
The United Kingdom Government has accepted all the ACMD recommendations 
except that relating to classification.  The Government published its response to the 
ACMD report.3 in October 2008.  The Home Secretary has asked Parliament to 
reclassify the drug back to Class B as a precautionary measure in response to both 
the known risks to health as well as the potential long term impacts on health where 
the evidence is not conclusive at this time, particularly around the availability and use 
of higher potency cannabis - sinsemilla (skunk). (Home Office 2008).  With 
Parliamentary agreement, reclassification to Class B will come into effect on 26 
January 2009.   The Association of Chief Police Officers (ACPO) has proposed a 
stronger enforcement approach for repeat offenders for cannabis possession through 
a robust escalation process, which includes a Penalty Notice for Disorder for a 
second offence (internal communiation form the Home Office).    
Gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) 
Reporting on the risk of Gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD), 
which are precursor chemicals that are rapidly converted to intoxicant gamma-
hydroxybutyrate (GHB), ACMD provisionally recommends they be brought under 
control of the Misuse of Drugs Act 1971 and licensing arrangements be made for 
their legitimate industrial use as solvents (ACMD 2008b). 
ACMD advice on steroids  
Following advice from the ACMD (2008c) Government announced, in August 2008, 
its intention to include 24 steroids and 2 non-steroidal agents (beta-2-agonists and 
growth hormones) under the Misuse of Drugs Act 1971 in Class C. ACMD 
                                                
3 See: 
http://drugs.homeoffice.gov.uk/publication-search/cannabis/acmd-cannabisreclassification 
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recommend inclusion as Schedule 4 (IV) substances under the Misuse of Drugs 
Regulations, so as not to preclude their legitimate use on prescription.4   
Restriction on prescribing of methamphetamine precursors  
Following public consultation and recommendation by the Commission on Human 
Medicines, the Medicines and Healthcare Products Regulatory Agency (MHRA) 
implemented tighter controls for pseudoephedrine and ephedrine, precursors used in 
the manufacture of methamphetamine, contained in nasal decongestants in cold and 
flu remedies.  Reporting structures developed by the Royal Pharmaceutical Society 
of Great Britain for pharmacists have been put in place together with controls for 
United Kingdom internet pharmacies.  Large packs of these decongestants have 
been replaced by smaller ones and sales limited to one pack per customer in retail 
pharmacies.5 
1.3 Institutional framework, strategies and policies 
1.3.1 Co-ordination arrangements 
The Home Office continues to be responsible for overall delivery of the Drug Strategy 
and is the lead department for a new Public Service Agreement (PSA 25) on 
reducing the harm caused by alcohol and drugs (see section 1.3.3).  It also has 
responsibility for a number of the key actions within the drug strategy’s three-year 
action plan, including actions on enforcement and overarching actions on 
communications and information campaigns, diversity and the evidence base. 
National Community Safety Plan 2008-11 
In July 2007 the Government published Cutting Crime: A New Partnership 2008-11 
(Home Office 2007a), which sets out a new strategic framework for community 
safety.  The National Community Safety Plan (HM Government 2007) covers the 
same period and has been revised to ensure it is in line with the new Crime Strategy 
and new Public Service Agreements (PSAs) (see 1.3.3).  It seeks a stronger focus on 
more serious violence, greater flexibility for local partners to deliver local priorities 
and specific outcomes to increase community confidence. 
1.3.2 National plan and/or strategies 
Three new drug strategies have been published in the reporting period, each 
accompanied by an action or implementation plan.  The United Kingdom strategy, 
Drugs: protecting families and communities.  The 2008 drug strategy reflects the 
devolution of powers to Northern Ireland, Scotland and Wales (HM Government 
2008a).  The Scottish Government also published its strategy, The Road to 
Recovery: A New Approach to Tackling Scotland’s Drug Problem (Scottish 
Government 2008a).  The Welsh Assembly Government‘s substance misuse 
strategy, Working Together to Reduce Harm – the Substance Misuse Strategy for 
Wales 2008-2018, deals with drugs, alcohol and other substances including 
prescription drugs (Welsh Assembly Government 2008a).  
 
All new strategies aim to make further progress on reducing the harms associated 
with drug use and each looks towards a greater focus on recovery, which is seen as 
requiring a change in the culture of service providers to affect it and even greater co-
ordination between services.  In both the United Kingdom strategy, as it relates to 
England, and in the Scottish strategy, there are concerns that service provision 
should be more focused on the particular needs of the individual. 
                                                
4 See: http://press.homeoffice.gov.uk/press-releases/crackdown-on-steriods  
5 See: http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON2033608 
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United Kingdom Drug Strategy 2008 to 2018 
The United Kingdom Government’s new ten-year drug strategy (2008-2018) was 
launched in February 2008, following a 12-week consultation between July and 
October 2007.  This strategy, Drugs: protecting families and communities. The 2008 
drug strategy (HM Government 2008a) is accompanied by a three year action plan 
(HM Government 2008b).  The aim is to restrict the supply of illegal drugs and reduce 
the demand for them; it also focuses on protecting families and strengthening 
communities. The four strands of work within the strategy are:  
• protecting communities through tackling drug supply, drug-related crime and anti-
social behaviour; 
• preventing harm to children, young people and families affected by drug misuse; 
• delivering new approaches to drug treatment and social re-integration; and 
• public information campaigns, communications and community engagement.  
 
Policies include: 
• embedding action to tackle drugs within the neighbourhood policing approach, to 
gather community intelligence and to increase community confidence; 
• targeting the drug-misusing offenders causing the highest level of crime, 
improving prison treatment programmes and increasing the use of community 
sentences with a drug rehabilitation requirement (DRR); 
• strengthening and extending international agreements to intercept drugs being 
trafficked to the United Kingdom; 
• extending powers to seize the cash and assets of drug dealers, to demonstrate 
that dealing does not pay; 
• focusing on the families where parents misuse drugs, intervening early to prevent 
harm to children, prioritising parents' access to treatment where children are at 
risk, providing intensive parenting guidance and supporting family members, such 
as grandparents, who take on caring responsibilities; 
• developing a package of support to help people in drug treatment to complete it 
and to re-establish their lives, including ensuring local arrangements are in place 
to refer people from Jobcentres to sources of housing advice and advocacy and 
appropriate treatment; 
• using opportunities presented by the benefits system to support people in re-
integrating into society and gaining employment, with a commitment to examine 
further how claimants can be incentivised to engage with treatment and other 
services; and  
• piloting new approaches which allow a more flexible and effective use of 
resources, including individual budgets to meet treatment and wider support 
needs. 
 
For more detailed information see Chapters 3, 5, 7 and 9 in this report.  
Scotland’s drug strategy  
A key priority of The Road to Recovery: A New Approach to Tackling Scotland’s Drug 
Problem is to reinforce the message that, more than just reducing the risk and harm 
associated with drug use, services should support people to move on, towards a 
drug-free life, as active and contributing members of society (Scottish Government 
2008a).  Problem drug use is seen as symptomatic of the failure of other policies to 
bring about a wealthier and fairer society.  There is, therefore, a belief that tackling 
the problem can only be achieved through effective policies on the economy, tackling 
poverty and on supporting families and children, in particular the children of drug 
using parents (see Chapter 9).  Therefore, the strategy is complemented by wider 
social policies including a new economic strategy (Scottish Government 2008b) and 
early years and early intervention policy (Scottish Government and COSLA 2008), as 
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well as increasing investment in drug services (see Chapters 5 and 9).  There is also 
to be a fresh approach to drugs education and prevention (see Chapter 3) and a 
stronger focus on law enforcement and drug-related crime (see Chapters 9 and 10).  
An action plan details key activities to be undertaken to achieve the aims and 
objectives of the strategy.  
 
Key priorities are: 
• better prevention of drug problems, with improved life chances for children and 
young people, especially those at particular risk of developing a drug problem, 
allowing them to realise their full potential in all areas of life; 
• to see more people recover from problem drug use so that they can live longer, 
healthier lives, realising their potential and making a positive contribution to 
society and the economy; 
• having communities that are safer and stronger places to live and work because 
crime, disorder and danger related to drug use have been reduced; 
• ensuring that children affected by a parental drug problem are safer and more 
able to achieve their potential; and 
• improving the effectiveness of delivery at a national and local level. 
 
Actions include: 
• the setting up of a Drug Recovery Network to promote and support the concept of 
recovery among local partners, service providers and people with problem drug 
use; 
• developing an outcomes based framework for assessing and managing 
performance at a local level focused clearly on recovery; 
• setting up a national support function to take forward the development and 
implementation of the recovery model in drugs services;  
• establishing a National Drugs Evidence Group to develop a co-ordinated 
approach to identify gaps in research and encourage innovation;  
• establishing of a Steering Group to develop more effective substance misuse 
education in schools; and 
• provision of ongoing multi-agency training to help identify children at risk at an 
early stage, to know when to seek support from specialist areas, and when to 
share information. 
 
For more detailed information see Chapters 3, 5, 7 and 9 in this report.  
Substance Misuse Strategy for Wales 2008 to 2018  
The substance misuse strategy for Wales, Working Together to Reduce Harm – the 
Substance Misuse Strategy for Wales 2008-2018, was launched in 2008 (Welsh 
Assembly Government 2008a).  The strategy has four aims: 
• reducing the harm to individuals (particularly young people) their families and 
wider communities from the misuse of drugs and alcohol, whilst not stigmatising 
substance misuse; 
• improving the availability and quality of education, prevention and treatment 
services and related support, with a greater priority given than under the previous 
strategy to those related to alcohol; and 
• making better use of resources – supporting evidence based decision making, 
improving treatment outcomes, developing the skills base of partners and service 
providers by giving a greater focus to workforce development and joining up 
agencies and services more effectively in line with Making the Connection.6 
                                                
6 See: http://new.wales.gov.uk/about/strategy/makingtheconnections/?lang=en 
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• Embedding the core Welsh Assembly Government values of sustainability, 
equality and diversity, support for the Welsh Language and developing user 
focused services and a rights base for children and young people in both the 
development and delivery of the strategy. 
 
The strategy is accompanied by a three-year implementation plan (Welsh Assembly 
Government 2008b).  Key areas for actions are:  
• preventing harm – helping children, young people and adults resist, reduce or 
delay substance misuse by educating them about the damage that substance 
misuse can cause to their health, their families and the wider community; 
• support for substance misusers - to improve their health and aid and maintain 
recovery thereby reducing the harm they cause themselves, their families and 
their communities; 
• supporting families – to reduce the risk of harm to children and adults as a 
consequence of substance misusing behaviour of a family member; and 
• tackling availability and protecting individuals and communities - reducing the 
harm caused by substance misuse related crime and anti-social behaviour, by 
tackling the availability of illicit drugs and the inappropriate availability of alcohol 
and other substances. 
 
For more detailed information on the strategy see Chapters 3, 5, 7 and 9 in this 
report.  
Responses to the strategies 
There has been a lot of media attention and comment on Drugs: protecting families 
and communities (HM Government 2008a), particularly at the consultation stage.  
These include responses from the ACMD7, the Royal Society for the Encouragement 
of Arts, Manufactures and Commerce (RSA)8 and the United Kingdom Drug Policy 
Commission (UKDPC).9  A major concern about the draft of this strategy was the lack 
of an accompanying statement of the evidence base, which was rectified in the final 
document. The strategy received praise for its focus on helping users to reintegrate 
into society.  The UKDPC, in its response to the Welsh strategy during the 
consultation, has welcomed the fact that it seeks to address all substance misuse, its 
focus on reducing harm and the emphasis on support for substance misusers, but 
expressed some concern about the evidence for drug education in the strategy (see 
Chapter 3.2).  A major response from UKDPC concerns the concept of recovery (see 
section 1.5.2) (UKDPC 2008a). 
1.3.3 Implementation of polices and strategies  
In England, Public Service Agreements (PSAs) set out the key priority outcomes the 
Government wants to achieve.  The 2007 Comprehensive Spending Review (CSR)10 
                                                
7 See: http://drugs.homeoffice.gov.uk/publication-search/acmd/acmdconsultresponse.pdf 
8 The RSA Drugs Commission is an independent body with members drawn from various 
fields and disciplines concerned with drug misuse.  The Drugs Commission was set up in 
January 2005 to examine the efficacy of current drugs policy and consider alternatives.  For 
more information see: http://www.rsadrugscommission.org/ 
9 The UK Drug Policy Commission an independent body established to provide objective 
analysis of UK drug policy and to improve political, media and public understanding of drug 
policy issues and the options for achieving a rational and effective (evidence-led) response to 
the problems caused by illegal drugs.  For more information see: http://www.ukdpc.org.uk/ 
10 Spending Reviews set firm and fixed three-year Departmental Expenditure Limits and, 
through Public Service Agreements (PSA), define the key improvements that the public can 
expect from these resources. The 2007 Comprehensive Spending Review set spending plans 
for 2008-11.  For more information see: 
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announced spending by Government over three years, 2008 to 2011, setting 30 new 
PSAs (HM Treasury 2007a).  Each PSA is underpinned by a single Delivery 
Agreement shared across all contributing government departments and taking effect 
from April 2008. PSA Delivery Agreement 25 is to reduce the harm caused by alcohol 
and drugs.  Progress will be measured by a number of indicators including: 
• the number of drug users recorded as being in effective treatment; 
• the rate of drug-related offending; and 
• the percentage of the public who perceive drug use or dealing as a problem in 
their area. 
 
At the local level, Local Authorities and their Strategic Partnerships, responsible for a 
wide range of services, and Primary Care Trusts (PCTs), responsible for health 
services, are measured by a set of 198 National Indicators (NI) which relate to 
specific PSAs (CLG 2007).  In each area, targets against the set of national 
indicators are negotiated through new Local Area Agreements (LAAs).  Each 
Agreement is expected to include up to 35 targets from among the national 
indicators.  The national indicator set includes the three PSA indicators listed above. 
 
It is of note that the previous PSA, “to reduce the use of Class A drugs and the 
frequent use of any illicit drug among all young people under the age of 25, 
especially by the most vulnerable young people”, is no longer valid.11  A new PSA 
(14) directly relates to young people’s substance misuse and is to “increase the 
number of children and young people on the path to success”.  This PSA is the 
responsibility of the Department for Children, Schools and Families (DCFS) and has 
an associated local indicator specifically on substance misuse by young people – the 
proportion of young people frequently using illicit drugs, alcohol or volatile 
substances (NI 115).   
 
In Scotland a National Performance Framework supports the delivery of the Scottish 
Government’s purpose: 
 
“To focus the Government and public services on creating a more successful 
country, with opportunities for all Scotland to flourish, through increasing 
sustainable economic growth”. 
 
The National Performance Framework contains 15 outcomes and 45 indicators.  
Progress on the outcomes is measured through these indicators.  Included in the set 
of national indicators is “reducing the estimated number of problem drug users in 
Scotland by 2011”. 
 
This National Performance Framework also underpins a new relationship between 
Government and local government through a Concordat agreed in November 2007 
(Scottish Government 2007).  Measures contained within the Concordat include the 
introduction of Single Outcome Agreements (SOAs).  Under the Concordat an SOA 
will be developed between central government and the local authority or Community 
Planning Partnership (CPP) in each area of Scotland.  From 2009 the SOA will be 
                                                                                                                                         
http://www.hm-treasury.gov.uk/spending_review/spend_index.cfm 
11 Other previous PSAs were to: reduce the harm caused by illegal drugs including 
substantially increasing the number of drug misusing offenders entering treatment through the 
criminal justice system, and to increase the participation of problem drug users in drug 
treatment programmes by 100% by 2008 and increase year on year the proportion of users 
successfully sustaining or completing treatment programmes.  See: 
http://drugs.homeoffice.gov.uk/publication-search/drug-strategy/technical-notes-
290704?view=Binary 
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between central government and the CPP.  The SOAs, therefore will help identify the 
contribution tackling drug use makes to the achievement of local outcomes.  SOAs 
for 2008/09 have been agreed and those for 2009/10 are currently in the process of 
being developed (Scottish Government 2008a; internal communication from the 
Scottish Government). 
 
The Scottish Government is also setting up a Drug Recovery Network to promote 
and support the concept of recovery among local partners, service providers and 
people with problem drug use and to effect cultural change among those working 
with, or affected by problem drug use.  Also, it will set up a national support function 
to take forward the development and implementation of the recovery approach in 
drugs services.  The specific functions and priorities which the national support 
function will provide are being considered by a Delivery Reform Group jointly 
supported by the Scottish Advisory Committee on Drug Misuse (SACDM) and the 
Scottish Ministerial Advisory Committee on Alcohol Problems (SMACAP), which has 
been set up to look at the future of alcohol and drug delivery arrangements.  The 
group will also develop and propose an outcomes-based framework for assessing 
and managing performance at a local level, focused clearly on recovery.  It will also 
develop and propose a clear statement of the strategic functions needed to 
implement the national strategy locally.  Finally, it will propose accountability 
arrangements between central government and partner organisations to ensure that 
resources are used efficiently and effectively and local partners can demonstrate to 
Government that this is the case.  The Scottish Government will publish and respond 
to the conclusions of the group in time to allow its work to inform accountability 
arrangements from April 2009. 
 
In Wales, the national strategy is accompanied by an implementation plan (Welsh 
Assembly Government 2008b) and a National Substance Misuse Strategy 
Implementation Board is to be established to oversee the delivery of the Strategy.  
This will have representation from key Welsh Assembly policy divisions, the Advisory 
Panel on Substance Misuse, non-devolved bodies and stakeholders.  The Board will 
also measure the impact of the strategy against the key performance indicators 
(published in the previous United Kingdom Focal Point report).  The lead 
responsibility for delivering this strategy at a local level will continue to rest with the 
22 Community Safety Partnerships in Wales.  Links with other relevant partnerships, 
particularly local Children and Young People’s Partnerships are to be strengthened.  
Co-ordination arrangements are also to be strengthened at regional level.12 
 
Within the Northern Ireland Executive’s, Programme for Government 2008-2011, 
under PSA 8: Promoting health and addressing health inequalities, there are a range 
of targets related to drug misuse, particularly among young people and vulnerable 
groups (Northern Ireland Executive 2007).  A report updating progress against the 
Northern Ireland alcohol and drug strategy, New Strategic Direction for Alcohol and 
Drugs (DHSSPSNI 2006), including its outcomes and indicators, is due to be 
published in late 2008. 
1.3.4 Evaluation of policies and strategies 
The Drug Harm Index 
The Drug Harm Index (DHI) was developed by the Home Office as the overarching 
measure for a previous Public Service Agreement target to: “Reduce the harm 
caused by illegal drugs (as measured by the Drug Harm Index encompassing 
measures of the availability of Class A drugs and drug-related crime)” and included 
                                                
12 Regions are coterminous with the four police force areas in Wales. 
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“substantially increasing the number of drug misusing offenders entering treatment 
through the criminal justice system.”13  The specific target to increase the number of 
drug-misusing offenders entering treatment through the criminal justice system to 
1,000 a week by the end of March 2008 (from a baseline of 438 entering treatment in 
March 2004), was met two months early, in January 2008.  The latest report on the 
Drug Harm Index14 shows a fall from 89.1 points in 2004 to 83.8 points in 2005.  This 
is a drop of 5.3 points or 5.9 per cent (Goodwin 2007).  This compares to a decrease 
of 18.2 per cent between 2003 and 2004.  The index has now fallen year-on-year 
since 2001.  It is suggested that the fall between 2004 and 2005 is largely due to 
further reductions in drug-related crime (most notably domestic and commercial 
burglaries, theft from a domestic vehicle, shoplifting and other thefts).  In terms of the 
health-related indicators, drug-related hepatitis C cases had a noticeable downward 
impact on the DHI, but this was more than offset by an increase in drug-related 
deaths from 1,495 in 2004 to 1,608 in 2005.  The only other variable with a large 
upward impact on the DHI was robbery.  The DHI will not be continued in future. 
1.4 Budget and public expenditure 
1.4.1 In law enforcement, social and health care, research, international actions, 
coordination, national strategies 
England  
Table 1.1 shows labelled public expenditure for England by the United Nations 
Classifications of Functions of Government (COFOG). 
Table 1.1: Public expenditure by COFOG in England, 2006/07 and 2007/08  
COFOG category 2006/07 2007/08 
 €m (£m) €m (£m) 
01 – General public services 67.4 (46.1) 50.4 (34.5) 
03 – Public order and safety 394.3 (269.7) 358.9 (245.5) 
07 – Health 962.6 (658.1) 958.2 (655.4) 
09 – Education 21.1 (14.4) 15.2 (10.4) 
10 – Social protection 10.4 (7.1) 10.5 (7.2) 
Total*  1462.8 (1000.0) 1399.2 (957.3) 
*Includes Prospect Programme (€6.7m (£4.6m) in 2006/07 and €6.3m (£4.3m) in 2007/08)  
Source: Home Office 
Northern Ireland 
Approximately €10.2 million (£7m) per year is allocated to the implementation of the 
Northern Ireland alcohol and drug strategy, New Strategic Directions (DHSSPSNI 
2006).  This funding does not include the amount allocated to statutory addiction 
services, or any additional funding being allocated at a local level to tackle 
inequalities related to alcohol or drug issues.  
 
                                                
13 A technical account of the DHI was published in March 2005 with data up to and including 
2003, along with a full description of data sources and methodology.  This report is available 
at www.homeoffice.gov.uk/rds/pdfs05/rdsolr2405.pdf.  An update was published in March 
2006 to incorporate some minor improvements to the methodology and data for 2004; see 
http://www.homeoffice.gov.uk/rds/pdfs06/rdsolr0806.pdf  
14 The previous DHI update included some minor methodological improvements.  Whilst the 
latest version of the DHI retains these changes, there have not been any further changes to 
the methodology.  However, certain data providers have retrospectively updated some of the 
historical data used to construct the DHI. Incorporating these data revisions has led to a slight 
increase in the value of the DHI between 1999 and 2004 compared to the previously 
published figures.  These changes have made little difference to the trend over time. 
UNITED KINGDOM FOCAL POINT REPORT 2008  
 30 
Table 1.2: Public expenditure in Northern Ireland, 2007/08  
 €m (£m) 
Allocation to Drug and Alcohol Coordination Teams (DACTs) 0.10 (0.07) 
Allocation to implement the national strategy across DACTs  7.01 (4.8) 
Substitute prescribing allocation to Health Boards 1.46 (1.0) 
Policy development/research 0.29 (0.2) 
Public information campaigns  0.44 (0.3) 
Needle and Syringe Exchange Scheme  0.15 (0.1) 
4 Regional Posts (Service User; Harm Reduction; Workplace 
Development and Workplace Policy) 
0.15 (0.1) 
Other Expenditure  0.73 (0.5) 
Total 10.34 (7.07) 
Source: Department of Health, Social Services and Public Safety, Northern Ireland 
Scotland  
In Scotland, a total of €96.3 million (£65.9m) was allocated to tackling drug misuse in 
2007/08 under the Justice portfolio. This consisted of €34.6 million (£23.7m) for drug 
treatment and rehabilitation services, €33.8 million (£23.1m) to the Scottish Crime 
and Drug Enforcement Agency (SCDEA), €20.6 million (£14.1m) for criminal justice 
interventions (including Drug Testing and Treatment Orders), and €7.3 million (£5m) 
to support the work of Drug Action Teams and centrally managed projects.15 
Significant resources outside the Justice portfolio budget are also applied to tackling 
drug misuse.  In the past this has included expenditure by local authorities on 
services for those affected by drugs and/or alcohol misuse, €61.8 million (£42.3m) in 
2006/07 and additional expenditure by Health Boards on treatment services from 
their unified budgets.   
 
Future funding proposals are tied to the key priorities of the new national drugs 
strategy.  Allocations to Health Boards to fund drug treatment and rehabilitation 
services and for centrally managed initiatives are to increase by 14 per cent over the 
period 2008 to 2011.  Expenditure on criminal justice interventions and the SCDEA is 
to increase slightly with a further €62.9 million (£43m) being made available over the 
next three years to implement the Hepatitis C Action Plan Phase II.  The Scottish 
Government is also investing €137.4 million (£94m) over the next three years to 
deliver a more visible policing presence by recruiting 1,000 more police officers, 
many of whom will be dealing with drug misuse. 
 
Audit Scotland is undertaking an exercise to identify the scale and effectiveness of 
public expenditure on measures to tackle drug misuse; it intends to report no later 
than Spring 2009.  This work will inform future spending priorities.   
Wales  
Funding for the Welsh substance misuse strategy will come from the investment of 
an extra €14 million (£9.6m) into the Substance Misuse Action Fund over the next 
three years, taking the total funding to over €39.5 million (£27m) per annum by 2010-
11.   Also, there will be an additional €4.39 million (£3m) over the next 3 years from 
the Health Inequalities Fund to take forward the alcohol actions within the 
implementation plan and nearly €16.1 million (£11m) a year ring-fenced funding 
provided to local Health Boards for tackling substance misuse.16  
                                                
15 http://www.scottish.parliament.uk/business/pqa/wa-08/wa0617.htm  
16 For more information see: 
http://new.wales.gov.uk/news/presreleasearchive/030308comm/?lang=en 
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1.4.2 Funding arrangements 
England  
Treatment  
There have been changes to the way funding for drug treatment has been allocated 
to local drug action teams.  Funding received by partnerships will now largely depend 
upon the number of individuals in the area in effective treatment in that year i.e. those 
who complete or are retained in treatment for 12 weeks or more.  Additional factors 
will be taken into consideration, including: the number of crack cocaine and/or opiate 
users being treated; the complexity of local caseloads; and the varying costs involved 
in providing treatment in different areas of the country.  These changes mean that, 
over the coming years, the variations in spending per person in treatment will 
continue to narrow with funding redirected from partnerships which have historically 
received a higher than average share per person in treatment of the national 
treatment budget, towards those who have received a lower than average 
allocation.17 
1.5 Social and cultural context 
1.5.1 Public opinions of drug issues 
In a public consultation18 by the Joseph Rowntree Foundation exploring the ‘social 
evils’ facing Britain today, amongst a number of concerns raised were drugs and 
alcohol, which were viewed as the consequence and cause of many other social 
problems, such as family breakdown and poverty (Joseph Rowntree Foundation 
2008). 
 
Results from the 2007/08 British Crime Survey (BCS) show that drugs were one of 
the two factors most commonly identified by people as the main causes of crime in 
Britain today (lack of discipline from parents was the second factor), mentioned by 71 
per cent of respondents.  The 2007/08 BCS shows a statistically significant decrease 
in overall perceptions of antisocial behaviour from 18 per cent in 2006/07 to 16 per 
cent in 2007/08, including a statistically significant decrease in the respondents 
reporting that people using or dealing drugs was a “very/fairly big problem in their 
area”, from 28 per cent to 26 per cent (Kershaw et al. 2008).   
1.5.2 Initiatives in parliament and civil society 
Consultation on drug strategies  
All recent drug strategies have undergone a process of public consultation.19   
                                                
17 See: http://www.nta.nhs.uk/news_events/newsarticle.aspx?NewsarticleID=7 
18 A web-based consultation was held from July to September 2007.  Anyone could contribute 
to this by visiting the website and listing their top three social evils.  Approximately 3,500 
people took part and a further 100 responses by post. However, this group was not 
representative of the British population generally; for example, black and minority ethnic 
groups and younger people were under-represented.  The results of this consultation can be 
found at: http://www.socialevils.org.uk/.  In addition, The National Centre for Social Research 
was commissioned to ensure that the potentially excluded groups be included.  In total, 60 
people took part in eight discussion groups held across England and Scotland in 2007 with 
participants recruited through a number of charitable organisations working with potential 
excluded groups, including people with learning difficulties, ex-offenders, people with 
experience of homelessness, unemployed people, care leavers and carers.  The results of 
this consultation can be found at: http://www.socialevils.org.uk/ 
19 See, for example: 
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Scotland’s Futures Forum 
Scotland’s Futures Forum20 was established by the Scottish Parliament in 2007 to 
look beyond immediate horizons to some of the challenges and opportunities to be 
faced in the future.  In 2007 it was asked to consider the question, “How can 
Scotland reduce the damage caused to its population through alcohol and drugs by 
half by 2025?”  It has published a report based on evidence gathered from some of 
the world’s leading experts in tackling drug and alcohol misuse, adopting a systems 
mapping approach to addressing the key issues (Scotland’s Futures Forum 2008a).  
A report containing the views of those consulted is also available (Scotland’s Futures 
Forum 2008b). 
 
Key findings were that: 
• transparent evidence based research should underpin all policy and practice, and 
this should be scrutinised in the public domain; 
• research shows a high association between drug problems and inequality; 
• a population-based approach is required to improve public health; 
• treatment and recovery networks make one of the most significant contributions 
to reducing drug harm and should be strengthened; 
• there are substantive questions to be answered about the effectiveness of the 
current heavy bias of resources towards enforcement and there needs to be a 
counterbalancing of resources on prevention and social well-being; 
• further discussion is needed to rebalance the regulation and prohibition for each 
substance; and  
• people will use a range of psychoactive drugs, balancing benefits and harm, for 
the foreseeable future. 
Consensus statement on recovery 
The UKDPC is seeking to develop a consensus statement defining recovery, 
following what it sees as increasing polarisation of opinion amongst professionals, 
academics and the media between the concepts of harm reduction and abstinence.  
The aim is to identify common ground and develop a description of the process of 
recovery from substance use problems which would encompass the wide range of 
individual experiences of recovery and the differing contributions that treatment and 
support services make to assisting those in recovery.  The statement, at the time of 
writing, is that: 
 
“The process of recovery from problematic drug use is characterised by voluntary 
sustained control over substance use which maximises health and well-being and 
participation in the rights, roles and responsibilities of society.” (UKDPC 2008a) 
 
It is suggested that: 
 
“Recovery is about building a satisfying and meaningful life, as defined by the 
person themselves, and involves participation in the rights, roles and 
responsibilities of society.  The word ‘rights’ is included here in recognition of the 
stigma that is often associated with problematic drug use and the discrimination 
users may experience and which may inhibit recovery.  Recovery embraces 
inclusion, or a re-entry into society, and the improved self-identity that comes with 
a productive and meaningful role. For many people this is likely to be able to 




20 For more information about the Futures Forum see: http://www.scotlandfutureforum.org/ 
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include being able to participate fully in family life and undertake work in a paid or 
voluntary capacity.” (UKDPC 2008a) 
 
“Recovery is a process, not a single event, and may take time to achieve and 
effort to maintain.  The process and the time required will vary between 
individuals.” (UKDPC 2008a) 
 
The place of substitute medication within the process is seen as important:  
 
“Recovery requires control over substance use (although it is not sufficient on its 
own).  This means a comfortable and sustained freedom from compulsion to use.  
For many people this will require abstinence from the problem substance or all 
substances, but for others it may mean abstinence supported by prescribed 
medication or consistently moderate use of some substances.” (UKDPC 2008a) 
The legalisation of illegal drugs 
Amongst a number of concerns over the past year has been the question of the 
legalisation of illegal drugs which was a topic for discussion in the British Medical 
Journal in 2007, with a number of contributors on the subject, some seeking it on the 
grounds that prohibition breeds crime and exacerbates drug problems, others 
arguing it will send out the wrong message.21  There has also been some debate 
about how dangerous ecstasy22 is, and there has been a major debate, led by the 
ACMD, on whether cannabis should be reclassified (see section 1.2.1).  As part of 
this review, the ACMD invited members of the public to a meeting in February 
2008.23 
Beckley Foundation report 
A report from the Beckley Foundation (Barrett et al. 2008)24 suggests that 
prohibitionist policies are dominant in most countries and marginalise and stigmatise 
the most vulnerable sectors of society, subjecting them to human rights violations.  It 
is suggested that a number of reforms within the United Nations are essential if a 
human rights-based approach to drug control is to be achieved. 
1.5.3 Mass Media Campaigns 
The first National Tackling Drugs Week, run between the 19th and 23rd of May 2008, 
allowed local agencies, involved in delivery of the Drug Strategy, an opportunity to 
publicise the work that they carry out to tackle drugs issues in the community.25   
 
In Scotland, Know the Score launched its Informing Parents campaign in March 2008 
which aimed to provide parents with information, advice and resources on drugs to 
help them become properly equipped to approach their children about this issue.26  A 
direct mailing to households with children under 16 years, grandparents and other 
family members was undertaken in June 2008.  Further targeted work, in 
partnerships with the education, youthwork, health and prison sectors is being 
developed (see also Chapter 3.3.1). 
                                                
21 See: http://www.nelm.nhs.uk/Record%20Viewing/vR.aspx?id=587105 
22 See: http://www.timesonline.co.uk/tol/news/uk/article3119399.ece 
23 See: http://drugs.homeoffice.gov.uk/news-events/events/ACMD-open-meeting-feb-2008 
24 The Beckley Foundation Drug Policy Programme (BFDPP,) is a non-governmental initiative 
dedicated to providing a rigorous independent review of the effectiveness of national and 




26 See: http://www.knowthescore.info/kts/898.html 
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2. Drug use in the population 
2.1 Overview 
Estimates of the prevalence of drug use in the general population in England and 
Wales are provided by the British Crime Survey.27  Similar surveys are undertaken in 
Scotland28 and Northern Ireland.29  Combining data from surveys undertaken in 
2006/07, it was estimated that just over a third of the adult population in the United 
Kingdom aged between 16 and 59 had used an illicit drug in their lifetime.  In 
England and Wales, for which the most complete time series data are available, 
prevalence of recent (last year) use had been fairly stable at around 11 per cent from 
1996 to 2003/04 but has subsequently fallen annually to just over nine per cent in 
2007/08. 
 
Young adults under 35 are much more likely to use drugs, and amongst those who 
are under 25 years old, recent and current (last month) prevalence is higher still. In 
England and Wales, amongst these young adults, there has nevertheless been a 
steady decline in the recent use of any drug since 1996 with a decrease from 24 per 
cent to 21 per cent between 2006/07 and 2007/08. 
 
Males are more likely to report recent and current use than females, but the 
difference varies according to age, tending to be more pronounced in the older age 
groups.   
 
Amongst the school age population, surveys of drug use prevalence have been 
undertaken in each of the four administrations of the United Kingdom.30  In England, 
for which the longest time series are available, drug use increased between 1998 
and 2003, but has fallen since then. 
 
Cannabis continues to be the most commonly used drug across all age groups, with 
prevalence rates close to those for use of any drug.  Use of other drugs is 
considerably lower.  Since the mid 1990s the British Crime Survey shows that use of 
cocaine powder increased substantially (with the greatest change before 2001/02) 
                                                
27 The British Crime Survey (BCS) is a victimisation survey which gathers information about 
experience of crime in England and Wales, and is designed to provide a complementary 
measure of crime to police recorded crime statistics.  It also asks respondents about their use 
of illicit drugs in a self-completion module.  In 2001/02 it became a continuous survey.  
28 The Scottish Crime and Victimisation Survey (SCVS, previously the Scottish Crime Survey) 
is similar in scope and aims to the BCS. Surveys were carried out, as part of the British Crime 
Survey (BCS) in 1982 and 1988, as the independent Scottish Crime Survey in 1993, 1996, 
2000, 2003 and as the SCVS in 2004 and 2006. 
29 The Northern Ireland Crime Survey is also similar to the BCS. Surveys were carried out in 
1994/95, 1998, 2001 and 2003/4 and the survey has been continuous since January 2005.  
The latest published results are for 2006/07.  In addition, a Drug Prevalence Survey, based 
on the EMCDDA model questionnaire, was carried out in Northern Ireland in 2002/03 and 
2006/07. 
30 Amongst the school age population, the main sources of information on drug use 
prevalence are surveys undertaken in schools.  In England, a survey of the prevalence of 
drug use, smoking and drinking amongst young people (11 to 15 year old school children), 
has been undertaken annually since 1998.  The Young Person’s Behaviour and Attitudes 
Survey was undertaken in Northern Ireland in 2000 for the first time, and repeated in 2003 
and 2007.  In Scotland, the Scottish Schools Adolescent Lifestyle and Substance Use Survey 
(SALSUS) is undertaken every two years. Results from the 2006 survey were reported in the 
UK Focal Point Annual Report 2007.  The Health Behaviour in School Age Children Survey 
(HBSC) provides data from Wales and is undertaken every four years with a two-year interim 
survey.  The most recent survey, was conducted in 2006. 
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and it is now the second most used drug amongst adults.  However, there has been 
a corresponding decline in the use of amphetamines, previously the second most 
used drug.  
2.2 Drug use in the general population 
Since submission of the 2007 United Kingdom Focal Point report, results have been 
published from the 2007/08 British Crime Survey (BCS), covering England and 
Wales, the 2006/07 Drug Prevalence Survey in Northern Ireland and the 2006/07 
Northern Ireland Crime Survey.   
2.2.1 Drug use in the United Kingdom  
By combining data from the 2006/07 BCS (Murphy and Roe 2007), the 2006 Scottish 
Crime and Victimisation Survey (SCVS) (Brown and Bolling 2007) and the 2006/07 
Drug Prevalence Survey in Northern Ireland (NACD and PHIRB 2008a) 31,32, an 
estimate has been produced for 16 to 59 year olds in the United Kingdom (Table A.1, 
Appendix A) showing that: 
• 35.4 per cent have used drugs in their lifetime (ever); 
• 10.2 per cent have used drugs in the last year (recent use); and 
• 6.0 per cent have used drugs in the last month (current use). 
 
Since the last United Kingdom estimate was produced in 2005, based on data from 
surveys undertaken around 2003, lifetime drug use has increased from 34.1 per cent. 
However, recent use has declined from 11.8 per cent and current use has declined 
from 7.1 per cent. 
 
Drug use prevalence is highest in Scotland across all recall periods and for each 
individual drug.  This contrasts with the United Kingdom estimate in the Focal Point’s 
2005 Report where drug use was lowest in Scotland.  However, the change is largely 
attributable to a change of methodology for the SCVS rather than to a large increase 
or decrease in individual countries within the United Kingdom.33  Reported drug use 
remains lowest in Northern Ireland. 
2.2.2 England and Wales: the British Crime Survey 
The latest findings from the 2007/08 British Crime Survey show that 9.3 per cent of 
16 to 59 year olds have used drugs in the last year and 5.3 per cent have used drugs 
in the last month (Table 2.1).  Cannabis was the most commonly used drug across all 
recall periods followed by cocaine for recent and current use.  Males were much 
more likely to report drug use than females across all recall periods but especially 




                                                
31 The Public Health Information and Research Branch (PHIRB), formerly the Drug and 
Alcohol Information and Research Unit (DAIRU). 
32 The 2006/07 All Ireland Drug Prevalence Survey is a survey of drug use in Ireland and 
Northern Ireland amongst 15-64 year olds carried out between October 2006 and May 2007 
using CAPI.  The overall sample for the survey was 6,969, with a sample size of 2,002 in 
Northern Ireland (62 per cent response rate).  The sample in Northern Ireland was stratified 
by Health and Social Services Board (HSSB) area and then random sampling was employed 
within the strata.  Results have been weighted by age gender and HSSB area. 
33 In 2006, the SCVS changed from paper completion to Computer Assisted Personal 
Interviewing (CAPI), which appears to have had an impact on reported drug use.  This 
change in methodology means it is now similar to the BCS methodology. 
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Table 2.1: Percentage of 16-59 year olds reporting having used individual drugs in lifetime, 
last year and last month in England and Wales, 2007/08 
Lifetime use Last Year use Last Month use
 Male Female Total Male Female Total Male Female Total 
Any drug 41.8 29.9 35.8 12.6 6.2 9.3 7.5 3.2 5.3
Amphetamines 14.4 9.0 11.7 1.3 0.7 1.0 0.5 0.2 0.4
Cannabis 35.9 24.4 30.0 10.1 4.8 7.4 6.0 2.4 4.2
Cocaine 10.3 5.1 7.6 3.3 1.3 2.3 1.5 0.6 1.0
Ecstasy 9.7 5.3 7.5 2.1 0.8 1.5 0.8 0.3 0.5
LSD 7.4 3.0 5.2 0.4 0.1 0.3 0.1 0.1 0.1
Magic mushrooms 9.7 4.1 6.9 0.8 0.2 0.5 0.1 0.1 0.1
Opiates 1.2 0.5 0.8 0.3 0.1 0.2 0.2 0.1 0.1
Base  13,209 15,291 28,500 13,120 15,211 28,331 13,103 15,202 28,305 
Source: Standard Table prepared for the United Kingdom Focal Point 
Trends in drug use 
Changes in recent use since 1996 are shown in Figure 2.1.  This shows a decline in 
overall drug use since 2003/04 from 12.3 per cent to 9.3 per cent and a 
corresponding decline in cannabis use from 10.8 per cent in 2003/04 to 7.4 per cent 
in 2007/08.  The increase in cocaine powder use and decrease in use of 
amphetamines since 1996 are also shown, with the greatest change occurring before 
2001/02.  However, while the use of amphetamines continues to fall, the recent 
increase in cocaine powder use appears to be stabilising with last year use falling 
slightly from 2.6 per cent in 2006/07, to 2.3 per cent in 2007/08.  In 2007/08 recent 
use of ecstasy and magic mushrooms was similar to the levels reported when the 
BCS started collecting drug use data, 1.5 per cent and 0.5 per cent respectively. 
Figure 2.1: Percentage of 16 to 59 year olds reporting having used drugs in the last year in 
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Note that the first three time intervals in this graph are greater than a year 
Source: Kershaw et al. 2008 
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2.2.3 Drug Prevalence Survey 2006/07 in Northern Ireland 
The first results from the 2006/07 Drug Prevalence Survey were published in 2008 
(NACD and PHIRB 2008a).34  They show that: 
• 28.0 per cent of adults aged 15 to 64 have ever used drugs; 
• 9.4 per cent have used drugs recently; and 
• 3.6 per cent are current drug users.  
 
As with other parts of the United Kingdom, cannabis was the most widely used drug: 
a quarter of adults (24.7%) reported lifetime use, 7.2 per cent recent use, and 2.6 per 
cent current use.  For recent use, cocaine (1.9%) and ecstasy (1.8%) were the next 
most commonly used drugs but current cocaine use (0.3%) was less common than 
current ecstasy use (0.8%) (Table 2.2).  
Gender 
A higher proportion of males than females reported recent use of any drug, 13.7 per 
cent compared to 5.2 per cent.   
Table 2.2: Percentage of 15-64 year olds reporting having used individual drugs in lifetime, 
last year and last month in Northern Ireland, 2006/07 (DPS) 
Drug Lifetime use Last Year use Last Month use  Male Female Total Male Female Total Male Female Total 
Any drug* 33.9 22.1 28.0 13.7 5.2 9.4 4.9 2.4 3.6
Amphetamines 7.3 4.4 5.8 1.1 0.9 1.0 0.4 0.2 0.3
Cannabis 30.1 19.3 24.7 10.3 4.1 7.2 3.7 1.6 2.6
Cocaine 7.4 2.9 5.2 2.8 0.9 1.9 0.7 0.0 0.3
Ecstasy 9.9 5.5 7.7 2.4 1.2 1.8 0.8 0.7 0.8
LSD 9.7 3.5 6.6 0.2 0.2 0.2 0.0 0.1 0.0
Magic mushrooms 11.2 2.4 6.7 0.1 0.3 0.2 0.1 0.0 0.0
Opiates 0.7 0.4 0.5 0.0 0.1 0.1 0.0 0.1 0.1
Base  893 1109 2,002 893 1109 2,002 893 1109 2,002 
*amphetamines, cannabis, cocaine, ecstasy, heroin, LSD, magic mushrooms, methadone, poppers and solvents 
Source: Standard Table prepared for United Kingdom Focal Point from Drug Prevalence 
Survey in Northern Ireland 
Trends in drug use 
Lifetime use of drugs increased from 20 per cent in the 2002/03 Drug Prevalence 
Survey to 28 per cent in 2006/07, recent drug use increased from 6.4 per cent to 9.4 
per cent but there was no significant change in current drug use.  The increase in 
lifetime and recent drug use may show that there is more experimentation in 
recreational drugs.  However, there have been changes in methodology35 which may 
have had an impact on reported drug use and results from NICS suggest that drug 
use is stable in Northern Ireland (see 2.2.4 below). 
2.2.4 Northern Ireland Crime Survey 2006/07 
Results from the Northern Ireland Crime Survey (NICS) 2006/0736 have been 
published (Ruddy and Brown 2007).  In 2006/07, amongst adults aged 16 to 5937: 
                                                
34 The 2006/07 All Ireland Drug Prevalence Survey is a survey of drug use in Ireland and 
Northern Ireland amongst 15-64 year olds carried out between October 2006 and May 2007 
using CAPI.  The overall sample for the survey was 6,969, with a sample size of 2,002 in 
Northern Ireland (62 per cent response rate).  The sample in Northern Ireland was stratified 
by Health and Social Services Board (HSSB) area and then random sampling was employed 
within the strata.  Results have been weighted by age gender and HSSB area. 
35 In 2006/07 the DPS in Northern Ireland changed from paper completion to CAPI. 
36 The fieldwork was carried out between April 2006 and March 2007. The sample size was 
2,390 giving a 91% eligible response rate. 
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• 27.3 per cent reported lifetime use of an illegal drug; 
• 8.4 per cent reported recent drug use; and 
• 4.3 per cent reported current drug use.  
 
Cannabis was again the most commonly used drug; lifetime use was reported by 
20.1 per cent of respondents, recent use by 6.3 per cent and current use by 3.0 per 
cent.  Cocaine and ecstasy were the next most commonly reported drugs for recent 
use.  There was once again a large gender difference in recent drug use with 10.6 
per cent of males reporting recent drug use compared to 6.4 per cent of females. 
 
The difference in prevalence between the two surveys in Northern Ireland is less than 
in previous sweeps.  However, it is difficult to compare the prevalence rates in the 
two surveys due to differences in the sampling and survey methodologies. 
Trends in drug use 
Lifetime use of any drug has remained stable since 2003/04 at around 27 per cent 
(Table 2.3).  However, there has been a decrease in recent and current drug use for 
16-59 year olds between 2003/04 and 2006/07.38 This trend exists for both males 
and females.   
Table 2.3: Percentage of 16 to 59 year olds reporting lifetime, last year and last month use of 
any drug in Northern Ireland, 2003/04 to 2006/07(NICS) 
Drug Lifetime use Last Year use Last Month use  Male Female Total Male Female Total Male Female Total 
2003/04 31.6 23.7 27.4 11.5 8.1 9.7 7.4 5.1 6.2
2005 32.0 21.0 26.2 12.4 4.5 8.2 7.5 2.5 4.9
2006/07 31.5 23.4 27.3 10.6 6.4 8.4 5.4 3.3 4.3
Source: Ruddy and Brown 2007 
 
Unlike in England and Wales where the fall in recent drug use is largely attributable 
to a fall in cannabis use, recent cannabis use in Northern Ireland has remained 
stable (6.4% in 2003/04 and 6.3% in 2006/07).  Recent cocaine use has also 
remained stable at around one per cent with decreases in reported ecstasy use 
(1.9% in 2003/04 to 0.9% in 2006/07) and amphetamines use (0.9% to 0.5%). 
2.3 Drug use amongst young adults 
Additional analyses have been undertaken from United Kingdom population surveys 
for the United Kingdom Focal Point to provide data for the 16 to 34 age group used 
by the EMCDDA.  The surveys also routinely report data for 16 to 24 year olds. 
2.3.1 Estimates for the United Kingdom (2008) 
By combining data from surveys as described in section 2.2.1, estimates of 
prevalence of drug use amongst 16 to 34 year olds show that: 
• 46.9 per cent have ever used drugs; 
• 19.0 per cent have used drugs recently; and 
• 11.3 per cent are current drug users (Table A.2, Appendix A). 
 
Lifetime use of any drug is the same as the estimate in the 2005 Focal Point annual 
report but recent and current use has declined from 21.4 per cent and 13.1 per cent 
                                                                                                                                         
37 Results differ slightly from standard table (ST)01 as it was provided on an EMCDDA basis 
and refers to 16 to 64 year olds not 16 to 59 year olds.  For comparison with results from 
previous surveys, 16 to 59 year olds have been used here. 
38 The total sample size for NICS 2003/04 was 2,121 and for NICS 2005, 2,381. 
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respectively.  As with the adult population, the decrease in recent and current drug 
use is largely attributable to a fall in cannabis use.   
 
Amongst 16 to 24 year olds the use of illicit drugs is higher still.  In the United 
Kingdom it is estimated that: 
• 45.2 per cent have ever used drugs; 
• 24.5 per cent have used drugs recently; and 
• 14.6 per cent are current drug users (Table A.3, Appendix A). 
 
Recent and current use are lower than in the 2005 estimate.  
2.3.2 England and Wales: the British Crime Survey 
Findings from the 2007/08 British Crime Survey show that 17 per cent of 16 to 34 
year olds have used drugs in the last year.  The most commonly reported drug was 
cannabis followed by cocaine and ecstasy (Table 2.4).  Males (22.5%) were almost 
twice as likely to be recent drug users as females (11.6%) and the difference 
increased amongst 25 to 34 year olds; 7.7 per cent of females aged 25 to 34 
reported any drug use compared to 19.2 per cent of males.39  Amongst 16 to 24 year 
olds, drug use is higher, 21.3 per cent reported recent drug use with cannabis again 
the most commonly used drug.  
Table 2.4: Percentage of 16-24 year olds and 16-34 year olds reporting last year use of 
individual drugs in England and Wales, 2007/08 by gender 
16-24 year olds 16-34 year olds 
 Male Female Total Male Female Total 
Any drug 26.3 16.4 21.3 22.5 11.6 17.0 
Amphetamines 2.6 2.1 2.4 2.2 1.5 1.8 
Cannabis 22.5 13.3 17.9 18.6 9.2 13.8 
Cocaine  6.8 3.3 5.0 6.3 2.9 4.5 
Ecstasy 5.2 2.6 3.9 4.3 1.9 3.1 
LSD 0.9 0.4 0.7 0.8 0.3 0.6 
Magic mushrooms 2.0 0.5 1.2 1.5 0.5 1.0 
Base  2,711 3,056 5,767 4,446 5,385 9,831 
Source: Standard Table prepared for the United Kingdom Focal Point 
Trends in drug use 
Recent use of any drug amongst 16 to 34 year olds decreased from 22.2 per cent in 
2002/03 to 17.0 per cent in 2007/08 (Figure 2.2).  Over the same period cannabis 
use has fallen from 20.0 per cent to 13.8 per cent.  Recent use of magic mushrooms 
increased to 2.2 per cent in 2004/05 falling steadily to 1.0 per cent in 2007/08.  Any 
cocaine use increased from 4.3 per cent to 5.4 per cent in 2006/07 but fell to 4.5 per 
cent in 2007/08. 
                                                
39 See Standard Table 01 for England and Wales 
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Figure 2.2: Percentage of 16 to 34 year olds reporting having used drugs in the last year in 
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Source: Standard Tables prepared for the United Kingdom Focal Point 
 
Amongst 16 to 24 year olds, the decreases seen since 2001/02 have continued in 
2007/08 (Figure 2.3).  Overall the proportion of 16 to 24 year olds reporting use of 
any drugs in 2007/08 is 21.3 per cent compared with 29.7 per cent in 1996 and 31.8 
per cent in 1998.  Since 1996 use of cannabis, amphetamines, magic mushrooms, 
ecstasy and LSD has decreased significantly while cocaine use has increased and all 
other drug use has remained broadly stable.  Between 2006/07 and 2007/08 there 
were significant decreases in the use of cannabis, ecstasy and amphetamines while 
increases in cocaine use over the last two years have not continued, with recent 
cocaine use remaining stable between 2006/07 and 2007/08.   
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Figure 2.3: Percentage of 16 to 24 year olds reporting having used drugs in the last year in 
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Source: Kershaw et al. 2008 
Frequency of Use 
Questions on frequency of use in the BCS have been completed by 16 to 24 year 
olds only since 2002/03.  Frequent use (defined as use of any drug more than once a 
month in the past year) among 16 to 24 year olds has decreased significantly since 
2003/04 (Table 2.5).   
Table 2.5: Frequent use: percentage of 16 to 24 year olds (all respondents) who have used 
any drug more than once a month in the past year in England and Wales, 2002/03 to 2007/08 
 Year 
 2002/03 2003/04 2004/05 2005/06 2006/07 2007/08 
Frequent use (%) 11.6 12.4 10.3 9.5 8.3 7.3* 
Base 3,311 5,234 6,070 5,768 5,577 5,630 
*Statistically significant change 2002/03 to 2007/08 
Source: Hoare and Flatley 2008 
 
Frequency of use differs with individual drug, 37 per cent of recent cannabis users 
reported frequent drug use compared to 23 per cent of recent cocaine powder users 
and 13 per cent of recent ecstasy users.  Hallucinogens were least likely to be used 
frequently, three per cent reported frequent use.  
Lifestyle and drug use amongst 16 to 24 year olds 
Regular nightclub goers (four or more time in the last month) were more than twice 
as likely to be recent drug users as those who had not visited a club in the last 
month, 33 per cent compared to 16 per cent.  The BCS also found that any drug use 
in the last year increases as the frequency of pub visits increases or the frequency of 
drinking alcohol increases.  Similar results were found for frequent drug use. 
2.3.3 Drug Prevalence Survey in Northern Ireland 2006/07 
Nineteen per cent of 15 to 24 year olds reported recent use of any drug.  Cannabis 
was the most commonly reported drug (13.7%) followed by ecstasy (3.7%) and 
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cocaine (2.3%) (Table 2.6).  Unlike the rest of the United Kingdom where recent and 
current use of cocaine amongst 16 to 24 year olds is higher than ecstasy use (Table 
A.3, Appendix A), in Northern Ireland ecstasy use is more commonly reported. 
 
However, amongst young adults aged 15 to 34, recent cocaine use is similar to 
ecstasy use (3.5% compared to 3.4%).  This reflects the higher use of cocaine by 25 
to 34 year olds who are twice as likely to report recent cocaine use as 15 to 24 year 
olds (5.0% compared to 2.3%). The higher prevalence amongst 25 to 34 year olds is 
due to much higher use amongst males in this age group; 8.6 per cent of 25 to 34 
year old males report recent use compared to 1.8 per cent of 15 to 24 year old 
males. Amongst females, 2.8 per cent of 15 to 24 year old females reported recent 
cocaine use compared to 1.4 per cent of 25 to 34 year old females.  An analysis of 
cocaine results from the 2006/07 survey showed that the median age of first cocaine 
powder use was 24 amongst males and 22 amongst females (NACD and PHIRB 
2008b).  These findings are indicative rather than definitive owing to the small 
numbers involved (see Standard Table 01). 
Table 2.6: Percentage of 15-24 year olds and 15-34 year olds reporting last year use of 
individual drugs in Northern Ireland, 2006/07 by gender (DPS) 
Drug 15-24 year olds 15-34 year olds  Male Female Total Male Female Total 
Any drug 25.5 12.2 19.0 24.1 10.4 17.3 
Amphetamines 2.2 1.6 1.9 1.8 1.7 1.7 
Cannabis 17.3 10.0 13.7 16.6 8.1 12.4 
Cocaine  1.8 2.8 2.3 5.0 2.1 3.5 
Ecstasy 4.2 3.1 3.7 4.2 2.6 3.4 
LSD 0.0 0.0 0.0 0.0 0.0 0.0 
Magic mushrooms 0.0 1.2 0.6 0.3 0.6 0.5 
Base  136 163 299 308 406 714 
Source: Standard Table prepared for United Kingdom Focal Point 
2.3.4 Northern Ireland Crime Survey 2006/07 
Findings from the 2006/07 NICS show that: 
• 38.7 per cent of 16 to 24 year olds reported lifetime drug use; 
• 22.0 per cent reported recent drug use; and 
• 9.5 per cent reported current use. 
 
Prevalence of recent and current drug use is greater than that reported in the Drug 
Prevalence Survey in Northern Ireland40 although the pattern of drug use is similar. 
Cannabis is the most commonly reported drug, 17.8 per cent reported recent use, 
followed by ecstasy (3.0%) and cocaine (2.0%).  For current use, however, cocaine 
(1.2%) is the second most reported drug followed by ecstasy and amphetamines 
(each 0.8%). 
 
As in the Drug Prevalence Survey in Northern Ireland, males aged 25 to 34 are more 
likely to be recent cocaine users than those aged 16 to 24, 4.1 per cent compared to 
2.7 per cent.  However, overall drug use is lower for 16 to 34 year olds than 16 to 24 
year olds mainly due to lower use of cannabis (Table 2.7). 
 
                                                
40 It should be noted that the Drug Prevalence Survey in Northern Ireland includes 15 year 
olds, which may lower overall drug prevalence rates. 
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Table 2.7: Percentage of 16-24 year olds and 16-34 year olds reporting last year use of 
individual drugs in Northern Ireland, 2006/07 by gender (NICS) 
Drug 16-24 year olds 16-34 year olds  Male Female Total Male Female Total 
Any drug 25.0 18.8 22.0 20.2 12.1 16.0 
Amphetamines 2.0 0.8 1.4 1.8 0.4 1.1 
Cannabis 19.1 16.0 17.8 15.9 10.2 13.0 
Cocaine  2.7 1.3 2.0 3.6 0.8 2.1 
Ecstasy 3.5 2.5 3.0 3.0 1.1 2.0 
LSD 0.0 0.4 0.2 0.2 0.2 0.2 
Magic mushrooms 1.6 0.0 0.8 0.8 0.0 0.4 
Base  176 166 342 444 476 920  
Source: Standard Table prepared for the UK Focal Point 
Trends in drug use 
Trends amongst young adults are similar to the general adult population.  Unlike in 
England and Wales, cannabis use has not decreased much, making overall drug 
prevalence rates more stable.  Recent ecstasy use has fallen from 4.5 per cent in 
2003/04 to 2.0 per cent in 2006/07, while the use of amphetamines and cocaine has 
also fallen. 
2.3.5 Drug use over the youth-adult transition 
A study carried out among a cohort in the West of Scotland41 found that lifetime drug 
use rose from 8.9 per cent at age 15, to 31.8 per cent at age 18, and to 57.7 per cent 
at age 23, rising little thereafter (Sweeting and West 2008).  At age 15 respondents 
mostly reported use of cannabis, volatile substances and magic mushrooms but by 
age 18, experience of drugs had widened.  While the greatest increase in lifetime use 
of cannabis occurred between the age of 15 and 18, use of other drugs increased 
most between the age of 18 and 23 and remained stable thereafter.  The use of 
‘hard’42 drugs continued to increase to age 30, largely due to a near doubling of 
lifetime cocaine powder use from 7.2 per cent to 13.4 per cent. 
 
Last year drug use peaked at age 23 (35%) and was similar at age 18 and 30 at 
around 23 per cent.  However, recent use of heroin, methadone and tranquilisers 
increased at age 30 and cocaine powder use almost doubled from 3.2 per cent at 
age 23 to 5.8 per cent at age 30.   
 
The authors conclude that there is considerable transitory use, particularly amongst 
cannabis only users and those initiating later.  They also found that cannabis only or 
other drug use was not higher among those from a lower social class background but 
there was a ‘student effect’; those from a non-manual background in full-time 
education at age 18 were most likely to report cannabis only initiation between age 
18 and 23.  
                                                
41 Data were taken from the youngest cohort of the West of Scotland Twenty-07 Study located 
in a predominantly urban area in and around Glasgow.  The study began in 1987 when the 
cohort were 15, with interviews repeated at age 18 (90% of wave 1 participants), age 23 
(67%), and age 30 (57%).  A total of 499 completed every interview. 
42 ‘Hard’ drugs defined in the study as barbiturates, tranquilisers, heroin, methadone, 
Temgesic, cocaine, crack, morphine, opium and PCP. 
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2.4 Drug use in the school and youth population 
2.4.1 England 
The latest survey of drug use, smoking and drinking in England was undertaken in 
2007 (Fuller 2008).  Key findings are that: 
• 17.3 per cent of 11 to 15 year olds had taken drugs recently and 9.5 per cent 
were current drug users; 
• recent drug use increased with age from 6.1 per cent of 11 year olds to 31.1 per 
cent  of 15 year olds; and 
• the prevalence of recent and current drug use was similar for boys and girls but 
boys were twice as likely to report drug use at the youngest age (age 11). 
 
Table 2.8 shows prevalence figures by drug.  Cannabis was the most commonly 
reported drug for recent and current use although pupils were more likely to report 
lifetime use of volatile substances.  Boys were more likely than girls to have ever 
used cannabis although the difference is less pronounced with recent and current 
use.  Girls were more likely to report use of stimulants, 7.4 per cent of girls reported 
recent use compared to 6.4 per cent of boys.  Use of cocaine powder, 
amphetamines, ecstasy and volatile substances was higher for girls across all recall 
periods.  
 
It should be noted that amyl nitrate (‘poppers’), while not reported in EMCDDA 
standard tables, is included in the ‘any drug’ figure shown and is the third most used 
drug (4.9% reporting recent use). 
Table 2.8: Percentage of pupils reporting use of individual drugs in the last month, in the last 
year and in lifetime, by gender in England, 2007  
Drug Lifetime use Last Year use Last Month use  Male Female Total Male Female Total Male Female Total 
Any drug 26.0 24.3 25.2 17.6 17.0 17.3 9.7 9.3 9.5 
Amphetamines 1.1 1.6 1.3 0.9 1.2 1.0 0.5 0.5 0.5 
Cannabis 12.1 10.9 11.5 9.6 9.2 9.4 5.4 5.0 5.2 
Cocaine powder 2.0 2.6 2.3 1.6 2.1 1.8 0.8 1.1 0.9 
Crack cocaine 1.3 1.6 1.4 1.0 1.0 1.0 0.4 0.4 0.4 
Ecstasy 1.7 1.9 1.8 1.0 1.6 1.3 0.5 0.8 0.6 
LSD 0.9 0.8 0.9 0.7 0.6 0.6 0.2 0.2 0.2 
Magic mushrooms 2.1 1.6 1.9 1.2 1.1 1.2 0.4 0.4 0.4 
Opiates 0.8 1.0 0.9 0.5 0.9 0.7 0.2 0.5 0.4 
Volatile substances* 12.7 14.2 13.5 5.6 6.8 6.2 2.4 2.8 2.6 
Base 4,064 3,749 7,813 4,064 3,749 7,813 4,064 3,749 7,813 
*includes glues, gas, aerosols and solvents 
Source: Fuller 2008 
Age  
Recent drug use sees the greatest increase between the age of 13 and 14 and 
continues to increase at age 15 (Table 2.9).   
Table 2.9: Percentage of pupils reporting use of individual drugs in the last year, by age in 
England, 2007  
 11 yrs 12 yrs 13yrs 14yrs 15yrs Total 
Boys 7.8 8.2 11.1 24.5 31.9 17.6 
Girls 4.4 7.1 13.8 23.9 30.3 17.0 
Total 6.1 7.7 12.4 24.2 31.1 17.3 
Base (boys) 615 881 829 807 932 4,064 
Base (girls) 596 747 798 715 893 3,749 
Base (total) 1,211 1,628 1,627 1,522 1,825 7,813 
Source: Fuller 2008 
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Trends in drug use 
Recent and current drug use has fluctuated in recent years but the overall trend since 
2001 is downwards (Figure 2.4). 











Source: Fuller 2008; Standard Tables prepared for United Kingdom Focal Point 
 
The recent use of cannabis continues to fall, driving the overall reduction in recent 
drug use since 2003 (Table 2.10).  The use of ecstasy and amphetamines fell slightly 
in 2007, both drugs to below 2001 levels, but cocaine powder use has increased.  
The use of magic mushrooms has continued to fall while LSD use has remained 
relatively stable.  The increase in drug use in 2007 seems to be largely attributable to 
an increase in volatile substance use in 2007; the use of any drug excluding volatile 
substances remained stable at 13.4 per cent in 2006 and 13.3 per cent in 2007. 
Table 2.10: Percentage of pupils reporting last year use of individual drugs in England, 2001 
to 2007 
 2001 2002 2003 2004 2005 2006 2007 
Any Drug 20.4 19.7 21.0 17.6 19.1 16.5 17.3 
Amphetamines 1.1 1.2 1.2 1.3 1.2 1.2 1.0 
Cannabis  13.4 13.2 13.3 11.3 11.7 10.1 9.4 
Cocaine powder 1.2 1.3 1.3 1.4 1.9 1.6 1.8 
Crack cocaine 1.1 1.0 1.2 1.1 1.0 0.8 1.0 
Ecstasy 1.6 1.5 1.4 1.4 1.5 1.6 1.3 
LSD 0.7 0.7 0.6 0.7 0.6 0.7 0.6 
Magic Mushrooms 2.1 1.5 2.1 2.0 1.8 1.4 1.2 
Opiates 0.8 0.8 0.9 0.7 0.9 0.7 0.7 
Volatile substances* 7.1 6.3 7.6 5.6 6.7 5.1 6.2 
Base  9,357 9,830 10,371 9,666 9,174 8,132 7,813 
*includes glues, gas, aerosols and solvents 
Source: Fuller 2008 
Frequency of use 
The proportion of pupils who usually take drugs as least once a month was five per 
cent in 2007, compared with four per cent in 2006, but a decrease from seven per 
cent in 2003.  Of those pupils who had taken drugs in the last year, 34 per cent 
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reported use at least once a month with girls slightly more likely to report frequent 
use than boys (35% compared to 33%).  The proportion of pupils reporting use of 
drugs on only one occasion was 29 per cent with younger pupils twice as likely to 
report use only once compared with older pupils (46% of 11 to 12 year olds who had 
taken drugs in the last year compared to 22% of 15 year olds) 
TellUs2 Survey 
The TellUs2 Survey43 carried out in Spring 2007 asked Year 8 (aged 12 to 13) and 
Year 10 pupils (aged 14 to 15) in England about their drug use (Ofsted 2007). 
Results show that: 
• 80 per cent had never used drugs 
• nine per cent reported current use of cannabis; and 
• three per cent reported current use of other drugs (excluding solvents) 
 
Current cannabis use was more prevalent amongst Year 10 pupils with 13 per cent 
reporting current use compared to four per cent of Year 8 pupils.  This is higher than 
in Fuller (2008). 
2.4.2 Northern Ireland 
The latest Young Person’s Behaviour and Attitudes Survey (YPBAS) was carried out 
in 2007 amongst 12 to 16 year olds.  Headline figures were published in a Bulletin in 
2008 (NISRA 2008a).  Key findings are that: 
• 19.3 per cent of pupils had ever used drugs; 
• 13.7 per cent had used drugs recently; and 
• 7.7 per cent reported current drug use. 
 
The most commonly reported drug across all recall periods was cannabis followed by 
solvents, and cocaine (Table 2.11).  Prevalence of any drug use is lower than in 
England largely due to lower levels of cannabis and volatile substance use.  
However, use of stimulants such as cocaine, amphetamines and ecstasy are similar 
or higher.  It must be noted that the survey in England includes 11 year olds, which 
may affect comparability. 
Gender 
There were no significant differences between males and females in the various drug 
prevalence rates across all recall periods. 
                                                
43 The TellUs2 survey was a survey of children and young people across England, asking 
about their views about their local area and including questions covering the five Every Child 
Matters outcomes.  111,325 responses were received from children in Year 6, 8 and 10.  Only 
those in Year 8 and Year 10 answered questions on drug use. 
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Table 2.11: Percentage of pupils reporting use of individual drugs in the last month, in the last 
year and in lifetime, by gender in Northern Ireland, 2007  
Drug Lifetime use Last Year use Last Month use  Male Female Total Male Female Total Male Female Total 
Any drug 19.4 19.3 19.3 13.7 13.8 13.7 8.0 7.4 7.7 
Amphetamines 1.6 2.0 1.8 1.0 1.1 1.0 0.4 0.4 0.4 
Cannabis 10.0 8.7 9.3 7.3 6.6 6.9 4.3 3.4 3.9 
Cocaine  3.2 4.2 3.7 2.6 2.9 2.7 1.4 1.2 1.3 
Cocaine powder 2.1 3.2 2.6 1.6 2.2 1.9 1.0 0.8 0.9 
Crack cocaine 1.3 1.9 1.6 1.1 1.2 1.1 0.6 0.6 0.6 
Ecstasy 2.8 3.0 2.9 2.2 2.4 2.3 1.1 1.3 1.2 
LSD 1.3 2.0 1.6 0.8 1.1 1.0 0.4 0.5 0.4 
Magic mushrooms 1.6 1.0 1.3 0.9 0.6 0.7 0.4 0.3 0.3 
Opiates 0.9 1.3 1.1 0.7 0.6 0.6 0.4 0.3 0.4 
Solvents  8.5 8.6 8.5 4.6 4.6 4.6 2.4 2.1 2.3 
Base 1,664 1,558 3,225 1,664 1,558 3,225 1,664 1,558 3,225 
Source: Standard Table prepared for United Kingdom Focal Point 
Age of first use 
Fifty-six per cent of those who had ever used cannabis started at age 13 or 14 with 
14 per cent first using cannabis at age 12 and less than ten per cent reporting 
cannabis use at a younger age (NISRA 2008b).  Almost a third (32%) of pupils first 
tried solvents before the age of 12 while the majority of cocaine powder users (70%) 
first used the drug at age 14 or older. 
Frequency of cannabis use 
Forty-one per cent of pupils who reported lifetime use of cannabis do not use any 
more, 24 per cent do so rarely and nine per cent used cannabis a few times a year.  
Twenty-six per cent used cannabis at least a few times a month with five per cent 
reporting daily cannabis use. 
2.4.3 Scotland 
Health Behaviour in School-aged Children Survey – cannabis use 
Results from the 2006 Health Behaviour in School-aged Children (HBSC) Survey 
have been published (Currie et al. 2008).44 Twenty-eight per cent of 15 year olds and 
seven per cent of 13 year olds reported lifetime use of cannabis.  Twenty-two per 
cent of 15 year olds and five per cent of 13 year olds reported recent cannabis use 
with 13 per cent and three per cent reporting current use respectively.   
Frequency of use 
Fifteen year old pupils were asked about the frequency of cannabis use.  The survey 
found that: 
• eight per cent can be classified as ‘experimental’45 users;  
• 10 per cent can be classified as ‘regular’ users; and 
• three per cent can be classified as ‘heavy’ users. 
Schools Adolescent Lifestyle and Substance Use Survey (SALSUS) 
Results from the 2006 SALSUS were reported in the 2007 Focal Point Report. 
Information Services Division (ISD) Scotland is currently commissioning for the 2008 
and 2010 surveys.  The 2010 survey will have a considerably larger sample than 
                                                
44 The school based survey is administered to a nationally representative sample of 1,500 
pupils in each age group; 11 years, 13 years and 15 years.  Questions on drug use are asked 
of 13 year olds and 15 year olds only. 
45 ‘Experimental users’ were those who had used cannabis once or twice in the last year; 
‘regular users’ were those who had used cannabis three to 39 times in the last year and 
‘heavy users’ were those who had used cannabis more than 40 times in the last year. 
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previously (30,000+ compared to 9,000 in 2008) which will be drawn from all schools 
in Scotland.  This will provide estimates at a local level. 
2.4.4 Wales 
The 2006 HBSC Survey report shows that 32 per cent of girls aged 11 to 16 and 30 
per cent of boys aged 11 to 16 reported lifetime cannabis use (WHO 2008).  This is 
higher than in both Scotland and England. 
 
Case and Haines (2008) carried out analysis on the 2003 HBSC Survey in Wales.46  
Forty-three per cent of pupils aged 11 to 16 years old reported lifetime drug use with 
22 per cent reporting recent use.  Lifetime drug use was much higher than in the 
2003 English school survey but recent use was similar.  
2.4.5 Knowledge of drugs amongst young school children 
A survey carried out amongst children aged nine to 11 in England and Northern 
Ireland47 found that more than half the children surveyed (56%) could name four or 
more drugs and this increased with age.  Cocaine was the most widely known drug 
with 71 per cent naming it, 64 per cent naming cannabis and 58 per cent naming 
heroin.  Less than six per cent named speed, solvents and glue and eight per cent 
named magic mushrooms (Life Education Centres 2008). 
2.5 Drug use among specific groups 
2.5.1 Armed Forces 
Compulsory drug testing in the Armed Forces was introduced by the Armed Forces 
Act 1996.48  Around 85 per cent of servicemen and women are tested annually 
(House of Commons Written Answers, 10th May 2006).  The proportion of individuals 
testing positive for drugs has increased from 0.62 per cent in 2003 to 0.98 per cent in 
2007 (Table 2.12), with the Army accounting for the vast majority of positive tests 
(92.6 per cent).  Over the same period, in the British Army there has been a 
decrease in the proportion of positive tests involving cannabis and a large increase in 
those involving cocaine; in 2003, 50 per cent of positive tests were for cannabis only 
and 22 per cent for cocaine only while in 2006, the figures were 31 per cent and 47 
per cent respectively.  This trend continued in the first half of 2007, with 25 per cent 
of positive tests for cannabis alone and 49 per cent for cocaine alone (Bird 2007). 
The proportion of positive tests that are for ecstasy alone has decreased from 20 per 







                                                
46 An opportunity sample of 3,088 pupils aged 11 to 16 was drawn from a random sample of 
22 secondary schools (10% of all schools in Wales) between September and December 
2003. 
47 The survey was carried out with 1,491 children aged 9 to 11 in England and Northern 
Ireland in April and May 2008.  Thirty schools were originally identified through local contacts 
and mapped against indices of deprivation to ensure a reasonable spread. Twenty-five 
returned questionnaires. 
48 EMCDDA reporting guidelines ask for information on conscripts. There is, however, no 
conscription (compulsory military service) in the United Kingdom. 
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Table 2.12: Drug tests and percentage positive in the British Armed Forces, 2000 to 2007 





2000 107,142 760 0.71
2001 96,504 705 0.73
2002 89,585 567 0.63
2003 95,376 594 0.62
2004 88,747 705 0.79
2005 91,711 863 0.94
2006 92,275 844 0.91
2007 74,522 731 0.98
Source: MOD 2006; House of Commons Written Answers, Tuesday 25th March 2008 
2.5.2 Ethnic Minorities 
Findings from the 2007/08 BCS in England and Wales show that people who 
described themselves as non-White were significantly less likely to be recent drug 
users than those who described themselves as White; five per cent compared to 10 
per cent.  Amongst 16 to 24 year olds the difference is much larger, eight per cent of 
non-White respondents were recent drug users compared to 23 per cent of White 
respondents (Hoare and Flatley 2008). 
2.5.3 Truants and Excludees 
Pupils in England who had ever truanted or been excluded are much more likely to 
be regular drug users, 14 per cent of truants and excludees reported drug use at 
least once a month compared to two per cent of other pupils.  There has, however, 
been a decrease in the proportion reporting regular drug use from 21 per cent in 
2003 (Fuller 2008). 
2.5.4 Health care professionals 
Raistrick et al. (2008) report on a survey of substance use amongst NHS staff in one 
NHS Region in England.49  Eleven per cent reported recent use of any drug, with use 
highest amongst nurses (11.6%) and lowest amongst health care assistants (8.8%).  
Cannabis was the most commonly used drug (8.6%) followed by 
ecstasy/amphetamines (2.5%) and tranquilisers (1.9%).  Opiate use was reported by 
0.9 per cent of respondents.  The authors report that drug use amongst health care 
professionals is similar to drug use in the general population. 
2.5.5 Lesbians, Gay Men and Bisexuals 
A survey of lesbian and bisexual women’s health50 found that lesbian and bisexual 
women were five times more likely to report recent drug use than women in general, 
30 per cent reported recent use compared to seven per cent in the BCS 2006/07 
(Stonewall 2008).   
 
                                                
49 A cross-sectional survey of health care professionals in Yorkshire Region in England was 
undertaken. The target sample consisted of qualified nurses and midwives, health care 
assistants and medical staff working in secondary care services where contact where 
substance misuse patients is particularly likely.  Fifteen wards or departments were randomly 
selected from the six health authorities and all staff asked to complete a questionnaire.  A 
total of 2,716 staff were targeted, 1,141 (42%) responded and 1,116 included their profession. 
50 In the summer of 2007, 6,178 lesbian and bi-sexual women in England, Scotland and 
Wales responded to an online and paper survey on their health needs and experiences.  The 
age range of respondents was 14 to 84. 
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Questions on drug use are included every two years in the Gay Men’s Survey.  
Results from the 2005 survey were published in the Focal Point’s 2007 Annual 
Report.  A survey was carried out in 2007 and will be published in Spring 2009. 
2.5.6 Looked after children 
In 2006, the Department for Children, Schools and Families (DCFS) (formerly the 
Department for Education and Skills) started collecting information on the number of 
looked after children identified as having a substance misuse problem.  Of the 44,200 
children looked after for at least 12 months in the year ending 30th September 2007, 
2,400 (5.4%) were identified as having a substance misuse problem (DCSF 2007). 
This is a slight increase from 5.1 per cent in 2006. 
2.6 Attitudes to and reasons for drug use  
The 2007 school survey in England found that 10 per cent of pupils think it is “okay to 
try cannabis to see what it’s like” with six per cent believing it’s okay to use cannabis 
once a week (Fuller 2008).  Older pupils were more likely to think cannabis use was 
okay, 23 per cent of 15 year olds thought it was okay to try, and 13 per cent to use 
weekly.  Only three per cent thought trying cocaine was okay compared to four per 
cent in 2003 despite an increase in use over the same period. 
 
Fifty-five per cent of pupils who had ever taken drugs said they did so on the first 
occasion to see what it was like, 18 per cent said they wanted to get high or feel 
good and 17 per cent said because their friends did.  Of those who had used drugs 
recently and on more than one occasion, 43 per cent said they did so because they 
wanted to get high or feel good, with 29 per cent saying they wanted to see what it 
was like and 21 per cent saying they had nothing better to do. 
2.7 Relationship with other indicators and trends in a wider context 
Consistency between indicators is discussed in the introductory section of this report 
and the relationship between general prevalence data, treatment demand data and 
problem drug use estimates is discussed in Section 4.6. 
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3. Prevention  
3.1 Overview  
Prevention of young people’s drug use is a key element of drug strategies in the 
United Kingdom.  Family interventions, education, regeneration of communities and 
tackling social exclusion and poverty are the main aspects of prevention.  Policies 
are embedded in, or complemented by, a much wider framework of social action to 
create the capacity of both individuals and communities to resist drugs, including 
policy for children and young people, aimed at enabling them to reach their full 
potential.  In England, a new Children’s Plan aims to facilitate this (DCSF 2007). The 
devolved administrations have similar documents, specifically Getting it Right for 
Every Child and Delivering a Healthy Future: An Action Framework for Children in 
Scotland (Scottish Executive 2006a;2007a); and Children and Young People: Rights 
to Action (Welsh Assembly Government 2004) in Wales.  In Northern Ireland, Our 
Children and Young People – Our Pledge: A 10 year strategy for children and young 
people in Northern Ireland, 2006-2016 (OFMDFMNI 2006) sets a framework for 
addressing the needs of young people.  Improved education and interventions for 
young people and families (especially those most at risk) and improved public 
information about drugs are priority areas.   
 
Universal drug prevention initiatives are an important area of policy.  Communication 
programmes, such as FRANK in England and Know the Score in Scotland, provide 
factual information and advice to young people and their families.  In Northern 
Ireland, the Health Promotion Agency develops public information campaigns for 
various target groups and settings, and in Wales a bilingual (Welsh and English) 
helpline, Dan 24/7, is available.  Throughout most of the United Kingdom, drug 
prevention is part of the national curriculum and the majority of schools have a drug 
education policy and guidelines around dealing with drug incidents.  Guidance on 
drug education recommends an approach that incorporates all psychoactive 
substances, including alcohol and tobacco, and places drugs education within the 
wider health and social education agenda. 
 
In England and in Wales, all local areas are expected to produce Children’s and 
Young People’s Plans for all services for children and young people, including 
prevention and treatment.  In Scotland, an Integrated Children's Services Planning 
Framework requires a single plan agreed with all relevant agencies to deliver 
integrated services for children and young people.  Current policy acknowledges that 
some groups of young people are more vulnerable to substance misuse problems 
than their peers and suggests more needs to be done for these young people.   
 
Communities are provided with assistance to build the capacity to resist drugs, 
through a range of initiatives which are delivered by local partnerships.  There are 
specific interventions targeting young people in deprived communities, for example, 
Positive Futures.  In Scotland, a number of projects receive time limited funding from 
the Scottish Government in partnership with Lloyds TSB Partnership Drugs Initiative 
(PDI)51, targeting children with, or at risk of, problem drug misuse, as well as those 
affected by familial drug use.  
 
Increasingly, family interventions are being set up, more specifically for problem drug 
users, to help support parenting, and therefore reduce the risk of drug use amongst 
their children, but also with wider objectives (see Chapter 9). 
                                                
51 See: http://www.ltsbfoundationforscotland.org.uk/index.asp?tm=16&cookies=True  
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3.2 Prevention Strategy  
3.2.1 New drug strategies  
Drugs: Protecting Families and Communities continues its commitment to prevention 
of drug use, particularly amongst the young (HM Government 2008a).  A key aim is 
to reduce the numbers of young people that start using drugs, with a commitment to 
expand drug prevention work to encompass younger people and families before they 
have problems.  Prevention will also focus on legal substances such as alcohol as 
well as volatile substance abuse.  The Government has pledged to strengthen the 
evidence base regarding the risk factors associated with substance misuse and the 
most effective interventions (HM Government 2008b). 
 
The Scottish Government’s drug strategy, The Road to Recovery: a New Approach 
to Tackling Scotland’s Drug Problem is based on the premise that prevention of drug 
use is preferable to the treatment of problem drug use at a later stage.  Provision of 
drugs information and effective communication, with the general public and young 
people in particular, is seen as a vital component.  Importance is also placed on early 
interventions and the Scottish Government is to develop an Early Years Framework 
in order to help the development of children and provide integrated support services.  
It also suggests that wider policies, currently under development, such as a new 
Economic Strategy are also necessary in order to have an impact on prevention 
(Scottish Government 2008a). 
 
The Welsh substance misuse strategy, Working Together to Reduce Harm: the 
Substance Misuse Strategy for Wales 2008-2018, also identifies prevention as a key 
area with a continued focus on education, and early interventions for the most at-risk 
children (Welsh Assembly Government 2008a).  
3.3 Universal prevention  
Universal prevention targets the entire population, regardless of individual levels of 
risk, at national, local community, school, or neighbourhood level with programmes, 
initiatives and messages aimed at preventing or delaying the onset of illicit drug use. 
3.3.1 Universal prevention campaigns  
Drugs: Protecting families and communities states that its communications will 
highlight the consequences and damage that can result from substance use and that 
it will send out the message that drug use is “unacceptable”.  It aims to develop 
communication and education campaigns that involve the community, young people 
and families (HM Government 2008a).   
FRANK 
The FRANK campaign has now been running for five years and the Government has 
stated its continued commitment to it (HM Government 2008a).  Following on from 
last year’s ‘Brain Warehouse’ cannabis campaign52, which was reported to have 
reached 67 per cent of young people and 56 per cent of adults through its television 
adverts (Home Office 2007b)53, it has recently launched a €1.5 million (£1m) multi-
                                                
52 The 'Brain Warehouse' advert was launched in October 2006.  The 'Brain Warehouse' 
theme was carried through online and with advertising on bus shelters and in buses.  The TV 
advert accompanied several radio adverts that carried a mix of cannabis related messages.  
See: http://www.brainwarehouse.tv/  
53 During February and March 2007 a total of 1607 face-to-face interviews were conducted 
with 471 parents of 11 to 18 year olds and 1226 young people aged between 11 and 24.  
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media campaign aimed at tackling cocaine powder use.54  This includes the 
publication of an information leaflet aimed at 15 to 18 year olds to raise awareness of 
the health and ethical issues surrounding cocaine powder use.  It forms part of a 
wider government initiative specifically focusing on the drug and is part of the Shared 
Responsibility55 campaign involving the Colombian government.  In addition to 
highlighting the personal and social consequences of cocaine powder consumption, 
the campaign also has an ethical component, focusing on the effects cocaine 
production has on the environment, such as the clearing of rainforests and pollution, 
as well as the human rights issues that it raises.   
 
FRANK has also produced a series of information materials in partnership with the 
Mentoring and Befriending Foundation including a pocket sized card entitled Safety 
First: Advice Card for mentors and befrienders56, containing advice on what to do in 
an emergency, such as how to place someone in the recovery position.  There are 
also information materials aimed at professionals who are involved in mentoring and 
befriending projects with young people.  
 
In Northern Ireland, the Health Promotion Agency57 has re-published a series of drug 
awareness leaflets and booklets originally released in 2006.  The campaign includes 
a booklet entitled ‘Your body, your life, your choice’ aimed at 14 to 17 year olds.  It 
provides information on different types of drugs and their effects, health risks, the law 
and contact details for the national drugs helpline.  A leaflet aimed at 11 to 13 year 
olds has also been re-issued.  Other communication materials recently re-released 
include a safer clubbing leaflet and leaflets aimed at parents containing drugs and 
solvents information. 
 
In its new drug strategy, the Scottish Government has stated its continued 
commitment to fund and further develop the Know The Score communication 
campaign.  A key aim of the strategy is that no-one should be ignorant of the 
consequences of drugs and that the necessary, factual information regarding drugs 
should be available so that individuals can make informed choices.  It goes on to say 
that this information should also be readily available for family members such as 
parents and grandparents so that they can engage in well-informed dialogues about 
drugs with younger members of the family (Scottish Government 2008a).  
 
In Wales, the Welsh Assembly Government continues to fund its own bilingual 
(Welsh and English) Drug and Alcohol Helpline, DAN 24/7, which is formally hosted 
by the North Wales Mental Health Trust, through its call centre facility.  The helpline 
is structured to provide a range of advice, guidance and information relevant to the 
context of the caller’s needs.  The past 12 months has seen a 50 per cent growth in 
calls with a growing trend linked to families and partners seeking advice. 
 
As part of the Welsh Assembly Government’s new strategy, campaigns linked to the 
promotion of the Helpline are to be introduced throughout the year with an emphasis 
on young people, advice associated with festivals, prisoners and their families, and 
how best to access treatment.  A target figure has been set to double the call volume 
for 2008/09.  These campaigns, allied with a range of leaflets and posters will also 
use web-based technology, texting and news-media to promote the helpline and its 
purpose.  The underlying ethos of the helpline is to make access to information easy, 
                                                
54 See: http://drugs.homeoffice.gov.uk/publication-search/frank/cocaine?view=Binary  
55 See: http://www.sharedresponsibility.gov.co/   
56 See: http://drugs.homeoffice.gov.uk/publication-
search/frank/safetyfirst?view=Standard&pubID=546481  
57 See: http://www.healthpromotionagency.org.uk/work/Drugs/publications.htm  
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simple and clear. In partnership with the service provider, the Welsh Assembly 
Government will be enhancing the skills of the call centre staff in order to equip them 
with the capacity to offer direct advice associated with safe drug and alcohol use and 
how best to get help when problems begin to arise (internal communication from the 
Welsh Assembly Government). 
3.3.2 School  
Review of drugs education in England 
A Department for Children, Schools and Families (DCSF) review of drugs education 
in England is currently in progress and once it is complete it is anticipated that the 
FRANK campaign will be developed to complement any changes made to drugs 
education in schools (HM Government 2008a). 
Blueprint Drug Education Research Programme  
A research report into the delivery of the Blueprint Drug Education Research 
Programme was published in November 2007.  In the report, the programme was 
assessed to establish if the different Blueprint components (namely: schools; 
parents; media; health policy; and community) were delivered as originally intended 
and to identify the factors that had a positive or negative influence on delivery.  It was 
found that delivery against the planned programme varied across the components.  
Delivery of the parent component was not as originally intended and only partially 
met the aim; the coverage from the media component reached between a fifth and a 
quarter of young people and parents respectively.  However, the majority of the 
school based lessons were delivered according to the original content and methods 
(Stead et. al 2007).  A further report aimed at practitioners and teachers has been 
published (Stradling et. al 2007).  An impact report is expected in late 2008. 
Drug, alcohol and tobacco education in schools in Scotland 
Scotland is currently undertaking a programme of education reform as part of the 
Curriculum for Excellence programme.  Guidance on teaching and learning around 
substance misuse forms part of the Health and Wellbeing learning outcomes and 
experiences, released in draft in May 2008 as part of Curriculum for Excellence.58  
Substance Misuse Education Steering Group 
The Welsh Assembly Government will establish a national substance misuse 
education steering group of experts and key stakeholders to monitor the delivery of 
this element of the new substance misuse strategy. The group will oversee the 
further development of substance misuse education, prevention and advice provision 
in schools and other educational settings (Welsh Assembly Government 2008a). 
All Wales School Liaison Core Programme 
The All Wales School Liaison Core Programme is delivered in partnership between 
the police and schools to mainstream pupils in education.  It became fully operational 
in 2004.  A second external evaluation of the programme was undertaken in 2007 
(Markit Training and Consultancy Ltd. 2007).  It assessed pupils on eight specific 
criteria using a model adapted from police training programmes, called KUSAB 
(considering pupils’ knowledge, understanding, skills, attitudes, behaviour, continuity 
and progression, coherence, and enjoyment of the substance use related education 
delivered within the programme) to give an indication of the knowledge and 
understanding gained as they experience it.  The results found that pupils’ knowledge 
and understanding of the subject matter had increased and that in general they 
                                                
58 For more information see Learning and Teaching Scotland, which is funded by the Scottish 
Government and is the main organisation for the development of the Scottish curriculum, 
including Curriculum for Excellence: http://www.ltscotland.org.uk/aboutLTS/ 
UNITED KINGDOM FOCAL POINT REPORT 2008  
 55
enjoyed the lessons.  Teachers were also generally positive about the programme.  
However, the evaluation was unable to quantify the programme in terms of its impact 
on pupils’ attitude and any future behaviour change.   
 
To achieve greater effectiveness, the programme has been extended in order to 
develop positive relationships with pupils that have the potential for disengagement, 
whilst maintaining the commitment to mainstream pupils.  The Disengaged Element 
of the Programme was successfully piloted in five youth crime ‘hot spot’ areas and 
will now be introduced out across Wales.  The client groups are from Pupil Referral 
Units or from units within mainstream schools, at each key stage, for children with 
educational and social behavioural difficulties, although some groups include pupils 
with special educational needs.   
 
It is of note that the United Kingdom Drug Policy Commission argues that generally, 
the evidence for drug education as a strategy for reducing drug use is weak, which 
makes evaluation of outcomes (including unintended consequences) from schemes 
especially important.  It suggests that the final impact report from the Home Office’s 
Blueprint drug education pilot, together with the long-term evaluation of outcomes of 
the All Wales School Liaison Core Programme will help the further development of 
secondary school programmes (UKDPC 2008b). 
Attitudes towards drugs education in schools 
The English school survey 
Nearly two thirds (61%) of secondary pupils in England aged 11 to 15 surveyed in 
2007 (see Chapter 2 for more details) recalled having received lessons about drugs 
in the last year, a similar figure to previous years (Fuller 2008).  Older pupils were 
more likely to recall having had such education (72% of Year 10 pupils compared to 
46% of Year 7 pupils).  Most pupils who remembered the lessons reported that they 
had helped them: think about the risks associated with drugs (95%); find out more 
about drugs (90%); learn that drugs are illegal (84%); and avoid drugs (80%) or think 
what to do if they were offered them (77%).  Just over a third (39%) of pupils thought 
that the lessons showed them that less young people than they thought took drugs 
and it is reported that most pupils had a quite accurate knowledge of how many 
people of their age actually take drugs. 
 
Younger pupils were more likely to say that the lessons helped them avoid drugs, 
think about what to do if offered drugs, realise that drugs are illegal, and see that not 
as many young people as they think take drugs compared to older pupils.  Older 
pupils were more likely to say that lessons helped them find out where to go for help 
or information about drugs.  Perhaps unsurprisingly, pupils who had taken drugs in 
the last month and also recalled having drugs lessons were significantly less likely 
than other pupils to say that the lessons had helped them think about the risks of 
taking drugs, what to do if they were offered them and to avoid taking drugs.  
Northern Ireland Young Persons’ Behaviour and Attitudes Survey 
In Northern Ireland the 2007 Young Persons’ Behaviour and Attitudes Survey 
(NISRA 2008a) (See Chapter 2 for more details) included questions regarding the 
type of drugs education (for example, talks/lessons, packs, leaflets, drama 
workshops, television advertisements) they have received in the past twelve months 
and where they received it.  School was the most popular response with 76 per cent 
of pupils responding that they received it there, a fifth had received it at a youth 
facility (such as a youth club or community centre), 17 per cent said ‘somewhere 
else’ and 15 per cent had not received it in any of these locations.  Pupils were also 
asked whether the education that they had received made them less inclined to take 
drugs.  Of those who responded, 91 per cent said ‘yes’. 
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3.3.3 Family  
The new United Kingdom Drug Strategy proposes to take a whole family approach to 
drug prevention.  It aims to ensure assessments for treatment take the needs of the 
family into account and that additional parenting support will be provided alongside 
drug treatment, including the targeting of drug misusers who have children (and their 
partners) by ‘Family Intervention Projects’59 which will be developed with parenting 
experts.  The Government has placed the early identification of at-risk children and 
families and the provision of suitable interventions as a priority and aims to provide a 
more focussed approach to the needs of the family as a whole and a tailored support 
service.  A package of interventions is proposed including parenting skills; drugs 
education for children; family support to help them stay together; addressing other 
problems; support for kinship carers and in some cases, intensive interventions (HM 
Government 2008a). 
 
Early intervention and therefore prevention of more serious problems, is also an aim 
of drug courts (see Chapter 9.2.5). 
3.3.4 Community 
In Scotland the Government proposes to fund sporting, cultural and arts based 
activities, aimed at young people from communities affected by crime, with money 
recovered through the Proceeds of Crime Act 2002 (Scottish Government 2008a).  
Funding will be targeted at areas with high crime and anti-social behaviour although 
the activities will be open to all children and young people.  The aim is to engage 
young people to engage in participatory and diversionary activities in order to 
increase their chances of gaining positive long-term outcomes.  Around 30,000 
young people across Scotland will be offered free football coaching and playing 
opportunities, as part of the ‘CashBack for Communities’ programme funded from the 
proceeds of crime.60   
Muslim Youth Involvement Project 
Mentor UK has commissioned the Right Start International Foundation to run the 
Muslim Youth Involvement Project61 in England, which will seek the views of young 
Muslims aged between 12 to 18 years old living in Birmingham and Tower Hamlets, 
London.  The aim of the project is to produce a drug prevention toolkit that can be 
used by agencies who are seeking to involve young Muslims.  The project aims to 
develop the skills, confidence, well-being and self esteem of young Muslims by 
engaging with them, gathering their views and providing them with training in areas 
such as group work and communication; drugs prevention; health promotion and 
community participation.  The project will also include activities, such as treasure 
hunts, sports and visits to the Houses of Parliament, which relate to the training and 
will allow participants to enhance their skills and put theory into practice.  
Mentor UK Youth Involvement Project 
The Youth Involvement Project62 has been running since 2005 engaging with young 
people aged 12 to 20 from England and Wales regarding their opinions on drugs.  In 
previous years they have provided input into drugs policy and guidance such as 








62 See: http://www.mentorfoundation.org/projects.php?pg=1&id=103  
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community based interventions to reduce substance misuse amongst vulnerable and 
disadvantaged young people (NICE 2007a). 
3.4 Selective prevention  
Selective prevention initiatives target subsets of the total population that are deemed 
to be at greater risk for substance misuse such as truants or young offenders. 
3.4.1 At risk groups  
Targeted Youth Support and Youth Taskforce Action Plan 
Key actions in Drugs: Protecting Families and Communities include the development 
of local, integrated drug prevention initiatives with vulnerable young people through 
Targeted Youth Support.63  This will be jointly managed by the Home Office and the 
DCSF.  A local focus will be encouraged in order to reduce the proportion of young 
people regularly using drugs.  Activities such as Positive Futures will continue and 
actions from the Aiming High for Young People64 strategy (HM Treasury 2007b) will 
be implemented in order to reduce the risk factors that are associated with drug 
misuse (HM Government 2008b). 
 
The DCSF has launched its Youth Taskforce Action Plan65 in England and has asked 
52 local areas to bid for funding to support delivery of the plan.  Around €19 million 
(£13m) in funding will be available to help deliver ‘Challenge and Support’ projects, 
an early intervention to stop future offenders at the first sign of problems such as 
truancy, bad behaviour in school or contact with the police.  Whilst a key objective of 
the project is to stop antisocial behaviour (ASB) by way of enforcement and support, 
it also aims to address the causes of ASB by utilising Individual Support Orders 
(ISOs)66 alongside Anti-Social Behaviour Orders (ASBOs67).  Whilst an ASBO 
requires the young person to refrain from acting in a certain way, an ISO also 
requires a young person to get help to tackle the cause of their behaviour; including 
drug or alcohol treatment or supervision by a Youth Offending Team worker.  If they 
fail to take that help they face a criminal record and a fine up to €1,500 (£1,000).  
Also, as part of the Youth Taskforce Action Plan, a targeted intensive (non-
negotiable) intervention will be applied to a thousand of the most ‘challenging’ young 
people, whereby they will agree to a contract and a support worker assigned to them 
will ensure that they get the required help to tackle their behaviour.  In cases of bad 
behaviour related to substance misuse, drug treatment would be made available.  
Evaluation toolkit 
The Centre for Public Health68 at Liverpool John Moores University has developed a 
toolkit for practitioners to help them self-evaluate their drug prevention services.  It 
                                                
63 For more information see: http://www.everychildmatters.gov.uk/resources-and-
practice/IG00206/ 
64 See: http://www.hm-treasury.gov.uk/media/2/6/cyp_tenyearstrategy_260707.pdf  
65 The Youth Taskforce was established in October 2007 to take the work of the Respect 
programme to the next stage and put an even greater focus on the twin track approach to 
promote earlier intervention and more positive activities for young people.  
66 ISOs can be attached to an ASBO on a young person and contain positive obligations 
which are designed to tackle the underlying causes of a young person's antisocial behaviour.  
ISOs can last for up to six months. 
67 An ASBO is a civil order that is placed upon an individual in order to protect the public from 
harassment, alarm or distress. They usually contain conditions that prohibit an individual from 
entering a defined area and/or acting in a specified anti-social manner and are effective for at 
least two years. See: 
http://www.crimereduction.homeoffice.gov.uk/antisocialbehaviour/antisocialbehaviour55.pdf  
68 See: http://www.cph.org.uk/substanceuse/index.aspx?teamid=23  
UNITED KINGDOM FOCAL POINT REPORT 2008  
 58 
has been designed to contain all the tools required by practitioners, managers and 
researchers to evaluate services that either they or others provide. The toolkit was 
piloted by a number of services and is currently being developed into an online 
version.  Building on this work, a further resource aimed at academics and/or 
evaluators at a postgraduate level is also under development. 
Inspiring Scotland 
Lloyds TSB Foundation for Scotland (a partnership between Government, trusts and 
foundations, businesses and charities) have developed a new initiative, Inspiring 
Scotland69 with funding and services provided for Scotland's most vulnerable people. 
Although it is currently managed by the Lloyds TSB Foundation it is anticipated that 
this initiative will in the future become a separate legal entity.  
Also, in Scotland, €4.4 million (£3m) will fund additional projects supporting at-risk 
young people and over €2 million (£1.4m) will fund free rugby coaching and playing 
activities for over 30,000 young people throughout the country by 2011.  An 
additional €877,000 (£600,000) will go to the CashBack for Communities Arts and 
Business Match Fund which will be used to support cultural activities for vulnerable 
youngsters. Arts and Business Scotland are encouraging Scottish businesses to 
match every €1.46 (£1) of government investment, in order to double the funding 
available and thereby releasing a minimum of €1.75 million (£1.2m) over the next two 
years. 
High Focus Areas 
An evaluation of some of the prevention initiatives working in High Focus Areas70 has 
been carried out by the Centre for Public Health at Liverpool John Moores University. 
The final report was submitted to the Department of Health in May 2008.  
3.4.2 At risk families 
There are a number of generic early interventions for families and/or children, 
including those families where parental substance misuse is seen as placing children 
at risk (see Chapter 9.2.4).    
3.5 Indicated prevention  
These interventions are designed to prevent the onset of problem drug use in 
individuals who already are experiencing early signs of substance abuse and other 
problem behaviours, including children at risk of individually attributable risk factors 
such as Attention Deficit Hyperactivity Disorder (ADHD).   
NICE: Clinical guideline for ADHD interventions 
The National Institute for Health and Clinical Excellence (NICE) is developing clinical 
practice guidelines for pharmacological and psychological interventions in children, 
young people and adults affected by attention deficit hyperactivity disorder in 
England and Wales.  A consultation period on the draft guideline71 closed at the end 
of March 2008 and the final guideline is due for publication in late 2008. 
                                                
69 See: http://www.inspiringscotland.org.uk/    
70 The High Focus Area (HFA) Initiative was launched in England in April 2005, as part of a 
joint strategy between the Home Office, the Department for Education and Skills and the 
Department of Health, in 30 local authority areas to support faster and sustained progress in 
implementation of universal, targeted and specialist services as set out in strategic guidance 
Every Child Matters: Young People and Drugs, and to learn from their experience.  The areas 
were selected on the basis of local need and levels of current service provision, including 
deprived/high crime areas where drug misuse problems are prevalent.   
71 See: http://www.nice.org.uk/nicemedia/pdf/ADHDConsFullGuideline.pdf  
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4. Problem drug use  
4.1 Overview  
Estimates of problem drug use in the United Kingdom reflect the drugs identified as 
problematic and the methodology used.72  Latest estimates for England are for 
2005/06, for use of opiates and/or crack cocaine (332,090), with additional estimates 
for opiate use (286,566), crack cocaine use (197,568), and drug injecting by users of 
opiates or crack cocaine (129,977).  In Northern Ireland latest estimates are for 2004 
for opiate and/or cocaine (including crack cocaine) use (3,303), with, also, an 
estimate for opiate use (1,395).  In Scotland the latest estimate is for 2003, for opiate 
and/or benzodiazepine use (51,582).  There are no recent estimates for Wales.  
Based on these, it is estimated that there are 403,547 problem drug users in the 
United Kingdom, and 156,398 injecting drug users (primarily of opiates or crack 
cocaine).73  
 
The Treatment Demand Indicator (TDI)74 measures presentations to structured drug 
treatment services by drug users; data are provided for those in contact with general 
practitioners, outpatient (community-based drug services) and inpatient services.  
Numbers presenting have increased substantially over the previous few years but 
appear to have stabilised in this latest reporting year. Latest combined data for the 
United Kingdom are for 2006/07 when there were 128,208 new demands for 
treatment, a small decrease from the previous year (128,446).  Where type of drug is 
known (in 95% of cases), opiates, mostly heroin, were the main primary drug 
reported (64%, n = 77,849).  Cannabis was the second most reported primary drug 
(16%, n = 19,108), and crack cocaine and cocaine powder accounted for seven per 
cent (8,372) and six per cent (7,096) respectively of primary drug reported.  The 
actual number of presentations for opiates as main drug stabilised in 2006/07, having 
increased in the previous year.  The same trend can be seen in presentations for 
primary crack cocaine, however when any use of crack cocaine is considered (not 
only as primary drug) there has been a much steeper rise in presentations, with 24 
per cent of new presentations reporting use.  Similarly with cocaine powder, where 
there has been a continued rise in presentations with 13 per cent reporting any use 
of it in 2006/07.  Presentations for cannabis have increased over time, and continue 
to do so, now representing nearly a quarter of first ever presentations (24%, n = 
11,325).75  Current injecting was reported by 25 per cent; 50 per cent report having 
never injected.  Forty-one per cent were aged between 25 and 34.  Amongst those 
presenting to treatment these characteristics have changed little over recent years. 
4.2 Prevalence and incidence estimates of PDU 
There is no information on incidence of PDUs.  
                                                
72 These are based on the capture-recapture method where possible, and where not, by the 
multiple indicator method. 
73 Estimates of injecting drug users are based on England estimates for opiate and/or crack 
injectors. 
74 The TDI is one of the five epidemiological indicators established by EMCDDA to monitor 
the drug situation in the European Union.  Currently it provides a measure of those presenting 
to treatment, for the very first time, or for the first time within the year.  It does not include 
those who are already in treatment in that year.  It can therefore best be described as a 
measure of treatment incidence. 
75 This could, in part be attributed to improved data reporting by young person’s drug 
services. 
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4.2.1 Prevalence estimates for England for 2005/06 
New estimates of the prevalence of problem drug use in England for 2005/06, 
nationally, and regionally, are from the second yearly sweep of a three-year project 
(Hay et al. 2007).  Estimates are for opiate and/or crack cocaine users, opiate users, 
crack cocaine users and injectors who use opiates and/or crack cocaine (Table 4.1).  
There were an estimated 332,090 problem drug users, a rate of 9.97 per thousand 
population aged 15 to 64; an estimated 286,566 opiate users, a rate of 8.60 per 
thousand population; an estimated 197,568 crack cocaine users, a rate of 5.93 per 
thousand population; an estimated 129,977 injectors who use opiates and/or crack 
cocaine, a rate of 3.90 per thousand population.  These suggest that national 
prevalence estimates for problem drug use have remained stable across the two 
years.  As in the previous sweep these latest estimates show marked variation in 
prevalence rates across Government Regions as well as distinct differences in 
prevalence by gender (Table 4.2) and age (Table 4.3). 
Table 4.1: Problem drug user estimates and rates per 1,000 population aged 15 to 64 in 
England, 2005/06 
 Estimate 95% Confidence Interval Rate 
95% Confidence 
Interval 
Opiate and/or crack cocaine 
users 332,090 324,546 – 346,345 9.97 9.74 –10.40
Opiate users 286,566 281,668 – 299,394 8.60 8.46 – 8.99
Crack cocaine users 197,568 190,786 – 208,322 5.93 5.73 – 6.25
Injecting drug users 129,977 125,786 – 137,034 3.90 3.78 – 4.11
Source: Hay et al. 2007 
Regional differences 
London had the highest prevalence of problem drug users, followed by Yorkshire and 
Humber and then the North West, although for opiate users and for injecting opiate 
and/or crack cocaine users Yorkshire and Humber was higher than London.  
Compared to other areas crack cocaine use was exceptionally high in London.  The 
East of England followed by the South East had the lowest prevalence estimates for 
all types of drug users (Hay et al. 2007). 
Gender  
The male to female ratio of problem drug users was 3.3:1 (Table 4.2). 
Table 4.2: Prevalence rate per 1,000 population of opiate and/or crack cocaine users by 
gender in England, 2005/06 
Female Male 
Rate 95% CI Rate 95% CI 
4.64 4.61 4.99 15.32 14.86 15.87 
Source: Hay et al. 2007 
Age 
The highest prevalence of problem drug was amongst those in the 25 to 34 age 
group (Table 4.3). 
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Table 4.3: Prevalence rate per 1,000 population of opiate and/or crack cocaine users by age 
group in England, 2005/06 
Age 
15 to 24 years 25 to 34 years 35 to 64 years 
Rate 95%CI Rate 95% CI Rate 95% CI 
10.07 9.85 10.66 21.43 20.76 22.24 6.10 5.96 6.39 
Source: Hay et al. 2007 
Trends  
The prevalence estimates per thousand population changed from 9.93 in 2004/05 to 
9.97 per thousand in 2005/06, this is not statistically significant.  There was no 
change in prevalence of opiate use and of crack cocaine use.  However, there was a 
statistically significant reduction in the prevalence of injectors of opiates and/or crack 
cocaine; the rate per thousand falling from 4.16 in 2004/05 to 3.90 in 2005/06.  
 
At the regional level there were no significant changes in problem drug use between 
2004/05 and 2005/06 in estimated prevalence rates for all problem drug users, nor 
was there a significant change to the estimated prevalence of crack cocaine use 
(Hay et al. 2007).  There was, however, a significant reduction in the prevalence of 
opiate use in the South West region and in injecting of opiates and/or crack cocaine 
in the North East and the West Midlands.  
4.2.2 Estimates of problem drug use in the United Kingdom 
Estimates of problem drug use provided by the United Kingdom Focal Point are 
based on the latest available research in the four countries (Hay et al. 2004; Hay et 
al. 2006a; Hay et al. 2006b; Hay et al. 2007).  These suggest an overall prevalence 
of 403,547 problem drug users, a rate of 10.19 per thousand population (Table 4.4) 
and 156,398 injecting drug users (predominantly of opiates and crack cocaine), a 
rate of 3.95 per thousand population (Table 4.5). 
Table 4.4: Estimates of problem drug use in the United Kingdom: number and rate per 1,000 
population  
Country Estimate 95% Confidence Interval Rate 
95% Confidence 
Interval 
England 332,090 324,546 346,345 9.97 9.74 10.40
Northern Ireland 1,395 1,316 1,910 1.28 1.21 1.75
Scotland 51,582 51,456 56,379 15.39 15.35 16.82
Wales 18,480 18,060 19,273 9.97 9.74 10.40
United Kingdom* 403,547 395,378 423,907 10.19 9.98 10.70
*Based on estimates of opiates and/or crack cocaine use in England for 2005/06, opiate use in Northern 
Ireland for 2004, and problem drug use in Scotland, 2003. Estimates for Wales are extrapolated from 
England estimates. 
Source: Standard Table prepared for the United Kingdom Focal Point 
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Table 4.5: Estimates of injecting drug use in the United Kingdom: number and rate per 1,000 
population 
Country Estimate 95% Confidence Interval Rate 
95% Confidence 
Interval 
England 129,977 125,786 137,034 3.90 3.78 4.11
Northern Ireland76 451 515 748 0.41 0.47 0.69
Scotland 18,737 17,731 20,289 5.59 5.29 6.05
Wales 7,233 7,000 7,625 3.90 3.78 4.11
United Kingdom* 156,398 151,032 165,696 3.95 3.81 4.18
*Based on estimates of injecting of opiates and/or crack cocaine in England for 2005/06, opiate and/or 
problem cocaine use in Northern Ireland for 2004, and injecting drug use in Scotland, 2003.  Estimates for 
Wales are extrapolated from England estimates.  Injecting estimates for Northern Ireland assume the 
same proportion injecting as England. 
Source: Standard Table prepared for the United Kingdom Focal Point 
Trends in prevalence of problem drug use  
Table 4.6 shows estimates provided over time; the dates refer to the year the 
estimate was produced rather than the year the estimate refers to.77  Table 4.7 
shows estimates for injecting drug use; again increases may reflect improved 
methodology rather than increased prevalence. 
Table 4.6: Estimates of problem drug use: number and rate per 1,000 population, aged 15 to 







2004* 360,811  9.34 8.99 9.79
2006** 357,160 344,263 375,615 9.26 8.92 9.73
2007*** 398,845 397,033 421,012 10.15 10.11 10.72
2008**** 403,547 395,378 423,907 10.19 9.98 10.70
* Based on estimates of problem drug in England for 2001 (Frischer et al. 2004), problem drug use in 
Northern Ireland for 2000 (McElrath 2002), and problem drug use in Scotland, 2000 (Hay et al. 2001). 
Estimates for Wales are extrapolated from England estimates. 
** Based on estimates of problem drug in England for 2001 (Frischer et al. 2004), problem drug use in 
Northern Ireland for 2000 (McElrath 2002), and problem drug use in Scotland, 2003 (Hay et al. 2004). 
Estimates for Wales are extrapolated from England estimates. 
*** Based on estimates of opiates and/or crack cocaine use in England for 2004/05 (Hay et. al 2006a), 
opiate and/or problem cocaine use in Northern Ireland for 2004 (Hay et al. 2006b), and problem drug 
use in Scotland, 2003 (Hay et al. 2004). Estimates for Wales are extrapolated from England estimates. 
**** Based on estimates of opiates and/or crack cocaine use in England for 2005/06 (Hay et. al 2007), 
opiate and/or problem cocaine use in Northern Ireland for 2004 (Hay et al. 2006b), and problem drug 
use in Scotland, 2003 (Hay et al. 2004). Estimates for Wales are extrapolated from England estimates. 
Source: Hay 2004; Hay 2006; Hay 2007; Hay 2008 
Table 4.7: Estimates of number of injecting drug users and rate per 1,000 population, aged 15 







2004 123,498 3.20 3.07 3.34 
2006 117,722 116,343 120,472 3.05 3.01 3.12 
2007 164,036 158,881 178,614 4.18 4.04 4.55 
2008 156,398 151,032 165,696 3.95 3.81 4.18 
Source: Hay 2004; Hay 2006; Hay 2007; Hay 2008 
                                                
76 This table makes the assumption that Northern Ireland shows the same proportion of 
injecting amongst the drug using population.  This assumption may not be entirely appropriate 
and therefore the rate of injecting should not be used in isolation.  However, it is an 
appropriate assumption for the United Kingdom given the size of the confidence interval.  
77 For more information on these estimates see previous United Kingdom Focal Point reports.  
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4.2.3 Problem drug use falling outside the EMCDDA definition 
There are no estimates of problem use other than those referred to above.  It is 
however of note that information obtained through the Drug Treatment Outcomes 
Study (DTORS), reported in 4.3.3 below, shows that 25 per cent of clients entering 
treatment in England had used unprescribed benzodiazepines in the four weeks prior 
to entry.  
4.2.4 Problem drug use for which estimates are not available  
The capture-recapture method has been used to estimate the prevalence of problem 
drug use within the United Kingdom.  Different studies employ different case 
definitions, partly to satisfy the policy need for certain estimates, but primarily to 
reflect the availability of suitable data.  A key assumption of the capture-recapture 
method is that it is applied to homogeneous groups of drug users.  Typically, heroin 
users, or heroin and/or crack cocaine users show a similar pattern of contact with 
treatment services and their involvement with criminal justice services is also 
relatively similar.  This is not the case for cocaine powder users, where it is difficult to 
differentiate (particularly in criminal justice data sources) between people who use 
cocaine powder problematically and those that use cocaine powder on an occasional 
or recreational basis.  Thus, it has not been possible to include problem cocaine 
powder use in PDU estimates for the United Kingdom (apart from in the specific case 
of Northern Ireland, where the nature and extent of drug use is known to vary 
significantly from the rest of the United Kingdom).  The prevalence estimates for 
England include crack cocaine use, and with the comparatively low levels of crack 
cocaine use found in previous studies in Scotland, it is felt that this estimate is 
sufficient as a proxy for the United Kingdom. 
4.3 Treatment Demand Indicator 
In 2006/07, 128,208 presentations to treatment services were recorded through the 
Treatment Demand Indicator (TDI); showing a very small decrease from the previous 
year (128,446).  Of known cases, 44 per cent (47,165)78 concerned drug users who 
sought treatment for the first time ever, a slight reduction from 2005/06 (49,625); in 
Northern Ireland first treatments accounted for a much greater proportion, (67%) of 
treatment presentations (such presentations accounted for 72% in the previous year). 
4.3.1 Treatment centres  
Reports to the TDI are based on structured treatment79 only and do not include low 
threshold services.  In the United Kingdom, type of treatment is defined by whether it 
is structured or not, rather than by the building or organisation providing that 
treatment, therefore any structured treatment offered in the community will be 
identified either as outpatient or GP treatment, not as being provided by so-called low 
threshold services.   
 
The vast majority of treatments are reported through outpatient services (94%, n= 
120,226)80 (Table 4.8). However, in Wales and Northern Ireland there is no 
information about treatment through either GPs or inpatient services; in both 
countries it is thought that GPs provide very little treatment except through shared 
                                                
78 In 20,686 cases (16%) it is not known whether this is a first treatment or whether the 
presenting drug user has been in treatment previously. 
79 Treatment where a care plan is provided. 
80 Most such services in the United Kingdom are specialist community based treatment 
services. 
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care arrangements with specialist drug services, in which case patients will be 
captured through monitoring of outpatient services.  
Table 4.8: Presentations by centre type in the United Kingdom, 2003/04 to 2006/07 
Centre type 2003/04 2004/05 2005/06 2006/07 
 n % n % n % n % 
Outpatient 91,659 91.9 111,434 94.6 121,202 94.4 120,226 93.8
GP 3,966 4.0 3,402 2.9 3,833 3.0 4,303 3.6
Inpatient  4,038 4.0 2,945 2.5 3,411 2.7 3,679 2.8
Total  99,663  117,781 128,446 128,208 
Source: Standard Tables prepared for United Kingdom Focal Point 
4.3.2 Data coverage  
Funding for community based treatment (outpatients) and non-hospital based 
residential treatment is linked to drug treatment monitoring systems and funding, and 
therefore data coverage is exceedingly high.  Hospital based services are not linked 
in the same way, nor, necessarily, is treatment provided by GPs in isolation from 
specialist drug services, therefore it is likely that there will be some under–reporting 
in these areas.  As noted above, low threshold interventions are not regarded as 
structured treatment and therefore are not monitored through the National Drug 
Treatment Monitoring System; all structured treatments provided by community 
based services are counted as outpatient treatment.  Only Northern Ireland has been 
able to provide TDI data on prison treatment.  Table 4.9 shows the number of units 
covered by centre type.  
Table 4.9: Number of units covered by centre type in the United Kingdom, 2006/07 
Treatment centre type Units Covered 
 n % 
Outpatient 2,535 98 
Inpatient 99 99 
GP 235  NK  
Source: Standard Tables prepared for United Kingdom Focal Point  
4.3.3 Profile of clients in treatment  
Drugs used 
In the United Kingdom data are missing on main drug in 4.7 per cent of cases, 
though for England the proportion missing is less than two per cent (1.7%) in 
Scotland 17.4 per cent and in Wales 21.2 per cent; records are complete for Northern 
Ireland. 
 
Where main drug is known, opiates (63.7%) remain the most reported primary drug 
amongst the TDI population and cannabis the second most reported primary drug 
(15.6%).  Cocaine powder and crack cocaine were reported by seven and six per 
cent respectively (Table 4.10).  These are not significantly different from previous 
years (Table 4.12).  There are some variations between parts of the United Kingdom.  
In Northern Ireland primary opiate use accounts for 17.1 per cent of presentations, a 
significant rise from the previous year (14.6%), with primary cannabis use accounting 
for 44.2 per cent.  Also, in Northern Ireland, 13.9 per cent of presentations were for 
primary benzodiazepine use, a problem previously associated with Scotland, 
although this is not reflected by the TDI (Table 4.10).  In England, 6.8 per cent of 
presentations were for primary crack cocaine use, compared to one per cent or less 
in the rest of the United Kingdom, and these accounted for the majority of crack 
cocaine presentations (97%) across the United Kingdom.  While England also 
accounts for the majority of cocaine powder presentations (89%), Northern Ireland 
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shows the highest proportion of primary cocaine powder users, at ten per cent, 
accounting for two per cent of the presentations for cocaine powder in the United 
Kingdom as a whole.  
Table 4.10: Number and percentage of drug treatment presentations by primary drug of use in 
the United Kingdom, 2006/07 
Drug England Northern Ireland Scotland Wales 
United 
Kingdom 
  n % n % n % n % n % 
Amphetamines 3,603 3.5 22 1.6 238 2.2 759 9.8 4,622 3.8 
Benzodiazepines 1,132 1.1 193 13.9 682 6.4 219 2.8 2,226 1.8 
Cannabis 15,857 15.5 613 44.2 1,438 13.5 1,200 15.4 19,108 15.6 
Cocaine powder 7,474 7.3 142 10.3 522 4.9 234 3.0 8,372 6.9 
Crack cocaine 6,908 6.8 6 0.4 70 0.7 112 1.4 7,096 5.8 
Opiates 65,592 64.1 237 17.1 7,151 67.0 4,869 62.7 77,849 63.7 
Other   1,770 1.7 173 12.5 570 5.3 377 48.5 2,890 2.4 
Sub Total 102,336  1,386  10,671  7,770  122,163  
Not Known  1,726 1.7 0 0 2,231 17.3 2,088 21.2 6,045 4.7 
Total 104,062  1,386  12,902  9,858  128,208  
Source: Standard Tables prepared for United Kingdom Focal Point  
 
The majority of all those presenting to treatment are treated within outpatient 
services, 62 per cent presenting with opiates as primary problem drug, and 16 per 
cent with cannabis.  Proportionately GPs (89%), followed by inpatient services (76%) 
see a larger number of those presenting with opiate as primary problem drug and 
considerably less of other users, except crack cocaine users who represent 14 per 
cent of those presenting to inpatient services (Table 4.11). 
Table 4.11: Primary drug by centre type in the United Kingdome, 2006/07  
Drug Outpatients Inpatients* GP* Total 
  n % n % n % n % 
Amphetamines 4,499 3.9 74 2.0 49 1.2 4,622 3.9 
Benzodiazepines 2,085 1.8 48 1.3 93 2.3 2,226 1.8 
Cannabis 18,865 16.5 99 2.7 144 3.6 19,108 16.1 
Cocaine powder 8,147 7.1 140 3.8 85 2.1 8,372 7.0 
Crack cocaine 6,555 5.7 478 13.1 63 1.6 7,096 6.0 
Opiates 71,450 62.4 2,784 76.2 3,615 89.0 77,849 62.9 
Other   2,849 2.5 29 0.8 12 0.3 2,890 2.4 
Sub Total 114,450  3,652  4,061  122,163  
Not Known  5,776  27  242  6,045 4.7 
Total  120,226 93.8 3,679 3.6 4,303 2.9 128,208  
* Data only for England and Scotland  
Source: Standard Tables prepared for United Kingdom Focal Point  
 
First treatment demands show a slightly different pattern (Table 4.12) with primary 
opiate use accounting for just less than half (48%) of first treatment demands, 
although they account for 57 per cent in Scotland but only eight per cent in Northern 
Ireland.  
 
Presentations with cannabis as primary drug accounted for a quarter of all first 
presentations in the United Kingdom, and in Northern Ireland for 50 per cent.  The 
third highest number of first demands were for primary cocaine powder problems, 
although accounting for a much lower proportion (11%) than primary opiate or 
cannabis use; first treatment presentations for primary cocaine powder problems 
accounted for nine per cent all such presentations in the previous year.   
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Table 4.12: Number and percentage of first drug treatment demands by primary drug of use in 
the United Kingdom, 2006/07 
Drug England Northern Ireland Scotland Wales UK 
 n % n % n % n % n % 
Amphetamines 1,746 4.5 10 1.1 129 3.4 160 11.1 2,045 4.5 
Benzodiazepine 462 1.2 156 16.7 242 6.4 56 3.9 916 2.0 
Cannabis  9,803 25.1 470 50.3 760 20.2 292 20.3 11,325 25.1 
Cocaine powder 4,450 11.4 100 10.7 314 3.4 87 6.1 4,951 11.0 
Crack cocaine 2,849 7.3 1 0.1 19 0.5 31 2.2 2,900 6.4 
Opiates 18,670 47.8 78 8.4 2,130 56.7 - 47.6 21,561 47.7 
Other 1,061 2.7 119 12.7 161 4.3 127 8.8 1,468 3.3 
Sub Total 39,041   934  3,755   1,436  45,166   
Not Known  858 2.2 0 0 808 17.7 333 18.8 1,999 4.2  
39,899 934 4,563 1,769 47,165 Total  84.63%  1.98%  9.67%  3.75%     
Source: Standard Tables prepared for United Kingdom Focal Point  
 
The majority of all those presenting to treatment for the first time are treated within 
outpatient services (95%), with a lower proportion presenting with opiates as primary 
problem drug (46%) than present to GPs (82%).  Twenty-six per cent of new 
treatments in outpatients were for cannabis (Table 4.13). 
Table 4.13: Primary drug by centre type, first drug treatment, 2006/07  
Drug Outpatients Inpatients* GP* Total 
 n % n % n % n % 
Amphetamines 1,995 4.7 29 2.4 21 2.0 2,045 4.3 
Benzodiazepines 858 2.0 13 1.1 45 4.3 916 1.9 
Cannabis 11,236 26.2 32 2.7 57 5.4 11,325 24.0 
Cocaine powder 4,857 11.3 51 4.2 43 4.1 4,951 10.5 
Crack cocaine 2,728 6.4 153 12.7 19 1.8 2,900 6.1 
Opiates 19,774 46.1 922 76.4 865 82.2 21,561 45.7 
Other   1,458 3.4 7 0.6 3 0.3 1,468 3.1 
Sub Total 42,906  1,207  1,053   45,166   
Not Known  1,915  7  43   1,965   
Total  44,821 95.0 1,214 2.57 1,130  2.47 47,165   
* Data only for England and Scotland  
Source: Standard Tables prepared for United Kingdom Focal Point  
Age  
Forty-one per cent of all treatment presentations were for those aged between 25 
and 34, this compares with 42 per cent in the previous year.  Twenty-seven per cent 
were under 25 (29% in the previous year).  As expected, those presenting to 
treatment for the first time ever were considerably younger, with 37 per cent under 
the age of 24 years (38% in the previous year) (Table 4.14).  
Table 4.14: Age of drug users identified through TDI in the United Kingdom, 2006/07 
 Age 
 <25  25 to 34 34> Missing All 
 n % n % n % n n 
All treatments 35,183 27.5 53,092 41.4 39,918 31.1 15 128,20
8First 17,691 37.5 16,516 35.0 12,956 27.5 2 47,165
Source: Standard Tables prepared for United Kingdom Focal Point by NDEC, 2008 
 
The age of those presenting for cannabis as main drug is lower than for all 
presentations.  In 2006/07 over half (53.4%) were under 20 and three quarters 
(74.5%) under 35 years of age.  The proportion under 20, and more particularly, 
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between 15 and 19 years has increased substantially over the past four reporting 
years (Table 4.15). 
Table 4.15: Age of individuals reporting cannabis as main drug, 2003/04 to 2006/07  
Year Age 
 <15 15 to 19 <20 15 to 24 25 to 29 30 to 34 15 to 34 
2003/04 11.1 32.9 44.0 50.5 12.9 10.5 73.9 
2004/05 11.5 36.9 48.4 52.7 11.3 9.8 73.7 
2005/06 11.3 40.2 51.5 55.1 11.0 8.9 75.0 
2006/07 11.1 42.4 53.4 56.3 10.1 8.1 74.5 
Source: Standard Tables prepared for United Kingdom Focal Point  
Gender  
Seventy-three per cent of presentations were male, 27 per cent female (Table 4.16).  
There was no difference for first presentations (Table 4.17).  This was the same as in 
previous years.  
Injecting status  
Half of those presenting to treatment were either current (in the last four weeks) 
injectors (24.9%) or had previously injected (24.9%) (Table 4.16).  Amongst first 
presentations the proportions having ever injected, but not currently (15.7%) or 
currently injecting was much lower (15.5%) (Table 4.17).  These proportions were 
very similar to previous years.  
Table 4.16: Injecting status by gender in the United Kingdom, 2006/07, all treatments  
Injecting status  Male Female Total 
 n % n % n % 
Ever injected, but not currently 19,624 26.4 6,221 22.5 25,845 25.3 
Currently injecting (in last month) 18,489 24.9 6,865 24.8 25,354 24.9 
Never injected 36,262 48.8 14,572 52.7 50,834 49.8 
Sub Total  74,375  27,658  102,033  
Not known/missing 18,610  7,565  26,175  
Total 92,985 72.5 35,223 27.5 128,208  
Source: Standard Tables prepared for United Kingdom Focal Point  
Table 4.17: Injecting status by gender in the United Kingdom 2006/07, first treatments  
Injecting status  Male Female Total 
 n % n % n % 
Ever injected, but not currently 4,886 16.6 1,451 13.5 6,337 15.7 
Currently injecting (in last month) 4,668 15.8 1,563 14.5 6,231 15.5 
Never injected 19,961 67.6 7,770 72.0 27,731 68.8 
Sub Total  29,515  10,784  40,299  
Not known 4,844  2,022  6,866  
Total 34,359 72.9 12,806 27.2 47,165  
Source: Standard Tables prepared for United Kingdom Focal Point  
4.3.4 TDI prevalence trends  
Table 4.18 shows that over the last four reporting periods presentations increased 
substantially for the first three years, but there has been no significant change in the 
number presenting in the last year.  Main trends are the relative decline in the 
proportion of presentations for opiates, compared to the steady increases in 
presentations for cannabis, cocaine powder and crack cocaine, the first two 
continuing to increase.  However, when considering use of any drugs (primary and/or 
secondary) there has been a much greater increase in use of both crack cocaine and 
cocaine powder over the last few years (Figure 4.2) with nearly a quarter of 
presentations reporting crack cocaine use (24%, n = 29,086) and 13 per cent 
reporting cocaine powder (n = 8,372). 
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Table 4.18: Number and percentage of drug treatment presentations by primary drug in the 
United Kingdom, 2003/04 to 2006/07 
Drug 2003/04 2004/05 2005/06 2006/07 
 n % n % n % n % 
Amphetamines 3,474 3.7 3,731 3.6 4,134 3.5 4,622 3.8 
Benzodiazepines 1,929 2.1 2,503 2.4 2,297 1.9 2,226 1.8 
Cannabis 9,849 10.7 14,801 14.1 18,793 15.8 19,108 15.6 
Cocaine powder 3,739 4.0 5,093 4.9 6,890 5.8 8,372 6.9 
Crack cocaine 4,980 5.4 5,842 5.6 6,857 5.8 7,096 5.8 
Opiates 66,012 71.4 70,179 67.0 77,580 65.1 77,849 63.7 
Other 2,494 2.7 2,662 2.5 2,540 2.1 2,890 2.4 
Sub Total 92,477  104,811  119,091  122,163  
Not Known 7,186  12,970  9,355  6,045  
Total 99,663  117,781  128,446  128,208  
Source: Standard Tables prepared for United Kingdom Focal Point  
Figure 4.2: Presentations for cocaine powder and crack cocaine in the United Kingdom, 
2003/4 to 2006/07  
 
Source: Standard Tables prepared for United Kingdom Focal Point 
 
While actual numbers reporting for cannabis are increasing, the rate of increase is 
considerably slower than previously.  Of note is the fact that the number presenting 
with opiates as primary drug remained stable in 2006/07.  Presentations for 
amphetamines have also remained stable, and those for benzodiazepines are 
declining.   
 
There has been no change in the number of first treatment presentations in the past 
year, though as with all presentations they showed a rapid increase from 2003/04 to 
2005/06 (Table 4.19).  Amongst this group, the number of presentations for cannabis 
has stabilised and presentations for opiates and crack cocaine declined for the first 
time.  Presentations for cocaine powder have increased, but not at the same rate as 
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Table 4.19: Number and percentage of first drug treatment presentations by primary drug, in 
the United Kingdom, 2003/04 to 2006/07 
Drug 2003/04 2004/05 2005/06 2006/07 
 n % n % n % n % 
Amphetamines 1,455 5.1 1,619 4.1 1,812 3.9 2,045 4.3 
Benzodiazepines 675 2.3 1,226 3.1 1,153 2.5 916 1.9 
Cannabis 5,289 18.6 8,653 22.1 11,506 24.8 11,325 24.0 
Cocaine powder 1,683 5.8 3,016 7.7 4,197 9.1 4,951 10.5 
Crack cocaine 1,722 6.0 2,589 6.6 3,116 6.7 2,900 6.1 
Opiates 16,656 57.8 20,464 52.3 23,021 50.0 21,561 45.7 
Other  1,329 4.6 1,525 3.9 1,528 3.3 1,468 3.1 
Sub Total  28,809  39,092  46,333  45,166   
Not Known 1,056  3,405  3,292  1,999   
Total 29,865  42,497  49,625  47,165   
Source: Standard Tables prepared for United Kingdom Focal Point  
4.4 PDUs from non-treatment sources 
4.4.1 PDUs identified outside the TDI  
The Arrestees Survey  
The third sweep of the Arrestees Survey (2005/06) (Boreham et al. 2007)81 found 
that 52 per cent of arrestees reported having taken one or more drugs in the month 
prior to arrest.  Twenty-six per cent had taken heroin, crack cocaine or cocaine 
powder; 13 per cent having used heroin; 13 per cent cocaine powder; and 11 per 
cent crack cocaine.  
 
Across all three surveys it was found that 41 per cent had been in treatment at some 
point.  In the third survey 32 per cent of frequent heroin users (those who used heroin 
five or more days a week) were currently in treatment.  In 2005/06, 26 per cent of 
those reporting previous treatment for heroin dependency reported no longer using 
heroin. 
 
For more information on the Arrestees Survey see Chapter 8.3.2. 
Statistics from the Northern Ireland Addicts Index 2007 
While not strictly from non-treatment sources Northern Ireland Addicts Index provides 
information about individuals reported to be addicted to drugs classified under the 
Misuse of Drugs Act 1971.  In 2007 the index82 showed that: 
• 257 persons were registered on 31st December 2007, a decrease of 31 from 288 
persons registered on 31st December 2006;  
• there were 51 new notifications;  
• there were 206 renotifications in 2007, compared to 190 in 2006; 
• 133 addicts have been registered between one and five years; 
• eighty-two cases were removed from the Addicts Index during 2007; 
• the gender profile in 2007 was similar to that in 2006, where 81 per cent of 
addicts were male in 2007, and 78 per cent in 2006,  
                                                
81 8,027 arrestees were surveyed.  The eligible population was were aged 17 or older who 
had been arrested on suspicion of committing an offence and who had not previously been 
interviewed within the current survey year.  The sample design was a stratified two-stage 
random probability sample.  A random selection of custody suites was first drawn and in each 
suite, a random sample of shifts.  CAPI3 interviews with a CASI self completion section were 
used; respondents were asked to provide an oral fluid sample for analysis of recent drug use. 
The overall response rate was 23 per cent in 2005–06. 
82 People are registered on this index if they are known to be, or if a medical practitioner 
considers them to be, addicted to one or more of 14 controlled drugs. 
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• the age profile changed slightly, with 29 per cent aged 29 years and under in 
2007, compared to 34 per cent in 2006; 
• heroin was the most frequently used notifiable drug, reported by 75 per cent, 
methadone by 28 per cent and cocaine powder by six per cent; and 
• forty-four per cent whose injecting behaviour was known reported currently 
injecting (42% in 2006) (PHIRB/DHSSPSNI 2008).  
4.4.2 Contact with non-treatment interventions and social and cultural context 
See Chapter 6 for information on needle exchange schemes and drug related 
infectious disease testing.  Also, see Arrestees Survey referred to above. 
4.5 Intensive or frequent patterns of use 
By their very nature, estimates of problem drug use are concerned with intensive 
patterns of use.   
4.6 Relationship of PDU estimates, TDI data and General Population Survey 
New presentations to treatment, as reflected through the TDI, appear to be stabilising 
in the United Kingdom.  As noted earlier, main trends are the relative decline in the 
proportion of presentations for opiates, compared to the steady increases in 
presentations for cannabis, cocaine powder and crack cocaine, the first two 
continuing to increase in this reporting year.  Of note is the fact that the actual 
numbers presenting with opiates has not continued to increase for the first time.  
Most recent PDU estimates for the United Kingdom are shown in Table 4.4 and 
primarily concern the use of opiates, but also crack cocaine.  The first two sweeps of 
English estimates appear to show the same stabilisation in use of opiates and/or 
crack cocaine as that found in the TDI population.  Population survey data is based 
upon a very different population than that reflected in PDU estimates; the former 
identifying relatively low use of opiates and crack cocaine.  In England and Wales 
there appears to be a fall in drug use, mainly reflected in a decrease in use of 
cannabis, though cocaine powder is rising, as within the TDI population.  Mentions of 
cocaine on death certificates are also rising (see Chapter 6).   
4.7 Treatment engagement  
The TDI distinguishes between all new presentations to treatment each year and first 
ever presentations (that is, first treatment demands).  The number and profile of all 
new presentations has been considered to reflect the wider demands made on the 
treatment sector, while the number and profile of the first ever treatment demands 
has been seen as reflecting changes in the emergent population of drug users newly 
entering treatment.  As can be seen in Table 4.18, data on all presentations suggests 
an increase in demand for cocaine powder and crack cocaine over time.  An increase 
can also be seen for cannabis, a drug not identified in the United Kingdom as 
problematic, though there are increasing concerns about its use, reflected in its 
proposed reclassification to Class B.  Presentations for crack cocaine and cannabis 
have not increased in the last year (Table 4.18).  The same pattern can be seen with 
first ever presentations (Table 4.18).    
 
Nevertheless, the TDI cannot be used to consider treatment engagement rates as 
they do not take account of those individuals already in treatment prior to, and during, 
the reporting period.  The National Drug Treatment Monitoring System (NDTMS) for 
England provides a better estimate of engagement.  NTMDS data show that, of those 
in treatment in 2006/07, 148,866 were problem opiate and/or crack cocaine users 
(either using these as primary drug or as a secondary or tertiary drug) (Table 4.20), 
that is 45 per cent of problem drug users (estimated for the previous year, 2005/06), 
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this compares with 42 per cent (136,228) in 2005/06.  The treatment figure for opiate 
users was 140,357, constituting 49 per cent (46% in 2005/06, n = 128,630) of the 
PDU estimate of opiate users, while the treatment figure for crack cocaine users was 
46,415 constituting 24 per cent of problem crack cocaine users (21% in 2005/06, n = 
39,832), indicating increased engagement.  This suggests that a higher number of 
problem drug users were in treatment in 2006/07 than in the previous year, despite a 
lack of increase in presentations to treatment for primary opiate or crack cocaine use, 
though there has been an increase in the number of crack cocaine users in 
treatment.  









 n n % n % 
Opiate and/or crack cocaine users  332,090 136,228 41.0 148,866 44.8 
Opiate users  286,566 128,630 44.9 140,357 49.0 
Crack cocaine users  197,568 39,832 20.2 46,415 23.5 
Source: Hay et al. 2007; Standard Tables prepared for the United Kingdom Focal Point  
 
Research  
The Drug Treatment Outcomes Research Study  
The Drug Treatment Outcomes Research Study (DTORS) is a longitudinal study 
designed to follow drug users in England seeking treatment over a period of up to 12 
months.83  DTORS provides a much wider understanding of the characteristics of 
those entering treatment than has been available through drug treatment monitoring 
systems, providing information about education, employment, accommodation, 
offending behaviour, experience of mental health services, parental status, parental 
responsibility and risk taking.  The study comprises three key elements, operated 
over a three-year period, namely: a quantitative study of outcomes; a qualitative 
study of treatment related issues; and a cost benefits analysis.  The first report, 
providing baseline information from interviews conducted with participants as soon as 
possible after an assessment for treatment, has been published (Jones et al. 2007). 
 
These baseline data suggest that the sample is representative of the treatment 
population identified through the TDI.  Three quarters (73%) were male; 20 per cent 
were aged 16 to 24 years, 45 per cent aged 25 to 34 years, 27 per cent aged 35 to 
44 years and seven per cent 45 years and over.  The majority were White (89%).  In 
the four weeks prior to interview respondents used a wide range of substances:  
• 62 per cent reported using heroin; 
• 50 per cent alcohol; 
• 49 per cent cannabis 
• 44 per cent crack cocaine; 
• 25 per cent unprescribed benzodiazepines;  
• 22 per cent other opiates; 
                                                
83 Respondents were recruited via drug treatment agencies within England.  One hundred of 
the 149 Drug Action Teams (DATs) in England were initially selected to take part in DTORS.  
Within each selected DAT, all agencies providing structured community treatment or 
residential treatment or referral were eligible to take part, as were all adults presenting with a 
drug problem (other than alcohol) for a new episode of drug treatment within a sampling 
window of between four and seven weeks.  Participation was voluntary.  The final sample 
represents 1,796 drug treatment seekers interviewed at 342 treatment facilities across 94 
DATs; the sample broadly represents the drug treatment-seeking population in England. 
UNITED KINGDOM FOCAL POINT REPORT 2008  
 72 
• 16 per cent unprescribed methadone; and  
• 16 per cent cocaine powder.  
 
Forty-nine per cent of primary heroin users, 24 per cent of primary crack cocaine 
users and 39 per cent of primary amphetamine users reported injecting it in the last 
four weeks and 28 per cent of heroin users reported injecting every day, or most 
days.  
 
For information about other characteristics of DTORS participants see Chapters 6 
and 8. 
The 2006 NTA survey of user satisfaction – Topping up  
The NTA 2006 user survey84 provides information about the continued use of illicit 
drugs by those in treatment (NTA 2007a).  While almost 90 per cent agreed or 
strongly agreed that such use had reduced, many respondents, particularly those 
receiving substitute treatment, reported using in addition to the substances 
prescribed, with fewer than 30 per cent reporting never using on top of prescribed 
substitute drugs and just over half reporting doing so ”sometimes”.  Of the 
respondents who reported using on top of prescriptions:  
• 81.6 per cent reported use of heroin;  
• 60 per cent, crack cocaine;  
• 57 per cent, cannabis;  
• 43 per cent, benzodiazepines; and  
• 19 per cent, amphetamines.  
 
A higher level of use on top of prescriptions was reported in the survey of clients 
using pharmacy based syringe exchange schemes.  Of those reporting use on top of 
a prescription:  
• 95 per cent reported using heroin; 
• 76 per cent, crack cocaine; 
• 27 per cent, amphetamines; and 
• 58 per cent, benzodiazepines.  
 
Overall, in both surveys, the majority (58%) of those who used on top of prescriptions 
used both heroin and crack cocaine.  
'Topping up' methadone  
In an analysis of patterns of heroin use among a treatment sample of Scottish drug 
users from the DORIS cohort, Bloor et al. (2008)85 looked at whether drug users on 
methadone maintenance used heroin less frequently than their peers following other 
forms of treatment and also to what extent those on methadone maintenance ‘top up’ 
with heroin.  It was found that there was no significant difference in the propensity of 
either group to abstain from heroin with 67 per cent of those on methadone 
maintenance treatment having ‘topped up’ on heroin in the three months prior to the 
                                                
84 Questionnaires were distributed to the clients of all structured drug treatment services in 
England.  In addition, a shorter questionnaire consisting of just the harm reduction questions 
were distributed to clients of pharmacy-based needle exchange services.  A total of 1,014 
drug services and 1,658 needle exchange pharmacies in England were asked to distribute 
self-completion questionnaires to their service users. 10,070 responses were analysed (8,765 
from the 2006 user survey and 1,305 from the pharmacy survey) Assuming that all 
questionnaires were distributed, the response rate to the main user survey was just over 12 
per cent and the response rate to the pharmacy study was approximately 3.5 per cent. 
85 Four hundred and one interviewees who responded at all four interview sweeps, recruited 
as new treatment entrants from 28 drug treatment agencies across Scotland.  Sixty-eight 
respondents were on methadone maintenance treatment.  
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interview.  However it was found that while drug users on methadone maintenance 
treatment were not more likely to achieve abstinence than drug users receiving 
another form of treatment they were significantly more likely to reduce the frequency 
of use.   
Characteristics of drug-using patients and treatment provided in primary and 
secondary settings 
In a paper exploring the differences in patient groups served, and treatment offered 
by primary and secondary care services in Birmingham (Day et al. 2007)86, it was 
found that patients treated in primary care were younger, with a mean age of 30.3 
years compared to 34.1 years, than those treated in secondary care services; they 
were more likely to be male, 77.1 per cent compared with 70.5 per cent; and had 
fewer drug related problems, the mean Christo Inventory for Substance Use 
Services87 was 56.9.  A higher percentage of primary care patients were receiving a 
prescription for maintenance therapy, 73.7 per cent compared with 64.9 per cent, 
with a greater proportion of these (21.4% compared with 10.0%) receiving 
buprenorphine, rather than methadone.  There was no significant difference in the 
mean doses of methadone or buprenorphine received in primary or secondary care.  
The authors suggest that the differences between the primary and secondary care 
settings were smaller than expected, although they were predominantly in the 
expected direction. 
Problematic drug use, ageing and older people 
Beynon et al. (2007a)88, carrying out research in Cheshire and Merseyside showed 
that the average age of drug users in contact with treatment services and syringe 
exchange programmes is increasing, the median age of those in treatment rising 
from 30.8 years in 1998 to 34.9 in 2004/05.  Increases were also seen in those 
accessing syringe exchange programmes; the median age of those attending being 
27.0 years in 1992 and 34.9 in 2004. 
                                                
86 Treatment staff in all statutory and non-statutory agencies were interviewed about the 
demographic details of all active patients, the treatment that each patient was receiving and 
their level of drug-related problems. 1,597 patients were being treated by drug treatment 
services, with 577 (36.1%) of these under the care of the primary care-based agency.   
87 The Christo Inventory for Substance-misuse Services (CISS) was developed as a single 
page outcome evaluation tool completed by drug/alcohol service workers either from direct 
client interviews or from personal experience of their client supplemented by existing 
assessment notes.  For more information see: 
http://www.ingentaconnect.com/content/els/03768716/2000/00000059/00000002/art00117 
88 The research is based on information from the monitoring of drug treatment services in 
Merseyside and cheshire form 1997 and monitoring of syringe exchange schemes since 
1991. 
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5. Drug-Related Treatment  
5.1 Overview  
United Kingdom drug strategies identify treatment as being effective in tackling 
problem drug use, and the need to quality treatment to be available.  Drug Misuse 
and Dependence: UK Guidelines on Clinical Management (updated in 2007) (DH et 
al. 2007) and, in England, Models of care for treatment of adult drug misusers: 
update 2006 (NTA 2006) provide the basic framework for drug treatment, offering 
guidance on the structure and range of services to be commissioned in each area, as 
well as guidelines on clinical practice.  The National Institute for Health and Clinical 
Excellence (NICE) also provides guidance in a number of areas.  Treatment 
providers are expected to offer advice and information, care planned counselling, 
structured day care programmes, community prescribing, inpatient drug treatment 
and residential rehabilitation.  In addition, drug misusers should be offered relapse 
prevention and aftercare programmes; hepatitis B vaccinations; testing and 
counselling for hepatitis B and C, and HIV; and needle exchange.  Oral opiate 
substitution maintenance treatment with methadone and buprenorphine is the most 
common pharmacological treatment used in treating heroin addiction; buprenorphine, 
injectable opiates, such as injectable methadone and injectable diamorphine, are 
also available. 
 
While providing treatment remains a priority, the role of other service providers; 
housing, employment, education and training has also become important, more 
particularly this year with new drug strategies having a much stronger focus on the 
need for recovery.  Coordination and integration between a range of providers is 
seen as key in helping problem drug users reintegrate into society and all new drug 
strategies in the United Kingdom focus on this area. 
 
Improving treatment for young people has been prioritised since 2005. 
 
With access to effective treatment being a priority of the United Kingdom drug 
strategies, treatment capacity has increased substantially.  This has been 
accompanied by significant financial investment.  Research initiatives are funded 
centrally to improve treatment engagement, and there are also a number of other 
initiatives to increase the capacity and improve effectiveness, for example nurse 
prescribing, guidance for pharmacists working with drug users, and continued 
encouragement to expand the role of general practitioners (GPs) in the treatment and 
care of drug misusers.  Attention is now being giving to measuring the health and 
social outcomes associated with treatments.  Treatment is also to become more 
personalised, to better meet the needs of individual users.  
5.2 Treatment System 
5.2.1 Treatment objectives within new drug strategies  
All new drug strategies continue to be concerned with the provision of better access 
to treatment, particularly for vulnerable and excluded groups and to encourage 
retention.  Drugs: protecting families and communities (HM Government 2008a) also 
looks towards linking treatment to the benefit system, the latter being a United 
Kingdom wide system; this may have implications for policy outside England (see 
below).  Throughout the United Kingdom, but more particularly in Scotland, it is 
expected that there will be a cultural shift in treatment services towards a greater 
emphasis on recovery (see Chapters 1 and 9). 
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There are a number of treatment objectives for England.  One is to target those most 
at risk.  A second objective is to improve the quality and effectiveness of treatment, 
with action to support more personalised treatment through effective clinical 
governance, and user and carer involvement; also, with outcome monitoring used to 
improve treatment targeting and effectiveness.  A further objective is a wider use of 
new treatment approaches; including the use of injectable heroin and methadone; 
contingency management; mutual support networks; and services making full use of 
up-to-date evidence on effective treatment.  A fourth objective is that there will be a 
radical new approach to services to help drug users re-establish their lives (see 
Chapter 9) (HM Government 2008a). 
 
The new drug strategy for Scotland (Scottish Government 2008a) has the promotion 
of recovery among problem drug users as its key focus (see Chapter 1).  Noting the 
debate in Scotland as to whether the aim of treatment should be harm reduction or 
abstinence (reported in last year’s United Kingdom Focal Point report) the Scottish 
Government suggests that this is a false dichotomy, but argues that recovery should 
be made the explicit aim of services for problem drug users.  This is defined in the 
Scottish Strategy as: 
 
“a process through which an individual is enabled to move on from their problem 
drug use, towards a drug-free life as an active and contributing member of 
society.” 
 
It is stated that the concept of recovery as a goal has been pioneered with success in 
the field of mental health, espoused through the Scottish Recovery Network.89  This 
approach has been put forward following a number of reviews undertaken in the 
previous year (see last year’s United Kingdom Focal Point), and importantly in the 
Essential Care report (SACDM 2008) (see Chapter 9). 
 
Delivery of drug treatment services are to be based on three principles: 
• recovery should be made the explicit aim of all services providing treatment and 
rehabilitation; 
• a range of appropriate treatment and rehabilitation services must be available at 
a local level; and 
• treatment services must integrate effectively with a wider range of generic 
services to address the needs of problem drug users, not just their addiction. 
 
This will involve: 
• an appropriate range of drug treatment and rehabilitation services to promote 
recovery from all types of drug use, not just opiate dependency, which is based 
on local needs and circumstances and must be available in each part of 
Scotland; 
• better integration of medical treatment with a wider range of services; 
• individual care plans; and 
• the principles of recovery are to be reflected in training and workforce 
development programmes that are expected to promote cultural change among 
practitioners. 
 
Substitute prescribing will continue to remain an important intervention. 
 
In the Welsh substance misuse strategy there is a strong focus on improving access 
to treatment, treatment engagement and improving treatment outcomes (Welsh 
                                                
89 See: http://www.scottishrecovery.net/content/ 
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Assembly Government 2008a).  There is an additional focus on helping substance 
misusers re-establish themselves in the community.  Areas for action include: 
expanding outreach; improving treatment outcomes by conducting proper 
assessments and by investing in evidence-based, quality services; driving better 
performance and efficiencies in treatment services; improving the overall capacity of 
services to tackle waiting times; prioritising services that tackle the areas of greatest 
harm, that is, those to support the most harmful drug and alcohol misusers; 
identifying and minimising barriers to accessing treatment; building citizen focused 
services that meet the needs of a range of specific groups (particularly young people, 
Black and minority ethnic communities, Welsh speakers and vulnerable women); 
engaging substance misusers, including children and young people in the planning 
and design of all services; and ensuring that user satisfaction surveys are conducted, 
using the results to further improve services; and working towards the full range of 
integrated treatment options being available in all areas, including the prison estate, 
prioritising the more deprived areas.  
 
It is noted that there remain gaps in treatment provision and to bridge these it is 
intended to make better use of existing services, expanding their capacity by training 
health and social care professionals in the field.  There will also be action taken to 
improve the knowledge of health and social care professionals, to enable them to 
recognise risk and the potential for treatment, so that they make appropriate referrals 
to specialist services and continue promoting increased substitute opiate prescribing 
across Wales, including supervised consumption, in line with the latest evidence.  
There will also be action to tackle the problem of access to inpatient detoxification 
and residential rehabilitation services in Wales.  It is also planned to establish service 
users groups and a national peer mentoring scheme.  
 
To improve retention in treatment the Welsh Assembly Government is commissioning 
a study of the causes and patterns of drop-out rates.  They will also pilot motivational 
interviewing training for care managers and key workers as part of their workforce 
development plan.  
 
Also in Wales, it is planned to provide a greater focus on over the counter (OTC) 
medicines and prescription only medicines (POM), noting the United Kingdom-wide 
All Party Parliamentary Group on Drugs Misuse inquiry into the misuse of POMs and 
OTC medicines.90  The Welsh Assembly Government will be asking their Advisory 
Panel on Substance Misuse to consider its recommendations.  The implementation 
plan includes a number of actions aimed at: encouraging more responsible 
prescribing; monitoring the purchase of sensitive products; reducing inappropriately 
prescribed medicines such as benzodiazepines in primary care; and ensuring that 
suitable services are available for those dependent on POMs and OTC medicines 
(Welsh assembly Government 2008b). 
5.2.2 Numbers in treatment  
Information from the National Drug Treatment Monitoring System (NDTMS) for 
England shows that in 2007/08, 202,666 individuals were in contact with structured 
drug treatment services, a four per cent increase since the previous year (195,464) 
(NTA 2008a).  Elsewhere in the United Kingdom drug treatment monitoring systems 
only measure the number entering treatment (see Chapter 4).  Figure 5.1 shows how 
the steep increase in numbers in treatment in England is now beginning to level off; 
new presentations having begun to plateau in 2004/05.  
                                                
90 See: http://www.brianiddon.org.uk/media/070724_APPGDMInq.htm 
UNITED KINGDOM FOCAL POINT REPORT 2008  
 77
Figure 5.1: Numbers in treatment monitored through NDTMS and new of presentations to 

























Source: NTA 2008a; Standard Table prepared for UK Focal Point  
5.2.3 Cost of treatment / value for money  
The National Treatment Agency for Substance Misuse (NTA) is working with the 
Department of Health, Home Office and the Treasury to further understand the costs 
of substance misuse treatment in England.91  The aim is to provide commissioners 
with a range of unit costs for interventions, allowing the purchase of the most 
effective interventions at a transparent price.  A pilot was carried out in the South 
East region and the project was expanded nationwide during 2006/07. Work is now 
beginning on the 2007/08 exercise following a period of consultation in the field.  A 
web-based tool has been developed for the 2007/08 exercise.  Work is on-going to 
sample primary care based projects across the country as well as some specialist 
drug treatment services, with a parallel exercise to be conducted for residential 
services.  
 
Also, the NTA has been asked by the Government to develop a model of drug 
treatment systems, and a related tool, that can help commissioning partnerships in 
delivering the best possible outcomes from the available resources for their treatment 
system.  A consultation documents, Improving the Value of Drug Treatment Systems 
was launched in October 2008 (NTA 2008b).  The document sets out a number of 
key assumptions about the treatment needs of opioid and crack cocaine users.  
5.2.4 Quality in treatment systems 
Guidelines on ethical prescribing 
The NTA (2007b) has published guidelines on ethical prescribing92, based on Drug 
Misuse and Dependence: UK Guidelines on Clinical Management (DH et.al 2007) 
and National Institute for Health and Clinical Excellence (NICE) guidance on 
methadone and buprenorphine for the management of opioid dependence (NICE 
2007b), both referred to in the 2007 United Kingdom Focal Point report.  The 
guidance states that the objective in prescribing is to give the patient the right 
medication at a dose that produces the greatest therapeutic benefit, without incurring 
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unnecessary risk of harm and that it is inappropriate for medications to be used as a 
reward, or to be withheld, or the dose reduced, solely as a punishment or sanction 
(see audit of prescribing in 5.2.5).  
Other new guidance  
The NTA has published guidance for young people’s substance misuse treatment, 
and needs assessment guidance (NTA 2008c).  Also, launched is new 
commissioning guidance for residential (Tier 4) services (NTA 2008d), and guidance 
for carers (NTA 2008e).  
Involving service users  
The NTA sponsored eleven service users from across England to attend the 
International Harm Reduction Association’s (IHRA) 18th International Conference in 
Warsaw, Poland in May 2007.  The service user group were asked to collect fresh 
evidence-based work on reducing drug-related harm and communicating these 
messages to the wider service user community in England on their return.  A report 
containing recommendations from the group based on their impressions of the 
conference has been published (NTA 2007d).  This has been further developed at 
the 2008 IHRA conference in Barcelona.   
 
The Scottish Government (2007b) has published new National Quality Standards for 
Substance Misuse Services in involving service users. There are also plans to 
develop a user forum in Wales (Welsh Assembly Government 2008b). 
5.2.5 Reviews/audits of the drug treatment system  
Audit of Prescribing Practitioners 
A survey of GPs has been conducted on behalf of the Department of Health and the 
NTA to identify the extent of inappropriate use of medication by clinicians, either for 
reward or punishment and to identify reasons why doses may be justifiably altered 
(COI and GfK-NOP 2007)93.  This Audit was commissioned as part of the 
improvement review of drug services looking into the safety of prescribing (see 
below) and contributed to developing guidance on ethical prescribing referred to 
earlier.94  It was found that: 
• most (86%) would only increase doses of methadone or buprenorphine as part of 
a patient’s care plan or in response to evidence of inadequate dose (82%); 
• over 95 per cent would only decrease doses of as part of a planned detoxification 
or because of concerns that the current dose was excessive (80%); 
• twenty-five per cent reported that if the patient continually declared no use of illicit 
drugs, they would take no action and 25 per cent that they would decrease the 
dose; 
• where patients continually declared use of illicit drugs, half (47%) said they would 
increase the dose, the rest reported a range of actions, though only four per cent 
stated they would discharge the patient; and 
                                                
93 A telephone survey was conducted over a two week period in autumn 2007 with 121 
clinicians at practices in England able to prescribe methadone or buprenorphine for the 
treatment of dependence.  The clinicians comprised GPs specialising in addiction, consultants 
in addiction, and other prescribing practitioners.  A database of all identified drug prescribing 
practices was used as the sample frame, or population, for this survey.  This comprised some 
380 unique practices. The survey was conducted in a random fashion which elicited a random 
and representative sample of practices and the questionnaire was designed by and the 
survey undertaken by independent research experts.  A response rate of 32 per cent was 
achieved.  
94 Respondents reported an average of 379 patients being treated with methadone or 
buprenorphine for dependence within their service, practice or centre.   
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• eighty-one per cent said that they would only prescribe antidepressants in 
response to a diagnosis of clinical depression, and 19 per cent to assist 
abstinence from stimulants. 
Improvement reviews of drug services 
Prescribing drugs safely, planning and coordinating treatment services  
A joint review95 by the Healthcare Commission and the NTA looked at whether local 
services prescribe drugs safely and appropriately and how well they plan treatment 
and coordinate services (Healthcare Commission and NTA 2007).  It found that 
improvements could be made across all areas of community prescribing services and 
care planning and care coordination.  It also found that 27 per cent of prescribing 
services had not undertaken any clinical audit in the 18 months prior to the review.  It 
was noted that although the majority (95%) of services have good policies on 
prescribing, some still prescribe insufficient doses to maintain service users and 
prevent the use of street drugs.  In addition, the review revealed the positive benefits 
of involving service users at all levels; in their own treatment, in planning specific 
services, and in planning the treatment system at a strategic level.  Improvements 
could also be made in relation to the consistent use of individual care plans with 48 
per cent of local drug partnerships being 'weak' in this area, and 32 per cent 'fair'.   
 
Key recommendations were that: 
• commissioners and service providers review their activity in relation to the 
national and local results of the review; 
• community prescribing services ensure that clinical governance arrangements 
are in place, that mechanisms to monitor their practice against guidelines are 
established, and that they undertake regular reviews or audits to ensure that all 
staff are treating all service users according to guidelines; 
• all services review their assessment and care planning tools, making use of best 
practice guidance; 
• all services ensure that they develop an individual care plan for each service 
user, involving users in the development and regular review of the plan. They 
should also ensure that the comprehensive assessment of each person who 
accesses treatment adequately covers any aspects of risk and looks at how 
these risks will be managed; 
• Strategic Health Authorities and regional NTA teams with responsibility for 
managing the performance of local drug partnerships and healthcare 
organisations (NHS and voluntary sector) should ensure that action plans are 
developed to address all areas of weak performance in the review assessment, 
and closely monitor the implementation of these plans. 
 
A review of drug treatment and harm reduction services is reported in Chapter 7.  
 
Also in 2006/07, an improvement review was undertaken looking at systems for 
managing services, to ensure that they meet the needs of their service users and are 
managed to deliver the best possible treatment to clients. 
 
Improvement reviews for 2007/08 are focusing on the extent to which various parts of 
the treatment system accommodate the diverse needs of local populations across 
the full range of service provision and the commissioning and provision of Tier 4 
                                                
95 There are two parts to an improvement review. In the first part, the performance of all 
organisations taking part in the review is assessed. In the second part, organisations or 
systems (approximately 10%) that received the weakest assessments are provided with help 
by NTA to develop an action plan to improve their performance.  Reviews assess chosen 
themes within the context of local drugs partnerships. 
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services (inpatient detoxification and residential rehabilitation).  An assessment 
framework for these reviews has been published (Healthcare Commission and NTA 
2008a).  
Healthcare Inspectorate Wales review of substitute prescribing services  
The first of a series of comprehensive reviews into the treatment of substance 
misuse in Wales has been conducted by the Healthcare Inspectorate Wales.96  This 
is to look at the planning, commissioning and delivery of treatments that involve 
prescribing drug substitutes in the community. 
Review of inpatient services, Wales  
Last year the Welsh Assembly Government commissioned a review of Tier 4 
services in Wales.  The key findings of the review were that: services were patchy 
across Wales and that better use of existing provision by ensuring that individuals are 
managed properly into, through, and out of, Tier 4 services; with appropriate 
preparation and support at the outset and effective wrap-around support and relapse 
prevention at the end of treatment. 
 
Guidance has been issued to all Community Safety Partnerships and they have been 
asked to prepare plans to increase capacity and improve the local and regional care 
pathways for Tier 4 services (Welsh Assembly Government 2008a).  
Review of relapse prevention and wraparound services, Wales  
A review of local provision of relapse prevention and wraparound services is to be 
undertaken in Wales, with plans developed to ensure that such services are 
delivered as a core element of an individual’s treatment plan with ready access to 
skills programmes and learning opportunities.  A ‘Continual Personal Development 
Opportunities’ module is also to be developed as part of the Substance Misuse 
Treatment Framework for Wales (Welsh Assembly Government 2008b). 
Clinical governance  
NTA has published a consultation draft of guidance on clinical governance in drug 
treatment.  The consultation closed on the 14th May 2008 (NTA 2008f).  In Wales, it is 
expected that appropriate clinical governance arrangements across all commissioned 
sectors be in place (Welsh Assembly Government 2008b). 
The implementation of the Treatment Outcome Profile  
The implementation of the Treatment Outcome Profile (TOP), developed for use at 
the start of treatment and in care plan reviews, and reported through the National 
Drug Treatment Monitoring System, is supported by a range of products, all of which 
can be downloaded from the NTA website97, these include guides for managers, 
keyworkers and service users, and training packs. 
 
A report of the development of the Treatment Outcomes Profile for measuring the 
effectiveness of substance misuse in England has been published in the journal, 
Addiction (Marsden et al. 2008).  
Scottish Drug Misuse Database Follow-up Reporting System  
In April 2008, the new Scottish Drug Misuse Database Follow-up Reporting System 
was introduced.  It provides outcome information that will, once fully implemented, 
enable the assessment of treatment effectiveness (Scottish Government 2008a). 
 
 
                                                
96 See: http://new.wales.gov.uk/news/latest/081006review/?lang=en 
97 See: http://www.nta.nhs.uk/areas/outcomes_monitoring/rollout_products.aspx 
UNITED KINGDOM FOCAL POINT REPORT 2008  
 81
Online directory of drug services  
A new online directory of drugs services is now available in Scotland.98 
Substance misuse assessment toolkit  
In Wales a substance misuse assessment toolkit was introduced nationally in 2008.  
Also, in Wales, a feasibility study is to be undertaken to consider the introduction of a 
common client record to aid the provision of integrated services (Welsh Assembly 
Government 2008b).   
5.2.6 Funding 
The Pooled Drug Treatment Budget, England 
The Pooled Drug Treatment Budget (PTB) funding for drug treatment in 2008/09 is 
being maintained at the 2007/08 level of €582 million (£398m).  Current plans are for 
this amount to continue each year to 2010/11.  For 2008/09 a further €36.1m 
(£24.7m) will be used for young people’s treatment.  In addition, there is significant 
expenditure on treatment through mainstream funding. 
5.2.7 Pilot treatment projects/trials  
Contingency management  
As part of the action plan that supports Drugs: protecting families and communities 
the NTA has established pilots to look at whether contingency management works in 
England and, if so, how best to apply it (HM Government 2008b).  Wales is also to 
pilot contingency management to help engage or maintain some individuals in 
treatment in certain circumstances (Welsh Assembly Government 2008a).  
5.2.8 Medical training 
A two-year project funded by the Department of Health (England), and led by a 
National Steering Committee including representatives from the Council of Heads of 
Medical Schools, the Department of Health, the Home Office and the General 
Medical Council has produced a consensus between all those interested in 
substance misuse in the undergraduate medical curriculum.  This was done largely 
through establishing a panel of experts and others and by developing national 
guidelines, and support teaching and learning about the subject in various ways. 
Guidance was published in December 2006, and includes short background sections 
on substance misuse and some guidance on good practice.  The heart of the 
document, though, is guidance on core aims and objectives: the project analysed the 
relevant aims and objectives which medical schools provided during the survey, and 
worked on drafts at and in between meetings of the Expert Panel.  The document 
was reviewed by experts, generalists and the national Steering Group and sent to 
medical school deans for comment before publication.  Funding has now been 
provided by the Department of Health for the implementation phase over the next 
three years.99  
Research 
The Drug Misuse Research Initiative  
A number of research projects funded by the Department of Health Policy Research 
Programme, Drug Misuse Research Initiative (DMRI)100 phase two (ROUTES), have 
                                                
98 See: http://www.scottishdrugservices.com/sdd/homepage.htm 
99 For further details see: http://www.sgul.ac.uk/depts/icdp/our-programmes/substance-
misuse-in-the-undergraduate-medical-curriculum/substance-misuse-in-the-undergraduate-
medical-curriculum_home.cfm 
100 For more information and executive summaries see: 
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been completed.  The initiative comprised ten projects in areas related to drug 
treatment and aimed to deliver research-based evidence to underpin the 
development and delivery of effective services and interventions in the field of drug 
misuse.  The value of the programme is around €2.05 million (£1.4m) from 2005-
2008.  The programme encompasses issues such as access to services, service 
configuration, retention in treatment, user outcomes and experiences and cost-
effectiveness.  It focused especially on routes through services and issues relating to 
children and families.  Projects now completed and in the public domain are reported 
below. 
Barriers to the effective treatment of injecting drug users 
The research aims were to provide information on how injecting drug users 
engagement with services could be improved and the cost/benefit implications of 
successfully completing uptake (Neale et al. 2007).101  Injectors reported that 
services had improved and become easier to access in recent years.  However, there 
was still insufficient support and many barriers limited service use.  These included 
structural aspects such as waiting lists and bureaucracy, but also individual 
circumstances and psychological and emotional state, such as poor motivation and 
feelings of shame and embarrassment.  It is suggested that the cost per injector of 
not entering treatment, with continued use of street drugs, high risk injecting and on-
going crime, over the previous six months has been €8,678 (£5,936).  Key strategies 
for reducing barriers to treatment were: providing more services (particularly 
substitute prescribing, psychiatric and counselling services, and advice/information), 
as well as targeting provision at those groups currently encountering access 
problems; improving existing services (for example, by re-organising current 
provision, investing in staffing and staff training, and addressing the poor 
communication systems operating within some services); and capitalising on those 
factors which can facilitate help seeking, such as encouraging and enabling 
supportive relationships and recognising when life events and changes in injectors’ 
emotional and psychological states of mind present positive opportunities for change.  
An executive summary of this research is available on the DMRI website.  
Early exit: estimating and explaining early exit from drug treatment 
In considering the factors that lead to an early exit, Stevens et al. (2008)102 found that 
a quarter of clients dropped out between assessment and 30 days in treatment.  
Predictors of early exit were: being younger; being homeless; and not being a current 
injector.  Also, those not in substitution treatment were more likely to leave treatment 
at this stage.  However, there were substantial variations between agencies, which 
point to the importance of system factors, suggesting that some were better than 
others at getting the basics right.  It appears that drug services may deter some drug 
users from engaging in treatment by following certain practices including; requiring 
drug users to go through repeated, lengthy assessment processes and multiple 
appointments to actually get treatment, not providing the treatment (especially 
residential rehabilitation and buprenorphine prescriptions) that some had hoped to 
                                                                                                                                         
http://www.lshtm.ac.uk/research/dmri/ 
101 The study was undertaken in three areas in the North west of England; a large city, a 
medium sized town and a small town within a rural area.  Seventy-five current injectors were 
recruited from three needle exchange programmes, with additional snowball sampling to 
ensure inclusivity of gender, ethnicity and primary drug injected (opiates and stimulants)  
102 Quantitative data (n=2,624) was derived from three English Drug Action Team areas; two 
metropolitan and one provincial.  Hierarchical linear modelling (HLM) was used to investigate 
predictors of early-exit while controlling for differences between agencies.  Qualitative 
interviews were conducted with 53 ex-clients and 16 members of staff from 10 agencies in 
these areas to explore their perspectives on early exit, its determinants and, how services 
could be improved. 
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get, insisting on supervised consumption of methadone, starting methadone 
prescription at doses that may be too low to help the drug user and mixing drug users 
who are at different stages of their 'treatment journey' in the same group work 
sessions.  An executive summary of this research is available on the DMRI website.  
Exploring young people’s views and experiences of specialist substance misuse 
services  
Graham et al. (2007) considered the views of young people of specialist substance 
misuse services.103  It was found that young people perceived a range of positive 
impacts arising from their contact with specialist substance misuse services.  In 
relation to substance use, people described services as helping them to see that their 
use was problematic, giving them the motivation to address it, and helping them to 
reduce or stop using.  An executive summary is available on the DMRI website. 
User involvement in efforts to improve the quality of drug misuse services 
This report describes a study that explored the involvement of people who use drugs 
in planning, commissioning and delivery of drug treatment services (Patterson et al. 
2007).104  There was found to be wide variation in the degree to which user 
involvement systems and structures have been established and wide ranging views 
about the rationale for this, nevertheless in the main, there was an attitude of 
acceptance and acknowledgement that people who use drugs and services had a 
contribution to make in relation to service development with an overall sense of 
enthusiasm and hopefulness regarding the potential for user involvement to make a 
real difference. 
Cost and cost-effectiveness of treatment as usual in drug misuse services. 
In a study designed to gather information about what actually happens in a sample of 
drug treatment services in terms of what kind of interventions are delivered and how 
effective and cost effective these interventions are when judged against key outcome 
domains (Raistrick et al. 2008).105  Specific objectives were: to describe treatment as 
usual in a range of different services; to estimate the range of costs of treatment; to 
estimate the cost effectiveness of treatment and investigate factors that facilitate and 
hinder successful involvement; and to measure the effectiveness of treatment.  All 
services were found to have made a positive response to those seeking help and all 
delivered statistically significant health and social gains, taking people out of the 
criminal justice system, with highly significant public sector cost savings, and getting 
                                                
103 The study involved 43 in-depth interviews with young people aged 12 to 20 who had 
accessed seven specialist services in five Drug Action Teams areas.  Purposive sampling 
was used and the key selection criteria were age, sex, ethnicity, referral route and nature of 
substance misuse.  The interviews were digitally recorded, transcribed verbatim, and 
systematically analysed using the Framework method.  Recruitment was carried out via drug 
workers who approached young people on behalf of the research team.  This means that the 
study represents the views of a group of young people who had relatively positive 
experiences of the services.  
104 This surveyed service commissioners, providers and users in a representative sample of 
50 of the 149 English Drug Action Teams (DAT) and conducted in-depth case studies in six 
DAT areas.  Surveys contained a mix of open and closed questions addressing study aims.  
The response rate for the survey was: commissioners (90%), 21; NHS Trusts (42%) and 
voluntary sector providers (NGOs) (64%). 
105 The study planned to recruit 400 service users from seven drug misuse agencies, chosen 
because of their differences.  All were community based but from different treatment sectors 
and were located in very different catchment areas.  The cohort was followed up at six 
months and outcomes determined the costs of treatment and change in the key domains of 
substance use, substance dependence, social satisfaction, and psychological morbidity.  The 
EuroQol was used as an outcome measure in order to allow comparisons with NICE criteria 
for cost effectiveness.  The seven participating agencies were intentionally.  
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people into health and social care systems, with some additional public sector cost. 
The size of the treatment effect was similar to that found in other areas of healthcare 
and within the NICE approved cost limit.  The key findings were: 
• the outcome measures package (RESULT) worked well; 
• at six months, societal costs were reduced from a mean of €7,915 (£5,414) to 
€6,042 (£4,133).  The mean change of €1,873 (£1,281) at 6 months was the 
result of reduced criminal justice costs (- €2,650) (-£1,813) and increased uptake 
on health and social care (+€778) (+£532); 
• the mean cost of treatment for the SIX  month period was €946 (£647); and  
• the mean change in Quality Adjusted Life Years (QALYs) for this study was 0.29 
QALY in 6 months (NICE considers €29,240 (£20,000) - €43,860 (£30,000) an 
acceptable cost per 1.0 QALY gain). 
 
Other projects as part of DMRI awaiting completion are:  
 
• A national survey of care co-ordination in drug treatment services. 
• Interventions supporting and meeting the needs of children and young people 
who have drug misusing carers. 
• A randomised trial of an assessment-led brief intervention with young people who 
use cocaine powder. 
• Interventions for children and families where there is problematic drug use. 
• Good practice in working with family members. 
Benzodiazepine dependence 
A survey106 of healthcare workers and high-dose benzodiazepine-dependent patients 
was carried out to obtain their views on service improvements for managing high-
dose benzodiazepine dependency.  It found that respondents distinguished between 
two types of benzodiazepine users; ‘housewives’ with anxiety problems and drug 
misusers.  Neither group was felt to have adequate support services (Kapadia et al. 
2007). 
Goals, motivation and treatment 
The DTORS baseline report provides information about goals, motivation and 
treatment amongst participants in drug treatment (Jones et al. 2007a).  It was found 
that 71 per cent of participants had previous experience of treatment.  Ninety-nine 
per cent were able to specify their treatment goals when asked about them.  Most 
commonly (72%) the goal was to stop taking all drugs.  Other goals included to ‘sort 
life out’ (49%); improve health (21%); and improve employment chances (19%).  
 
To measure motivation the Circumstances, Motivation and Readiness (CMR) scale 
was adopted for the study, measuring external influences to enter treatment, such as 
legal and family pressure, and external influences that would inhibit retention in 
treatment, such as relationships.  The scale also measures levels of motivation 
(based on a recognition of the problems caused by drug use and the need to make 
changes) and a measure of readiness for treatment (i.e. a recognition of treatment 
being a necessary route in making changes to drug use and a willingness to enter).  
Respondents average scores for external influences to enter treatment ranged from 
8.5 to 10.4 (between chosen subgroups) out of a maximum score of 15, showing 
relatively neutral levels of external pressures (legal and family) to enter treatment.   
                                                
106 Two focus groups were conducted, one of drug workers and high dose benzodiazepine 
users and one of drug workers and general practitioners. Groups discussed gaps in service 
provision for benzodiazepine dependency.  Based on a thematic analysis of the discussion, a 
pilot questionnaire was developed.  The final version was sent to all 210 GPs and 21 drug 
workers in one inner-London borough.  The response rate was 105 (50%) and 13 (62%), 
respectively.  
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The International Treatment Effectiveness Project  
The International Treatment Effectiveness Project (ITEP) is part of the NTA 
effectiveness strategy, which identified areas for enhancing the quality of treatment 
interventions (Campbell et al. 2007).107  The project was a collaboration between the 
NTA, the Institute of Behavioural Research (IBR) in Texas and several service 
providers in the north west of England and London.  ITEP utilised a care planning 
approach (referred to as “mapping”) in the form of a manual, which was used by 
trained keyworkers with their clients.  It is suggested that previous research had 
shown that these psychosocial interventions had a number of positive outcomes in 
terms of clients’ treatment experiences and reductions in illicit drug use.  
 
It is reported that staff were positive about the training and psychosocial 
interventions, most agreed that they were relevant to their needs and useful, but not 
all made use of them; lack of time was cited as a barrier.  However, services that 
implemented mapping found that clients had better rapport with their keyworkers, 
there were improved levels of client participation in treatment and clients benefited 
from better peer support, compared to clients in those services that did not receive 
mapping, or received very little.  It was, therefore, concluded that there was a positive 
effect on engagement with treatment where mapping was used. 
Involving drug users in treatment decisions 
Fischer and Neale (2008) explore the problems that can arise when trying to involve 
illicit drug users in decisions about their own treatment.108  It was found that problems 
can be substantial and complex and that difficulties in implementing user involvement 
in drug treatment decision making could be grouped under five broad headings:  
• the perceived characteristics; 
• the needs and expectations of drug users; 
• the attitudes of professionals; 
• the nature of treatment dynamics; and 
• structural factors affecting service provision. 
 
They conclude that user involvement is achievable but difficult and that policymakers 
and practitioners who seek to promote it will consequently need to develop strategies 
for overcoming the kinds of problems identified in order that participation is not 
unnecessarily hampered and the benefits of involvement can be maximized.  
 
                                                
107 Four services, comprising 24 sites, in Greater Manchester took part in the project. Two 
services from London were also involved, but due to differences in training schedules the 
results from London services were not available prior to publication.  Questionnaires were 
completed by service staff and clients, which assessed the organisational climate and clients’ 
opinions of their treatment.  Data were collected in two waves: one before the implementation 
of the psychosocial interventions and the other three months after implementation.  In 
addition, two questionnaires were completed by keyworkers trained in implementing the 
manual, which measured views on training and, at a later period, their views on how useful 
the manual was. 
108 Data were collected as part of a larger study of drug-user involvement in service planning, 
service delivery and individual treatment decisions (Fischer et al. 2007), reported in last 
year’s United Kingdom Focal Point report.  Semi-structured interviews were conducted in four 
case-study drug services: two specialist community prescribing agencies (one in Scotland 
and one in England) and two residential rehabilitation agencies.  Semi-structured interviews 
(n¼187) were conducted in two specialist community prescribing agencies and two residential 
rehabilitation agencies.  Seventy-nine new treatment clients were interviewed, and 59 of 
these were re-interviewed three months later.  Interviews were also conducted with 27 agency 
staff and 22 individuals who had referred the drug users into treatment.  
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Women’s drug use and treatment in the United Kingdom 
In a review, Simpson and McNulty (2008) explore how women’s experience of drug 
use differs from men, and the implications that this has for delivering drug treatment.  
They conclude that women face different problems; including pregnancy, childcare 
responsibilities, mental health problems and abuse; many are also engaged in sex 
work.  However, gender tailored services are limited, and they therefore argue that 
drug services in the United Kingdom need to be better tailored to meet the specific 
needs of women. 
The impact of violence and abuse on engagement and retention rates for women in 
substance use treatment 
In a study to explore what is known about the impact of violence and abuse towards 
women on their rates of engagement and retention in substance use treatment, 
Galvani and Humphreys (2007)109 found that the research literature was extremely 
limited and no reliable conclusions can be drawn from it.  Key informant data resulted 
in four relevant themes: women facing the “push-pull” of wanting to attend treatment 
but being pressured not to by perpetrators; women facing an increased risk of abuse 
if they attend treatment through the perpetrator reasserting control; the enormity of 
the situation for women coping with dual problems; and practical barriers, for 
example, a male-oriented service. 
Harm reduction findings from NTA 2006 user survey 
This report investigates the harm reduction support received by the users of drug 
services, as well as pharmacy-based needle exchange services (See 7.3.1).  
5.3 Pharmacologically assisted treatment  
5.3.1 Withdrawal treatment 
See the NTA Briefing on naltrexone implants in 5.2.4 above. 
Research  
Detoxification in rehabilitation services in England 
Meier et al. (2007) looked at self-reported treatment provision in 87 residential 
rehabilitation services in England, 34 of whom reported that they offered 
detoxification services within their treatment programmes.  It was found that although 
there were no differences in self reported treatment philosophies, residential 
rehabilitation services that offered detoxification were typically of shorter duration 
overall, had significantly more beds and reported offering more group work than 
residential rehabilitation services that did not offer detoxification.  Outcomes were 
also different, with twice as many clients discharged on disciplinary grounds from 
residential rehabilitation services without detoxification facilities.  Given these findings 
the authors question the current United Kingdom classification of residential drug 
treatment services as either detoxification or rehabilitation and suggest the need for 
greater research focus on the aims, processes and outcomes of this group of 
treatment providers. 
5.3.2 Substitution treatment 
Only in Northern Ireland is substitute prescribing monitored. 
Statistics from the Northern Ireland Substitute Prescribing Database: 31 March 2007 
It is reported that during 2006/07: 
                                                
109 The study comprised a literature review and interviews with 13 key informants drawn from 
substance use treatment providers. 
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• 463 individuals were in contact with substitute prescribing treatment services; and 
• 95 individuals discontinued from the scheme, the main reason given was 
‘managed discontinuation of substitute prescribing’ (DHSSPSNI 2007a). 
The prescribing of heroin 
In 2008 the British Medical Journal110 was involved in a debate on the question of 
whether heroin addicts who are hard to treat should be prescribed heroin.  Opinion 
was divided, whilst some proposed that such treatment is appropriate under specific 
circumstances, others suggested that it is not appropriate as it merely stabilises the 
user and does not treat the effects of misuse; also that there is inconclusive evidence 
with respect to heroin prescribing.  
 
In Scotland three practitioners have a licence to prescribe diamorphine for the 
treatment of substance misuse but are not currently using it (internal communication 
from the Scottish Government).  
 
Also see guidelines on ethical prescribing in section 5.2.4, and the audit of 
prescribing practitioners and the improvement review of prescribing drugs in 5.2.5 
above. 
Research 
Community pharmacies and the provision of opioid substitution services 
In a survey of clinical activity and attitudes with regard to the treatment of opioid 
misusers by community pharmacists in 2005, Sheridan et al. (2007)111 replicated a 
survey undertaken in 1995 (Sheridan et al. 1996).  It was found that there had been a 
major increase in the number of patients to whom individual pharmacies were 
dispensing, from 54 per cent in 1995 to three-quarters; the overall number of patients 
being dispensed opioid prescriptions increased from 5,284 to 12,772.  Another 
change had been the widespread introduction of supervised consumption of 
methadone and buprenorphine, with nearly two thirds undertaking this supervision. 
 
However, it was suggested that there is still considerable unutilised capacity, in 
particular for the supervision of substitution treatment, with 92 per cent of dispensing 
community pharmacies willing to do so.  Also, a minority of respondents endorsed an 
expansion in their role, such as the administration of naloxone in an emergency, 
supervision of self-administration of injectable opioid maintenance treatment and 
administration of hepatitis B vaccinations.   
                                                
110 See: http://resources.bmj.com/bmj/about-bmj 
111 A random one-in-four sample (n = 2473) of the approximately 10 000 registered 
community pharmacies across England was selected.  The sample was stratified by the 28 
Strategic Health Authorities (SHAs) of England.  This replicated a previous survey in 1995, 
but the 2005 questionnaire was slightly modified to allow entry of information on more 
patients.  A 95 per cent (2349/2473) overall response rate was achieved.   
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6. Health correlates and consequences 
6.1 Overview  
The United Kingdom submits two sets of tables to the EMCDDA based on three 
definitions of drug-related death (DRD); each is slightly different.  The EMCDDA 
definition refers to deaths caused directly by the consumption of one or more illegal 
drug.112  The definition used by the Office for National Statistics (ONS) is a much 
wider definition and includes legal drugs.113  The third definition, used to measure 
deaths for the United Kingdom Drug Strategy, is where the underlying cause is drug 
abuse, drug dependence, or poisonings where any of the substances scheduled 
under the Misuse of Drugs Act 1971 are involved.  This definition has been adopted 
by the General Mortality Registers (GMRs) across the United Kingdom and is a 
subset of the ONS definition.  Information on deaths is also available from the 
Special Mortality Register (SMR).114  In the United Kingdom, based on the EMCDDA 
definition, DRDs rose steadily from 1996, when 1,152 deaths were registered, until 
2000, fell until 2003, and have peaked and fallen since.  Latest information is for 
2006 when there was a fall to 1,785 from 1,812 since the previous year.  Males are 
more likely to suffer DRDs than females, by over 4:1, with the difference reducing 
over the last decade.  Overall, the average age at death has gradually risen, in 2006 
it was 36.5 compared to 33.9 in 2000.  Males were approximately four years younger 
than females at death (35.6 years and 40.0 years respectively).  Information on 
deaths in 2007 is also available suggesting a small rise in numbers, but it is not 
based on the EMCDDA definition for the United Kingdom.  There are variations in 
patterns across the United Kingdom, with Scotland showing a more conspicuous 
increase over time than elsewhere.  Most deaths are associated with opiates, chiefly 
heroin/morphine and methadone.  Deaths where there is mention of cocaine have 
risen steadily and in 2007 there were 243.  
 
HIV prevalence among injecting drug users (IDUs) in the United Kingdom has been 
at around one per cent since the mid-1990s, although in London it has been higher 
at, or near, four per cent.  There is emerging evidence that suggests a possible 
increase in transmission in recent years. There were an estimated 2,000 people 
living with HIV infection acquired through injecting drug use in 2004, of whom 600 
were thought to be undiagnosed.  Prevalence of hepatitis C (HCV) has been much 
higher at around 40 per cent of IDUs, and there is evidence of increased incidence.  
Prevalence of antibodies for hepatitis B (anti-HBc) declined in the early 1990s, and 
has levelled off at around 20 per cent.  Other infections among IDUs, such as wound 
botulism and injecting site infections, are also a continuing problem.  Data suggests 
that prevalence remains stable, although HIV is slightly lower in 2007 than in the 
previous year, when it increased a little; nevertheless prevalence remains higher than 
                                                
112 These deaths are known as 'overdoses', 'poisonings' or 'drug-induced deaths'.  This 
definition was agreed by the EMCDDA group of national experts: see methodological notes 
'Drug-related death EMCDDA definition' in the 2005 statistical bulletin and DRD standard 
protocol v3.1.   
113 The ONS definition uses ICD-10 codes equivalent to F11-F16, F18, F19, X40-X44, X60-
X64, Y85, Y10-Y14 from 2000, prior to that IC9 codes 292, 304, 305.2-9, E858-8, E950.0-.5, 
E980.0 -.5, E962.0. 
114 The data source for SMR are inquests into drug-related deaths reported by Coroners in 
England, Wales, Northern Ireland, Guernsey, Jersey and the Isle of Man & Procurators Fiscal 
in Scotland. 
UNITED KINGDOM FOCAL POINT REPORT 2008  
 89
in 2000.  There has been little change in the prevalence of hepatitis C in the last 
year, however, prevalence is again higher than at the beginning of the decade. 115 
 
Prevalence and attribution of dual diagnosis remain difficult to estimate.  Depression, 
anxiety disorders, personality and psychotic disorders are commonly reported 
amongst drug users, although prevalence varies with setting and specific sub-
populations.  It has been suggested that from 1993 to 1998 there were at least 
195,000 co-morbid patients and 3.5 million general practitioner (GP) consultations 
involving such patients in England and Wales.  The level of co-morbidity is increasing 
at a higher rate among younger patients, which indicates that co-morbidity may 
increase in future years. Approximately one-third of psychiatric discharges involve a 
supplementary rather than a main diagnosis of drug use.  In these cases, the most 
common diagnoses were schizophrenia, mood (affective) disorders and alcohol 
misuse.  
 
Evidence of the extent of other physical health problems associated with problem 
drug use116 are not readily available.   
 
The impact of maternal drug use on unborn children is well known as is the fact that 
babies are affected by withdrawal from maternal drug use.  In the United Kingdom, 
there is little evidence of HIV transmission to babies through maternal infection 
specifically associated with drugs However, there is a risk of hepatitis transmission, 
particularly HCV, where the risk of transmission amongst babies whose mothers test 
positive is six per cent.  
6.2 Drug-related deaths and mortality of drug users 
6.2.1 Direct overdoses and indirect drug-related deaths 
Using the EMCDDA definition of drug-related death, the latest information across the 
United Kingdom is for 2006.  There were 1,785 deaths, a decrease of 1.5 per cent 
since 2005 (1,812) (Figure 6.1).  Differences exist between parts of the United 
Kingdom; deaths in Scotland increased from the previous year (from 352 to 416), but 
in England and Wales fell from 1,429 to 1,345, and in Northern Ireland, 31 to 24.117  
                                                
115 Data on the prevalence of blood borne infectious diseases amongst injecting drug users 
(IDUs) are provided by a number of sources.  The Unlinked Anonymous Prevalence 
Monitoring Programme’s (UAPMP) surveys of IDUs in contact with drug services in England, 
Wales and Northern Ireland (Hope et al. 2001; Unlinked Anonymous Steering Group 2002); 
the Centre for Research on Drugs and Health Behaviour’s surveys of IDUs recruited from 
community settings in England (Hunter et al. 2000); and the Scottish Centre for Infection and 
Environmental Health's (SCIEH) surveys of IDUs attending community and drug agency 
settings in Glasgow (Taylor et al. 2000).  SCIEH also holds anonymous epidemiological data 
on all those who have had a named HIV antibody test in Scotland since 1989 (on the HIV 
Denominator Database).  All collect behavioural data and oral fluid for testing for antibodies to 
hepatitis C (anti-HCV).  The main sources of information on newly diagnosed HIV/AIDS 
infections are from voluntary cases reporting from laboratory reports of newly diagnosed 
infections by microbiologists and clinicians.  For England, Wales and Northern Ireland, reports 
are made to the Health Protection Agency’s Communicable Disease Surveillance Centre 
(CDSC) whilst new diagnoses in Scotland are reported to Health Protection Scotland.  
Laboratory report data for England and Wales, Scotland, and Northern Ireland are available 
from the following websites: http://www.hpa.org.uk for England and Wales; 
http://www.hps.scot.nhs.uk/ for Scotland; and http://www.cdscni.org.uk for Northern Ireland.  
116 These includes thrombosis, blood clots and gangrene as well as health problems that are 
associated with problem drug users’ lifestyles including poor diet. 
117 Information is from GROS for England and Wales and Scotland for year of registration of 
death.  Northern Ireland data is based on year of death, this is because of a backlog in 
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The rate per 100,000 population was 2.95, but in Scotland the rate was 8.13, in 
England and Wales, 2.50 and in Northern Ireland, 1.38.  







Northern Ireland 9 12 24 11 22 27 23 16 28 31 24
Scotland 208 188 230 272 318 376 417 331 387 352 416
England & Wales 935 1,064 1,202 1,353 1,374 1,608 1,417 1,243 1,294 1,429 1,345
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Source: Compiled by J Corkery with data supplied by the General Mortality Registers and 
NISRA 2008 
 
The slightly different Drug Strategy definition, which measures the impact of the 
United Kingdom Drug Strategy118, shows the number of deaths in 2006 was 2,025; 
higher than the EMCDDA definition, a fall of two per cent since 2005 (1,987).  The 
total number of deaths in 2006 using the ONS definition was 3,201, a fall of 3.3 per 
cent from the previous year (3,311).  Deaths fell steadily from 2001 but, since 2004, 
have risen and continued to do so in 2006 (ONS 2007).  Differences between the 
three definitions are shown in Figure 6.2. 
 
                                                                                                                                         
registration mentions means that deaths going back as far as 2001 may not have been 
registered until 2007, therefore distorting the number of deaths in a given year. 
118 This definition is mainly relevant to England, but for the purpose of this report, it used to 
compile data on DRDs across the United Kingdom. 
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Figure 6.2: Comparison of total number of deaths using three definitions in the United 
Kingdom, 1996 – 2006   
Source: Compiled by J Corkery with data obtained from General Mortality Registers and 
NISRA 2008 
Age and Gender  
Based on the EMCDDA definition, 80.6 per cent (1,438) of deaths involved males 
and 19.4 per cent (347) females.  The average age of those dying was 36.5 years 
(SD 11.4), with males (35.6 years, SD 10.5) tending to be about four years younger 
than females (40.0 years, SD 14.3) (Figure 6.3).  Age at death tended to be higher in 
Northern Ireland than in the rest of the United Kingdom.  Overall, the highest number 
of deaths occurred in the 35 to 39 age group; this was true for both males and 
females.  Figure 6.3 shows the number of deaths by age group and gender. 
Figure 6.3: Deaths by age and gender United Kingdom, 2006: EMCDDA definition  
 











































ONS 'Standard' 3,118 3,310 3,482 3,653 3,478 3,704 3,457 3,166 3,396 3,311 3,201
EMCDDA DRD 1,152 1,264 1,456 1,636 1,714 2,011 1,857 1,590 1,709 1,812 1,785
UK Drug Strategy 1,440 1,558 1,739 1,941 1,930 2,172 2,037 1,780 1,887 1,987 2,025
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
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6.2.2 Drug-related deaths in 2007 
Statistics on drug-related deaths in England and Wales for 2007 have been 
published (ONS 2008).  This provides information on deaths using both the ONS and 
drug strategy definition.  However, at the time of writing it was not possible to 
categorise deaths in England and Wales in 2007 using the EMCDDA definition.  
Information on deaths from Scotland (GROS 2008) and Northern Ireland (NISRA 
2008) for 2007, allows for categorisation using all three definitions.  Using the 
EMCDDA definition, deaths in Scotland continued to rise in 2007, by eight per cent, 
from 416 to 450.  Deaths registered to the end of 2007 in Northern Ireland fell 
substantially, from 24 to six.  
 
Based on the drug strategy definition, deaths in the United Kingdom rose slightly (by 
2%) in 2007, from 2,025 to 2,069, this rise being seen in England and Wales (from 
1,573 to 1,604) and in Scotland (from 421 to 455), but there was a fall in deaths in 
Northern Ireland, from 31 to 10. 
 
Based upon the much broader ONS definition, there was a small increase (2.7%) 
from 3,201 to 3,290.  Increases can be seen in England and Wales (from 2,570 to 
2,640) and in Scotland (from 578 to 630), but there was a decrease in Northern 
Ireland from 53 to 20. 
Drugs mentioned on death certificates in the United Kingdom  
New information on drugs mentioned on death certificates are available for 2006 and 
2007 (Table 6.1).  Most deaths continue to be associated with opiates (chiefly 
heroin/morphine and methadone), often in combination with other drugs and alcohol.  
Table 6.1 shows that mentions of heroin/morphine on death certificates increased by 
14.4 per cent in 2007, having fallen in 2006.  There was also an increase in mentions 
of cocaine in both years.  Mentions of methadone also increased in 2006 and 2007, 
with 2007 figures being 50 per cent higher than in 2005. 
Table 6.1: Drug mentions on death certificates in the United Kingdom, 2002 to 2007 
Drug Year 
 2002 2003 2004 2005 2006 2007 
Heroin/ Morphine 1,120 874 979 1,049 978 1,119 
Methadone 297 289 290 294 338 440 
Cocaine 160 158 193 221 225 243 
Ecstasy 76 67 62 69 66 58 
Diazepam 357 287 223 208 178 205 
Temazepam 92 106 87 56 55 52 
Source: Compiled by J Corkery with data obtained from General Mortality Registers and 
NISRA 2008 
6.2.3 Special Mortality Register: The National Programme on Substance Abuse 
Deaths (np-SAD) 
Data from the SMR (np-SAD) database are broadly consistent with those from ONS.  
The np-SAD Annual Report for 2008 (Ghodse et al 2008). 
• In 2007 there was an increase of about 13 per cent from 1,366 to 1,539. 
• The demographic profile remains consistent with previous reports.  The majority 
of cases were males (77%), under the age of 45 years (71%), and White (95%). 
• Throughout the period 1997 to 2007 about two-thirds of cases had a history of 
drug abuse or dependence, and on average death was 14 years earlier than for 
those without such a history. 
• In 2007, 69 per cent of cases died in a defined residential address, 19 per cent in 
hospital, and 12 per cent elsewhere (e.g. a public place).   
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• In 2007, 49 per cent of those who died were unemployed. Forty-three per cent 
lived with others, compared to 45 per cent who lived alone, whilst five per cent 
were of no fixed abode. • The principal underlying causes of death were: accidental poisoning (63%); 
intentional self-poisoning (13%); and poisoning of undetermined intent (12%). 
• Opiates/opioids (heroin/morphine, methadone, other opiates/opioid analgesics), 
alone or in combination with other drugs, accounted for the majority (71%) of 
fatalities.  Heroin/morphine, alone or in combination with other drugs, accounted 
for the highest proportion (48%) of fatalities. 
• Deaths involving methadone were more likely to be the result of illicit (70%) 
rather than prescribed drugs. 
• The proportion of cases involving methadone increased from 17 per cent to 20 
per cent; the number of such cases increased from 264 to 295. 
• The proportion of cases involving cocaine increased from 11 per cent to 16 per 
cent; the number of such cases increased from 174 to 239. 
• The proportion of cases involving hypnotics/sedatives increased from 17 per cent 
to 21 per cent; the number of such cases increased from 259 to 309 . 
• The proportion of cases involving alcohol in combination with other substances 
increased from 34 per cent to 38 per cent; from 525 to 554.  
• There was one death involving LSD; the first notified since 2002.  
 
To date, there were six cases in both 2006 and 2007 where methamphetamine was 
reported in the post mortem toxicology to the np-SAD.  In one of the cases in 2007, 
death was due to mixed drug poisoning including methamphetamine.  In other cases 
it seems likely that the presence of the substance was associated with the use of 
ecstasy. 
 
The np-SAD is aware of a minimum of 12 deaths in England and Wales (there have 
been none in Scotland or Northern Ireland) up to the end of 2007 where piperazines 
have been found at post-mortem; one of these has yet to go to inquest.  Details for 
three of the cases are given in the literature review below (Elliot and Smith 2008).  
For the 11 cases occurring in 2006 to 2007 reported to np-SAD, benzylpiperazine 
(BZP) and 3-Trifluoromethylphenylpiperazine monohydrochloride (TFMPP) were 
found in six cases; BZP in four cases, and chlorophenylpiperazine (CPP) in one 
case. In two cases piperazines (BZP; BZP and TFMPP) were mentioned specifically, 
along with other substances, in the cause of death. In a further case CPP was 
included in the substances where the death was described as multiple mixed drug 
intoxication.  
 
One death from cocaine toxicity, following the swallowing of cocaine powder mixed 
with water, occurred in 2007.  This is believed to be the first such case in the United 
Kingdom. 
6.2.4 Deaths associated with Volatile Substance Abuse 
There were 49 deaths associated with volatile substance abuse in 2006 (45 in 2005).  
This is the third lowest figure since 1981 and compares with a peak of 152 in 1990 
(Field-Smith et al. 2008).  Gas fuels, including 21 lighter fuel deaths, accounted for 
27 cases; aerosols for six; nitrous oxide five; ‘poppers’ three; and other substances 
accounted for seven cases.  Six of the deaths occurred in the under 18 years age 
group, eight were aged 18 to 24 years, and 17 were aged 25 to 34 years.  The 
median age was 33 years (range 15 to72 years). 
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6.2.5 AIDS 
Deaths of injecting drug users (IDUs) (including IDUs who have sex between men) 
accounted for 7.9 per cent (1,269/16,102) of the total number of AIDS deaths in 
England and Wales up to the end of December 2007.  In Northern Ireland the 
proportion was five per cent (4/79), but in Scotland it was 51 per cent (727/1,438).  
The decline in the number of deaths of IDUs with AIDS seen in recent years has 
leveled off.  The United Kingdom figure of 51 for 2006 (79 in 2005) is about 37 per 
cent of the peak level in 1995 (212).  By the end of December 2007, 34 deaths had 
been reported for that year; the number is likely to increase (personal communication 
to John Corkery from Health Protection Agency). 
Research  
Geographical variation in DRD in England and Wales  
A paper accompanying the publication of the latest drug-related death figures in 
England and Wales, considered geographical variations in death (based on the drug 
strategy definition) between 1993 and 2006 (Griffiths et al. 2008).  The Government 
regions with the highest mortality rates over this period were the North West, 
Yorkshire and the Humber, and London; however, by 2004 to 2006 London had 
amongst the lowest rates anywhere.  Rates were highest in urban areas and lower in 
rural areas. 
Problems associated with defining and classifying drug-related deaths  
The problems associated with defining and classifying drug-related deaths is the 
subject of an article by Corkery (2008).  This summarises different approaches to 
defining what constitutes a DRD and how they can be classified.  DRDs usually fall 
into two broad categories: those directly attributable to the consumption of drugs 
(both illegal and licit), for example. overdose and poisoning, and indirect, those which 
occur as a consequence of having a drug habit that exposes individuals to the risk of 
dying in some other way, e.g. blood-borne infections or accidents.  Most attention is 
currently given to direct or acute DRDs rather than the long-term consequences of 
drug abuse.  Problems associated with accurately deriving DRD statistics are 
outlined.  It is suggested that despite limitations, such information is essential for 
identifying issues related to drug use and measuring progress against targets set for 
reducing DRDs. 
Drug deaths in the North Staffordshire area  
Smith and Crome (2007) report that the annual reports for drug abuse deaths in the 
North Staffordshire area are, as a whole, about average for the country.  The figures 
for the period 2001 to 2005 indicate an average of just over eight deaths per annum 
in the under 30 age group, with a peak of 13 in 2002 and only six in 2005.  
Interestingly, deaths from drug abuse, which invariably involve heroin in all age 
groups, typically and increasingly take place in the older age groups.   
Deaths identified in the DORIS cohort 
Secondary analysis of the DORIS cohort study119 found that 38 deaths occurred, 
giving a standardised mortality ratio for the cohort of 1,244 (Bloor et al. 2008) but only 
22 were classified as drug-related deaths.  From estimates of the size of the problem 
drug using populations in both England and Scotland, the contribution of deaths in 
drug users to national death rates was estimated; the attributable risk fraction for 
Scotland is 17.3 per cent and that for England is 11.1 per cent.  Excluding estimated 
numbers of deaths in drug users brings down the age-standardised mortality at ages 
15 to 54 years from 196 to 162 per 100,000 in Scotland and from 138 to 122 per 
100,000 in England; 32 per cent of the extra mortality in Scotland is due to drug use.  
                                                
119 1,033 Scottish drug users recruited in 2001/02 and followed up at 33 months. 
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The researchers conclude that the standardised mortality ratio for Scottish drug users 
is 12 times as high as for the general population.  The higher prevalence of problem 
drug use in Scotland than in England accounts for a third of Scotland’s excess 
mortality over England.   
Drug deaths in Fife, 2005 to 2007 
The Fife Drug Deaths Monitoring and Prevention Group investigated drug deaths in 
Fife in 2005-07 (Baldacchino et al. 2008).  The number of deaths was higher in 2006 
(19) and 2007 (20) than in 2005 (15) but below the Scottish average.  The 
investigation found that deaths were more likely to occur in socially deprived areas 
and areas with other drug-related problems.  The mean age of decedents was 31 
years (range 17 to 48).  Multiple morbidities were present in the youngest and oldest 
individuals; the youngest tending to have psychological conditions; the oldest had 
physical health problems.  Most deaths occurred in Spring and at the weekend.  
Heroin/morphine (80%), diazepam (43%) and alcohol (35%) were the three main 
substances of misuse detected. Benzodiazepines are the substances most 
commonly implicated (89%).  Psychostimulants (for example, MDMA) were involved 
in 10 per cent of deaths; however there is a recent emergence (2007) of deaths 
involving cocaine. These findings are consistent with Scotland-wide research but not 
reflected in United Kingdom national research where heroin/morphine, alcohol and 
other opioids are the most frequently detected substances of misuse.  Twenty-two 
per cent were receiving pharmacological treatments; most were prescribed 
methadone (18%).  Of these decedents, 16 per cent were still on a methadone 
programme when they died. 
Withdrawal of co-proxamol  
Legislative changes in 2005 led to a phased withdrawal of co-proxamol from the 
United Kingdom market.  Sandilands and Bateman (2008) undertook a retrospective, 
observational study of mortality relating to poisoning by single agents in Scotland for 
the period 2000 to 2006.  Mortality data were obtained from the General Register 
Office Scotland, and primary care prescribing data from the Information and Statistics 
Division of the Scottish Executive Health Department.  A significant reduction in the 
proportion of poisoning deaths involving co-proxamol was observed following the 
changes in legislation (mean 2000 to 2004, 37 deaths, 21.8% of total poisoning 
deaths; 2006, 10 deaths, 7.8% of total poisoning deaths).  The most significant 
reduction was seen in male out-of-hospital deaths (mean 2000 to 2004, 17 deaths 
21.8% of total poisoning deaths; 2006, two deaths 2.9% of total poisoning deaths). 
This was associated with a decline in prescriptions by 60 per cent within six months 
of legislation.  The authors argue that legislation has resulted in a major reduction in 
the number of deaths associated with co-proxamol poisoning in Scotland, with no 
compensatory increase in mortality from poisonings from other common analgesics.  
They extrapolate that a minimum of 300 lives across the UK have been saved by the 
withdrawal of co-proxamol. 
Suicide and homicide by people with mental illness  
In June 2008 the Centre for Suicide Prevention published its findings for Scotland on 
suicide and homicide by people with mental illness (CSP, 2008).120  Amongst the 
range of issues explored were the roles of alcohol and drug misuse in such deaths.   
 
There was a history of alcohol misuse in 785 suicides by patients with mental illness 
(an average of 131 deaths per annum) and a history of drug misuse in 522 (an 
average of 87 deaths per annum).  Dual diagnosis (severe mental illness and drug or 
                                                
120 The study covers 1,373 patient suicides in the period January 2000 to December 2005; 
and 58 homicides by patients in the period January 2000 to December 2004. 
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alcohol dependence/misuse) was found in a quarter of patient suicides, 343 in total, 
an average of 57 deaths per annum.   
 
More than three quarters (45) of patients who were perpetrators of homicide had a 
history of drug misuse.  Almost three quarters (41) had a history of alcohol misuse. 
About a quarter (13) were identified as having a dual diagnosis.   
 
In both suicide and homicide, most were not under the care of addiction services.  
The report concludes that alcohol and drugs are the most pressing mental health 
problems in Scotland and makes recommendations for development of services. 
Confidential enquiries into maternal deaths in the United Kingdom  
The seventh report on confidential enquiries into maternal deaths in the United 
Kingdom reported on deaths between 2003 and 2005 (Lewis 2007). Maternal deaths 
are extremely rare; 295 women died from causes directly or indirectly related to their 
pregnancy, out of more than two million mothers who gave birth in the United 
Kingdom during this period.  Eleven per cent of those who died of any cause had 
problems with drugs or alcohol; 60 per cent of the latter were known to drug services.  
Fifty-seven women out of the 98 women whose deaths were attributable to 
psychiatric causes had problems with substance abuse; 45 were misusing drugs and 
12 were alcohol dependent.  One death resulted from volatile substance abuse.  The 
majority of those who were drug dependent were using heroin, but most were also 
using methadone, amphetamines, cocaine, benzodiazepines and some were also 
using alcohol.  A small number died from suicide, the rest died from an accidental 
overdose, physical consequences of their abuse or related medical conditions.  
Some died from domestic abuse.  Many of the subjects were socially excluded; most 
being homeless or living in very inadequate conditions.  The report concludes that 
substance misuse makes a significant contribution to maternal mortality in general, 
and especially to psychiatric causes. 
Drug-related deaths among newly released prisoners 
Farrell and Marsden (2008) investigated drug-related deaths among newly released 
prisoners in England and Wales.121 They recorded 442 deaths, of which 261 (59%) 
were drug-related.  In the year following release, the drug-related mortality rate was 
5.2 per 1,000 among men and 5.9 per 1,000 among women.  All-cause mortality in 
the first and second weeks following release for men was 37 and 26 deaths per 
1,000 per annum, respectively (95% of which were drug-related).  There were 47 and 
38 deaths per 1,000 per annum, respectively, among women, all of which were drug-
related.  In the first year after prison release, there were 342 male deaths (45.8 were 
expected in the general population) and there were 100 female deaths (8.3 expected 
in the general population).  Drug-related deaths were attributed mainly to substance 
use disorders and drug overdose.  Coronial records cited the involvement of opioids 
in 95 per cent of deaths, benzodiazepines in 20 per cent, cocaine in 14 per cent and 
tricyclic antidepressants in 10 per cent. They concluded that newly released 
prisoners are at acute risk of drug-related death.  
Alcohol and heroin/opiate overdose 
Hickman et al. (2008a) reviewed the evidence in support of the hypothesis that 
alcohol increases the risk of a heroin/opiate overdose through a pharmacological 
interaction.  A few facts are already well established, including that: opiate overdose 
deaths rarely involve a single drug; alcohol is the most common substance involved; 
there is a negative association between alcohol and morphine concentration at post 
mortem; and post-mortem levels of morphine are often below the levels expected of 
                                                
121 They took into account a national sample of 48,771 male and female sentenced prisoners 
released during 1998-2000 with all recorded deaths included to November 2003.   
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highly tolerant individuals.  Although the existing evidence, according to the authors, 
is consistent with the hypothesis that heroin users who drink alcohol may require less 
heroin to overdose than those who do not drink (all other factors being equal), other 
causal (and non-causal) pathways could not be ruled out.  They suggested that 
alcohol could be associated negatively with tolerance, or confounded by other 
factors.  
Mortality and piperazines  
Elliott and Smith (2008) used ultraviolet and liquid chromatography-mass 
spectrometry data to distinguish the structures of positional isomers of TFMPP and 
CPP, and confirm the presence of BZP and 3-TFMPP in three UK fatalities (road 
traffic deaths and a fatal fall), with two cases involving both drugs.  These are the first 
reported cases of 3-TFMPP in post-mortem fluid. In all cases, other drugs and/or 
ethanol were found. BZP was found at concentrations of 0.71, <0.50, and 1.39 mg/L 
and 3-TFMPP was found at concentrations of 0.05 and 0.15 mg/L in post-mortem 
blood. Concentrations were also measured in urine. Although BZP and 3-TFMPP 
were not the direct cause of death, it is suggested that the toxicological findings may 
assist the interpretation of future cases involving these drugs.  
Patterns of mortality amongst injecting and non-injecting drug users in contact with 
treatment services 
Hurst et al. (2007) studied the causes of death amongst individuals in contact with 
treatment services in the North West of England.122 There were 285 individuals 
confirmed as having died over the period, three-quarters of whom were male. 
According to the drug strategy definition of DRD, 93 (33%) of those confirmed as 
dead, died from a DRD.  Those who died from a DRD were significantly younger 
(mean age 33.2 years) than those who died of other causes (mean age 39.9 years).  
Seventy-six had an injecting history.  Individuals with an injecting history were 
significantly more likely to die from a DRD than those with no injecting history.  They 
were also more likely to die from heart complications, 23 per cent (n=19) compared 
to 7 per cent (n=5) of non-injectors.  The study also found that a large minority of 
non-DRDs were attributable to liver disease (16%, n=31), with 24 deaths being 
directly linked to alcohol.  The authors conclude that the disparate causes of death 
amongst injectors and non-injectors highlight the need to address general physical 
and psychological health of those in treatment rather than concentrate on specific 
diseases. 
6.3 Drug-related infectious diseases 
Information on infectious disease is based on Shooting Up: Infections among 
injecting drug users in the United Kingdom 2007. Update 2008 (HPA et al. 2008).  
 
6.3.1 HIV 
The overall prevalence of HIV seen among IDUs in 2007 was similar to that seen in 
recent years, and remains higher than that seen in the late 1990s.  The Unlinked 
Anonymous Prevalence Monitoring Programme (UAPMP) survey of current and 
former IDUs in England, Wales and Northern Ireland indicates an overall HIV 
prevalence of 1.1 per cent in 2007 (HPA et al. 2008).  In London, the prevalence was 
3.9 per cent, whilst elsewhere in England it was 0.56 per cent.  Combining data for 
                                                
122 The regional National Drug Treatment Monitoring System (NDTMS) dataset were 
interrogated to identify individuals who treatment services reported as having died between 
April 2003 and March 2006. Death certificates were obtained from the Office for National 
Statistics (ONS) and injecting status was determined by NDTMS data and information from 
the Cheshire and Merseyside Inter Agency Database, which collects data on those in contact 
with agency and pharmacy exchanges in the region.  
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2006 and 2007, the prevalence of HIV infection among IDUs in the UAPMP agency 
survey in Northern Ireland was 1.9 per cent and in Wales, 1.1 per cent. 
 
There is evidence that ongoing HIV transmission among IDUs within the United 
Kingdom has increased in recent years.  In particular, HIV prevalence amongst 
recent initiates (those injecting for less than three years) in England, Wales and 
Northern Ireland has been elevated since 2003.  The prevalence among the recent 
initiates participating in the UAPMP survey was 1.0 per cent in 2007 compared to 
0.25 per cent in 2002. 
 
In Scotland, the prevalence of HIV among IDUs is monitored through the surveillance 
of people undergoing voluntary confidential HIV testing.  This found a HIV prevalence 
of 0.3 per cent among IDUs undergoing testing during 2007; this compares with 
prevalences of 1.4 per cent to 3.2 per cent in the early to mid-1990s and 0.5 per cent 
to 0.9 per cent during the period 1998 to 2006.  
 
The annual number of HIV diagnoses among IDUs in recent years has been low and 
relatively stable, at an annual average of 144 reports during the period 1998 to 2007.  
By the end of June 2008, 152 HIV diagnoses, where infection was thought to have 
been acquired through injecting drug use, have been reported in the United Kingdom 
for 2007 (62 in London, six in Scotland, and 84 elsewhere).  This figure is likely to 
rise further as additional reports are received for 2007.  Whilst the annual number of 
reports of newly diagnosed HIV infections associated with injecting drug use has not 
changed greatly over recent years, the proportion of the reports from outside London 
and Scotland has increased from 34 per cent during the period 1993 to 1997 to 49 
per cent during 2003 to 2007.  Of the 152 new diagnoses in 2007, probable country 
of infection was reported for 61 per cent (93).  Where reported, 48 per cent (45) of 
infections were thought to be acquired within the United Kingdom and 52 per cent 
(48) outside of the United Kingdom, mostly in Southern Europe. 
 
In 2007, 1,065 HIV-infected IDUs were seen for HIV-related treatment or care in 
England, Wales and Northern Ireland, a 22 per cent increase since 2000 when 870 
IDUs were seen for care.  In Scotland, 364 HIV-infected IDUs were seen for HIV-
related treatment or care in 2007, a 13 per cent decrease since 2000 when 417 IDUs 
were seen for care. 
6.3.2 Viral hepatitis 
The prevalence of hepatitis C infection among IDUs remains high overall.  Of the 
current and former IDUs participating in the UAPMP agency survey in 2007, two-
fifths (39%) had antibodies to hepatitis C123, which is similar to that seen in recent 
years (2006, 41%).  The overall hepatitis C prevalence in England was 42 per cent, 
however, there were very marked regional variations from 21 per cent in the North 
East to 58 per cent in London and 60 per cent in the North West (data from 2006 and 
2007 combined).  The prevalence in Wales and Northern Ireland was lower than 
most of the English regions; combining data from 2006 and 2007, hepatitis C 
prevalence in Wales was 21 per cent, and in Northern Ireland it was 29 per cent.  
 
Those IDUs participating in the UAPMP survey who had ever been homeless were 
more likely to have antibodies to hepatitis C (42%) than those who had not (29%). 
 
                                                
123 The sensitivity of the oral fluid test used in the UAPMP agency survey is approximately 93 
per cent. 
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Amongst current IDUs participating in the UAPMP survey the prevalence of hepatitis 
C has increased since the beginning of the decade, from 33 per cent in 2000 to 40 
per cent in 2007.  There were higher prevalences of hepatitis C infection among 
several sub-groups of current IDUs.  Those who reported injecting crack cocaine in 
the past four weeks were more likely to have hepatitis C (56%) than those who had 
not (32%), as were those who reported injecting cocaine powder (48%, compared 
with 39% of those who had not).  Higher prevalence was also associated with the use 
of some injection sites; those who had injected into their groins in the past four weeks 
were more likely to have hepatitis C (53%) than those who had not (35%). 
 
In 2007, the estimated sero-prevalence of hepatitis C was 74 per cent among 358 
IDUs surveyed at needle exchanges in Glasgow, similar to the estimated sero-
prevalence of 71 per cent found among 435 Glasgow IDUs recruited from needle 
exchanges in 2005. Among 57 current IDUs surveyed in Glasgow in 2007 who had 
commenced injecting in the previous five years, the sero-prevalence of hepatitis C 
was 57 per cent; this compares to a sero-prevalence of 50 per cent among 81 
equivalent IDUs surveyed in 2005.   
Research  
Needle Exchange Surveillance Initiative (NESI) in Scotland 
In a survey of 667 IDUs recruited from needle exchanges in three NHS Boards in 
Scotland in 2007124, prevalence of antibodies to hepatitis C was 61 per cent 
(Palmateer et al. 2008).  Prevalence was highest amongst those aged over 25 and 
those who had started injecting over three years ago. 
Homelessness and the risk of Hepatitis C 
In a critical review of homelessness and the risk of hepatitis C, Neale (2007) 
suggests that although it is difficult to estimate the number of homeless people who 
are misusing drugs or the number of drug users who are homeless, United Kingdom 
and international literature indicates a significant overlap between the two groups; a 
situation described as a ‘double jeopardy’. 
Hepatitis C infection among female IDU sex workers 
A study of female IDU sex workers in Glasgow125 identified an hepatitis C antibody 
prevalence of 81 per cent; a considerably higher rate than the wider injecting 
population of Glasgow (Taylor et al. 2008).   
6.3.3 Sexually transmitted infections 
Research 
Sexual health risk amongst dance drug users 
A study by Mitcheson et al. (2008) using data taken from the 2003 Mixmag survey, 
compared sexual health risk amongst dance drug users with general population data 
from the United Kingdom National Survey of Sexual Attitudes and Lifestyles 2000 
Survey (NATSAL 2000).126  They found that dance drug users were more likely to 
                                                
124 All clients attending selected needle exchanges in Greater Glasgow and Clyde, Lothian 
and Lanarkshire NHS Boards were invited to take part if they had injected drugs on a least 
one occasion.  667 participants completed the survey during May through December 2007 
and 640 participants (96%) voluntarily provided a saliva sample for testing for HCV 
antibodies. 
125 All women attending the health and social care drop-in centre situated in Glasgow’s “Red 
Light Area” during a four-week period in 1999 were invited to participate.  98 female sex 
workers provided a saliva sample for anonymous HCV testing and completed a questionnaire. 
126 Data on dance drug users were taken from the 2003 Mixmag Drug Survey, a self-selecting 
survey of readers of a dance music magazine.  The questionnaire was printed in the 
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have concurrent sexual partnerships and to have had unprotected sex in the past 
year; 39.2 per cent of men and 41.1 per cent of women with two or more sexual 
partners in the last year reported unprotected sex compared to 15.4 per cent and 
10.1 per cent respectively in the NATSAL sample.  Both males and females in the 
Mixmag sample were more likely to have been diagnosed with a sexually transmitted 
infection than those in the NATSAL sample with the difference more pronounced 
amongst females; 23.3 per cent of females in the Mixmag sample had been 
diagnosed with a sexually transmitted infection (STI) compared to 12.6 of the 
NATSAL sample. 
DTORS 
Baseline data from the Drug Treatment Outcomes Research Study (DTORS) (see 
Chapter 4.6) show that 48 per cent of treatment seekers had unprotected sex in the 
past three months, although 70 per cent of those involved regular partners only 
(Jones et al. 2007). 
6.3.4 Other infectious morbidity 
The following information is reported in Shooting Up: Infections among injecting drug 
users in the United Kingdom 2007. Update 2008 (HPA et al. 2008).   
 
Cases of wound botulism continue to occur among IDUs in the United Kingdom.  In 
2007, 11 suspected cases were reported, fewer than in each of the previous three 
years, with 22, 28 and 41 cases reported in 2006, 2005, and 2004 respectively. 
 
Cases of tetanus continue to occur albeit at lower numbers than in 2003 and 2004.  
In the three year period 2005 to 2007, seven of the 14 cases of tetanus reported in 
the United Kingdom were IDUs (four in 2005, one in 2006, and two in 2007) 
indicating tetanus continues to affect IDUs, albeit at lower levels than in 2003 and 
2004.  
 
Cases of severe infection related to both meticillin resistant Staphylococcus aureus 
and Group A streptococci continue to occur among IDUs. 
 
Symptoms of a possible injecting site infection appear to be common among IDUs, 
with 34 per cent of IDUs participating in the UAPMP survey in 2007 reporting they 
had experienced either an abscess, sore or open wound, possible symptoms of an 
injecting site infection, during the previous year.  The reporting of such a symptom 
was associated with having been homeless in the last year, with 39 per cent of those 
homeless during the last year reporting a symptom compared with 32 per cent of 
those not homeless. 
 
These symptoms of possible injecting site infections were found to be associated 
with a number of factors among current IDUs.  Overall, 40 per cent of the current 
IDUs participating in the UAPMP survey in 2007 reported these symptoms during the 
last year.  Current IDUs who used the following injection sites during the last four 
weeks reported higher levels of symptoms: hands (52%, compared with 35% of those 
who had not), groin (45%, compared with 37% of those who had not), legs (63% 
compared with 34% of those who had not) and feet (67%, compared with 36% of 
those who had not).   Higher levels of symptoms were also found among those who 
                                                                                                                                         
September edition of the magazine and was also available online.  In 2003, 1,105 people 
living in the UK completed the sexual behaviour questionnaire.  The NATSAL survey used 
postcode randomisation to generate a sample and 11,161 interviews were completed, a 
response rate of 65.4%.  There are clear differences between the sampling strategies of the 
two surveys. 
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in the last four weeks had injected crack cocaine (49%, compared with 34% of those 
who had not) or cocaine powder (51%, compared with 38% of those who had not). 
 
In July 2008, the Health Protection Agency issued an alert about the possible 
presence of contaminated heroin.127  In the previous month, two cases of a rare 
wound infection involving the bacterium Clostridium Novyi had been identified in 
Southern England, one of which had resulted in a fatality.  A similar outbreak of 
severe systemic sepsis related to soft tissue inflammation occurred in IDUs in 2000 
and again in late 2003/early 2004. 
 
A survey recruiting IDUs from community settings at seven locations across England 
from 2003 to 2005 collected self-reported information on injecting practice, symptoms 
of injection site infections (abscess or open wound) and health service utilisation data 
using a questionnaire (Hope et al. 2008).  This study also made cost estimates by 
combining questionnaire data with information from national databases and the 
scientific literature.  It found that 36 per cent of the 1,058 participants reported an 
injection site infection in the last year.  Those reporting an injection site infection were 
more likely to be female and aged over 24, and to have: injected into legs, groin, and 
hands in last year; injected on 14 or more days during the last four weeks; cleaned 
needles/syringes for reuse; injected crack cocaine; have antibodies to hepatitis C; 
and previously received prescribed substitute drugs.  Two-thirds of those with an 
injection site infection reported seeking medical advice; half attended an emergency 
department and three-quarters of these reported hospital admission.  Simple 
conservative estimates of associated healthcare costs range from €22.7 million 
(£15.5m) per year to as high as €44 million (£30m); though if less conservative unit 
cost assumptions are made the total may be much higher, €69 million (£47m)). The 
vast majority of these costs are due to hospital admissions and the uncertainty is due 
to little data on length of hospital stays (Hope et al. 2008).  
6.4 Psychiatric co-morbidity (dual diagnosis) 
6.4.1 Prevalence  
Scotland  
In Scotland during 2006/07, 42 per cent of new clients accessing treatment services 
reported mental health problems as a co-occurring health issue (ISD 2007). 
 
Inpatient hospital data from Scotland show that, in 2005/06, 6.6 per cent of 
psychiatric inpatient discharges had a diagnosis of drug misuse (as either a main or 
supplementary diagnosis), a rate of 33 discharges per 100,000 population.  Drug 
misuse was the primary diagnosis in 58 per cent of these discharges.  The rate per 
100,000 population has remained stable since 2001/02 with a decrease in 2005/06 
(Figure 6.4). 
                                                
127See:http://www.info.doh.gov.uk/doh/embroadcast.nsf/vwDiscussionAll/9AAE30210778592
A8025749100426322  
UNITED KINGDOM FOCAL POINT REPORT 2008  
 102
Figure 6.4: Psychiatric inpatient discharges with a diagnosis of drug misuse in Scotland, 





























Source: ISD 2007 
 
Fifty-three per cent of psychiatric inpatient discharges with a discharge diagnosis of 
drug misuse, recorded use of multiple drugs or other psychoactive substances.  
Opioid use was the most commonly recorded drug (26%) followed by cannabinoids 
(16%).128 
Research  
Co-morbid substance misuse in psychiatric patients 
Sinclair et al. (2008) reported on the prevalence of substance misuse in patients 
admitted for psychiatric inpatient care in a Mental Health Trust in England.129  Alcohol 
was the most common substance of misuse, with 51 per cent of men and 29 per cent 
of women screening positive for harmful use of alcohol (defined as a score of eight or 
more on the Alcohol Use Disorders Identification Test (AUDIT)).  Thirty per cent of 
participants reported use of one or more illicit substances in the month prior to 
admission; the most commonly reported illicit drug was cannabis followed by cocaine 
powder.  There were statistically significant differences between genders in last 
month use of cannabis (35% of males reported use compared to 11% of females), 
amphetamines (9% and 2% respectively), and ecstasy (10% and 2% respectively).  
Almost two-thirds (64%) of those reporting illicit substance use screened positive for 
harmful use of alcohol.  
Dual diagnosis in psychiatric and drug treatment services 
Manning et al. (2008) explored the differences in dual diagnosis disorders among 
patients in psychiatric and drug treatment services.130  Prevalence rates of dual 
                                                
128 Figures for 2005/06 are provisional (due to two areas having incomplete information) at the 
time of writing and may therefore, be subject to revision.   
129 The study examined rates of co-morbid substance use in patients admitted for psychiatric 
inpatient care in Oxfordshire Mental Health Trust between 1 July 2005 and 31 October 2005.  
Of the 238 patients admitted during the study period, 178 (74.8%) agreed to participate in the 
study, 52 per cent were male and 48 per cent were female. A structured data collection 
proforma was completed for all patients including class of non-prescribed drug use in the 
month prior to admission. 
130 Patients were recruited from four treatments services in one London Borough.  Of the 456 
patients at the four treatment sites, 222 screened positive for dual diagnosis and 159 took 
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diagnosis (including alcohol) differed between treatment services, they were: 
community mental health service (37%), inpatient psychiatry service (56%) and drug 
dependence treatment service (91%).  There were differences between the severity 
of psychiatric and drug disorders and the authors suggest that the term dual 
diagnosis can be misleading, masking the diverse range of complex needs amongst 
patients. They highlight the difference between drug dependent patients with anxiety 
and depressive problems and patients with serious mental illness such as psychosis, 
who abuse drugs such as cannabis. 
DTORS: Baseline study 
Twenty-three per cent of treatment seekers in DTORS had been diagnosed with a 
mental health condition in their lifetime and 37 per cent had been referred to a 
psychiatrist, psychologist or other mental health worker.  Twenty-eight per cent had 
received psychiatric treatment, with 11 per cent receiving treatment in the last three 
months (Jones et al. 2007). 
6.4.2 Personality disorders 
Research 
Genotype effects in schizophrenia and interactions with cannabis  
Zammit et al. (2007) examined whether variants within the cannabinoid receptor 
(CNRI) genes are associated with schizophrenia and whether these effects vary 
according to cannabis use.131  They found that there was no evidence of association 
between schizophrenia and CNRI genotypes or of interactions between cannabis use 
and CNRI.  Similarly, there was no evidence for any association between COMT 
variation and cannabis use in the sample of those with schizophrenia. 
Effects of cannabidiol on schizophrenia-like symptoms 
A study of the effects of cannabidiol on schizophrenia-like symptoms in people who 
use cannabis132 found that participants with both delta-9-THC and cannabidiol (CBD) 
present in hair samples had lower levels of unusual experiences (hallucinations and 
delusions) than those with delta-9-THC only (Morgan and Curran 2008).  The authors 
suggest the findings may support previous work showing the antipsychotic properties 
of CBD.  They stress the importance of distinguishing between different cannabinoids 
and suggest that this has implications for the debate over the link between cannabis 
use and psychosis. 
Prevalence and incidence of schizophrenia in the UK, 1996 to 2005 
A study carried out by Frisher and Crome for the Advisory Council on the Misuse of 
Drugs (ACMD) examined the prevalence and incidence of schizophrenia and 
psychoses among 900,000 patients attending 183 general practices in the United 
Kingdom between 1996 and 2005 (ACMD 2008).  This tested the projections of 
                                                                                                                                         
part in the study (72%).  A number of standardised measures were used to screen for mental 
health and substance misuse disorders. 
131 Genotype effects of CNRI were studied in a case-control sample of 750 individuals with 
schizophrenia and 688 controls, with interactions for these genes studied in small sub-
samples.  A case-only design of 493 of the schizophrenia group was used to examine 
interactions between cannabis use and catechol-O-methyltransferase (COMT) (research has 
suggested that variations in the COMT gene can increase the risk of psychosis in adolescent 
cannabis smokers) 
132 The sample consisted of 140 individuals taking part in a longitudinal study involving groups 
categorised as current and former ketamine users, other drug users and non-users.  Using 
hair analysis, 54 individuals screened positive for cannabis.  The sample was divided into 
three groups: those with delta-9-THC only (n=20); those with delta-9-THC and CBD (n=27); 
and those with no cannabinoids (n=85).  The short form of the Oxford Liverpool Inventory of 
Life Experiences (OLIFE) was used to assess psychosis proneness.  
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Hickman et al. (2007) (reported in UK Focal Point 2007 Annual Report) which 
claimed that an increase in cannabis use would lead to an increase in schizophrenia.  
However, Frisher and Crome found that, despite the increase in cannabis use, both 
the prevalence and annual incidence of schizophrenia and psychoses have 
decreased. 
Incidence of psychotic disorders 
Kirkbride et al. (2008) looked at whether the incidence of first episode psychoses had 
changed over a 20 year period in a single setting.133 The study found that, while the 
incidence of non-affective or affective psychoses had not changed, there was a linear 
increase in the incidence of substance-induced psychosis.  They conclude that there 
has been a change in the syndromal presentation of non-affective psychoses over 
time away from schizophrenia towards other non-affective disorders such as 
substance-induced psychosis, which is consistent with increases in substance 
toxicity rather than prevalence or vulnerability to substance misuse. 
6.4.3 Anxiety 
In the study by Manning et al. (2008) (see 6.4.1), eight out of 14 drug treatment 
patients were diagnosed with anxiety. 
6.4.4 Affective disorders 
In the study by Manning et al. (2008) (see 6.4.1), six out of 14 drug treatment 
patients were diagnosed with an affective disorder.  
6.5 Other drug-related health correlates and consequences 
The ACMD published a report summarising the available United Kingdom and 
international evidence on the impact of cannabis on public health (ACMD 2008a) 
(see Chapter 1.2.1). 
6.5.1 Somatic co-morbidity 
In Scotland police issued a warning about poor quality “red heroin”, which crystallises 
quickly.  This means that users are likely to inject more quickly which could cause 
vein damage, abscesses and deep vein thrombosis.134 
Research  
Crack cocaine-heroin speedball injecting  
Rhodes et al. (2007) reported on a qualitative study with crack cocaine-heroin 
speedball injectors.135  The latter was associated with a higher level of vein damage 
and a shift towards groin injection.  Participants identified deep vein thrombosis, 
septicaemia and bacterial infections as complications associated with groin injection 
and the authors identified five main strategies used by injectors to reduce risks 
                                                
133 Data from three similar studies that took place in Nottingham, England between 1978 and 
1999 were obtained.  The entire population at-risk aged 16-54 over three time periods (1978-
80, 1993-95, and 1997-99) were followed up and all participants presenting with ICD-9/10 first 
episode psychosis were included.  Standardised incidence rates were calculated at each time 
period with possible change assessed using Poisson regression. 
134 See: http://news.bbc.co.uk/1/hi/scotland/south_of_scotland/7533614.stm  
135 Exploratory qualitative interviews with 44 crack-heroin injectors were undertaken in 2006 
as part of a wider project using video-recorded observations of injecting drug use and 
injecting environments (see Focal Point Annual Report 2006).  Purposive sampling was 
employed weighted towards current and recent injectors with recent experience of unstable 
housing.  The sample comprised of current injectors who reported ever having injected crack-
heroin speedball.  The study took place in Bristol and London. 
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associated with groin injecting.  They are: checking the colour of the blood flushing 
into the syringe; seeking assistance from other injectors to help locate and administer 
an injection; rotating injections between groins; selecting an appropriate-length 
needle; and cleaning the injection site.  The article concluded that speedball injection, 
and crack cocaine specifically, increase health harms such as abscesses, cellulites 
and other skin infections.  
6.5.2 Non-fatal drug emergencies 
It is difficult to monitor trends in non-fatal drug emergencies as classification is based 
on ICD-10 codes, clinical judgement and disclosure by patients.  Furthermore, data 
may also include patients who would not be classified as drug misusers in the 
context of this report.136 Data are available across the United Kingdom but cannot be 
combined as there may be differences in recording practices.137 
 
Data are collected for England through Hospital Episode Statistics.138 In 2006/07 
there were 870 inpatient finished consultant episodes (FCEs) due to a primary 
diagnosis of acute substance intoxication, a five per cent decrease from 2005/06.  
Seventy-seven per cent of these were classed as emergencies, most commonly, 
‘multiple or other psychoactive substances’ (32%).    
 
In England, during 2006/07, there were 9,777 episodes of poisoning by drugs (ICD-
10 code T40 which includes overdose but excludes intoxication meaning inebriation), 
99 per cent of which were emergencies.  This is a reduction of two per cent on the 
2005/06 figure.  The majority of episodes (56%) were due to ‘other opioids’ (including 
codeine and morphine) and a quarter (24%) were due to heroin or methadone.  The 
recent increases in heroin poisonings reported last year were not seen in 2006/07, in 
fact there was a nine per cent decrease from 1,908 episodes to 1,738.  There were 
also 2,061 FCEs with a diagnosis of poisoning by psychostimulants with abuse 
potential (ICD-10 code T43.6), 91 per cent of which were emergencies. 
 
Since 2000/01 there has been a large increase in the number of cocaine poisonings 
from 262 episodes to 833 in 2006/07.  Over this period the proportion of all 
poisonings which are attributable to cocaine has risen from 3.5 per cent to 8.5 per 
cent.  However, the number of cocaine poisonings and proportion of all poisonings in 
2006/07 is only slightly higher than in 2005/06 suggesting that the recent increases in 
cocaine related poisonings may have slowed (Table 6.2).   
Table 6.2: Hospital Episode Statistics: Inpatient episodes due to poisoning by cocaine in 
England, 2000/01 to 2006/07 
Primary diagnosis 2000/01 2001/02 2002/03 2003/04 2004/05 2005/06 2006/07 
Poisoning by cocaine 262 317 360 520 641 807 833 
Source: The Information Centre (2008) 
 
Data from the Information Services Division, Scotland (ISD) show that during 
2006/07 there were 1,541 inpatient episodes with a primary diagnosis of poisoning by 
drugs (ICD-10 code T40), the majority of which (59%) involved other opioids.  Heroin 
                                                
136 For example, poisoning by drugs also include those who may have overdosed on drugs 
such as codeine. 
137 For example, data from England refer to all patients treated in NHS hospitals in England 
and could include patients from Wales, who may also be counted in statistics from Wales. 
138 Hospital Episode Statistics (HES) is the national statistical data warehouse for England of 
the care provided by NHS hospitals and for NHS hospital patients treated elsewhere. Data 
refer to finished consultant episodes (FCEs) and not persons. See: 
http://www.dh.gov.uk/en/Publicationsandstatistics/Statistics/HospitalEpisodeStatistics/index.ht
m 
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poisoning was responsible for 20 per cent of episodes, methadone for seven per cent 
and cocaine for four per cent. There were a further 244 episodes with a diagnosis of 
poisoning by psychostimulants with abuse potential (ICD-10 code T43.6).  No 
information on how many were emergencies is available.  Over the same period 
there were 50 episodes of acute substance intoxication. 
 
Data from Health Solutions Wales show that, during 2006/07, there were 652 
episodes with a primary diagnosis of poisoning by drugs (ICD-10 code T40), almost 
all of which were emergencies.  Fifty-seven per cent were due to other opioids, 24 
per cent due to heroin and five per cent due to cocaine. Over the same period, there 
were 82 inpatient episodes with a primary diagnosis of acute substance intoxication, 
91 per cent of which were emergencies. This is half the number recorded in 2005/06 
(internal communication from Health Solutions Wales). 
 
The Welsh Assembly Government is currently carrying out a study of non-fatal drug 
emergencies.  The research will review near misses in the Accident and Emergency 
department of a Swansea hospital and is due to be published at the end of 2008 
(internal communication from the Welsh Assembly Government). 
 
Data from the Department of Health, Social Services and Public Safety Northern 
Ireland (DHSSPSNI) show that, in 2006/07, there were 790 inpatient episodes with a 
diagnosis of poisoning by drugs (ICD-10 code T40), 97 per cent of which were 
emergencies (internal communication from DHSSPSNI). 
6.5.3 Other health consequences 
Seventeen per cent of treatment seekers participating in DTORS reported poor 
health with older users more likely to perceive their health as poor; 24 per cent of 
those aged 35 and over reported poor health compared to 14 per cent of those aged 
25 to 34 and 13 per cent of those aged 16 to 24 (Jones et al. 2007). 
Research  
Real-world memory and executive processes in cannabis users and non-users 
A study by Fisk and Montgomery139 (2008) found that cannabis users did not differ 
significantly from non-cannabis users on any of the measures of executive 
functioning or associative learning.  However, cannabis use did appear to have an 
adverse impact on real-world memory. 
6.5.4 Pregnancies and children born to drug users 
Hospital Episode Statistics show that in England during 2006/07, there were 172 
episodes of foetus and newborn affected by maternal drugs of addiction (ICD10 code 
P04.4) and 1,269 episodes of babies with neonatal withdrawal symptoms from 
maternal use of drugs of addiction (P96.1), of which 5.5 per cent were emergencies.  





                                                
139 Samples of cannabis users and non-cannabis users were drawn from an existing database 
containing a range of measures for substance abusers and drug naive individuals. Members 
of the database were recruited from university students and the snowball method and were 
aged between 20 and 22.  A number of measures were used to test individuals with different 
sample sizes for each test. 
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Table 6.3: Effect of maternal drugs of addiction in England, 2003/04 to 2006/07 
Primary diagnosis 2003/04 2004/05 2005/06 2006/07 
Foetus and newborn affected by maternal use 
of drugs of addiction 205 262 170 172 
Neonatal withdrawal symptom from maternal 
use of drugs of addiction 1,096 1,246 1,276 1,269 
Source: The Information Centre (2008) 
 
Data from Wales show that in 2006/07 there were 6 episodes of foetus and newborn 
affected by maternal drugs of addiction (ICD10 code P04.4) and 57 episodes of 
babies with neonatal withdrawal symptoms from maternal use of drugs of addiction 
(P96.1), 19 per cent of which were emergencies. 
 
There were fewer than five inpatient episodes in 2006/07 with a diagnosis of foetus 
and newborn affected by maternal use of drugs of addiction. 
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7. Responses to health correlates and consequences  
7.1 Overview 
In 2001 an action plan to reduce DRDs was introduced in England and Wales (DH 
2001).  This was updated as part of Reducing Drug-related Harm: An Action Plan 
with a focus on three key areas: campaigns, improving delivery and surveillance (DH 
and NTA 2007). In Scotland a strategy and action plan to reduce DRDs was 
published in 2005 (SACDM 2005).  
 
In the 1980s, United Kingdom drug policy was led by a public health approach aimed 
at containing HIV transmission.  The subsequent action, involving harm reduction 
measures, is regarded as having been successful in helping to contain HIV amongst 
injecting drug users (IDUs); providing free needles and syringes, promoting the safe 
disposal of used equipment, information campaigns on safer sex and safer injecting, 
and HIV/AIDS counselling, support and testing.  Treatment for infectious diseases is 
provided as part of the National Health Service (NHS), including the provision of anti-
retroviral treatment for HIV and HCV. 
 
A Hepatitis C Action Plan for England was published in 2004 (DH 2004), prioritising 
prevention of infection and disease progression and Reducing Drug-related Harm: An 
Action Plan is also concerned with infectious disease.  A Hepatitis C Action Plan for 
Scotland was launched in 2006 (Scottish Executive 2006b) and a second phase of 
the plan, supported by €63 million (£43m) over three years, was launched in May 
2008 (see section 7.3.1 below).  An Action Plan for the Prevention, Management and 
Control of Hepatitis C was launched in Northern Ireland in 2007.  The National 
Institute for Health and Clinical Excellence (NICE) in England has published clinical 
guidelines that recommend the use of contingency management in order to 
encourage testing for and vaccination against infectious diseases (NICE 2007c).   
 
Standards of care for problem drug users with mental health problems were agreed 
in 2001 (HAS 2001).  Guidance on good practice (DH 2002a) and the provision of 
services were developed in England.  The Department of Health highlighted the need 
for generic health services to work in partnership with other agencies, such as drug 
services (DH 2002b).   
 
Treatment for wound infections is available through primary care, A&E departments, 
and in some areas, through needle exchange schemes and specialist drug services.  
Those in prison have access to HIV and hepatitis testing, and vaccination against 
HBV.   
 
Increasingly there is a recognition of the needs of pregnant drug users, with systems 
in place to ensure that they are identified and that their needs, and those of their 
babies, are met. 
7.2 Prevention of drug-related deaths  
The National Treatment Agency (NTA) reports on its website that throughout 2007/08 
a programme of initiatives aimed at reducing drug related harm140 will be introduced 
under the three main headings of campaigns, improving delivery and surveillance, 
which were outlined in the Reducing Drug-related Harm: An Action Plan (DH and 
NTA 2007).  In October 2008 a campaign to reduce drug-related death (and drug–
related infectious disease) was launched as part of the action plan. 
 
                                                
140 See: http://www.nta.nhs.uk/areas/drug_related_deaths/default.aspx  
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In Scotland, the National Forum on Drug-related Deaths141 recommended in its latest 
annual report that the Scottish Government should allocate dedicated funding with 
the specific aim of reducing drug-related deaths.  It also recommended that suicide 
prevention in drug users should be a key priority as around a quarter of drug-related 
deaths were either intentional or of undetermined intent (Scottish Government 
2007c). In its response to the report the Scottish Government has stated that funds 
have been allocated to take this action forward (Scottish Government 2008c). 
7.2.1 Overdose prevention 
Protocols in emergency setting  
The Welsh Assembly Government (2008b) is to develop protocols within emergency 
settings to develop, test and introduce interventions to reduce unnecessary deaths to 
those at most risk and encourage entry to services.  
Investigation into drug-related deaths in Scotland  
An investigation into DRDs in Fife, Scotland (see Chapter 6), made a series of 
recommendations for reducing the number of DRDs including: an integrated 
approach towards care for those who had recently been released from prison and 
sharing of information between agencies; overdose training, for the family of drug 
users and others who may witness an overdose, covering such areas as Cardio-
Pulmonary Resuscitation (CPR)142 and the administration of naloxone; prevention/ 
treatment of a benzodiazepine overdose; monitoring and sharing of information on 
near misses and integrated care for complex cases; a review of current drug and 
alcohol education provision for 15 to 16 year olds; investigating the possibility of 
introducing arrest referral and early intervention schemes; local analysis of heroin 
composition, to establish purity levels and cutting agents, in order to inform overdose 
strategies relative to the composition and quantity of heroin consumed (Baldacchino 
et al. 2008).  
A review of drug treatment and harm reduction services  
A review by the Healthcare Commission and NTA assessing the provision of 
treatment for substance misusers looked at the commissioning of drug treatment and 
the provision of harm reduction services across the 149 local drug partnerships in 
England.  It was reported that some good progress has been made in relation to the 
provision of harm reduction services, and that there has been significant progress in 
developing systems and protocols to reduce the number of DRDs.  However, it was 
also reported that more needs to be done to further reduce DRDs (Healthcare 
Commission and NTA 2008b).   
Database on drug-related deaths in Scotland  
In the July 2008 edition of the National Forum on Drug Related Deaths’ ‘Drug Death 
matters’ newsletter it is reported that the Scottish Government will be developing a 
national database of drug-related deaths and an examination of the circumstances 
behind them (Scottish Government 2008d). 
                                                
141 The National Forum on Drug Related Deaths was established as a result of the Scottish 
Executive’s 2005 action plan ‘Taking Action to Reduce Scotland’s Drug Related Deaths’.  The 
forum is made up of representatives from the medical profession, police, prison service, 
ambulance service, government and academia.  The forum investigates trends in drug-related 
deaths and disseminate good practice through the ‘Drug Death Matters’ newsletters.  One of 
its main remits is to produce an annual report for Scottish ministers with recommendations for 
further action as required.  
142 See: http://www.sja.org.uk/sja/first-aid-advice/lifesaving-procedures/cpr-for-adults.aspx  
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Information campaign  
The National Forum on Drug-related Deaths report also called for a national 
information campaign targeting drug users to highlight the dangers of combining 
substances such as methadone with alcohol, and cocaine and alcohol (Scottish 
Government 2007c).  This has been accepted by the Scottish Government (Scottish 
Government 2008d). 
Safer nightlife guidance 
The Home Office and London Drug Policy Forum143 have launched a second edition 
of guidance designed to promote good practice in bars and nightclubs.  It aims to 
protect individuals who go to bars, nightclubs and other events, and those who work 
in them, with a particular emphasis on those who use drugs.  In particular, it is aimed 
at licensing authorities, police and fire officers, venue managers/promoters and 
health promotion workers (London Drug Policy Forum/ Home Office 2008). 
Consumption rooms 
The National Forum on Drug-related Deaths recommended the identification of 
intensive support techniques for those at high risk of overdose and a review of 
methods used in other countries, including consumption rooms.  It is suggested that if 
schemes such as those in Australia, Canada and Switzerland have been evaluated 
as effective in reducing drug-related deaths, then service commissioners should 
carefully consider the possibility of them being set up in Scotland (Scottish 
Government 2007c).  In response to this, the Scottish Government states that it does 
not support the need for drug consumption rooms and has no plans to introduce 
them (Scottish Government 2008c). 
Pharmacological antagonists 
The National Forum on Drug-related Deaths in Scotland recommends that a pilot 
scheme of take-home naloxone (running in Glasgow since early 2007) should be 
evaluated and, if it has been successful, an extension of the scheme across Scotland 
should be considered.  In the pilot project, drug users and their families are given 
naloxone to prevent heroin overdoses and training is given in basic life support and 
overdose awareness (Scottish Government 2007c).  In the July 2008 edition of its 
‘Drug Death matters’ newsletter, the Forum reported that there is a plan to introduce 
take-home naloxone to more individuals in Scotland following a successful pilot.  It is 
hoped that the project will be adopted by the local NHS as a core harm reduction 
intervention that is available to family and friends as well as service users (Scottish 
Government 2008d). 
 
The Welsh Assembly Government has commissioned research into the use of 
naloxone by family/friends in the event of an illicit drug overdose.  The pilot study is 
due to take place during 2008 (internal communication from the Welsh Assembly 
Government).  Protocols and guidelines in the use of naloxone are to be issued (The 
Welsh Assembly Government (2008b). 
Briefing on naltrexone implants  
The NTA has issued a briefing on naltrexone implants, noting that in its technological 
appraisal of naltrexone, NICE did not comment on implants.  NTA suggest that while 
such implants have been prescribed privately, following discussion with the 
                                                
143 The London Drug Policy Forum is based in the City of London local authority, supporting 
and advising on policy and practice regarding drug issues.  It develops resources for a range 
of stakeholders and promotes good practice on education and prevention, community safety 
and improving services for drug users. See: 
http://www.cityoflondon.gov.uk/Corporation/LGNL_Services/Community_and_living/Communit
y_advice/London_Drug_Policy_Forum/   
UNITED KINGDOM FOCAL POINT REPORT 2008  
 111
Department of Health, the NTA is not in a position to promote such treatment, 
particularly as naltrexone implants are not licensed for relapse prevention, nor is 
there sound evidence for this treatment (NTA 2007c). 
Research  
Witnessing heroin overdose 
Strang et al. (2008) carried out a study to assess carers’ experiences of witnessing 
heroin overdose, whether they would be interested in training on overdose treatment 
and their specific training requirements.144  Eighty-eight per cent of carers were 
interested in receiving training on how to treat an overdose while waiting for an 
ambulance.  Thirty-three per cent had heard about naloxone but only 26 per cent had 
ever previously been given advice on it.  The authors conclude that there is an 
extensive population of carers who have been overlooked and would benefit from 
overdose training.  They suggest that piloting such training would be appropriate. 
7.3 Prevention and treatment of drug-related infectious diseases 
Hepatitis C Action Plan for Scotland: Phase two 
Phase one of the Hepatitis C Action Plan for Scotland, covering the period 
September 2006 to March 2008, aimed at increasing awareness of hepatitis C 
among professionals and gathering evidence through numerous surveys and other 
investigations to inform proposals for the development of hepatitis C services.  The 
results of phase one have been published by Health Protection Scotland (HPS 2007).  
The second phase of the Hepatitis C Action Plan for Scotland was launched in May 
2008 and covers the three years 2008/09 to 2010/11 and will be supported by a 
budget of €63 million (£43m).  Key aims are to raise awareness of the disease, 
reduce the number of new infections and to increase the numbers in treatment.  The 
action plan covers 34 specific areas such as improved treatment, testing, diagnosis, 
support services and care for those at risk of contracting the disease in addition to 
those who are already infected.  In addition annual surveys of hepatitis C prevalence 
and incidence among IDUs across Scotland are to be undertaken, and there is to be 
a survey of hepatitis C prevalence and incidence among prisoners (Scottish 
Government 2008e).  
7.3.1 Prevention 
Reducing Drug-related Harm: An Action Plan 
As part of the implementation of the Action Plan on Reducing Drug-related Harm in 
England (DH and NTA 2007), in October 2007 new data were provided to local 
partnerships about hepatitis C prevalence for their local area.  In October 2008 a 
campaign to reduce drug-related infectious disease (and drug-related death) was 
launched as part of the action plan.  
Hepatitis C Action Plan for Scotland and Northern Ireland  
In phase two of the Hepatitis C Action Plan for Scotland there is a specific focus on 
prevention and education amongst injecting drug users with an aim of improving links 
between support and health services (see above) (Scottish Government 2008e). 
 
An Action Plan for the Prevention, Management and Control of Hepatitis C in 
Northern Ireland was launched in 2007 (DHSSPSNI 2007b).  Objectives are to 
increase awareness and understanding and to improve treatment.  Actions include a 
                                                
144 Self-completion questionnaires were distributed through nine support groups in England 
for families affected by drugs and alcohol.  147 carers responded, 80 per cent of whom were 
parent-carers.  Heroin was the main drug of abuse for 86 per cent of users, of whom half had 
already had an overdose.  
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review of surveillance arrangements for hepatitis C.  Amongst IDUs specific actions 
are: training, information and guidance on blood borne viruses for professionals; the 
development of local multi-agency arrangements for hepatitis C prevention; and to 
further develop needle exchange schemes. 
ACMD Prevention Working Group on hepatitis C prevention 
An inquiry has been undertaken by the Prevention Working Group on hepatitis C 
prevention145 (consisting of ACMD members, HPA staff and co-opted experts) into 
preventing HCV amongst injecting drug users (IDUs).  They will consider:  
• the epidemiology of hepatitis C; 
• evidence on the effectiveness of interventions against hepatitis C; and 
• effective interventions and delivery (e.g. coverage, intensity) in the United 
Kingdom. 
 
The results of the inquiry are due to be reported in 2009. 
Assessment of harm reduction services in Wales  
The Welsh Assembly Government is to assess the range of safe, effective and cost-
effective services currently targeted at injecting drug users against international 
practice to inform the delivery of the National Public Health Service Blood-Borne 
Virus Action Plan for Wales (Welsh Assembly Government 2008b).  There is also to 
be consideration of how harm reduction services can respond to the needs of 
stimulant users. 
Review of harm reduction services 
The review by the Healthcare Commission and NTA assessing the provision of harm 
reduction services found significant deficiencies were reported in the provision of 
hepatitis B vaccination and the testing and treatment of hepatitis C (Healthcare 
Commission and NTA 2008b).  The majority (95.3%) reported that less than 50 per 
cent of their service users had a recorded test date for hepatitis C.  Just over a third 
(37%) did not have access to HIV testing with access to pre and post-test 
counselling.  In addition, 36 per cent of partnerships did not have hepatitis C testing 
integrated into their open access services.   
Harm reduction findings from the NTA 2006 user satisfaction survey 
The NTA in England reported on client satisfaction levels with harm reduction 
services received by users of specialist drug services and, via a separate survey, 
with clients of pharmacy-based needle exchanges.  It found that whilst many service 
users received a range of harm reduction advice, many did not.  
 
The results of the surveys found that 65 per cent had a care plan (66% who attended 
specialist services and 59% of those attending pharmacies) and harm reduction 
goals were included in most plans; these included goals to reduce the risk of the 
spread of blood borne viruses.  However, a substantial amount of clients responded 
that they had not received many of the harm reduction interventions that they were 
asked about.  Around 20 per cent of current injectors had not received hepatitis B 
immunisation, but felt it would be appropriate for them.  Nearly a third of current 
injectors thought a general health check would be appropriate, but they had not 
received one and a quarter stated that they would like to have their injecting sites 
checked, but they had not received this service. 
 
The report concludes that harm reduction services require enhancement across the 
whole treatment system (NTA 2007a). 
                                                
145 See: http://drugs.homeoffice.gov.uk/publication-search/acmd/ACMD-minutes-may-
2007?view=Binary  
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Information campaigns 
Drugs: Protecting Families and Communities. Action Plan 2008-2011 (action number 
78), proposes a national information campaign to raise awareness of blood-borne 
viruses (HM Government 2008b).  
 
The Health Protection Agency issued a warning to injecting heroin users about a 
batch of the drug that has been linked to an infection caused by Clostridium novyi 
See Chapter 6.6.1). 
Vaccination 
The proportion of IDUs in the Unlinked Anonymous Prevalence Monitoring 
Programme (UAPMP)146 survey who have taken up an offer of hepatitis B vaccination 
has increased markedly over time, rising from 25 per cent in 1998 to 66 per cent in 
2007.147  Self-reported vaccination uptake varied by region and country (combining 
2006 and 2007 data), and in Wales was 57 per cent and in Northern Ireland 79 per 
cent (HPA et al. 2008). 
 
The Needle Exchange Surveillance Initiative (NESI) established in Scotland to 
measure and monitor the prevalence of hepatitis C, HIV and injecting risk behaviour 
among injecting drug users, has reported on the results of data collected in two 
Scottish Health Boards.  It found that rates of uptake of hepatitis B vaccination (at 
least one dose) ranged from 62 to 75 per cent.  Three-quarters reported having been 
tested for hepatitis C in the past, though far fewer had been tested in the last year.  
Between 64 per cent and 80 per cent had been tested for HIV (Palmateer et al. 
2008)148  
 
The 2006/07 Healthcare Commission and NTA joint improvement review in England 
highlighted limitations in existing provision of hepatitis B vaccine to IDUs with only 
four per cent of local areas rated as either excellent or good in relation to it  
(Healthcare Commission and NTA 2008b).  Reducing Drug-related Harm: An Action 
Plan contains plans for a campaign on hepatitis B vaccination targeted at drug users 
most at risk of contracting an infectious disease (DH and NTA 2007). 
 
In its substance misuse strategy, the Welsh Assembly Government suggests that 
there is a case for using rewards (contingency management) to engage or maintain 
some individuals in treatment in certain circumstances, for example, to increase the 
percentage of injecting drug users completing vaccination courses against hepatitis 
B.  They will work with partners to develop criteria for supporting and are evaluating a 
number of contingency management pilots across Wales.  In addition, the numbers 
of drug users completing immunisation for hepatitis B is to be measured as part of a 
key performance indicator (Welsh Assembly Government 2008b). 
Syringe provision  
The 2006/07 Healthcare Commission and NTA review indicated that most local areas 
had weaknesses in their service provision with only 12 per cent rated as either good 
or excellent in relation to the provision out-of-hours needle exchange services  
(Healthcare Commission and NTA 2008b).  A shortfall in the provision of out-of-hours 
needle exchange was also reported.  Just under half (44%) of local drug partnerships 
scored ‘weak’ in this area.  Only 21 per cent of partnerships opened most of their 
                                                
146 See Chapter 6 for methodology. 
147 Vaccination uptake data should be interpreted with caution as they are based on self-
reports. 
148 667 participants completed a voluntary anonymous survey from May to December 2007.  
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needle exchange services on Saturdays and only two per cent opened them on 
Sundays.  
 
In 2007, almost all (92%) of the current and former IDUs participating in the UAPMP 
survey in England, Wales and Northern Ireland reported ever accessing a needle 
exchange scheme, and amongst recent initiates (those who reported first injecting 
during the previous three years) it was 86 per cent (HPA et al. 2008). 
 
Northern Ireland has a national syringe exchange database, which has been 
monitoring activity since 2001 in the nine pharmacies that offer syringe exchange.  In 
2007/08: 
• there were 11,387 visits to participating pharmacies by users of the scheme, an 
increase of 14 per cent from 2006/07; 
• 116,935 syringes were issued in 2007/08, an increase of 20 per cent from 
2006/07; 
• 42 per cent of visits involved the return of used equipment; and 
• 86 per cent of visits were made by male clients (PHIRB/DHPSSPNI 2008). 
 
Since the scheme started, the number of visits per annum has doubled while the 
number of syringes issued has risen by more than 70 per cent.  However, the 
proportion of visits that involve the return of used equipment has fallen from 67 per 
cent in 2001/02 to 42 per cent in 2007/08 (Table 7.1). 
Table 7.1: Syringe provision: number of visits, syringes issued and proportion involving return 
of used equipment in Northern Ireland, 2001/02 to 2007/08  




% visits involving 
return of used 
equipment 
2001/02 5,213 67,989 67 
2002/03 6,043 67,516 61 
2003/04 7,508 82,731 59 
2004/05 7,440 86,056 54 
2005/06 8,797 85,801 44 
2006/07 9,997 97,684 40 
2007/08 11,387 116,935 42 
Source: DAIRU/DHSSPSNI 2003; 2005; 2006; PHIRB 2008 
 
Results from two Scottish Health Boards participating in NESI showed that around 60 
per cent of current IDUs obtained an average of at least two needles/syringes per 
day, mostly from pharmacy exchanges (Palmateer et al. 2008).149   
Needle exchange monitoring systems  
A new national web based system to collect information from local needle exchange 
services in England was introduced in April 2008 in order to improve the quality and 
consistency of data collection.150  It collects information such as the number of 
syringes exchanged; the return rate; the estimated number of clients in contact with 
services; paraphernalia distributed and the main drug that is being injected by clients.  
In order to fulfil the criteria set out in the Reducing Drug Related Harm Action Plan 
(DH and NTA 2007), and so that partners such as the HPA can use the data to 
support their work and quantify the public health benefits of needle exchange 
                                                
149 Six hundred and sixty-seven participants completed a voluntary anonymous Survey from 
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services, the aim of the system is to monitor the amount of activity in services so that 
benchmarks can be set and distribution can be increased in future. 
 
As part of phase two of the Hepatitis C Action Plan for Scotland a data collection 
system to monitor the provision of injection equipment in Scotland is to be developed 
(Scottish Government 2008e).   
Needs assessment for needle and syringe facilities 
A needs assessment for needle and syringe exchange facilities is to be carried out in 
Wales, that will inform future plans to deliver accessible services which meet the 
identified demand (Welsh Assembly Government 2008b). 
Guidance on Needle Exchange Services 
The National Institute for Health and Clinical Excellence (NICE) is due to publish 
guidance on the optimum provision of needle exchange services in February 2009.151  
A supporting review of effectiveness, qualitative data and health economic evidence 
has been undertaken and has been released for consultation.  The importance of this 
guidance is underscored by an earlier review of syringe exchange provision which 
found that there were no national monitoring and reporting systems in place at 
needle exchange services and the data that were collected were often inconsistent 
and low quality (NTA 2008g).  
Research 
Stigma and injecting drug use  
Simmonds and Coomber (2007) consider how social stigma impacts on populations 
of injecting drug users (IDUs) and operates within them; and the consequences this 
has for drug prevention and harm reduction.152  It was found that IDUs concern for 
being recognised or ‘seen’ as IDUs affected service uptake and/or their interaction 
with services.  It went on to say that ‘normal’ IDUs tended to stigmatise those they 
believed to be ‘worse’ than them, primarily the homeless.  
Paraphernalia and condom provision 
Research 
Distributing foil to promote transitions from heroin injecting to chasing: an evaluation  
Research was conducted into an intervention that distributed special foil packs to 
IDUs from four needle exchange services in order to promote the transition from 
injecting heroin to the less risky practice of smoking or ‘chasing’ (Pizzey and Hunt 
2008).  It was reported that an increased number of clients attended the services, 
including non-injecting heroin users, with over half of the total clients (54%) taking the 
foil packs when they were available.  The authors suggest that the distribution of the 
foil packs is a useful way of engaging with clients attending needle exchange 
services about harm reduction in terms of reducing injecting risks and making the 
transition away from injecting to less harmful methods of consumption. 
Safety, risks and outcomes from the use of injecting paraphernalia   
In Scotland, paraphernalia items and injection preparation methods were laboratory 
tested to identify any theoretical health benefits/risks they posed, in order to establish 
those that presented the least risk to health (Scottish Government 2008f).  An 
                                                
151 See: http://www.nice.org.uk/guidance/index.jsp?action=download&o=37995 
152 This paper is based on research into barriers into safer injecting in the south west of 
England.  Qualitative interviews were conducted with safer injecting service providers (syringe 
exchange schemes and injectors users of these services.  Interviews were undertaken with 
12 of the pharmacists from all 13 local pharmacies.  Ninety-one injecting drug users were 
interviewed.   
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investigation was also conducted to establish the impact that the supply of 
paraphernalia had on health, and sharing practices in IDUs.  In addition to needles 
and syringes, the results found that the least (theoretical) risks were posed by: 
cleaning of hands before preparation; sterile citric or ascorbic acid sachets with clear 
usage information; use of Sterifilt filters; the use of single use cookers accompanied 
by equipment and preparation advice.  Qualitative data gained in this study 
supported the supply of such items although the quantitative data was inconclusive. 
Citrate provision at syringe exchange programmes 
Beynon et al. (2007b) examined the impact of citrate provision153 at syringe exchange 
programmes in the North West of England, to investigate whether its introduction had 
an effect on the number and/or frequency of injecting drug users accessing the 
services and the number of syringes dispensed.  The results showed that in general 
the introduction of citrate did not have an effect on the number of injectors attending 
the services, but long term clients did attend more frequently after the introduction of 
citrate.  This meant that staff had more opportunities to engage with these longer 
term clients and therefore the potential to increase the number of harm reduction 
interventions and referrals to other support services.  
Provision of injecting paraphernalia by pharmacists  
With pharmacies comprising over three-quarters of needle exchange outlets in the 
United Kingdom, Scott et al. (2007)154 considered whether pharmacists offering 
needle exchange were aware of legal changes in 2003 permitting the supply of 
injecting paraphernalia.  Forty-two per cent of pharmacists said they were.  However, 
just two per cent were able to fully describe it, 41 per cent could partially describe it, 
and 59 per cent were either out of date, wrong or did not know.  It was found that 34 
per cent supplied one or more items of paraphernalia; most commonly citric acid.  
The authors suggest that pharmacists appear to have little involvement with 
decisions around supply and recommended that knowledge of the new law should be 
improved and that involving pharmacists more in local decisions may increase their 
feelings of accountability for the service they provide to injectors. 
7.3.2 Counselling and testing 
One of the aims of the Hepatitis C Strategy for England is to utilise voluntary 
confidential testing in order to increase the proportion of IDUs who know that they are 
infected.  It is recommended that everyone who attends a drug treatment service 
should be offered a test.  According to the 2007 Health Protection Agency annual 
report there has been around a ten-fold increase between 2002 and 2006 in the 
amount of tests carried out in these services, reportedly due to oral fluid screening.  
This is in addition to a high number of tests carried out by GPs at their surgeries.  
Diagnosis of hepatitis C infection is increasing in England with a ten per cent 
increase in new cases between 2005 and 2006 (HPA 2007). 
 
As part of phase two of the Hepatitis C Action Plan for Scotland, NHS Quality 
Improvement Scotland (QIS) will develop standards for hepatitis C testing and the 
treatment, care and social support of individuals infected with hepatitis C.  In addition, 
a surveillance system to monitor hepatitis C testing practice in Scotland will be 
developed (Scottish Government 2008e).  
 
 
                                                
153 In the United Kingdom it has been legal to provide citrate to injecting drug users to 
solubilise heroin since 2003.   
154 A survey of pharmacy based needle exchanges in the South West of England (N = 
143),undertaken using telephone interviews six months after the main law change. 
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Research 
Dried blood spot testing for hepatitis C 
A study to assess whether an uptake in hepatitis C testing among IDUs would follow 
on from the introduction of dried blood spot testing in drug treatment and prison 
settings found some preliminary evidence to support its use (Hickman et al. 
2008b).155  The study was based on the premise that dried blood spot testing would 
increase the opportunity for testing as it did not have some of the drawbacks that 
came with venous blood collection (the usual method for testing) such as problems 
finding a suitable vein, lack of trained staff or willingness to take blood and risk of 
needle stick injuries.  It found that six months after the introduction of dried blood 
spot testing at these sites there had been a positive effect on the percentage of 
patients who had had a hepatitis C test carried out in all but one of the sites, with an 
average increase of 14.5 per cent.  
7.3.3 Infectious disease treatment 
2008 Audit of Hepatitis C Action Plan for England 
Following on from a 2006 audit of hepatitis C healthcare (APPHG 2006), in which it 
was found that less than ten per cent of Primary Care Trusts (PCTs) were effectively 
implementing the Hepatitis C Action Plan for England (DH 2004), a further review 
was conducted in 2007 in PCTs and NHS Trusts across England.  It reported that 
although services have improved markedly since the last review there are still 
discrepancies depending on country of residence.  Services for particular groups 
such as prisoners, IDUs and children are provided in 80 per cent of PCTs (an 
improvement from 68% since 2006).  Nearly three-quarters of PCTs (95 out of the 
128 that responded) reported making special provisions for drug users and the report 
recommends that all PCTs should make extra provision for each of the specific 
groups (including drug users) in future (APPHG 2008) in line with the 
recommendations made in the Hepatitis C Action Plan. 
Research 
Scoping study on services for those with hepatitis C 
In a scoping study to consider services for those with hepatitis C (not only drug 
users) in Scotland, Wilson et al. (2008)156 found that 80 per cent had not received 
treatment.  Of these, 21 per cent attributed this to a continuing use of alcohol or other 
drugs.  However, results from the report by the Needle Exchange Surveillance 
Initiative found that between 56 per cent and 76 per cent of those reported as having 
received a HCV-positive test result had been referred to a specialist hospital 
appointment (Palmateer et al. 2008).  
                                                
155 The research was conducted in England in Wales at 22 specialist drug clinics and six 
prisons. 
156 Seventy-nine participants in the study were recruited by using convenience and snowball 
sampling at three sites in Glasgow, two peer support services for people living with hepatitis C 
(c-level and Anan Cara) and via those involved in the Scottish Drugs Forum.  Individuals were 
eligible if they had ever received a positive hepatitis C antibody test.  
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7.4 Intervention related to psychiatric co-morbidity  
7.4.1 Guidance for practitioners  
NICE guidance: Severe Mental Illness with Problematic Substance Misuse 
NICE have commissioned the National Collaborating Centre for Mental Health to 
develop clinical guidelines for the assessment and management of severe mental 
illness in conjunction with problematic substance misuse.157  
Guidance for Criminal Justice Integrated Teams 
The Home Office Drug Interventions Programme (DIP) and the Drug Strategy Unit 
have commissioned the Specialist Clinical Addiction Network (SCAN) to produce a 
practice guide for Criminal Justice Integrated Teams (CJITs).  The guide will include 
contributions from a wide range of stakeholders including clinicians, commissioners, 
and practitioners, informed by a working group from SCAN.  While it is not the core 
role of CJITs to manage or treat the mental health element of a client’s co-occurring 
mental health problems, the guide will enable them to recognise and refer clients to 
appropriate care.158  
Closing the Gaps – Making a Difference 
Following a review of existing guidance, care and support that is available for 
individuals in Scotland with co-occurring substance use and mental health problems, 
the Scottish Government has published a series of recommendations for change and 
improvement including: increased awareness of co-morbidity and a reduction in the 
stigma associated with it; and improved support and service provision for individuals 
and their carers.  Specific recommendations made in the report include: training of 
frontline substance misuse staff in suicide risk assessment and prevention; an 
agreed assessment tool to be used by substance misuse services and mental health 
agencies to identify co-morbidity; developing the ability of substance misuse services 
to meet the mental health needs of their clients in terms of psychological treatments; 
and developing a training needs plan for psychological therapies (Scottish 
Government 2007d). 
Protocols between mental health and substance misuse services, Wales  
Protocols between mental health and substance misuse services are being 
developed in Wales to ensure there are clear lines of accountability between services 
for the care of individuals with co-occurring substance misuse and mental health 
problems.  Progress on delivering the protocols will be monitored through the Welsh 
Assembly Government’s performance management framework for the NHS (Welsh 
Assembly Government 2008b).  
7.4.2 Community orders and mental health 
The Community Order is a generic community sentence.  There is a choice of 12 
different requirements that can be attached to an order including drug and alcohol 
treatments and a Mental Health Treatment Requirement (MHTR).  It is reported that 
the use of community sentencing is increasing and suggested that the application of 
the MHTR is infrequent and differential (Seymour and Rutherford 2008).  It is also 
reported that as part of their community sentence, offenders who have both mental 
health and drug problems are more likely to be issued with an alcohol or drug 
treatment requirement rather than an MHTR, and that this group may face particular 
                                                
157 See: http://www.nice.org.uk/guidance/index.jsp?action=byID&o=11815#keydocs 
158 For more information see: http://drugs.homeoffice.gov.uk/drug-interventions-
programme/guidance/throughcare-aftercare/Mental_Health/ and: www.scan.uk.net 
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difficulties accessing necessary treatment and services.  The authors claim that the 
MHTR may be a viable alternative to custodial sentences for offenders with mental 
health problems, but are unable to substantiate this as there is currently “an absence 
of a clear understanding of its application and effect”.  In response to this, the 
Sainsbury Centre for Mental Health will be conducting research across nine London 
Boroughs in 2008 regarding the use of MHTR, how it is delivered and the impact that 
it has made.  
Research  
A brief screening instrument to detect the possibility of substance misuse problems in 
community patients with severe mental illness.  
This study aimed to develop a brief screening tool which could be used in community 
settings to detect the possibility of harmful substance use amongst community-based 
patients with severe mental illness. It was based on the Dartmouth Assessment of 
Lifestyle Instrument (DALI) (Ley et al. 2007).159  The Simple Substance Use 
Screening Scale (SUSS) was developed, which correctly classified 86 per cent of 
participants for problematic alcohol use (sensitivity 88%, specificity 84%) and 84 per 
cent for problematic drug use (sensitivity 82%, specificity 84%).  It is suggested 
because of its brevity and simplicity, SUSS would be a useful screening tool for use 
in routine community mental health practice. 
7.5 Interventions related to other health correlates and consequences 
Research  
Needle fear among female injecting drug users 
In research looking at elements of needle phobia amongst female injecting dug users 
Tompkin et al. (2007)160 found that most were fearful of needles prior to their first 
experience of injecting drug use and that for some, their fear of needles continued 
during their later injecting experiences.  It was found that this fear was not limited to 
injecting drug use, but many feared medical procedures that involved needles.  This 
resulted in their refusing or delaying such procedures, including blood tests and 
immunisations.   
7.5.1 Non-fatal drug emergencies and general health related treatment  
Research  
Club specific ambulance referral guidelines 
A set of guidelines was developed by medical professionals with input from club 
owners/ promoters to improve pre-hospital care for recreational drug users who had 
become unwell whilst in a clubbing environment (Wood et al. 2008).  It included 
guidance for assessing unwell clubbers, when to call an ambulance, hospital transfer, 
and training of club medic staff to use the guidelines.  Club medic staff were trained 
to use the guidelines and reported that after training they were able to assess unwell 
clubbers, use the guidelines and know when to call an ambulance.  The authors 
conclude that a range of individuals with varying medical knowledge can be trained to 
use the guidelines and recommend that they are disseminated widely to potentially 
reduce morbidity and mortality associated with recreational drug toxicity in clubs. 
                                                
159 The Dartmouth Assessment of Lifestyle Instrument (DALI) is an 18-item self-report 
screening questionnaire which was developed to identify DSM-IV substance use disorder 
amongst patients with severe mental health problems in a simple and efficient manner.  In this 
study a random sample of 400 potential participants were selected from a Community Mental 
Health Team case-load census population.  Interviews were completed with 282 people.  
160 Forty-five injecting drug using (IDU) women who had experience of being injected with 
illicit drugs by other drug users 
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7.6 Interventions concerning pregnancies and children born to drug users 
All Wales maternity record  
An all Wales maternity record is being introduced in Wales which will include 
questions to help identify mothers with a substance misuse problem (Welsh 
Assembly Government 2008b). 
Research 
Specialised maternity care 
A study looking at the provision of care in a specialised maternity unit for drug 
users161 suggested that it was a model of good practice (Toner et al. 2008).  
Particular aspects of the service were highlighted as making a positive contribution to 
maternal-child outcomes including: effective multi-agency and multidisciplinary 
working; early engagement; a non-judgemental approach; consistency and clarity 
across complex services; and continuous development.  The need for more postnatal 
provision was identified as one area for development. 
Managing pregnant injecting drug users  
Problems associated with managing pregnant injecting drug users were discussed in 
the British Medical Journal (Bell and Harvey-Dodds 2008).  The authors suggest that 
these patients often present late to health professionals, may have chaotic lifestyles, 
including poor care of themselves, and their capability to care for their children may 
be compromised.  It is also noted that injecting drug use can have adverse effects on 
pregnancy and perinatal outcomes such as an increased risk of still birth, neonatal 
death, placental abruption, premature birth or small for gestational age.  Methadone 
maintenance is recommended for pregnant opioid dependant women as it has been 
reported that it can improve birth weight (when compared to heroin use); it can help 
to engage women with specialist drug services; it produces more pharmacological 
stability than heroin; withdrawal from methadone in pregnancy has been shown in 
some studies to be associated with a relapse to heroin.  However, methadone is 
associated with an increased risk of neonatal abstinence syndrome; few recent, long 
term studies have been carried out on postnatal development.  
7.7 Drug driving  
7.7.1 Prevention and reduction of driving accidents related to drug use 
Following a consultation exercise earlier in the year, the Sentencing Guidelines 
Council (SGC)162 published definitive guidelines regarding sentencing and associated 
issues around death caused by dangerous driving.  It covers four offences, including 
causing death by careless driving while under the influence of drugs (or alcohol) or 
failing to provide a specimen without a reasonable excuse. The maximum sentence 
for this offence is 14 years imprisonment.  It is recommended that the seriousness of 
the offence is associated with the level of impairment caused by the consumption of 
drugs with the implication that as the degree of intoxication increases, so therefore, 
should the sentence (SGC 2008).   
 
                                                
161 The study used a mixed-methodology approach utilising quantitative data from 
administrative systems and qualitative data from semi-structured interviews with 18 
professionals and six service users. Service users were recruited by midwives and members 
of the hospital team. 
162 The Sentencing Guidelines Council Assist courts in England and Wales by reviewing and 
providing sentencing guidelines see: http://www.sentencing-
guidelines.gov.uk/news/index.html  
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The British Medical Association has  called  on  the  government  to undertake a 
campaign to educate the public about the effect of illegal and certain prescribed 
drugs on driving ability and to ensure speedier and more specific and co-ordinated 
research to establish appropriate drug testing devices.163 
                                                
163 See: http://www.bma.org.uk/ap.nsf/Content/DrugsDriving  
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8. Social correlates and consequences 
8.1 Overview 
A number of studies in the United Kingdom have shown that there is a strong 
association between problem drug use and social exclusion; drug problems are most 
serious in those communities where social exclusion is acute.  A recent study 
suggests that up to 240,000 drug users in England receive out of work benefit; three 
quarters of the estimated number of problem drug users.  A high proportion of the 
homeless are problem drug users, evidence suggests up to 80 per cent, and lacking 
educational qualifications; studies suggest up to 40 per cent lack any GCSEs164.  
Also, vulnerable young people (those in care, the homeless, truants, school 
excludees and young offenders) are more likely to use drugs, use more often, and 
use a wider range of drugs.  
 
Drug use per se is not a crime in the United Kingdom, but possession, dealing and 
trafficking are specific offences under the Misuse of Drugs Act 1971.  While within the 
United Kingdom recorded crime is falling, recorded drug offences continue to rise.  In 
addition, the number of persons dealt with by the courts for drug offences, cautioned 
or issued formal cannabis warnings, has also risen, mainly for cannabis related 
offences.  
 
General criminal offences routinely recorded by the police do not contain information 
on the offenders’ drug habits, neither do specific drug law offences.  It is therefore not 
possible to provide an accurate estimate of the number of offences that are drug-
related, but there is substantial research evidence of the link between drug use, 
particularly use of heroin and crack cocaine, and acquisitive crime.  Around three-
quarters of the users of these drugs admit to committing crime to support their habit.  
Over two-thirds of those in custody are reported to be problematic drug users.  
However, acquisitive crime, to which drug-related crime makes a substantial 
contribution, has continued to fall in recent years.  
 
The economic and social costs of Class A drug use in England and Wales combined 
are estimated to have been around €22.2 billion (£15.4bn) in 2003/04165.  This 
equates to €66,693 (£44,231) per year per problematic drug user.  The associated 
confidence range is between €22.0 billion (£15.3bn) and €23.2 billion (£16.1bn).  The 
total economic and social costs of Class A drug use in Wales has been estimated to 
be around €1,140 million (£780m), with drug-related crime accounting for 90 per cent 
of this; health service costs are estimated to be €25.7 (£17.6m) per year.  The 
Scottish Government has commissioned research to produce an initial estimate of 
the economic and social costs associated with illicit drug use.   
                                                
164 GCSEs (General Certificate of Secondary Education) are the principal means of assessing 
pupil attainment at the end of compulsory secondary education in England, Northern Ireland 
and Wales; see: http://www.dfes.gov.uk/qualifications/mainSection.cfm?sId=1.  The 
equivalent in Scotland is the Standard Grade see: 
http://www.scotland.gov.uk/Publications/2007/03/20130930/1. 
165 Conversion rate is the December 2004 monthly average spot exchange rate quoted by the 
Bank of England. 
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8.2 Social exclusion  
8.2.1 Homelessness  
Baseline data from DTORS (see Chapter 4.7) shows that 60 per cent of drug users 
seeking treatment had stayed in stable accommodation166 in the four weeks prior to 
interview, a further 18 per cent stayed in a mix of stable and unstable 
accommodation, and the remaining 21 per cent stayed in unstable types of 
accommodation only (Jones et al. 2007). 
8.2.2 Unemployment 
In a feasibility study aimed to estimate the number of problem drug users accessing 
benefits through the Department of Work and Pensions, Hay and Bauld (2008)167 
estimated that, of the approximately 330,000 problem drug users (opiate and/or crack 
cocaine users) in England in 2006, 81 per cent (266,798) were in receipt of benefit, 
representing 6.6 per cent of all those receiving benefit.  Over three-quarters were 
male, a much higher proportion than within the general population (52%) (Table 8.1).  
A high proportion of problem drug users receiving benefits were aged from 25 to 34 
(43%), this compares with 19 per cent of all those receiving benefits (Table 8.2). 
Table 8.1: Gender of all persons receiving benefit and of problem drug users estimated to be 
receiving benefits in England, 2006 
 Male Female Total 
 n % n %  
Problem drug users 202,987 76.1 63,527 23.8 266,798
All receiving benefit 2,083,020 51.6 1,951,850 48.5 4,034,870
Source: Hay and Bauld 2008 
Table 8.2: Age of all persons receiving benefit and of problem drug users estimated to be 
receiving benefits in England, 2006 
 Age 
 <25 25-34 >34 Total 
 n % n % n % n 
Problem drug users 45,124 17.9 114,645 43.0 104,356 39.1 266,798
All receiving benefit 607,450 15.1 761,300 18.9 2,666,950 66.1 4,034,870
Source: Hay and Bauld 2008 
 
The Green Paper (consultation document) on welfare reform, No one written off: 
reforming welfare to reward responsibility (see Chapter 9.2.3) suggest that 100,000 
problem drug users receiving benefit are not in treatment (DWP 2008).168 
 
DTORS reported that around three-quarters (77%) of drug users recruited to the 
study were unemployed.  With only nine per cent in paid employment, 28 per cent 
reported that they were unemployed but looking for work or training; 24 per cent were 
                                                
166 Stable accommodation was defined as accommodation that you own or rent, 
accommodation owned by friends or family (stay rent free), accommodation owned by 
friends/family (where you pay rent), in a hostel (residential). Unstable accommodation was 
defined as in-patient or drug or alcohol treatment, in prison or other custody, slept rough on 
the streets, in a park etc. (without a roof), in a squat, other medical establishment, in a hostel 
(night drop-in centre), in a mobile home or caravan. 
167 This combined capture recapture estimates of the number of problem drug users (see 
Chapter 4) with DTORS (see Chapter 4), and the Work and pensions Longitudinal Study, see: 
http://www.dwp.gov.uk/asd/tabtool.asp 
168 This report suggests that there are up to 240,000 problem drug users receiving out of work 
benefit.  This number excludes those receiving Disability Living Allowance; Hay and Bauld 
estimate the number of the latter to be around 24,766. 
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unemployed but not looking for work; and 25 per cent reported they were unable to 
work and receiving long-term sickness/disability benefits, a lower proportion than 
estimated by Hay and Bauld (33%, n = 86,869) (2008).  Four per cent were in 
residential treatment; four per cent reported that they were temporarily unable to 
work, and two per cent reported that they were doing something else (Jones et al. 
2007). 
 
The Scottish Government’s drug strategy suggests that only about 15 per cent of 
treatment-seeking drug users are currently in employment or training (Scottish 
Government 2008a). 
8.2.3 School drop out 
Baseline data from DTORS reported that 38 per cent of clients seeking drug 
treatment had left school before the statutory minimum age of 16, with a further 49 
per cent having left full-time education at age 16 or 17 (Jones et al. 2007a). 
8.2.4 Sex workers  
In the DTORS baseline report ten per cent of females and one per cent of males 
reported being engaged in prostitution in the previous four weeks; all had taken 
heroin and/or crack cocaine (Jones et al. 2007). 
8.2.5 Families  
DTORS baseline data also reported on the number of drug misusers seeking 
treatment whose partner used drugs, and also those who were parents (Jones et al. 
2007).  Thirty-eight per cent of respondents had a partner who took drugs, most 
commonly women (61% compared with 25% of men).  Recent heroin use was 
associated with an increased likelihood that the partner also took drugs. 
 
Forty-nine per cent had children under the age of 16.  However three-quarters (75%) 
of these lived apart from all their children who were aged under 16, and three per 
cent lived apart from some of them.  Forty-four per cent of mothers, compared with 
17 per cent of fathers had at least one of their children living with them.  For 52 per 
cent of these respondents their children were living with the other parent, for 20 per 
cent they were living with other family members, for eight per cent their children were 
in care and for five per cent they were living elsewhere.  
 
In the new Welsh substance misuse strategy it is estimated that as many as 17,500 
children and young people in Wales live in families affected by parental drug use 
(Welsh Assembly Government 2008a). 
Research 
The impact of Parental Drug/Alcohol Problems on Children and Parents 
Reporting on research into the impact of parental drug/alcohol problems on children 
and parents, Fraser et al. (2008)169 supported previous research finding that most 
parents recognised their need for help; had obtained treatment for their drug/alcohol 
use; and were often ambivalent or self-critical about their parental ability.  It was 
suggested that parents preferred help from treatment services, with drug misusers 
suggesting that methadone had helped stabilise the lives, rather than help from 
social workers.  Furthermore, a desire to look after their children properly or to 
                                                
169 This was a small-scale research project which used semi-structured interviews and a 
‘Draw and Write’ technique for children under the age of ten.  Twenty-five parents from 18 
families and eight children (four under the age of ten. 
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resume responsibility for their care, were powerful motivators for them to stop using 
drugs/alcohol.   
8.3 Drug-related crime 
8.3.1 Drug offences 
DTORS reported that ten per cent of those seeking treatment sold drugs in the four 
weeks prior to interview (Jones et al. 2007). 
Recorded crime: drug offences 
Police recorded crime statistics170 show that while in the United Kingdom as a whole, 
crime decreased in 2007/08, there was a substantial increase in drug offences.  
Table 8.3 shows that in England and Wales drug offences rose by 18 per cent 
between 2006/07 and 2007/08 (Kershaw et al. 2008).  Increases in recent years have 
been largely attributable to increases in the recording of cannabis possession 
offences which account for 69 per cent of all recorded drug offences.  In 2007/08 
cannabis possession offences increased by 21 per cent, following increases of nine 
per cent in 2006/07 and 36 per cent in 2005/06.  This rise is largely associated with 
the increased use of police powers to issue warnings for the possession of cannabis. 
The number of these warnings increased by 28 per cent in 2007/08, a rise of 22,900 
detections compared with 2006/07.  There was an increase in possession of other 
drugs of 15 per cent in 2007/08 compared with the previous year.171  Recorded drug 
crimes also increased in Northern Ireland, with an increase of 13 per cent between 
2006/07 and 2007/08 (PSNI 2008).  In Scotland (latest data is for 2006/07), which 
has a different legal system to that in England, Wales and Northern Ireland, and 
which does not issue cannabis warnings (cannabis warnings are not issued in 
Northern Ireland either), there was a four per cent reduction in the number of drugs 
crimes recorded between 2005/06 and 2006/07 (Scottish Government 2008g).  
                                                
170 Data is recorded by the police for notifiable offences.  These include all offences that could 
possibly be tried by jury (these include some less serious offences, such as minor theft that 
would not usually be dealt with this way). For more information see: 
www.countingrules.homeoffice.gov.uk 
171 For more information on cannabis warnings see Policing cannabis - use of cannabis 
warnings- ACPO Guidance available at : http://www.acpo.police.uk/policies.asp 
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Table 8.3: Recorded crime: Drug offences in the United Kingdom by offence type and country, 
2002/03 to 2007/08  
 Year 
 2002/03 2003/04 2004/05 2005/06 2006/07 2007/08 
England and Wales  
Trafficking*  22,435 24,628 24,190 25,276 26,550 28,130 
Possession  119,896 118,006 120,866 152,602 167,003 200,019 
Other drug offences** 989 877 781 601 680 809 
Total offences 143,320 143,511 145,837 178,479 194,233 228,958 
Northern Ireland 
Trafficking  291 405 375 349 473 529 
Possession  1,633 2,184 2,247 2,595 1,938 2,191 
Total offences 1,924 2,589 2,622 2,944 2,411 2,720 
Scotland 
Trafficking  10,148 9,537 9,333 9,613 10,890 9,827 
Possession  30,510 32,463 32,268 34,440 31,329 30,559 
Other drug offences *** 280 275 222 194 203 360 
Total offences 40,938 42,275 41,823 44,247 42,422 40,746 
United Kingdom 
Trafficking  32,874 34,570 33,898 35,238 37,913 38,486 
Possession  152,039 152,653 155,381 189,637 200,270 232,769 
Other drug offences 1,269 1,152 1,003 795 883 1,169 
Total offences  186,182 188,375 190,282 225,670 239,066 272,424 
* Trafficking usually includes production, supply, possession with intent to supply, possession on a ship, 
carrying on ship and unlawful import and export.  
** For England and Wales ‘other drug offences’ mainly concerns permitting premises to be used for the 
production, supply and use of drugs. 
*** For Scotland ‘other drug offences’ includes production and manufacture of drugs (not illegal 
cultivation) , money laundering related offences and other drugs offences not designated as trafficking 
or possession.  
Source: Kershaw et al. 2008; NISRA 2004; PSNI 2006; PSNI 2008; 
Scottish Government 2008g 
Arrests for drug offences 
Information on persons arrested for drug offences is also available for England and 
Wales, and for Northern Ireland.  Table 8.4 shows that in England and Wales in 
2006/07, 89,200 persons were arrested for drug offences, an increase of less than 
one per cent from 2005/06.  Data for England and Wales for 2007/08 are not yet 
published.  In Northern Ireland in 2007/08, 1,896 persons were arrested for drug 
offences, an increase of 9.8 per cent from the previous year (Table 8.4).  Arrests for 
possession have reduced considerably since 2004 with the introduction of a 
‘cannabis warning’, rather than an arrest for possession of cannabis for personal use. 
Table 8.4: Number of persons arrested for drug offences in England and Wales, and Northern 
Ireland, 2002/03 to 2007/08 
 Year 
 2002/03 2003/04 2004/05 2005/06 2006/07 2007/08 
England and Wales 131,100 113,100 84,800 88,600 89,200  
Northern Ireland  1,295 1,754 1,356 1,440 1,726 1,896 
Total  132,395 114,854 86,156 90,040 90,926  
Source: Ministry of Justice 2008a; PSNI 2004; 2006b; 2008b  
Convictions for drug offences 
Data presented to the EMCDDA over the last few years has been for persons found 
guilty, cautioned or dealt with by compounding for drug offences, which is recorded in 
such a way as to be able to be broken down by drug.  Latest data is on an all offence 
basis rather than a principal drug offence basis; data provided in previous Focal Point 
Reports was based on principal drug offence.  New information reported this year for 
the United Kingdom as a whole is for both 2005 and 2006 (Table 8.5).  There were 
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118,706 offences in 2005 and 124,344 in 2006, an increase of 4.5 per cent.  There 
were 55,984 cannabis-related offences in 2006, an increase of 2.1 per cent since 
2005 (54,813).  There were 15,471 convictions for heroin offences, a very marginal 
increase since 2005 (15,629).  There were 7,422 offences concerning amphetamines 
in 2006, an increase of 8.1 per cent since 2005 (6,864); 6,233 offences concerned 
ecstasy in 2006, a small decrease of 1.6 per cent since the previous year (6,337).  
The largest increase was for cocaine powder, with 15,470 offences in 2006, an 
increase of 28.6 per cent since 2005 (12,028).   
Table 8.5: Persons found guilty or cautioned for drug offences in the United Kingdom 2000 to 
2006 by individual drug  
 Year 
 2000 2001 2002 2003 2004 2005* 2006* 
Amphetamines 6,637 4,950 5,820 6,163 6,249 6,864 7,422
Cannabis 75,989 72,691 83,152 85,768 82,845 54,813 55,984
Cocaine powder 5,451 3,090 6,990 7,905 9,382 12,028 15,470
Crack cocaine 1,216 1,460 1,830 2,270 2,450 3,734 4,076
Ecstasy 6,630 7,880 6,590 5,940 6,209 6,337 6,233
Heroin 12,297 12,380 11,860 11,277 12,412 15,629 15,741
LSD 260 150 90 150 90 183 172
* Data for 2005 and 2005 is on an all offence basis rather than a principal drug offence basis; data for 
2000 to 2004 is based on principal drug offence. 
Source: Standard Table prepared for the United Kingdom Focal Point 
8.3.2 Other drug-related crime 
DTORS reports that amongst those seeking drug treatment 43 per cent reported 
having committed at least one of 15 different offences in the previous four weeks, 
some of which were related to offences under the Misuse of Drugs Act (see above).  
Seventy-three per cent reported committing an offence in the previous 12 months.  
Forty-four per cent of clients reported that they had reduced their offending rates in 
the four weeks prior to interview.  Thirty-nine per cent reported committing an 
acquisitive crime during this period, offences committed included: 
• shoplifting (26%); 
• buying or selling stolen goods (20%); 
• stealing something else (8%); and 
• selling drugs (10%) (Jones et al. 2007). 
 
Use of heroin and crack cocaine was a key determinant of offending, with those who 
used both heroin and crack cocaine (59%), and those who used crack cocaine only 
(51%), being more likely to report offending those who used heroin only (39%) or 
those that used neither drug (24%).  Nine per cent reported committing more than 
one offence a day.  An average (median) of €190 (£130) was obtained via offending 
over the last four weeks, which was higher for those using heroin and crack cocaine, 
€380 (£260). 
 
The third sweep of the Arrestees Survey (2005/06) (Boreham et al. 2007)172 found 
that 52 per cent of arrestees reported having taken one or more drugs in the month 
previous to arrest.   
                                                
172 8,027 arrestees were surveyed.  Respondents were interviewed in 72 custody suites 
across England and Wales. Interviews were conducted throughout the year on all days of the 
week and at all times of the day.  The eligible population was defined as people aged 17 or 
older who had been arrested on suspicion of committing an offence and who had not 
previously been interviewed within the current survey year.  The sample design was a 
stratified two-stage random probability sample.  A random selection of custody suites was first 
drawn. Within each suite, a random sample of shifts was then selected.  Interviews were 
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Of these: 
• 41 per cent had taken cannabis; 
• 13 per cent heroin; 
• 13 per cent cocaine powder; 
• 11 per cent crack cocaine; and  
• eight per cent ecstasy. 
 
Of those who reported taking heroin, crack cocaine or cocaine powder in the month 
previous to arrest, 26 per cent had taken heroin and crack cocaine, 40 per cent had 
taken cocaine powder only, and 17 per cent had taken heroin only.  It is reported that 
this pattern of polydrug use was different from 2003/04 and 2004/05, reflecting a 
consistent trend of a relative decrease in the use of heroin and crack cocaine and a 
relative increase in the use of cocaine powder.  Overall, 26 per cent had taken 
heroin, crack cocaine or cocaine powder in the previous month.   
 
As in previous surveys regular users (at least weekly) of heroin and crack cocaine 
were more likely to have committed acquisitive crime in the 12 months previous to 
arrest (81%) than those who did not take heroin or crack cocaine regularly (30%).  
Also, 79 per cent of regular heroin or crack cocaine users had been arrested in the 
year previous to being surveyed compared to 48 per cent who reported 
occasional/no use of heroin or crack cocaine.  Self reported heroin and crack cocaine 
use by those reporting multiple drug use fell over the three sweeps of the survey, but 
use of cocaine powder increased.  The proportion of respondents who had ever 
injected drugs decreased from 18 per cent to 13 per cent. 
 
There was an increase in those reporting treatment for heroin in the 12 months 
previous to arrest, from 34 per cent to 41 per cent.  Also, there was an increase from 
23 per cent to 32 per cent in the proportion of frequent heroin users (those who used 
heroin five or more days a week) currently in treatment.  In 2005/06, 26 per cent of 
those reporting previous treatment for heroin dependency reported no longer using 
heroin. 
Property crimes 
See the DTORS baseline report above. 
Illegal prostitution 
See 8.2.6 above. 
Prescription offences 
Information is not available pertaining only to drugs classified under the Misuse of 
Drugs Act. 
Violence under the influence 
In the DTORS baseline report two per cent reported committing violent theft and a 
further six per cent other violent crime (Jones et al. 2007).  However, it is not 
reported whether these crimes were committed under the influence drugs.  
                                                                                                                                         
attempted with all eligible respondents within the selected shifts.  This design meant that the 
sample would be representative of all arrest events over a 12-month period.  The interview 
consisted of a CAPI3 interview of around 20 minutes with a substantial CASI self completion 
section, which contained the most sensitive questions about offending behaviour, drug and 
alcohol use and treatment for drugs. Audio-CASI was available for respondents with literacy 
problems. In addition, respondents were asked to provide an oral fluid sample for analysis of 
recent drug use.  The overall response rate was 23 per cent in 2005–06. 
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Driving offences  
For England and Wales information on recorded crime for the offence of ‘causing 
death by careless driving when under the influence of drink or drug’ is available.  In 
2007/08 there were 418 such offences.  There has been a steady increase in such 
offences since 1997 (291), but latest data show a nine per cent fall from the previous 
year (459) (Kershaw et al. 2008). 
8.4 Drug use and prison 
8.4.1 Drug use in prison  
Review of treatment in prison 
In a review of prison-based drug treatment funding, Pricewaterhouse Coopers (2007) 
suggest that there are over 81,000 people in prison (annual turnover estimated to be 
135,000 per annum) in England and Wales, with over half of these thought to be 
problem drug users (see Chapter 9.3.1 for more information on the review). 
Mandatory Drug Testing in prisons in England and Wales  
Under Mandatory Drug Testing (MDT) in England and Wales173, prisoners are subject 
to random mandatory tests for amphetamines, barbiturates, benzodiazepines, 
cannabis, cocaine, methadone and opiates.  The overall random MDT positive rate 
has dropped from 24.4 per cent in 1996/97 to 9.1 per cent in 2007/08.  The 
breakdown of these figures shows positive tests for cannabis coming down from 20.2 
per cent in 1996/97 to 4.1 per cent in 2007/08.  Positive tests for opiates have 
dropped from 5.4 per cent in 1996/97 to 4.3 per cent in 2007/08.  This is the first year 
that the overall figures for England and Wales have shown a higher percentage of 
positive tests for opiates than cannabis (internal communication from the Ministry of 
Justice).  
Buprenorphine misuse in Prisons in England and Wales  
Following concern about the misuse of buprenorphine in prisons in England and 
Wales, during February to April 2007 all MDT samples were screened for 
buprenorphine.  It was found that the misuse was a significant problem.  The rate for 
positive MDT tests for all prisons in the survey period excluding buprenorphine was 
8.9 per cent.  Inclusion of universal buprenorphine test results increased the rate to 
10.2 per cent, an increase of 1.3 per cent.  The rate of positive tests was as high as 
20.4 per cent of testing in one prison (Ministry of Justice 2007a). 
Addictions Testing Measure (ATM) 
In Scotland, Addiction Prevalence Testing174 was carried out across all prisons during 
July 2007 and January 2008.  The results confirmed that 64 per cent of prisoners 
                                                
173 The other forms of mandatory drug testing used in prisons are; suspicion testing, frequent 
testing, risk testing and on-reception testing.  Voluntary drug testing (VDT) is also used to 
provide prisoners with additional incentives and support to stay drug free.  In 2007/08, 32,808 
VDT compacts were in place.  
174 An Addictions Testing Measure (ATM) was introduced in 2007 in Scotland to provide 
evidence of progress and distance travelled towards the Offender Outcome of 'reduced or 
stabilised substance misuse'.  SPS aims to ensure that prisoners make positive progress 
towards the Offender Outcomes during their time in custody.  This can be referred to as the 
"prisoner journey".  All admissions arriving in custody in two months of the year are tested for 
the prevalence of illegal drugs.  Similarly all prisoners leaving custody are tested on a similar 
basis to assess the positive impact of addictions programmes.  These tests are designed to 
support measurement of SPS' progress in achieving a reduction in the number of prisoners 
testing positive for drug use on entry compared with exit.  Prisoners are tested at other times 
during their sentence to support their own participation in addictions programmes and 
prescribing, or to inform other operational decisions such as prisoner management. 
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tested on reception had illegal drugs in their system.  By way of comparability, 
liberation testing revealed that 26 per cent tested positive for drugs on release. 
The Scottish Prison Service Prisoner Survey 
The 10th prisoner survey undertaken in 2007 by the Scottish Prison Service found 
that: 
• seven out of ten of prisoners (69%) reported that they had used illegal drugs in 
the year before coming into prison; 
• half (51%) reported that they had used drugs in prison at some point in the past; 
• a majority of these individuals (82%) reported that their drug use had changed 
during their current period in prison with a majority (74%) reporting a decrease in 
drug use; 
• less than a third of prisoners (30%) reported that they had used illegal drugs in 
the month immediately prior to survey completion;  
• a small minority (3%) reported injecting drugs in prison in the last month. Of these 
the majority (80%) stated that they had shared injecting equipment; 
• nearly half (45%) reported that their drug use was a problem for them on the 
outside and that they were under the influence of drugs at the time of their 
offence (50%); and  
• a quarter (26%) indicated that they committed their offence to get money for 
drugs.  
 
Amongst those reporting drug use in the 12 months prior to custody (69%) the most 
commonly reported drugs used were:  
• cannabis (79%);  
• benzodiazepines (60%); 
• cocaine (60%); and  
• heroin (53%). 
 
The most common drugs reported in the last month while in custody were:  
• heroin (70%); 
• cannabis (64%); 
• benzodiazepines (45%); 
• other opiates (25%); 
• methadone (not on prescription) (18%); 
• cocaine (17%); 
• temazepam (12%); 
• ecstasy (9%); and 
• amphetamines (5%).  
 
There has been a small decrease in those having used drugs in prison from 55 per 
cent in 2003 to 51 per cent in 2007 (Scottish Prison Service 2008). 
 
A report about minimising the supply of drugs into prisons in Northern Ireland 
suggests that there is no evidence of a significant problem with the use of Class A 
drugs (NIPS 2008).  However, there have been small amounts of heroin, cocaine and 
associated paraphernalia found in the past year.  Cannabis remains the primary drug 
used by prisoners in Northern Ireland, commonly in resin form, with in the past year 
over 650g found, which would have a monetary value of about €14,600 (£10,000) in 
the prison environment.  Also, around 3,600 benzodiazepine tablets have been found 
in the past year, in some cases in large quantities. 
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8.5 Drug use in the workplace 
Most drug testing in the United Kingdom is conducted in safety-critical industries 
such as shipping, railways and construction, where pre-employment and random 
drug testing is mandatory.  Employers conducting random drug tests found a 34 per 
cent increase in positive tests for cocaine in 2007, with one in 145 employees testing 
positive for cocaine, suggesting they had consumed it in the previous two days.175   
8.6 Social costs  
Based on the methodology used in research into the social and economic costs of 
problem drug use in England (Gordon et al. 2006) it is estimated that the costs in 
Scotland are approximately €3.9 billion (£2.6bn).176  It is of note that research has 
been commissioned to refine this estimate (Scottish Government 2008a).  Also so 
based on research by Gordon et al. the total economic and social costs of Class A 
drug use in Wales has been estimated to be around €1,140 million (£780m), with 
drug-related crime accounting for 90 per cent of this; health service costs are 
estimated to be €25.7 (£17.6m) per year (Coles and Pates 2008). 
                                                
175 See: http://www.ft.com/cms/s/0/a9b96b42-d69e-11dc-b9f4-0000779fd2ac.html 
176 Conversion rate is the December 2006 monthly average spot exchange rate quoted by the 
Bank of England. 
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9. Responses to social correlates and consequences  
9.1 Overview  
Social reintegration is a key element of recovery within new strategies in England, 
Scotland and Wales.  The strategy for Northern Ireland, published in 2006 also 
recognises the need to provide support with housing and employment and wider 
support with social reintegration.  There are various programmes to help drug users.  
The Supporting People Programme, introduced in 2003, provides housing related 
support to vulnerable groups generally, including people with drug problems.  
Progress2work (p2w), initiated in 2002 supports those who are drug free or stabilised 
in gaining employment.  The Building Safer Communities Fund aims to build 
communities that are resistant to drugs.  Social inclusion programmes such as 
Positive Futures can bridge the gap between universal and targeted services (see 
Chapter 3).  Attention is also focused on the impact of parental drug use on children.  
In addition, there are a growing number of responses to neighbourhood problems 
associated with problem drug use, including drug dealing.  For example, the Anti-
Social Behaviour Act 2003 seeks to stop the use of premises for drug dealing.  Also, 
there is guidance to tackle the inappropriate disposal of drug paraphernalia. 
 
The Drug Interventions Programme is a key part of the Government’s strategy for 
tackling drugs and reducing crime in England and Wales.  Introduced in 2003, new 
elements have been phased in each year since.  The programme aims to get drug-
misusing offenders out of crime and into treatment and other support.  Some 
interventions operate right across England and Wales, while additional intensive 
elements operate in those areas with the highest acquisitive crime. 
 
In Scotland, Drug Treatment and Testing Orders (DTTOs) provide offenders with 
access to treatment services as a requirement of the order whilst piloting is taking 
place of drug testing of arrestees to enable individuals to engage on a voluntary 
basis with treatment services.   
 
There are a range of measures to prevent drugs entering prison including clearly-
defined searching procedures covering all possible routes; passive and active drug 
dogs, with passive dogs available to all prisons; CCTV surveillance of all social visit 
areas and low-level fixed furniture; and comprehensive measures to tackle visitors 
attempt to smuggle drugs, including closed visits, visit bans and police arrest.  New 
initiatives including mobile phone blocking to prevent contact with dealers, and body 
orifice searches are also being introduced.  Since April 2006, in England and Wales, 
responsibility for prison health services has been fully devolved to the National 
Health Service (NHS), and an Integrated Drug Treatment System (IDTS) has been 
developed to improve the availability and quality of drug treatment in prison, bringing 
it on a par with treatment in the community.  Scotland is reviewing the feasibility of 
placing responsibility for health care with the NHS.  For the first time in the United 
Kingdom a syringe-exchange programme will be piloted in a Scottish prison. 
9.2 Social reintegration  
All new drug strategies in the United Kingdom are concerned with helping problem 
drug users recover and re-establish themselves in the community by aligning 
strategies on social exclusion and poverty, housing, education and training, and by 
providing support to avoid relapse.  
 
In England key actions are:  
• pooling of budgets for treatment and other interventions; 
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• individual budgets for treatment and wider support;  
• personalisation of treatment; and 
• a renewed focus on outcomes (HM Government 2008a). 
 
These are expected to identify more effective incentives and delivery mechanisms for 
treatment and support for housing, training, employment and State benefits for drug 
misusers.  There will be six initial pilot areas by late 2008. 
 
In Wales, the Welsh Assembly Government is to produce a module of the Substance 
Misuse Treatment Framework for Wales on Continual Personal Development 
Opportunities, which includes education, training, volunteering, work experience, 
employment, day services and leisure pursuits.  There are also plans to explore 
opportunities to access European Structural Funds to support provision of these 
services (Welsh Assembly Government 2008a). 
 
In Scotland, the new drug strategy has its main focus on recovery and therefore it is 
considered that policies and services need to be designed to enable drug uses to 
reintegrate.  This is seen to require a cultural change within treatment services for 
drug users (see Chapter 1).  In anticipation of this the Scottish Government 
commissioned a report by the Scottish Advisory Committee on Drug Misuse 
(SACDM) (2008) to address the additional non-medical aspects of services required 
to ensure that people with substance use problems are given every opportunity to 
recover.  The Committee suggested that the approach to treatment be more 
aspirational and that this will involve the development of a national philosophy of care 
with a focus on recovery.  
 
Key actions, within the Scottish Government’s Action Plan in this area are: 
• the setting up of a Drug Recovery Network to promote and support the concept of 
recovery; 
• an appropriate range of drug treatment and rehabilitation services to promote 
recovery; 
• setting up a national support function to take forward the development and 
implementation of the recovery model in drugs services;  
• developing an outcomes based framework for assessing and managing 
performance at a local level focused clearly on recovery; 
• establishing a National Evidence Group to develop a co-ordinated approach to 
identify gaps in research and encourage innovation (Scottish Government 
2008a). 
9.2.1 Housing  
A further aim of Drugs: protecting families and communities, mainly relevant to 
England, is to improve access to accommodation with updated guidance to Local 
Authorities on their strategic housing role, a new rough sleeping strategy, identifying 
improvements in services available to rough sleepers, and an increase in the number 
moving on from hostels and homelessness services.  There will also be continuing 
investment in the Supporting People177 and Adults Facing Chronic Exclusion 
programmes.178  Local Authorities are to receive at least €219 million (£150m) over 
three years to help them prevent and tackle homelessness. 
 
                                                
177 See: http://www.spkweb.org.uk/ 
178 See: http://www.communities.gov.uk 
http://www.cabinetoffice.gov.uk/social_exclusion_task_force/news/2007/070618_steps.aspx 
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The Home Office Drug Interventions Programme (DIP), Communities and Local 
Government, the Ministry of Justice National Offender Management Service (NOMS), 
the Housing Corporation, the Department of Health’s Care Services Improvement 
Partnership (CSIP) and the National Treatment Agency for Substance Misuse have 
identified the need to consider the issue of housing and related support services for 
drug users. They are working with a national stakeholder group from both housing 
and the drug fields to identify practice and solutions which may inform the prevention 
of homelessness amongst drug users.  A practice paper will be produced in 2008. 
The paper is being written to support the development, planning and delivery of 
housing and housing support services for drug users.  It builds on recent practice 
findings and work undertaken by the Audit Commission (2004), Homeless Link 
(2007), McKeown (2006), CSIP (2007) and Addaction (Stephenson 2006).  It will also 
take account of provisions such as The Respect Standard for Housing Management 
(Home Office and Communities and Local Government 2006).   
 
Emerging findings suggest that housing179 and related support services for drug 
users can contribute to improving outcomes on crosscutting areas such as 
preventing homelessness, reducing evictions and abandonments, increasing 
engagement and retention in drug treatment, improving health and social well-being, 
reducing re-offending, acquisitive crime and the causes and effects of anti-social 
behaviour (internal communication from the Home Office).  
 
Working Together to Reduce Harm – the Substance Misuse Strategy for Wales 
2008-2018 also highlights the need for housing to be a core element of services for 
drug misusers, noting that over the next year the Welsh Assembly Government will 
be developing a ten-year plan to tackle homelessness, reviewing actions required to 
meet the needs of homeless substance misusers (Welsh Assembly Government 
2008a).  There is a dedicated funding stream within the Social Housing Grant 
programme to address accommodation needs. 
Research  
Homelessness, substance use, and the effect of material marginalisation and 
psychological trauma 
Research into homelessness supports previous findings that substance use, both 
alcohol and drugs, precipitates and exacerbates homelessness and marginality 
(McNaughton 2008).180  The author suggests that once housed, a key problem was 
isolation and boredom, with deterioration in mental and physical health, leading some 
who had stopped using to relapse.  It is concluded that for many who have been 
marginalised it is not enough to gain employment and be housed, much wider 
support is required to prevent relapse. 
Effective Services for Substance Misuse and Homelessness in Scotland  
In a review of the international literature, Pleace (2008) found that research suggests 
that there is a strong mutually reinforcing relationship between substance misuse and 
homelessness.  The report highlighted the need to ensure that there is awareness in 
general homelessness and substance misuse services of the needs of homeless 
people with a substance misuse problem and to set realistic service outcomes that 
are tailored to the service user. 
                                                
179 Housing is taken to include a range of options, including social housing, the private rented 
sector, home ownership including low cost home ownership and supported housing. 
180 Twenty-eight people who were or had recently been homeless, selected from a sampling 
frame of 70 who had taken part in an earlier stage of research.  
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9.2.2 Education, training  
In Wales the new strategy seeks to raise awareness amongst local partnerships of 
the needs of substance misusers to improve their access to skills programmes and 
learning opportunities (Welsh Assembly Government 2008a). 
 
For Scotland see 9.2.3 below. 
9.2.3 Employment  
As referred to in Chapter 5, a strategic objective of Drugs: protecting families and 
communities is a new focus on services to help drug users re-establish their lives. 
Key actions include:   
• Government departments to agree good practice guidance on securing treatment 
and support in gaining employment for drug users in receipt of benefits, in 
particular: 
− the referral of drug users in receipt of benefits into treatment;  
− provision of an appropriate ‘safety net’ of support, to which other claimants 
would be entitled;  
− for drug users in treatment, the use of the housing, employment and other 
indicators within the Treatment Outcome Profile to monitor the effectiveness 
of provision;  
− guidance for carrying out medical assessments of fitness for work; and  
− joint planning by Primary Care Trusts, Jobcentre Plus181 and local authorities 
to co-ordinate the management of drug misusers in treatment into work; 
• annual agreement between treatment providers, jobcentres and housing support 
services on cross-agency support for drug users in receipt of benefit; and 
• a requirement through the use of Jobseeker’s Direction or Work Focused 
Interview process182, that drug misusers claiming working age benefits attend a 
discussion with a drug treatment provider, where they are not already in contact. 
 
These actions are proposed in the new Green Paper on reform of the welfare 
system, No one written off: reforming welfare to reward responsibility which proposes 
action to meet a Government target of an 80 per cent employment rate (DWP 2008).  
It is proposed that legislation be introduced underpinning people’s obligations to 
work, including a requirement for those identified as having problems with crack 
cocaine or opiates to take action to stabilise their drug habit and to take steps 
towards employment, in return for receiving benefits.  The Green Paper suggests that 
of the estimated 240,000 problem drug users183 who are in receipt of out-of-work 
benefits, 100,000 are not in treatment.  
 
The Department of Work and Pensions (DWP) is responsible for benefits throughout 
the United Kingdom.  However, Scotland, Wales and Northern Ireland have 
responsibility for treatment and therefore these proposals will have implications for 
treatment systems outside England.   
 
In Scotland, The Road to Recovery suggests that action to improve employability 
must become more aspirational, with treatment and care services providing ongoing 
support to help with recovery (Scottish Government 2008a).  The Employability 
Framework, Workforce Plus184 is seen as central to this and is consistent with the 
                                                
181 For more information see: www.jobcentreplus.gov.uk 
182 For more information see: http://www.dwp.gov.uk/  
183 This figure differs from that in the feasibility study by Hay and Bauld reported in Chapter 8 
as it excludes problem drug users identified as receiving disability allowance.  
184 For more information see: 
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broader approach to integrating services emphasised in the Essential Care report 
(SACDM 2008).   
 
One area emphasised in the Scottish strategy is the need for greater flexibility in 
prescribing and supervised dispensing to meet the needs of those entering 
employment. 
Research 
Getting drug users back into the labour market  
The United Kingdom Drug Policy Commission has commissioned a study concerned 
with getting problem drug users (back) into the labour market.  The aims are to: 
• review the particular challenges problem drug users (PDUs) face in re-entering 
the employment market (e.g. skills, medication, work experience, support 
mechanism, homelessness etc);  
• consider the impact of the current legislative frameworks and benefit structures 
on PDUs participation in the labour market;  
• understand the perceptions, attitudes, practice and experiences of employers 
with respect to employing this group;  
• identify some examples of effective support systems for PDUs; and  
• identify the subsequent implications for national policy and service delivery 
bodies. 
Drug treatment and the achievement of paid employment 
In a paper aimed at identifying which aspects of drug treatment are most closely 
associated with recovering drug users’ ability to obtain paid employment it was found 
that there is a close relationship between the cessation of illegal drug use and 
individuals’ ability to obtain paid employment (McIntosh et al. 2008).185  It was 
suggested that while abstaining from drug use is unlikely to be successful on its own, 
the factor that showed the strongest independent association with the achievement of 
paid employment was assistance with finding work, and the authors suggest that 
these findings strongly support the provision of employment support programmes as 
the most important mechanism for helping recovering drug users to obtain 
employment. 
9.2.4 Children of drug using parents 
In both Scotland and Wales concern about the impact of parental substance misuse 
upon children has been of major concern (see previous United Kingdom Focal Point 
reports).   
 
                                                                                                                                         
http://www.scotland.gov.uk/Publications/2006/06/12094904/0 
185 This article reports on a logistic regression analysis of the factors associated with the 
achievement of paid employment 33 months after the initiation of treatment for drug 
dependency.  It is based on data collected in the course of the Drug Outcome Research in 
Scotland (DORIS) study.  The study has involved over a 1,000 problem drug users recruited 
from 33 drug treatment agencies located across Scotland, with recruitment sites chosen to 
represent a range of drug treatment modalities, including prison based treatments.  The 
socio-demographic profile of DORIS respondents is nearly identical to that of individuals in 
Scotland starting a new drug treatment in 2001, as reported in the Scottish Drug Misuse 
Database. Respondents were 69 per cent male, with a mean age of 28.  The great majority of 
respondents reported that their main drug was heroin.  The first round of interviews was 
conducted with 1,033 individuals seeking treatment for a drug problem in 2001/02 (DORIS1).  
Respondents were followed up at 8, 16 and 33 months (DORIS2, DORIS3 and DORIS4).  
The employment outcome variable used in the analysis is based upon the data collected at 
DORIS4.  The analysis focused on paid employment.  
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In the new Scottish drug strategy a dedicated chapter, Getting it right for children in 
substance misusing families, outlines the approach to supporting children affected by 
parental substance misuse, with key actions to improve their life chances, including: 
• provision of ongoing multi-agency training to help identify children at-risk at an 
early stage; 
• supporting sharing and embedding of good practice on single and inter-agency 
assessment of, and planning for, children; 
• developing more accurate prevalence figures for children affected by substance 
misuse; 
• strengthening the focus of adult substance misuse services on the needs of 
children and families by including relevant outcomes in the commissioning 
framework; 
• promoting the creation of integrated services to provide equality of access to 
treatment for all drug users; 
• in the context of the Early Years Framework186, work to improve parenting 
capacity, recognising the role of wider family and community networks in 
promoting resilience in children and their families; 
• promoting support for young carers; 
• promoting collaborative working between Child Protection Committees and 
Alcohol and Drug Action Teams in planning and meeting the needs of this group; 
and 
• promoting good practice in supporting children affected by parental substance 
misuse (Scottish Government 2008a). 
 
Also in Scotland, social work legislation has been examined in the light of this issue. 
Social workers were found to have sufficient powers to compel parents not engaging 
with services to do so, where this is appropriate (internal communication from the 
Scottish Government). 
 
In Wales, the strategy suggests that a proposed Legislative Competency Order for 
Vulnerable Children and Child Poverty187 will enable legislation in relation to the 
welfare of children and young people. The Welsh Assembly Government is to consult 
on a strategy for vulnerable children in the context of this new legislative framework.  
This will include support to parents who may need help for their mental health, 
substance misuse or other problems that may affect a child’s opportunities and well-
being.  As noted in the previous United Kingdom Focal Point report a number of 
family intervention projects have been established in Wales, including the Early 
Parental Intervention Projects, ‘Option 2’ and ‘Families First’ (see below).  The Welsh 
Assembly Government is to develop an integrated family support tool to assist local 
authorities working with families where substance misuse is an issue.  Young carers 
are identified as a group needing support in Caring about Carers.188  Guidance on the 
identification and assessment of young carers is included in Health and social care 
for adults: creating a unified and fair system for assessing and managing care.189  
Similarly, there is concern that support should be offered to parents and the 
Strengthening Families190 programme for parents of young people aims to reduce 
                                                




188 For more information see: http://www.wales.nhs.uk/documents/Jane-Hutt-reports-to-
Assembly-Members-on-a-strategy-for-carers-in-Wales-e.htm 
189 For more information see: 
http://new.wales.gov.uk/publications/circular/circulars2002/NAFWC092002?lang=en 
190 For more information see: 
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and prevent substance misuse and other problem behaviours in young people.  An 
evaluation has been commissioned which will be published later in 2008.  
 
Drugs: protecting families and communities also places an increased priority on 
children and families affected by substance misuse, suggesting that there will be 
increased support for carers taking responsibility for the children of substance 
misusing relatives.  Also, as part of this, it is recommended that substance misuse 
training for social workers should be provided.  
 
All strategies acknowledge that access to effective treatment should enhance the 
parenting capacity of drug misusers and that treatment services must act where 
substance misusers have children or there are children in the household, and 
recognise that they have a responsibility, in partnership with others, to ensure the 
child’s well-being. 
Drug courts  
Drug Courts, already available in Scotland, have been established in England 
following a process evaluation of two pilot courts.191,192  The evaluation found that 
continuity of the judiciary, ability to understand offender motivation and, in particular, 
the points at which an offender is most likely to make progress in reducing or 
stopping drug use, were key components of success (Matrix Knowledge Group 
2008). 
Training for social workers  
The British Association of Social Workers have called for employers and educators to 
provide more support in working with substance misusing clients, suggesting that 
specialist modules on substance misuse should be taught on both qualifying and 
post-qualifying training programmes, in order to meet the demands of a growing 
prevalence in social workers’ cases.  Currently, substance misuse is not a mandatory 
part of a social work degree.193 
Research 
Evaluation of the ‘Option 2’ service 
The ‘Option 2’ service, funded by the Welsh Assembly Government, has been 
operational in Wales since 2000.  It is an early intervention service for families where 
children are at risk of harm and the parents have drug or alcohol problems.  It offers 
brief and intensive support to the families to prevent the children being placed into 
care, wherever possible.  An evaluation of the service has recently been published 
(Forrester et. al 2007) investigating differences between children receiving the 
                                                                                                                                         
http://www.childreninwales.org.uk/inyourarea/parentingprojects/5358.html 
191 The Dedicated Drug Court (DDC) framework for England and Wales provides for specialist 
courts which exclusively handle cases relating to drug-misusing offenders from conviction 
through sentence to completion (or breach) of a community order with a Drug Rehabilitation 
Requirement (DRR).  This framework establishes five distinguishing core characteristics: 
specialism, the DDC exclusively handles cases relating to drug-misusing offenders from 
conviction through sentence, to completion or breach of their orders; continuity, the DDC will 
try to ensure sustained continuity of magistrates’ bench or district judge throughout the period 
an offender comes before the DDC; training, sentencers and other court staff receive 
additional training on working with drug-misusing offenders and the DDC model; processes, 
processes are designed to ensure all necessary information is before the court when 
required; and partnership, the DDCs are designed to ensure effective multidisciplinary 
working with other criminal justice system agencies and professionals. 
192 See: http://www.justice.gov.uk/news/newsrelease010408b.htm 
193 For more information see: 
http://www.communitycare.co.uk/Articles/2008/08/07/109065/basw-group-social-workers-
need-more-substance-misuse-training.html 
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‘Option 2’ service and a comparison group.  It was reported that the service did not 
reduce the proportion of children entering care but the time spent in care by those 
children was significantly reduced for varying reasons, that is, they tended to stay in 
care for a shorter time, they took longer to enter care and a higher proportion 
returned home after a spell in care.  It also found that at the end of the study a third 
of children in the comparison group were in care and a quarter of the ‘Option 2’ 
children were in care.  It was reported that the ‘Option 2’ project brought about 
significant financial savings in terms of reducing the need for public care and its 
associated costs.  
Families First 
The Families First project in Middlesbrough works with families who are facing 
problems related to substance misuse and who have reached a ‘crisis point’ and is 
based on the ‘Option 2’ service.  The Department of Health in England has 
commissioned an evaluation of the project.  Results from the latest interim report194 
showed that at the twelve month follow up stage a range of positive outcomes for the 
families involved were reported including reduced conflict within the family, children 
kept out of the care system and drug and alcohol use stabilised.  The final report will 
be available in December 2008.  
‘Mind the Gap’ Grandparents Project 
An evaluation report has been published regarding the short-term impact of 
information resources that were developed as a result of the ‘Mind the Gap’ 
grandparents’ project.  The aim of the project was to develop resources for support 
agencies of grandparent carers (e.g. drug treatment agencies, social services).  The 
project yielded a resource pack for grandparents who are providing care for their 
grandchildren as a result of substance use.  There is also a resource pack available 
for professionals working with these groups.  The evaluation found that in general, 
support agencies had a greater understanding of grandparents’ needs as a result of 
the project, although it was reported that it may be too soon to expect major changes 
in service provision (McWhirter 2008).  A series of reports has been published by 
Mentor UK regarding the development of these information materials195. 
 
The Welsh Assembly Government has commissioned research in the following 
areas.  
• A pilot study of a Family Support Service to collect evidence on the applicability 
and effectiveness of an American, evidence based model of family support.  
Emerging findings are due in December 2008 and the full report is due in April 
2009. 
• Family/carer support services in North Wales are to conduct a community 
engagement research project to identify the type of family support services 
required.  
• An evaluation of the Early Parental Intervention Pilot Projects, commissioned in 
five areas, which are intended to improve outcomes of children in families where 
one adult member has substance misuse problems, by working with the adults.  
This will be carried out between February 2008 and October 2009. 
9.3 Prevention of drug related crime  
The mainstay of preventing, or reducing drug related crime continues to be through 
identifying drug-misusing offenders as early on as possible in the criminal justice 
process and engaging them in appropriate treatment and support.  
                                                
194 See: http://www.cph.org.uk/substanceuse/index.aspx?teamid=23  
195 See: http://www.mentorfoundation.org/projects_around_the_world.php?nav=3-27-34-
86&id=91  
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In England and Wales the Drug Interventions Programme (DIP) was initiated to 
ensure that those committing such crimes access treatment and support.  The 
Programme is a key component for delivering against a range of cross-Government 
targets and indicators concerned with reducing offending and drug misuse, improving 
health and combating social exclusion. 
 
In Scotland drug misusers, identified through the justice system are referred into 
treatment through the use of Drug Treatment and Testing Orders (DTTOs).  These 
orders provide disposals for high tariff offenders who might otherwise receive a 
custodial sentence.   
9.3.1 Assistance to drug users in prisons  
There has been increased concern about the ability of prisons to cope with the health 
care needs of a rising prison population.  The British Medical Association (BMA) has 
been critical, not only of the failure to provide additional funding for healthcare, 
rehabilitation programmes and post-release monitoring services, but also with the 
continued availability of drugs within prisons and have recommended that there need 
to be new measures to address drugs problem in prisons (see below).196  
 
The United Kingdom Drug Policy Commission has argued that more evidence is 
needed to support the range of drug interventions in prisons.197  
 
Issues arising from the continuing increase in the prison population have been 
considered by Lord Carter (2007) in his review of the prison system, suggesting that 
as well as an expansion of prison capacity, changes are needed in existing 
sentencing legislation to modify the use of custody for certain types of low risk 
offenders and offences, reserving custody for the most serious and dangerous 
offenders.  Following this review it has been suggested by the Ministry of Justice that 
community sentences, including drug rehabilitation programmes, can be a more 
effective punishment than short prison sentences.  
 
In Scotland, the Scottish Prison Service is to publish a new Substance Misuse 
Strategy, which will complement the Scottish Government’s drugs strategy (Scottish 
Government 2008a).  Following the report from the Independent Prisons Commission 
in Scotland, there will be a review of chaotic drug users who stay for short periods in 
custody.198  
 
The Welsh Assembly Government has commissioned an evaluation of the 
Transitional Support Scheme which provides mentoring support for short-term 
prisoners who have a substance misuse problem.  The scheme aims to increase 
access to substance misuse treatment, and also to help with homelessness, 
unemployment, and relationship problems.  
Prevention 
Supply Reduction 
With concerns expressed by the BMA, the Ministry of Justice called for a review of 
measures to disrupt the supply of illicit drugs into prison in England and Wales, 
including recommendations to improve the effectiveness of such measures.199  The 
                                                
196 See: http://www.bma.org.uk/ap.nsf/Content/Prisonreforms 
197 For more information see: : http://www.ukdpc.org.uk/Publications.shtml#RDURR  
198 See: http://www.scotland.gov.uk/News/Releases/2007/10/23103516 
199 See: http://www.justice.gov.uk/news/announcement110308c.htm 
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review report was published in July 2008.  It stressed the difficulties faced by prisons 
in trying to keep out drugs and made ten recommendations, all of which were 
accepted by the Government.200 These included the further introduction of mobile 
phone blocking technology and body orifice security scanners (BOSS), and the 
further development of intelligence frameworks.  
 
Following a recent survey of buprenorphine misuse in prisons (Ministry of Justice 
2007a) (see Chapter 8.4.1) testing for it as part of mandatory drug testing was 
introduced in prisons in England and Wales from 1 April 2008.201  
 
A report concerned with minimising the supply of drugs into prisons in Northern 
Ireland makes a number of recommendations including: 
• the introduction of mandatory drugs and alcohol testing ; 
• increased searching of prisoners leaving the visits area; 
• taking further steps to explore the deployment of mobile phone blockers; 
• closer co-operation between the Prison Service and the police to target known 
drug users and traffickers; 
• improved use of CCTV to observe prisoners suspected of drugs possession; and  
• the introduction of random searching of staff and contractors by passive drugs 
dog (NIPS 2008). 
Harm reduction  
As part of the Hepatitis C Action Plan for Scotland Phase 2 (Scottish Government 
2008e), the Scottish Prison Service (SPS) has developed a harm reduction 
awareness session given to all prisoners on admission, which is repeated pre-
release.  This provides information on overdose risk due to loss of tolerance, blood-
borne viruses, and how to access treatment and support.  SPS also plan to pilot an 
in-prison needle exchange.  This action has been carried over from the Phase 1 of 
the action plan, but has been delayed due to union opposition.  In 2008 SPS 
implemented the provision of harm reduction packs for prisoners engaged in injecting 
behaviour.  The packs consist of water ampoules, citric acid, Sterispoons, swabs, 
filter and foil.  Condoms, lubricant and dental dams have been available in the since 
March 2007 (internal communication from the Scottish Government).   
 
Following a pilot in 2007, disinfectant tablets are provided in all adult prisons in 
England and Wales (HM Prison Service et al. 2007).  Possible uses are reported to 
be the cleaning of shaving equipment, toothbrushes, cutlery, crockery and cleaning 
cell toilets.  Also, it is noted that they may be used to disinfect illicitly held needles 
used for injecting and tattooing.202    
Treatment  
A review of prison-based drug treatment funding in England suggests the need for a 
more strategic and evidence-based approach to service delivery 
(PricewaterhouseCoopers 2008).  The report recommended eight steps which should 
be taken to build upon and improve delivery and extract better value from resources 
invested.  The principal recommendation is to set up a National Offender Drug 
Strategy Group to commission a series of projects that would: 
• articulate and agree the key outcomes needed both in prison and on release into 
the community;  
• establish a set of national minimum standards for drug treatment;  
                                                
200 See: http://www.justice.gov.uk/news/announcement070708a.htm for review and the 
Government’s response.  
201 See: http://www.justice.gov.uk/news/announcement130308a.htm 
202 Disinfectant tablets have been available in Scottish prisons since 1993. 
UNITED KINGDOM FOCAL POINT REPORT 2008  
 142
• identify opportunities for achieving efficiency savings to invest in prison and 
offender drug treatment services;  
• examine the case for prioritising some groups of prisoners and offenders;  
• develop a commissioning model at national, regional and local level;  
• develop a single health and criminal justice funding stream to target services 
more effectively; and  
• agree systems for improved information sharing to support better quality 
performance management and case management. 
 
A Prison Drug Treatment Review Group to oversee the development of prison drug 
treatment has been established.203  
 
The Department of Health (DH) and the National Offender Management Service 
(NOMS) have jointly developed the Integrated Drug Treatment System (IDTS). This 
aims to provide more effective and needs based treatment in prison through the 
closer integration of prison clinical drug services and Counselling, Assessment, 
Referral, Advice, Throughcare services (CARATs).  The €18.6 million (£12.7m) 
allocated to IDTS in the 2007/08 financial year will rise to €37.1 million (£25.4m) in 
2008/09, and DH has indicated further increases to £39 million in 2009/10 and €63 
million (£43m) the year after.  As of April 2008, 29 prisons had received funding for 
full IDTS (i.e. enhanced clinical treatment and psychosocial support), with a further 
24 having received funding for enhanced clinical treatment only.  DH’s planned 
investment will lead to introduction of enhanced clinical services in a further 38 
prisons in 2008/09 and all prisons by 2011.  
 
In the 2007 Scottish Prison Service Prisoner Survey, half (51%) of problem drug 
users responding to the survey reported having been assessed for drug use upon 
arrival in custody.  Forty per cent stated that they had asked if they required 
treatment for their drug use, and 35 per cent reported that they had received 
treatment during their sentence.  Thirty per cent expressed concern that their drug 
taking would be a problem upon release (Scottish Prison Service 2008).  
 
The Scottish Government are to review the feasibility of a potential transfer of 
primary health care to the NHS (Scottish Government 2008a). 
 
In Wales there is to be a review of treatment and support services within the prison 
estates against the treatment module for offenders, with plans to be developed to 
improve service provision (Welsh Assembly Government 2008b). 
Throughcare and aftercare and social reintegration  
There is growing evidence that providing support for families of drug misusers helps 
alleviate their own stress and enables them to better support the latter throughout 
their rehabilitation and reintegration.  Further, the existence and maintenance of good 
family relationships can also help reduce re-offending and improve treatment 
outcomes for those leaving custody and/or treatment (Home Office 2007c).  The 
Home Office Drug Interventions Programme is currently focusing on work that 
supports the needs of families of drug misusing offenders at arrest and release.204  
 
A new package of measures aimed at helping prisoners become drug free and into 
work has been announced by the Ministry of Justice (2008b).205  Measures include 
                                                
203 See: http://www.justice.gov.uk/news/announcement170308a.htm  
204 For more information see: http://drugs.homeoffice.gov.uk/drug-interventions-
programme/guidance/throughcare-aftercare/UnlockingPotential/ 
205 See: http://www.justice.gov.uk/news/newsrelease310108a.htm 
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the launch of a new drive to involve more employers, from the corporate, public and 
voluntary sectors, in training offenders and offering them employment, and the 
drawing up of contracts with prisoners in return for opportunities to learn new skills.  
 
In Scotland, there is to be a review of a pilot project to improve the integration of 
medical treatment with wider ‘wraparound’ therapeutic support; to give consideration 
to establishing it in all prisons; and the development and implementation of an 
information sharing protocol between Throughcare Addiction Services (TAS)206 and 
the Enhanced Addiction Casework Service (EACS)207 (Scottish Government 2008a). 
Research 
Literature review of programmes for drug-using offenders  
A review of the international literature208 on programmes for problem drug-using 
offenders, including those in the prison system, suggests that the strongest evidence 
for the most effective strategies in reducing drug use and offending behaviours is for 
therapeutic communities and interventions modelled on the court approach and 
substitute treatments, with little evidence for the effectiveness of drug testing and 
intensive forms of supervision (McSweeney et al. 2008a; UKDPC 2008c; and 
UKDPC 2008d).  In the custodial setting it is suggested there is evidence to support 
the use of methadone and lofexidine for the management of opioid detoxification, and 
that trials of methadone maintenance in prison indicate that retention in such 
treatment is associated with reduced reincarceration, hepatitis C and mortality.  
There is also strong evidence for the effectiveness of therapeutic communities in 
reducing drug use and/or recidivism.  Abstinence based treatment developed along 
the lines 12-step programmes have also been shown to achieve significant and 
sustained reductions in drug use and offending, and recidivism.  It is suggested that, 
although founded on solid principles from community treatment, there has been little 
evaluation of most interventions in the prison setting, including CARATs.  There has 
also not been an evaluation of the effectiveness of drug-free wings. 
A review of drug and alcohol treatments in prison and community settings 
A review of drug and alcohol treatments in prison and community settings 
commissioned and conducted on behalf of the Prison Health Research Network209 
found that there was a lack of high-quality research in this area, particularly clinical 
trials from the United Kingdom, with a lack of evidence for some recommended 
interventions such as brief psycho-social sessions focusing on advice, information 
and support (Roberts et al. 2007).  It is further argued that the evidence from 
community settings shows that psychosocial interventions are effective for opioid 
dependence only when delivered in combination with pharmacological detoxification 
treatment.  The authors argue that the interaction between approaches is of 
particular importance to prison populations where the aim is to keep prisoners drug-
free on release and that the 28-day psychosocial intervention recommended for 
prisoners with problematic drug misuse does not have a strong evidence base 
behind it and should be evaluated as a priority.  
 
                                                
206 For more information see: 
http://www.scotland.gov.uk/Topics/Justice/criminal/16910/tas 
207 For more information see: 
http://www.cjscotland.org.uk/index.php/cjscotland/dynamic_page/?title=addictions_prison 
208 Quantitative evaluative research studies were graded by use of the Scientific Methods 
Scale, with an additional category.  
209 The Prison Health Research Network is funded by Offender Health at the Department of 
Health, and is a collaboration between several universities, based at the University of 
Manchester. For more information see: www.phrn.nhs.uk/prison/   
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The authors also suggest that the pharmacological evidence base for treating 
offender populations is severely lacking in the England and Wales, with policy on 
methadone maintenance based heavily on one study from Australia.  The evidence 
for treating dependence on substances other than opioids shows very limited 
success to date in community settings, and is non-existent in offender settings.  The 
one area where there is evidence is for therapeutic communities; this is based on a 
Cochrane review which concluded that the latter may be favourable to prison alone 
or other treatment programmes, but that the studies that have been conducted are 
lacking in methodological quality.  They suggest that there should be offender-
specific research rather than importing findings from community based treatments. 
Experiences of prison among injecting drug users 
In research looking at found that whilst negative experiences of prison and drug 
treatment prevailed, users identified recent policy and practice changes had 
positively influenced healthcare provision for drug users in prison, in particular the 
provision of maintenance prescribing (Tompkins et al. 2007).  Also, it was found that 
drug users often saw prison as an opportunity to detoxify and consider their drug use.  
9.3.2 Urban security policies in the prevention of drug related crime  
The Drug Interventions Programme 
The Drug Interventions Programme continues to be the main focus of action in 
England and Wales to reduce drug-related crime with continued work to engage 
those identified through the criminal justice system into treatment and/or other help 
and support.  It includes interventions such as drug testing on arrest or charge, 
required assessment, restriction on bail, and conditional cautions with a drug 
rehabilitative condition (the DIP Condition).210  Following an evaluation of the early 
schemes (Blakeborough and Pierpoint 2007) conditional cautioning was implemented 
throughout England and Wales by the end of March 2008.  Approximately 5,900 
conditional cautions211 were issued by the Crown Prosecution Service and police 
between April 2005 and January 2008.212  The new Drug Strategy seeks to increase 
the number of conditional cautions with a DIP condition to 2,000 by March 2009, 
which means doubling current usage.213  Revised guidance on the use of conditional 
cautioning with a DIP condition has been published (Home Office 2008b). 
 
Drug Rehabilitation Requirements (DRRs) are also to be extended with plans for 
1,000 such orders by 2009.214  To this end the probation service is to receive an 
additional €58.8 million (£40m) to pilot intensive alternatives to custody and the 
provision of more rigorous non-custodial regimes, as well as an investment of €20.3 
million (£13.9m) over the next three years to fund six new intensive alternatives to 
custody projects.215,216  Such regimes will not be limited to drug–using offenders.  
                                                
210 Such cautions are given to offenders aged 18 or over, on admission of the offence, who 
agree to complete a set of conditions instead of being charged and prosecuted.   
211 Conditional cautions are an alternative to prosecution.  They are intended to be a swift and 
effective means of dealing with straightforward cases where the offender is willing to admit 
the offence and agree to comply with specified conditions. 
212 See: 
http://frontline.cjsonline.gov.uk/search/index.php?searchterm=conditional&page=46 




215 See: http://www.justice.gov.uk/news/newsrelease110308c.htm  
216 See: http://www.justice.gov.uk/news/announcement310108b.htm 
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Also, new guidance for the management of drug users under probation supervision 
has been published (Home Office 2007d).   
 
See also DIP work around the provision of support for families in section 9.3.1 above. 
 
In addition, DIP continues to work with a range of partners to identify and promote 
practice which supports rehabilitation.  The specific focus is on those activities and 
approaches adopted by local partnerships, projects and service users which have 
contributed to building steps towards employability.  Practice examples available on 
the DIP webpage identify common themes alongside a framework of questions 
designed to support and capture further information on local examples of success.217  
Self-funded intensive DIP work 
A total of 176 police custody suites can now conduct testing on arrest or charge; 14 
of these, across seven police forces in England and Wales, have the power to test 
only on charge rather than at any point during custody.  Some areas have expressed 
interest in self-funding of drug testing and detailed guidance has been issued on the 
criteria that need to be met to qualify for self-funded intensive status.  Merseyside 
Police was the first force to achieve self-funded intensive status and now operates 
drug testing across the force (internal communication from the Home Office).  
DIP Guidance on working with prostitutes 
Good Practice Guidance to Increasing the Engagement of Adults Involved in 
Prostitution within the Drug Interventions Programme provides an overview of the 
issues associated with involvement in street-based prostitution and problematic drug 
use, and suggests how local CJITs can forge effective links with local specialist 
projects working with adults involved in prostitution (Home Office 2007e).  It also 
describes the types of support and services required. 
Offender Management Bill  
The Offender Management Bill aims to reduce re-offending and better protect the 
public by improving the way in which offenders are managed.  In particular, the Bill 
seeks to remove the public sector monopoly on the provision of probation services 
and enable the Secretary of State to commission services from the best available 
provider in the public, private or voluntary sector.  The Bill, supporting documents, 
and progress through parliament are published on the United Kingdom Parliament 
website.218 
Young offenders  
A new Joint Youth Justice Unit for England and Wales, based within the Ministry of 
Justice, will merge the responsibilities of the former Ministry of Justice Youth Justice 
and Children Unit with those of the Young Offender Education Team from the 
Offenders Learning and Skills Unit, formerly part of the Department for Education and 
Skills (DfES).  Youth justice policy and sponsorship of the Youth Justice Board were 
made the joint responsibility of the Ministry of Justice and the newly created 
Department for Children Schools and Families (DCSF) following Machinery of 
Government changes in June 2007.  
Citizen participation 
The concept of community justice is part of the Government's agenda to tackle anti-
social behaviour and the crime associated with it.  Community justice brings the 




218 See: http://www.publications.parliament.uk/pa/pabills/200607/offender_management.htm 
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justice system and the community together to solve problems, reduce crime and build 
confidence.  Community courts have now started hearing cases at nine locations.  
Section 178 of the Criminal Justice Act 2003 provides the power for the court to 
review offenders’ progress as they carry out community orders; some offenders will 
be drug users subject to treatment orders.  This means that when an offender is 
given a community penalty the court can order that the offender comes back to court 
on a regular basis and for their behaviour during the sentence to be considered.  This 
increased oversight by the judge or magistrates brings increased responsibility and 
encouragement for offenders to comply with the conditions of the sentence.  It will 
also give the court the opportunity to support the offender as they face challenges 
and adapt the conditions of the sentence if conditions change.219 
 
The first evaluations of community courts in North Liverpool (McKenna 2007) and 
Salford (Brown and Payne 2007) found that of the offenders surveyed, 79 per cent 
indicated that problem-solving meetings had helped them to address their problems.  
Seventy-six per cent of them thought the support they received was better than 
previously received in a traditional court.220 
Structured Deferred Sentence  
Following an evaluation, there are plans to extend the Structured Deferred Sentence 
in Scotland which has been piloted in five courts (Macdivitt 2008).221  This is a low-
tariff intervention providing structured social work for offenders post-conviction, but 
prior to final sentencing, primarily aimed at offenders with underlying substance 
misuse problems (and also mental health, learning difficulties or unemployment).  
The purpose is to provide a relatively short period of focused supervision as part of a 
deferred sentence with the specific objectives of assessing need and therefore 
matching more effectively intensity of intervention/supervision, as well as building 
offender motivation for positive change; reducing the frequency of seriousness of 
offending behaviour; avoiding premature or unnecessarily intensive periods of 
supervision in the community; and meeting the needs of the courts. 
Drug Treatment and Testing Orders: Scotland 
Drug Treatment and Testing Orders (DTTOs) continue to be the main community 
sentence imposed on drug using offenders in Scotland, although until recently, used 
only with high tariff offenders.  In June 2008, two pilots extending them to lower tariff 
offenders commenced.  A total of 696 DTTOs were made in 2006/07, up 16 per cent 
from 599 in 2005/06 (Scottish Government 2007h). 
Research 
The effectiveness of DIP in reducing offending 
Skodbo et al. (2007), in research into the effectiveness of DIP, found that when 
comparing offending levels pre- and post- DIP contact, levels in the six months 
following DIP were lower than in the six months before.222  The research also found 
that Tough Choices223 increased through-flow and reduced attrition from the 
                                                
219 See: http://www.communityjustice.gov.uk/ 
220 The evaluations are based mostly on interviews with staff, community members and 
offenders early on in the life of the projects.  
221 See: http://www.scotland.gov.uk/News/Releases/2008/04/15102026 
222 Methodological limitations (the absence of a control group) mean that this does not 
represent a full outcome evaluation and accordingly was not possible to calculate how much 
of the observed change in offending was due to DIP.  Two cohorts were examined. All those 
who tested positive for heroin, crack or cocaine in DIP intensive areas in England during two 
time frames;7,727 individuals who tested positive at the point of charge during the period 1 
July to 31 October 2005 and 11,015 testing on arrest form 1 April to 30 June 2006. 
223 For more information see: http://www.homeoffice.gov.uk/rds/pdfs07/horr02c.pdf 
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programme.  It is, therefore, suggested that the criminal justice system can be an 
effective route for getting drug misusing individuals into treatment and that the use of 
semi-coercive approaches can improve engagement in intervention programmes.  
However, there was a subgroup of around a quarter for whom offending increased 
following contact and it is argued that more work is required to identify those who 
have successfully continued through DIP, as well as those who have not done so, to 
establish why DIP is associated with good outcomes for some individuals and not for 
others.   It is also suggested that there is a need to explore the circulation of 
individuals through DIP to establish how many times individuals pass through, the 
frequency of their contact, and the impact of this on outcomes and offending. 
Treatment Retention in DIP 
In looking at treatment retention in DIP, Best et al. (2008) ask whether those who are 
in the programme primarily because their drug use leads to offending fare better than 
those whose offending is not necessarily associated with their drug use, examining 
completion rates in one DIP programme by crime behaviours and drug use.224  It was 
found that relatively few cases had positive outcomes, although treatment retention 
exceeded expectations in around one quarter of cases; less than five per cent of 
cases were successfully completed, some form of positive outcome was reported in 
14 per cent of cases, but that 57 per cent had negative outcomes, such as breaching 
the requirements of the order or failure to attend.  Twenty-nine per cent were still 
open six months after the start of the programme.  
A case-study of substitute opiate prescribing for drug-using offenders 
In a case study of DIP clients, Keene et al. (2007) found that of 180 offenders offered 
treatment as part of the programme, 103 (57%) successfully engaged and 59 (32%) 
stayed six weeks or more.  The majority of referrals (94%) were for heroin misuse 
and 45 per cent also reported crack cocaine use.  Twenty-seven per cent injected.  
Those who engaged initially were more likely to be injectors (70% compared to 30% 
of those who did not engage), females, polydrug users, and older clients.  But those 
who stayed in treatment for at least six weeks were more likely to be non-injectors 
(60% stayed in treatment compared to 40% who did not), male and from ethnic 
minority groups.  Qualitative analysis of 40 semi-structured interviews with clients 
emphasised the benefits of fast access and friendly helpful staff.  However, clients 
believed that drug use itself was interlinked with social, economic and psychological 
problems and identified a need for comprehensive wraparound services and help 
with housing and employment.  The complexity of the relationship between drug use 
and crime was seen as reflecting the complexity of these underlying problems.   
Drug users assessed by DIP teams in non-intensive areas 
In a report highlighting emerging trends in DIP client characteristics, Duffy and 
Beynon (2008)225 found that: 
• clients under 25 comprised the largest group (29%); 
• there was no significant difference in gender between those under 25 and older 
clients; 
• both sets of clients were predominantly White (96%);  
• drug use profiles were different, while heroin was the most common drug in both 
age groups, the percentage using it amongst younger clients was significantly 
lower (46% compared with 75%), rates of crack cocaine use were also higher 
                                                
224 This was a retrospective case-note study based on all files opened over a three-month 
window, examining outcomes three months after the last case was opened.  A total of123 files 
were examined. 
225 Data for the assessment completed by DIPs team in 31 DAATs in England during 2006/07 
were used.  Any client under 18 were removed, as were any clients who reported they had 
not used drugs in the month prior to assessment.  Data on 5,242 clients were analysed. 
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amongst older clients (41% compared with 26%), and those under 25 were more 
likely to report use of cocaine powder, cannabis, amphetamines and ecstasy; 
• combined use of heroin, methadone, crack cocaine or cocaine powder were also 
higher amongst the older group; 
• much of the evidence presented points to a less problematic profile of drug use 
amongst those under 25, with greater levels of cannabis and cocaine powder use 
but lower levels of heroin and crack cocaine use; 
• those under 25 were significantly less likely to report lifetime injecting or to have 
injected in the previous month, however amongst this group those who had 
injected were more likely to have injected recently;  
• older clients were more likely to have been in treatment in the past two years; 
and  
• a higher proportion of the older group reported daily alcohol use. 
Literature review of programmes for drug-using offenders 
In their literature review of programmes for drug-using offenders McSweeney et al. 
(2008a) suggest that the evidence is equivocal as to the impact of drug testing as 
part of a community order on drug use and offending, and engagement in treatment.  
However, they note that there is some evidence of the success of DIP in improving 
treatment engagement and reducing drug use and offending.  Similarly, DTTOs 
appear to be successful in promoting reductions in drug use and offending for those 
completing them, however, more than half fail to do so.  There is also evidence that 
Prolific and other Priority Offender schemes are associated with reduced offending.  
In addition, there is some evidence of the success of drug courts, mainly based on 
evidence from users, but also noting the evidence from Scotland.  Restriction on bail 
was found to have some positive effects in terms of compliance and treatment 
engagement, but the impact on offending and retention is unclear.   
The effect of drug treatment upon the commission of acquisitive crime  
Research as part of the longitudinal Drug Outcome Research in Scotland (DORIS) 
study examining the association between acquisitive crime and drug treatment found 
a strong independent effect of drug consumption and drug consumption-related 
variables in accounting for acquisitive crime (Mckintosh et al. 2007).226  Results 
showed substantial reductions in acquisitive crime following treatment, but the 
influence of treatment is indirect and mediated by its effect on drug use.  However, it 
is suggested that, insofar as drug treatment reduces the need for individuals to 
engage in acquisitive crime by moderating their use of illegal drugs, the social and 
economic benefits to society from such programmes are likely to be substantial. 
Street policing of problem drug users 
A study carried out for the Joseph Rowntree Foundation227 found that policing 
encounters with problem drug users were primarily aimed at managing a ‘risky’ 
population and were rarely initiated in response to a specific crime (Lister et al. 
2008).  Encounters often involved running name checks, enquiring about their 
presence and behaviour and moving them elsewhere.  Rarely were formal police 
                                                
226 Follow-up interviews were conducted with 1,033 individuals who started treatment for 
problem drug use in, 2001/2. Respondents were interviewed on four occasions over a 33-
month period. Stepwise logistic regression models were constructed to test the independent 
effect of 22 co-variables upon the commission of acquisitive crime or the likelihood of being 
arrested for it. 
227 The study was conducted over an 18-month period in three police force areas in England 
and Wales and focused on one division in each.  The main sources of data were interviews 
with 42 police officers and 62 problem drug users and over 100 hours of observation 
accompanying policing personnel in street contexts.  Fieldwork data was supplemented by 
administrative data supplied by the three police forces. 
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powers used and welfare-orientated activities (such as referrals to drug treatment 
services) were, similarly, not common.  Problem drug users resented such regular 
low-level use of police authority and felt that it was not a deterrent to involvement in 
drugs and/or crime.  The authors suggest that the frequent contact between policing 
personnel and problem drug users could be used constructively to help users access 
treatment and harm reduction services.  They argue that the strategy of moving 
problem users elsewhere will not address problem drug users’ problems and suggest 
the need for a multi-agency approach to street policing issues. 
Evaluation of mandatory drug testing of arrestees pilots in Scotland 
The Scottish Government is seeking to commission a formative evaluation of the 
pilots for mandatory drug testing of arrestees in three police stations in Scotland 
(Aberdeen, Edinburgh and Glasgow).  The pilots are running for two years, from June 
2007 until June 2009.228 
9.4 Drug driving  
The police are empowered to conduct compulsory tests on drivers for impairment 
and for the presence of drugs.  Tests for impairment are already carried out using 
Field Impairment Testing, simple tasks of cognition and physical co-ordination.  Tests 
for the presence of a drug have to be carried out using a device of a type approved 
by the Secretary of State.  A specification for such a device is currently being 
finalised, it will then be for manufacturers to prepare devices in line with the 
specification and submit them for testing (internal communication from the Home 
Office). 
 
During the Association for Chief Police Officers’ (ACPO) 2007 Christmas Drink/Drug 
Driving Campaign in England and Wales229, 550 field impairment tests were carried 
out on drivers under the suspicion of drug driving, of which 28 per cent were 
subsequently arrested.  This is a lower proportion than in the 2006 campaign when 
38 per cent of the 666 field impairment tests resulted in an arrest. 
9.5 Drug testing in the workplace  
A survey of employers in the United Kingdom found that 22 per cent of respondents 
test employees for drug and alcohol use, either randomly or when hiring new 
individuals and that a further nine per cent said they were planning to introduce 
testing (CIPD 2007).230  Sixty-five per cent of responding organisations do not test 
and have no plans to do so.  Fifteen per cent had dismissed at least one person 
because of drug problems in the past two years.  Manufacturing and production 
organisations are much more likely to test employees, with more than a third having 
a testing regime in place and a further 16 per cent planning to do so. Safety-critical 
organisations are most likely to carry out testing of employees, with 53 per cent doing 
so.  The most common approach is to test when an employee is suspected of drug or 
alcohol misuse as a result of performance issues or because of inappropriate 
behaviour, the next most common approaches are post-incident testing and pre-
employment testing.  Only two per cent of non-profit organisations test employees. 






230 The analysis is based on replies from 505 United Kingdom-based Human Resource 
professionals in organisations employing a total of more than 1.1 million people.  No 
information is given about the survey methodology. 
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In Wales, substance misuse policies in the workplace will be encouraged through the 
Corporate Health Standard and by launching small workplace awards for Small and 
Medium Enterprises (SMEs), and by promoting links between Community Safety 
Partnerships and local SMEs.  A seminar on substance misuse in the workplace will 
be held in January 2009 (internal communication from the Welsh Assembly 
Government). 
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10. Drug markets 
10.1 Overview 
The United Kingdom Threat Assessment of Serious Organised Crime 2008/09 
suggests that despite law enforcement efforts, “the market in the United Kingdom 
remains attractive to traffickers and dealers because of the high profits to be made.”  
Class A (heroin, cocaine and ecstasy) and other drugs are widely available 
throughout England, Scotland and Wales while in Northern Ireland the Class A drug 
market is relatively small (SOCA 2008). 
 
Heroin: Most identified supply chains to the United Kingdom follow well-established 
trafficking routes.  The primary trafficking route is overland from Afghanistan to 
Europe, transiting from Iran through Turkey and also through Armenia and 
Azerbaijan, before being moved to the Balkans, and then overland to Europe.  Most 
of the heroin moved along these routes ends up in the Netherlands before entering 
the United Kingdom.  In addition, a quarter of Afghan heroin arrives directly by air 
routes from Pakistan, via couriers and parcels. 
 
Cocaine: The Iberian Peninsula, predominantly Spain, and the Netherlands, continue 
to be the main entry points into Europe for shipments of cocaine from South America 
(primarily Colombia and Venezuela) destined for the United Kingdom.  Shipment 
routes transiting the Caribbean and west Africa are also common with organised 
crime groups.  It is believed cocaine enters the United Kingdom via ports in the south 
east of England.  Commercial flights are also used to import ‘little and often’ from the 
Caribbean. 
 
Ecstasy: Almost all of the ecstasy consumed in the United Kingdom is manufactured 
in the Netherlands or Belgium, and commonly enters by sea through Dover, 
Felixstowe and Harwich.  A number of sites making up tablets have been found, 
mostly in the North of England.  Synthetic drug production in the Netherlands and 
Belgium relies heavily upon precursor chemicals made in China, obtained through 
criminal networks from Chinese companies.  
 
Cannabis: Cannabis is imported into the United Kingdom from Europe in bulk by 
organised criminals, sometimes in mixed loads alongside Class A drugs, and in 
smaller amounts for sale, and for personal use.  In addition, there has been an 
increase in intensive hydroponic cultivation of cannabis within the United Kingdom, 
predominantly run by Vietnamese. 
 
The overall picture of United Kingdom drugs distribution appears increasingly 
complex and diverse.  Many traffickers in the United Kingdom, particularly White 
British criminals import and distribute more than one type of drug.  London, 
Birmingham and Liverpool continue to be important centres for drugs distribution but 
other smaller cities and towns are also involved.  In Scotland, the main source of 
heroin is from Liverpool via the Glasgow area.  
 
In general the quantity of seizures has been rising in the United Kingdom, cannabis 
being the most seized drug. The number of herbal cannabis seizures has increased 
since the introduction of cannabis warnings and there have been increasing seizures 
of cannabis plants.  However, seizures mainly in Class A drugs have achieved short-
term disruptions rather than a sustained reduction in the size of the United Kingdom 
drugs market.  The Serious Organised Crime Agency (SOCA) suggests that drug 
seizures are more likely to impact on purity of drugs at street level than price.   
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Purity of cocaine powder has fallen since 2003 at street level although the average 
purity of seizures by HM Revenue and Customs (HMRC) is stable suggesting 
increasing adulteration within the United Kingdom.  Heroin purity has increased since 
2003 while crack cocaine has seen a reduction in purity.  The potency of cannabis 
seized by police and sent to the Forensic Science Service (FSS) has decreased in 
recent years but a number of studies suggest that the potency of the increasingly 
market dominant sinsemilla (skunk) cannabis is much higher. 
 
The price of cocaine powder, heroin and ecstasy has decreased since 2003 while the 
price of other drugs has remained stable.  
 
The most recent estimate of the size of the illicit drug market in the United Kingdom 
is €7.6 billion (£5.3bn) in 2003/04231, with a wide margin of error of €5.8 billion (£4bn) 
to €9.5 billion (£6.6bn).232   
10.2 Availability and supply 
10.2.1 Availability in the general population 
The 2006 Scottish Crime and Victimisation Survey (Brown and Bolling 2007) found 
that 38 per cent of those reporting taking any drugs in the last month found it ‘very 
easy’ to acquire their most regularly used drug.  A further 42 per cent said it was 
‘fairly easy’ to do so.  However, it is suggested that it had become more difficult to 
acquire drugs since the previous survey in 2004, when 68 per cent said it was ‘very 
easy’ to obtain their main drug.  
10.2.2 Availability amongst school children and young people 
A survey of school children in England (Fuller 2008) (see Chapter 2) asked pupils 
whether they had ever been offered drugs and how easy it would be to obtain them.  
In 2007: 
• 36 per cent of pupils reported ever being offered drugs; 
• the likelihood of ever having being offered drugs increased with age, 60 per cent 
of 15 year olds had been offered drugs compared to 13 per cent of 11 year olds; 
• boys were slightly more likely to have been offered drugs than girls, 38 per cent 
compared to 34 per cent;  
• 30 per cent of pupils thought it was easy to obtain drugs, a slight decrease from 
33 per cent in 2001; and 
• there has been a small increase in the proportion of pupils believing it is easy to 
obtain cocaine from 15 per cent in 2001 to 18 per cent in 2007. 
Trends 
The proportion of pupils reporting ever having been offered drugs has decreased 
since 2003 (Table 10.1).  There has been a steady decline since 2002 in pupils 
reporting being offered cannabis, from 28 per cent to 22 per cent and little change in 
the figures for other drugs.  
                                                
231 Conversion rate is the December 2004 monthly average spot exchange rate quoted by the 
Bank of England. 
232 The study used a survey-based demand side approach to estimate market size. Data from 
the Schools Survey 2003, the Offending Crime and Justice Survey 2003 and the Arrestees 
Survey 2003/04 were analysed to estimate the prevalence of drug use, frequency of use 
quantity used and expenditure on drugs by juveniles, the general adult population and adult 
arrestees.  Estimates of price and quantities were compiled from a number of sources 
including NICS price data and FSS purity data.  The estimate was based on data sources for 
England and Wales and extrapolated to the United Kingdom as a whole. 
UNITED KINGDOM FOCAL POINT REPORT 2008  
 153
Table 10.1: Percentage of pupils who reported ever being offered individual drugs in England, 
2001 to 2007 
Drug 2001 2002 2003 2004 2005 2006 2007 
Any drug 42 40 42 36 39 35 36 
Cannabis  27 28 27 25 25 23 22 
Cocaine powder 9 9 9 8 9 9 10 
Crack cocaine 9 7 9 8 8 7 8 
Ecstasy 10 9 9 7 8 7 7 
Heroin  7 6 7 5 6 5 6 
Base 9,357 9,859 10,390 9,715 9,175 8,132 7,813 
Source: Fuller 2008 
 
In Northern Ireland, results from the Young Person’s Behaviour and Attitudes Survey 
(YPBAS) show that 17 per cent of pupils had been offered cannabis and just over a 
quarter (26%) believed it would be easy to obtain (NISRA 2008a). 
Cannabis supply and young people 
Ninety-three per cent of young cannabis users interviewed for a qualitative study on 
cannabis supply233 in England said that cannabis was either ‘very easy or ‘fairly easy’ 
to obtain, with 79 per cent saying they could get hold of it in less than an hour (Duffy 
et al. 2008).  Over half (55%) bought cannabis from a known seller, with 69 per cent 
of these describing their main seller as a friend.  Around a quarter (23%) never 
bought cannabis themselves but were given it by a friend, a further 16 per cent 
reported that a friend bought it on their behalf and only six per cent bought from an 
unknown seller.  Age was an important factor in the way young people obtained 
cannabis with the average age of those buying direct from a seller higher than those 
whose friends gave them cannabis or bought it on their behalf.  Respondents who 
bought from an unknown seller were older than those who bought from a known 
seller. 
 
Young people tended to buy cannabis from people on average three years older than 
themselves and often financed the purchase by ‘chipping in’ with friends.  Over three-
quarters (78%) reported sharing cannabis with friends.  The majority of respondents 
stated that their sellers supplied only cannabis, although a quarter of respondents 
stated that their seller supplied other drugs, mostly ecstasy.  Cannabis sellers who 
supplied other drugs were more common in rural areas.  Forty-five per cent of 
respondents had either sold or brokered access to cannabis, the majority (72%) had 
brokered access to cannabis or sold on only one or two occasions. 
 
The authors suggest that cannabis supply to young people is different from 
conventional descriptions of drug markets and is primarily based around friendship 
and social networks.   
Sources of supply amongst school children 
The 2007 school survey in England found similar results to Duffy et al. (2008).  
Eighty-two per cent of pupils who reported last year cannabis use obtained it on the 
most recent occasion from a friend, around half of whom were the same age.  Only 
one per cent of pupils obtained cannabis from a stranger.  Pupils who had used 
                                                
233 The study comprised of semi-structured interviews with young people aged between 11 
and 19.  Respondents were purposively selected to fit one of two criteria: they had used 
cannabis at least once in the last three months and/or had brokered access or sold cannabis 
in the last 6 months.  Interviews were undertaken with 182 young people from sites in the 
South-West of England and London.  The majority were recruited from youth centres with the 
remainder from school/college, Youth offending teams, school exclusion units or snowballing. 
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Class A drugs in the last year were more likely than cannabis users to obtain their 
drugs from a stranger, six per cent of pupils reported doing so (Fuller et al. 2008). 
10.2.3 Availability and supply in the 2005/06 Arrestees Survey  
Availability 
The Arrestees Survey234 asked respondents about the availability of heroin, crack 
cocaine and cocaine powder (Boreham et al. 2007).  In 2005/06, amongst those who 
had used heroin in the last year, 75 per cent said heroin was available all the time 
with a further 18 per cent saying it was available most of the time.  Only three per 
cent said heroin was not available often.  Crack cocaine and cocaine powder 
availability showed a similar pattern to heroin availability but respondents were less 
likely to say cocaine powder was available all the time (68%). 
Selling drugs 
In 2005/06, six per cent of respondents had ever sold heroin, four per cent crack 
cocaine and five per cent cocaine powder.  Those who had used individual drugs in 
the last year were more likely to have ever sold them; 31 per cent of those who used 
heroin at least once a week had ever sold it compared to three per cent who did not.  
Similarly 21 per cent of those who used crack cocaine once a week reported ever 
selling it compared to three per cent of other respondents. 
10.2.3 Production, sources of supply and trafficking patterns within the country and 
from and towards other countries 
Cannabis production, supply and market 
Cannabis continues to be imported into the United Kingdom in significant quantities 
but commercial cultivation of cannabis within the United Kingdom is rising, 
particularly the high potency sinsemilla type known as skunk (SOCA 2008).  A report 
by the Advisory Council on the Misuse of Drugs (ACMD) on cannabis and 
classification claims that United Kingdom-sourced cannabis now supplies the 
majority of users in the United Kingdom (ACMD 2008a). 
 
In late 2007, an Association of Chief Police Officers (ACPO) Survey of police forces 
in England and Wales found that 1,564 factories had been discovered across 19 
areas.  In Scotland in 2006/07, 70 factories were discovered, an increase from under 
ten in 2005/06 (ACMD 2008a).  Between 1 April 2007 and 31 March 2008, 3,032 
cannabis factories were discovered in the United Kingdom (internal communication 
from the ACPO).  Factories are mostly run by Vietnamese and located in residential 
properties.  Often illegal immigrants smuggled into the country work in these factories 
to pay off debts to smugglers (SOCA 2008).  
Research  
The market share of different types of cannabis 
Hardwick and King (2008) found that the market share of sinsemilla has increased 
markedly over recent years from 15 per cent in 2002 to 81 per cent in 2008235 (Table 
10.2).  However, the authors found a statistically significant difference in the market 
share of herbal cannabis across different regions in England and Wales.  
 
 
                                                
234 The Arrestee Survey was a nationally representative survey of arrestees in 75 custody 
suites in England and Wales carried out for three years 2003/04 to 2005/06.  Further details 
on survey methodology can be found in section 4.4.1 
235 Methodology for each estimate differs and are all taken from publications where the main 
focus is on potency. 
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Table 10.2: Estimated market share of different cannabis types  
Year Sinsemilla Traditional Herbal Cannabis Resin 
2002 15% 15% 70% 
2004/05 55% 45%* 
2008 81% 3% 16% 
*market share between traditional herbal and resin not stated in study 
Source: Hardwick and King 2008; Potter et al. 2008  
 
In Duffy et al.’s (2008) qualitative study amongst young people, 43 per cent said they 
usually bought skunk, 33 per cent bought herbal cannabis and 10 per cent bought 
resin.236  A study by Rethink, the mental health charity, found that three-quarters of 
recent drug users had used skunk, but only 35 per cent of cannabis users preferred 
using skunk with 50 per cent preferring to use herbal cannabis (Rethink 2008). 
Drug markets and the illicit drug trade in the United Kingdom 
Two reports looking at aspects of the drug market in the United Kingdom were 
published in the last year.  The Home Office commissioned a qualitative study of 
drug traffickers and dealers237 to understand how high level drug dealers operate and 
how markets for illicit drugs work (Matrix Knowledge Group 2007) and the United 
Kingdom Drug Policy Commission commissioned a literature review looking at 
strategies to tackle illicit drug markets and distribution networks (McSweeney et al. 
2008b).  Both concluded that the drug trade in the United Kingdom is flexible and 
adaptable. 
The illicit drug trade in the United Kingdom 
The Home Office study (Matrix Knowledge Group 2007) found that there is a high 
and stable demand for illegal drugs, the market is fragmented, there is a tendency for 
dealers of heroin and cocaine to specialise and that there are higher mark-ups for 
heroin than cocaine across the supply chain.  It also found that the majority of those 
interviewed entered the market through family and friends and suggests that, for 
individuals with contacts, barriers to entry to the market are negligible. 
 
The study also found huge diversity between drug dealing enterprises in terms of 
their structures and operations although there was homogeneity in the fact that 
profits came primarily through revenue generation rather than cost control.  The 
majority of dealers (around three-quarters) attempted to grow their operations with 
those able to adapt to new circumstances and exploit new opportunities, the most 
successful. 
 
Significant numbers of dealers felt that the risk of imprisonment was not a deterrent 
but were more troubled by asset recovery efforts.  The report concluded that it is 
possible to gather new and insightful information about the market conditions of the 
illegal drugs trade by interviewing convicted high-level dealers. 
Strategies to tackle illicit drug markets and distribution networks 
The United Kingdom Drug Policy Commission report (McSweeney et al. 2008b) 
concludes that drug markets are intractable, and that tackling drug markets requires 
a range of responses, and there needs to be a mix of supply and demand reduction 
measures.  The study also recommends that the effectiveness, cost-effectiveness 
and value for money of drug strategies, particularly law enforcement strands, be 
                                                
236 144 young people specified what type of cannabis they bought. 
237 The research team interviewed 222 offenders, the large majority of whom were serving 
sentences of seven years or more.  The study adopted purposive sampling using Home 
Office data and information from the Police National Computer (PNC). 
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examined and that measurable outcomes be developed that focus on harm 
reduction. 
10.3 Seizures 
Latest information on seizures in the United Kingdom is for 2006/07. Previous data 
were published on a calendar year basis.  Data are provided by all law enforcement 
agencies in England and Wales and police only in Scotland and Northern Ireland.  
There were 209,566 seizures of drugs in the United Kingdom in 2006/07, an 11 per 
cent increase from the previous year (Table 10.3).  Since 2004, the number of 
seizures has increased by 57 per cent, largely due to the introduction of cannabis 
warnings in England and Wales, which has resulted in increased seizures of 
cannabis.  There was a 44 per cent increase in seizures of herbal cannabis between 
2005 and 2006/07 and a 36 per cent increase in the number of cannabis plant 
seizures. The latter reflects the growing discovery of cannabis factories since 2004 
(see section 10.2.3 above); numbers of cannabis plant seizures have doubled and 
the quantity of cannabis plants seized has risen by 285 per cent (Table 10.4).  
Possibly as a result of changing markets for cannabis, cannabis resin seizures have 
fallen, as has the quantity seized. 
Table 10.3: Number of seizures of drugs by law enforcement agencies in the United Kingdom, 
2003 to 2006 
Drug  2003 2004 2005 2006/07* % change from 2005 
Amphetamines 6,952 7,254 8,656 9,291 + 7.3 
Cannabis – herbal 36,839 42,814 74,575 107,424 + 44.1 
Cannabis – resin 60,068 52,218 59,204 43,128 - 27.2 
Cannabis plants  2,904 2,995 4,331 5,906 + 36.4 
Cocaine powder 7,707 8,763 13,272 18,064 + 36.1 
Crack cocaine 4,814 4,974 6,479 6,812 + 5.1 
Ecstasy type 
substances  
7,577 7,388 7,539 9,620 + 27.6 
Heroin 12,965 13,674 16,402 16,552 + 0.9 
LSD 131 152 229 191 - 16.6 
Total 133,716 133,288 189,032 209,566 + 11 
*in 2006/07 seizures data moved to a financial year basis 
Source: Standard Table prepared for the United Kingdom Focal Point 
 
The number of cocaine powder seizures has continued to increase, although the 
quantity has decreased with 63 per cent of all cocaine powder seizures in England 
and Wales under one gram in weight (Smith 2008).  Between 2005 and 2006/07, the 
number of heroin seizures remained stable, although quantity decreased.  Crack 
cocaine seizures increased both in number and in weight.  Ecstasy seizures also 
increased and the number of tablets seized more than doubled between 2005 and 
2006/07.  
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Table 10.4: Quantity of seizures of drugs by law enforcement agencies in the United Kingdom 










Amphetamines  Kg 1,424 1,389 2,330 1,660 - 28.8 
Cannabis – herbal Kg 29,412 21,496 20,650 25,760 + 24.8 
Cannabis – resin Kg 65,379 64,920 50,395 23,850 - 52.7 
Cannabis plants  Plant 83,972 95,103 212,971 366,057 + 71.9 
Cocaine powder Kg 7,773 4,644 3,862 3,321 - 14.0 





7,435 4,991 3,244 6,849 + 111.1 
Heroin Kg 2,732 2,260 1,970 1,087 - 44.8 
LSD Dose (000s) 2 82 1,090 7 - 99 
*in 2006/07 seizures data moved to a financial year basis 
Source: Standard Table prepared for the United Kingdom Focal Point 
Other seizures 
There has been a significant increase in the quantity of opium seized entering the 
United Kingdom.  Since the beginning of 2006 more than 500kg of opium has been 
seized, with three seizures in excess of 150kg (SOCA 2008).  There has also been a 
rise in the proportion of tablets seized by police which have been found to contain 
piperazines (BZP, TFMPP and CPP) (see Standard Table 15). 
 
Two seizures of bromo-benzodifuranylisopropylamine238, commonly called ‘bromo-
dragonfly’, have been recorded in 2008. These are the first known seizures of the 
drug in the United Kingdom (internal communication from LGC Forensics). 
10.4 Price/purity 
The price of drugs in the United Kingdom appears to be influenced by the purity or 
potency of the substance involved.  The price of weaker cannabis strains such as 
resin is lower than the stronger herbal cannabis, which in turn is cheaper than more 
potent strains of sinsemilla.  There are also anecdotal reports that a ‘two-tier’ market 
exists for cocaine powder, with a more adulterated product selling for less than 
higher quality cocaine powder.  Furthermore, reports suggest that, within the ecstasy 
market, low purity pills are being sold for very little while higher quality crystal/powder 
MDMA is sold at a much higher price (DrugScope 2007).  
10.4.1 Price of drugs at street level  
Drug prices in the United Kingdom come from a number of sources.  Law 
enforcement agencies239 collect national data on drug prices while the Independent 
Drug Monitoring Unit (IDMU)240 survey festival goers.  DrugScope conduct a random 
                                                
238 Bromo-benzodifuranylisopropylamine is a synthetic drug, which is one of a group of drugs 
closely related to MDMA. It has hallucinogenic properties and is more potent than ecstasy but 
less potent than LSD. 
239 Figures provided are derived from returns by police forces in the United Kingdom. The 
information is obtained from a number of sources including: prisoner interviews, informants, 
test purchases, recording procedures and intelligence.  The figures shown in this chapter are 
the averages of the police force data returns, rather than the most representative price, and 
therefore may differ from figures quoted elsewhere from the same source (See Standard 
Table 16 for fuller details of methodology). 
240 IDMU is an independent commercial research organisation conducting research including 
surveys of drug users. They estimate drug prices by distributing random questionnaires at 
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snapshot of drug prices in different areas of the United Kingdom but until recently 
only provided local estimates.241 
Mean price of illicit drugs in the United Kingdom 
Data from law enforcement agencies suggest that the price of heroin and cocaine 
powder has again fallen.  Prices for other drugs remain stable while the apparent rise 
in cannabis prices can be explained by a change in methodology (Table 10.5).   
There are considerable regional variations in the price of drugs across the United 
Kingdom, for example, heroin costs an average of €64.33 (£44) in the North of 
England compared to €131.58 (£90) in Northern Ireland. 
Table 10.5: Law enforcement agencies: Mean price of illegal drugs in the United Kingdom, 
2003 to 2007 
Price per gram except where otherwise stated 
2003 2004 2005 2006 2007 Drug  










£9.00 £8.00 £10.00 £9.00 £9.00 Amphetamines €12.82 €11.52 €14.73 €13.37 €13.16 
£2.54 £2.54 £2.64 £2.68 ** £3.95 Cannabis herb** €3.62 €3.66 €3.89 €3.98 ** €5.78 
£2.32 £2.00 £1.94 £2.12 ** £2.82 Cannabis resin** €3.31 €2.88 €2.86 €3.15 ** €4.39 
    £6.21 Cannabis 
(sinsemilla)     €9.09 
£55.00 £51.00 £49.00 £49.00 £46.00 Cocaine powder €78.35 €73.45 €72.15 €72.81 €65.79 
£19.00 £18.00 £19.00 £18.00 *** £65.00 Crack cocaine*** €27.07 €25.92 €27.98 €26.75 *** €95.02 
£5.00 £4.00 £4.00 £3.00 £3.00 Ecstasy (per 
tablet) €7.12 €5.76 €5.89 €4.46 €4.39 
£62.00 £55.00 £54.00 £52.00 £48.00 Heroin €88.33 €79.21 €79.52 €77.27 €70.17 
£3.00 £3.00 £3.00 £3.00 £3.50 LSD (per dose) €4.27 €4.32 €4.42 €4.46 €5.12 
Note : The source data were provided rounded, usually to the nearest pound. 
*Conversion rates are the December monthly average spot exchange rates quoted by the Bank of 
England  
**Before 2007 the cannabis values were based on the price for an ounce.  In 2007 this changed to being 
based on a usual street deal of 1/8oz.  The price has been converted to gram equivalent  
*** Crack cocaine prices before 2007 were provided per rock (0.2g) not per gram.  2007 prices cannot 
be compared to earlier prices 
Source: United Kingdom Law Enforcement Agencies  
 







                                                                                                                                         
pop festivals combined in recent years with a web-based survey.  In 2007 the survey was 
web-based only resulting in a smaller sample. 
241 Information collected by journalists from Druglink, the organisation’s magazine, who call 
100 drug services, DATs, police forces and service user advocates in 20 areas of the United 
Kingdom. 

















DrugScope published price data for the United Kingdom in 2008 (DrugScope 2008), 
which are broadly comparable to other price data sources.  Although cannabis prices 
appear lower than other sources, they are based on an ounce price not 1/8 ounce.  
The figures show that the price of ketamine and ecstasy has fallen since 2006 while 
crystal or powder MDMA has also fallen slightly.  The figures suggest an increase in 
the price of heroin in 2008.  In their 2007 survey, DrugScope reported that for 
cocaine powder a more heavily cut product sold for €44 (£30) a gram and a purer 
form of the drug for around €73 (£50) a gram (DrugScope 2007).  Prices shown in 
euros in Table 10.7 should be interpreted with caution as there was a substantial 
change in the exchange rate between 2007 and 2008. 
Table 10.7: DrugScope: Mean price of drugs at street level in the United Kingdom, 2006 to 
2008 
Price per gram except where 
otherwise stated 







£9.70 £9.80 £9.00 Amphetamines €14.41 €14.33 €11.35 
£2.47 £3.07 £3.14 Cannabis herb** 
(standard quality) €3.67 €4.49 €3.96 
£1.91 £1.94 £1.80 Cannabis resin** €2.84 €2.84 €2.27 
£4.27 £4.73 £4.63 Cannabis (high 
quality)** €6.35 €6.91 €5.84 
£43.00 £43.00 £42.00 Cocaine powder €63.90 €62.86 €52.98 
£28.00 £25.00 £20.00 Ketamine €41.61 €36.55 €25.23 
£3.00 £2.40 £2.30 Ecstasy (per tablet) 
€4.46 €3.51 €2.90 
£46.00 £43.00 £49.00 Heroin €68.36 €62.86 €61.81 
£40.00 £38.00 £39.00 MDMA €59.44 €55.55 €49.20 
* Conversion rates are the monthly average spot exchange rates quoted by the Bank of 
England (December monthly averages for 2006 and 2007, July average for 2008) 
** Cannabis prices are converted from ounce prices 
Source: DrugScope 2008 
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A qualitative study of drug traffickers and dealers (Matrix Knowledge Group 2007) 
(see section 10.2) found that there was a perception among dealers that law 
enforcement activity impacts on price.  The study reports that there is price variation 
across different geographical areas in the United Kingdom.  Data from law 
enforcement agencies supports this claim, with average cocaine powder prices 
ranging from €59 to €80 (£40 to £55) across different regions. 
10.4.2 Purity of drugs at street level and composition of drugs/tablets 
Information on the purity of drugs is from the FSS, covering most of England and 
Wales.242  Latest data are for 2007 (Table 10.8).  Purity of amphetamines has 
remained stable since 2003 while the mean MDMA content of ecstasy has fallen.  
However, the mean MDMA content of ecstasy seized in 2007 was slightly higher than 
in 2006.  Heroin purity has continued to increase although there have been reports in 
2008 of a lack of ‘good’ quality heroin at street level (DrugScope 2008). 
Table 10.8: Street level mean percentage purity of certain drugs in the United Kingdom, 2003 
to 2007 
Drug 2003 2004 2005 2006 2007 
Amphetamines 10.8 9.0 10.1 10.6 10.9 
Cocaine powder 51.2 42.4 42.7 34.5 33.2 
Crack cocaine 69.6 63.7 64.8 49.5 52.3 
Ecstasy 64.5 66.7 66.3 48 51.8 
Heroin (brown) 32.7 39.9 46.5 43.5 49.8 
Source: Forensic Science Service Ltd 2008 
Cocaine purity 
The mean purity of cocaine powder at street level continues to fall and is now at 33.2 
per cent compared to 51.2 per cent in 2003.  The decrease reflects the emergence of 
more sophisticated cutting agents such as benzocaine, phenacetin and lignocaine, 
which are able to bind to the cocaine.   While the average purity of cocaine powder 
seized by police has fallen, the average purity of cocaine powder seized by HMRC 
has remained stable suggesting increased adulteration within the United Kingdom 
(SOCA 2008).  There has also been a fall in the purity of crack cocaine, reflecting the 
trend in cocaine powder.   
Cannabis potency 
Data provided to the ACMD by the FSS show that the potency of traditional imported 
herbal cannabis and cannabis resin has fallen since the late 1990s but the potency of 
sinsemilla has increased (Table 10.9).  The data show that in the last two years there 
has been a decline in the potency of sinsemilla.  However, it is difficult to monitor 
trends from these data as samples are not generally representative of what is 








                                                
242 All police seizures submitted to FSS for purity analysis in England and Wales. 
243 Further information on methodology and limitations of the data can be found in Standard 
Table 14. 
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Table 10.9: Mean THC content (%) of different types of cannabis in England and Wales, 
1995-2007 
Year Sinsemilla Herbal cannabis Resin 
1995 5.8 3.9 - 
1996 8.0 5.0 - 
1997 9.4 4.0 - 
1998 10.5 3.9 6.1 
1999 10.6 5.0 4.4 
2000 12.2 8.5 4.2 
2001 12.3 - 6.7 
2002 12.3 - 3.2 
2003 12.0 - 4.6 
2004 12.7 - 1.6 
2005 13.7 1.9 5.5 
2006 10.8 2.1 2.7 
2007 10.4 2.6 4.5 
Source: ACMD 2008a 
 
The potency levels reported in the FSS data are lower than in the Home Office 
Potency Study described below. 
Research  
Home Office Cannabis Potency Study 2008 
Hardwick and King (2008) report on the potency244 of various types of cannabis 
confiscated by police forces in England and Wales in late 2007.245  The mean THC 
concentration of sinsemilla was 16.2 per cent (range = 4.1 to 46%), median potency 
15 per cent and the mean THC concentration of traditional imported herbal cannabis 
was 8.4 per cent (range 0.3 to 22%), median potency nine per cent.  The mean 
potency of cannabis resin was 5.9 per cent (range = 1.3 to 27.8%) with a median 
potency of five per cent.  The mean CBD content of cannabis resin was 3.5 per cent 
(range = 0.1 to 7.3%) while the CBD content of herbal cannabis was less than 0.1 
per cent in almost all samples. 
Potency of cannabis in England in 2005 
Potter et al. (2008) studied the potency of cannabis seized by police in England in 
2004/05.246  They found that the mean potency247 of sinsemilla was 13.3 per cent 
(range = 1.15 to 23.17%) and the median 13.98 per cent.  The mean potency of 
herbal cannabis was 3.1 per cent (range = 0.28 to 11.81%), median 2.14 per cent 
and the mean potency of resin was 3.7 per cent (range = 0.44 to 10.76%), median 
3.54 per cent.  Potency levels differed across geographical areas.  Like Hardwick and 
                                                
244 Potency of cannabis is defined as the concentration (%) of tetrahydrocannabinol (THC), 
the main active ingredient of  cannabis.  Cannabis also contains other cannabinoids, one of 
which is cannabidiol (CBD). CBD is thought to have anti-psychotic properties. 
245 In late 2007, police were requested to submit samples of cannabis confiscated from street-
level users when issuing a warning to their usual service provider for laboratory examination.  
2,921 samples were submitted for analysis.  Samples were visually examined and a random 
selection of herbal cannabis samples were submitted for detailed microscopic examination to 
distinguish sinsemilla from traditional imported cannabis.  Further random samples were 
examined to determine THC and CBD content.  Concentrations of total THC and CBD were 
determined using either gas-chromatography or gas-chromatography coupled to mass-
spectrometry with THC and CBD as external standards. 
246 452 samples were collected from the police property stores of five constabularies in 
England and visually assessed.  Chromatographic analysis was undertaken using the method 
developed by de Meijer et al. (2003). 
247 THC concentration. 
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King (2008), the study found there to be overlaps in the potency of the different types 
of cannabis.  The authors also note the low levels of CBD in herbal cannabis and 
sinsemilla and stress the need to measure CBD in addition to THC content. 
10.4.3 Price and purity of drugs in the Arrestees Survey  
Respondents to the Arrestees Survey 2005/06 were asked whether the relative price 
and purity of drugs had increased, decreased or stayed the same over the past six 
months. Overall, a net proportion248 of respondents believed that the price of 
individual drugs had decreased although crack cocaine (14%) had not decreased as 
much as heroin (29%) or cocaine powder (27%).  There were also net decreases 
reported for the purity of each individual drug although cocaine powder (8%) had not 
decreased as much as other drugs.  The survey suggests that the price of heroin, 
cocaine powder and ecstasy decreased in relative terms (controlling for purity) while 
the price of crack cocaine increased marginally. 
Table 10.10: Proportion of arrestees reporting that the price and purity of individual drugs had 
increased, stayed the same or decreased in the past six months and the net decrease in 
England and Wales 2005/06 
Drug Increased Same Decreased Net decrease 
Price 
Heroin 14% 43% 43% 29% 
Crack cocaine 18% 50% 32% 14% 
Cocaine powder 14% 45% 41% 27% 
Ecstasy 11% 30% 59% 48% 
Purity 
Heroin 7% 64% 29% 22% 
Crack cocaine 7% 69% 23% 16% 
Cocaine powder 9% 74% 17% 8% 
Ecstasy 6% 69% 25% 19% 
Source: Boreham et al. 2007 
                                                
248 Net proportion is the difference between those reporting the price had increased and those 
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11. Sentencing statistics 
11.1 Options available 
In the United Kingdom, the law regarding drug possession, production, dealing and 
trafficking is principally covered by the Misuse of Drugs Act 1971.  The Act divides 
drugs into three classes249 depending upon their relative harm and sets maximum 
criminal penalties for related offences (see Chapter 1).  However, while the law 
covering these drug offences is the same across the United Kingdom, there are three 
separate criminal justice systems that are responsible for administering the law: one 
each for England and Wales; Northern Ireland; and Scotland.  These systems have 
evolved over a considerable period of time and differences in policing and 
prosecution mean that the options available for dealing with drug offences differ 
across the United Kingdom. 
 
The methods used by police in dealing with those suspected of drugs offences 
depend on the nature of the offence, the class/type of drug involved, the options 
available and the codes and guidelines that have been issued by the appropriate 
professional bodies.   
11.1.1 Measures available for drug offences 
In the United Kingdom the possession of drugs is a criminal offence but the use of 
drugs is not.  At all stages of the prosecution system there is a large amount of 
discretion with police, prosecutors and judges all able to decide on an appropriate 
level of action.  
Police 
Since 1st April 2004 the main recording codes for drug possession in England and 
Wales have been split into two categories: possession of controlled drugs (excluding 
cannabis); and possession of controlled drugs (cannabis).  The difference between 
the two offences is that an extra police disposal, the cannabis warning, exists for the 
latter offence.  A cannabis warning can be given for possession of small amounts of 
cannabis only.  The offender is not arrested nor does the disposal result in a police 
criminal record. 
 
While police have the discretion to issue a simple caution for drug offences, both 
possession and trafficking250, conditional cautions can only be administered with the 
agreement of the Crown Prosecution Service (CPS) and only for possession cases.  
Guidelines on the use of different measures are published in England and Wales.  
For example, the Association of Chief Police Officers (ACPO) has published 
guidelines on the use of cannabis warnings (ACPO 2007) and in 2008 the Home 
Office issued an updated circular on the use of simple cautions.251  Guidance on the 
use of conditional cautioning was updated in 2007.252  The measures available to 
police to deal with offenders outside of the court system have also been set out in a 
police booklet (Office for Criminal Justice Reform 2007) (Table 11.1).  
 
                                                
249 See: http://drugs.homeoffice.gov.uk/drugs-laws/misuse-of-drugs-act/  
250 The term trafficking is used in this chapter to refer to drug production, supply, possession 
with intent to supply and unlawful import/export 
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Table 11.1: Measures which can be used by police for drug offences in England and Wales 
Action Possession Trafficking Restrictions 
Cannabis warning YES NO Over 18 yrs, cannabis only 
Caution - simple YES YES Over 18 yrs 
Caution - conditional  YES NO Over 18 yrs, possession only, 
with CPS approval 
No further action YES YES  
Reprimand or final warning YES NO Aged 10 to 18 yrs only 
 
In Northern Ireland, similar disposals to England and Wales exist for police.  Although 
ACPO guidelines on cannabis warnings extend to Northern Ireland, this disposal is 
not used by police in Northern Ireland.   
Prosecution 
In Scotland, the police do not have the same powers to issue cautions to offenders 
for drug offences, although it is a fundamental principle of policing that police retain 
the discretion to issue informal verbal warnings for trivial or minor offences of any 
nature. The system of police fixed penalty notices does not extend to offences under 
misuse of drugs legislation.  
 
If a case is reported to the Crown Office and Procurator Fiscal Service (COPFS), 
which is responsible for the prosecution function in Scotland, the Procurator Fiscal 
has at his or her disposal a wider range of measures than the Crown Prosecution 
Service (CPS) in England and Wales, and the Public Prosecution Service (PPS) in 
Northern Ireland does (Figure 11.1). 





















In England, Wales and Northern Ireland cautions can only be administered by police 
although the prosecution service can refer the case back to the police where they 
believe a caution, or in Northern Ireland an informed warning, is the best option.  
Each prosecution service has its own code for prosecution which includes evidential 
standards and public interest considerations and sets out the options for alternatives 
to prosecution.253   
                                                
253 See: The Code for Crown Prosecutors: 
http://www.cps.gov.uk/victims_witnesses/code.html; COPFS Prosecution Code: 
By CPS (England and Wales) 
• No further action 
• Refer to police for caution 
 
By PPS (Northern Ireland) 
• No prosecution 
• Require police to administer informed warning 
• Require police to administer caution 
 
By COPFS (Scotland) 
• A warning by the Procurator Fiscal 
• Option of paying a fine 
• Option of referral for specialist support or treatment 
• Option to carry out unpaid work in the community 
• Option of paying compensation 
• No further action 
UNITED KINGDOM FOCAL POINT REPORT 2008  
 167
Courts 
A number of disposals are available at a court level and are at the discretion of the 
magistrate, sheriff or judge. 
Custodial sentence 
The most punitive measure available at court is a custodial sentence.  The maximum 
sentence that can be given is set out in the Misuse of Drugs Act 1971 and depends 
upon the class of drug and the type of offence.  The only circumstances where a 
minimum sentence is stipulated is in cases where an adult is convicted of a third 
Class A drug trafficking offence; in these cases the Crime (Sentences) Act 1997 
specifies a minimum seven year tariff.  
 
The maximum sentence length that can be given across the United Kingdom is also 
determined by the type of court the offender is tried in. 
Suspended sentence 
A suspended sentence can be given when the court feels that a sentence of less 
than 12 months is appropriate.  The maximum length of the order is two years and 
during that time a number of requirements can be set (see community sentence 
requirements below).   
Community sentence 
For all crimes committed on or after 4th April 2005, a single community order with a 
range of possible requirements can be given.  These requirements are: compulsory 
(unpaid) work; participation in any specified activities; programmes aimed at 
changing offending behaviour; prohibition from certain activities; curfew; exclusion 
from certain areas; residence requirement; mental health treatment (with consent of 
the offender); drug treatment and testing (with consent of the offender); alcohol 
treatment (with consent of the offender); supervision; and attendance at an 
Attendance Centre. 
Fine 
A court may impose a fine for any offence although more serious crimes are more 
likely to receive a fine in conjunction with another penalty.  The maximum fine 
depends on the type of court; in England and Wales, Crown Courts can impose an 
unlimited fine while the maximum fine that can be imposed by a Magistrates Court is 
€7,300 (£5,000).254 
Absolute/conditional discharge 
A person can receive an absolute or conditional discharge where the court feels no 
punishment is necessary.  Absolute discharges require nothing from the offender 
while conditional discharges may impose restrictions on future conduct (for a 
maximum period of three years). 
Other disposals 
Other disposals include binding over (either to keep the peace or be of good 
behaviour), confiscation orders, where a court can confiscate the value of the 
estimated proceeds from drug trafficking, forfeiture orders where property can be 
forfeited in relation to the offence, and compensation orders. 
                                                                                                                                         
http://www.copfs.gov.uk/Publications/2001/05/prosecutioncode ;and PPS Code for 
Prosecutors: http://www.ppsni.gov.uk/site/default.asp?CATID=77  
254 For more information on maximum fines see: 
http://www.cps.gov.uk/legal/section10/chapter_a.html  
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Compounding 
In addition to the above measures, Her Majesty’s Revenue and Customs (HMRC) in 
the United Kingdom have the option of ‘compounding’, an administrative sanction 
involving a financial penalty for those found carrying no more than ten grams of 
cannabis. 
11.1.2 Drug driving 
The offence of driving while under the influence of drugs is covered by a different Act 
of Parliament than possession/trafficking offences.  The Road Traffic Act 1988 makes 
it a criminal offence for any person who, when driving, or attempting to drive, a motor 
vehicle on a road or other public place, is unfit to drive through drink or drugs. An 
offence is also committed if a person, unfit through drink or drugs, is in charge of a 
motor vehicle in the same circumstances.  A further offence of failure to provide a 
specimen for analysis is also included in the Act.  The penalties for drug driving are 
similar for drink driving, reflecting the fact that the offences are grouped together as 
one offence.   
 
Measures available are: disqualification; a fine; community order; and imprisonment.  
In almost all cases the offender is likely to go to court with more severe punishment 
likely for those with additional offences such as causing death by careless driving 
while under the influence of alcohol or drugs. 
11.2 Data Collection Systems 
A fundamental principle of policing in the United Kingdom is police discretion.  This is 
exercised at many different levels from deciding whether to stop and search a person 
to deciding whether to arrest and put forward the offender for prosecution.  
Consequently, sentencing statistics do not provide a comprehensive picture of the 
outcome of drug offences but, in most cases, are a reflection of administrative 
systems and police priorities, and relate only to drug offences where a formal action 
is taken. 
 
It is worth bearing in mind that data collection systems relating to crime recording 
(including drug offences) are principally designed to be of operational use, not to be 
used as a research tool.  This means that query tools are geared towards individual 
case or offender level information retrieval rather than complex interrogations based 
on common criteria.  Similarly, extracts from these systems on the level and 
outcomes of crime are essentially performance management driven, which dictates 
the level of detail required.   
 
All police forces in the United Kingdom have local computerised recording systems.  
The actual system used differs across forces and are often standalone databases 
which mean that informal procedures, such as cannabis warnings, may not be 
consistently recorded from force to force, nevertheless the crime should still be 
recorded as the United Kingdom has a National Crime Recording Standard (NCRS).  
Providing a judicial sanction such as a formal caution or a conviction takes place then 
this will be accurately recorded on the Police National Computer System (PNC).255  
Technological advances in the capabilities of specialised police recording system 
software means this picture is improving and data quality should therefore become 
more reliable. 
 
Data on drug law offences are drawn from different sources across the United 
Kingdom reflecting the differences in legal systems. 
                                                
255 See: http://www.npia.police.uk/en/5977.htm  
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11.2.1 England and Wales 
Crime and arrests data 
Local police forces have a legal requirement to provide specified information to the 
Secretary of State.256  The annual data requirement (ADR) stipulates what data 
forces are required to collect and what they must submit to the Home Office.  This 
includes data in relation to recorded crime, arrests (for notifiable offences which 
includes drug offences) and cautions.  Since 1st April 2004, police forces have been 
required to provide data centrally on cannabis warnings and ACPO have recently 
recommended including cannabis warnings in the ADR to improve the quality of 
these data (internal communication from ACPO).  Data are recorded on local police 
systems and extracts from these administrative systems are collated centrally. 
Stop and search 
At the first point of the criminal justice system, when a member of the police stops a 
suspect, any search of that person carried out under the Police and Criminal 
Evidence Act 1984 (PACE) must be recorded.  Records must include, amongst other 
items, the following: 
• name of person or description; 
• person’s self-defined ethnic background; 
• purpose for search; 
• grounds for search; and 
• the outcome. 
 
This means that is it possible to identify the proportion of stop and searches carried 
out under the suspicion of drug offences and how many of these result in an arrest 
for drug offences.   
Recorded crime  
Statistics on recorded crime are provided by local police forces at an aggregated 
level so drug offences are not available by individual drug.  This breaks down drug 
offences into the main codes of: trafficking; possession; and other drug offences, and 
gives absolute numbers only.   Police forces submit monthly CrimSec 3 returns which 
contain these data and are generated from their local databases.  Recorded drug 
offences are governed by the Home Office Counting Rules (HOCR)257 which specify 
how many crimes should be recorded against an offender.  The general rule is one 
crime for each offender or group of offenders meaning that, for example, if one 
offender is found in possession of various drugs, only the drug offence which carries 
the highest maximum penalty will be recorded.  Similarly, if three people are caught 
manufacturing a controlled drug only one crime would be recorded. 
Arrests data 
Data on arrests for recorded crime are also provided via aggregated returns to the 
Home Office drawn from police force databases.  Information is published at offence 
category level only so it is not possible to break arrests down into supply and 
trafficking offences.  Data are for offender and include sex, age group and ethnicity.   
Where a person has been arrested for more than one recorded crime at the same 
time, the offence with the highest maximum penalty is recorded.  Arrests data cannot 
be compared to recorded crime data because, as the last example above shows, one 
crime could result in three arrests.  In addition, recorded crime includes cannabis 
possession offences which may be dealt with by a cannabis warning and therefore 
does not constitute an arrest. 
                                                
256 The Police Act 1996, section 45(1) 
257 See PACE Code A 2008: http://police.homeoffice.gov.uk/publications/operational-
policing/PACE_CODE_A_(July_2008).pdf   




Data on cautions are provided to the Ministry of Justice by police forces on a monthly 
basis from extracts drawn from local police databases, and collated in a central 
database, the cautions database.  This provides data on the number of offenders 
brought to justice (OBTJ) by means of a caution and contains information on offence 
type, sex, age and police force area.  Data are available by individual drug type.  If an 
offender is arrested for multiple related offences, the decision to issue a caution 
should be based on the most serious offence (Home Office Circular 16/2008).  
Cautions data cannot be compared with recorded crime data as one crime could 
result in multiple cautions being issued.  Furthermore, they cannot be directly 
compared with arrest data as the offence for which a caution was administered may 
differ from the offence for which the offender was originally arrested.   
Court data 
Data on court proceedings in England and Wales are collated in a central database, 
the Ministry of Justice’s court proceedings database, with information supplied 
directly from courts.  Various extract files are produced on a monthly basis including 
one for drug offences (Home Office 2004).  The data extracted are on a ‘principal 
offence’ basis, which records the court disposal for the most serious offence dealt 
with and uses the offender as the statistical unit.258 It is possible, however, to extract 
data on a different basis; for example, the United Kingdom Focal Point’s Standard 
Table 11 is produced on an ‘all offence’ basis.  Data are provided on offence type, 
disposal, gender and age, and can be presented by individual drug type. 
Her Majesty’s Revenue and Customs data 
There have been no reliable data on compounding for drug offences since 2000 
(Home Office 2004). 
 
Importation/exportation  
Data on importation and exportation offences are available but by drug class only not 
individual drug type. 
Data Linkage 
Court and police databases are administrative systems and are not linked at present.  
Information about the outcome of offences and offender details are contained on the 
PNC which is used purely for operational purposes.  The PNC is not designed to be 
the repository of statistical information and lacks an interrogation tool to allow this 
(Francis and Crosland 2002). 
 
Statistical data are based on extracts from large complex databases and it is not 
possible to compare crime and arrests data with cautions and court proceedings 
data.  This is due to a number of factors: the offence classification numbers for court 
proceedings do not directly compare to the aggregated offence categories used for 
crime and arrests data; court proceedings data refer to the year of the final court 
decision rather than year of arrest; and the offence that a person is finally dealt with  
may be different from the offence for which he/she was originally arrested or charged 
with.  Furthermore, crime and arrests data are published on a financial year basis 
while cautions and court outcomes are published on a calendar year basis. 
                                                
258 The principal offence is the offence where the heaviest penalty was given or, if the same 
penalty is given for two different offences, the offence where the statutory maximum penalty is 
highest. 
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11.2.2 Scotland 
Data on recorded crime in Scotland are provided by police forces to the Justice 
Analytical Service section of the Scottish Government.  The method of recording is 
governed by the Scottish Crime Recording Standard (SCRS), which was introduced 
in 2004.  Scottish data on recorded crime are not directly comparable to data from 
England and Wales due to differences in the counting rules.  
  
Police forces send returns to the Scottish Government containing a simple count of 
the number of offences recorded by offence type.  Data cannot be compared to 
statistics on action taken against offenders, as one offence may lead to several 
persons being charged. Equally, an offender may be charged with several offences. 
 
All cases to be reported to the Crown Office Procurator Fiscal Service must initially 
be recorded on the Criminal History System (CHS) at the Scottish Police Services 
Authority (SPSA) (previously the Scottish Criminal Records Office), which has an 
interface with the PNC.  The COPFS uses a live, operational database to manage 
the processing of reports submitted by the police and holds information at charge 
level.   Outcomes are recorded against charges and data on disposals and reasons 
for no further action are published on an aggregated level for all offences.259   
 
The Scottish Court Services’ ‘COP2’ system holds data on disposals and feeds this 
into the CHS.  Data are recorded at offender level and on a principal offence basis.  
Data on court outcomes are extracted from the CHS for the Scottish Government’s 
Court Proceedings Database and published annually by offence type. 
 
The CHS is the hub of the Integration of Scottish Criminal Justice Information 
Systems (ISCJIS) programme260, which aims to allow communication between the IT 
systems of the various criminal justice organisations in Scotland.  However, this is 
primarily for operational use and is not designed for research purposes. 
11.2.3 Northern Ireland 
Crime and arrests data 
Data on recorded crime in Northern Ireland are provided by police forces to the 
Police Service of Northern Ireland (PSNI).  As in England and Wales, the recording of 
crime is governed by HOCR and the NCRS.  Arrest and charge information is 
recorded on a central NICHE261 custody database.  Data on arrests and charges are 
extracted as two separate data files but there are some common fields such as 
custody reference number that could be used to match charges to arrests. 
Cautions and court data 
Data on cautions are provided by police forces and extracted from the PSNI’s 
Integrated Crime Information System (ICIS).  Cautions data cannot be matched to 
arrest charge data at present but, in future, may be included on the NICHE database. 
 
Court data are also obtained from ICIS data extracts. PSNI are responsible for 
collecting the data which means that coverage is restricted to criminal proceedings 
where PSNI are involved (NIO 2008).  Data are available by class of drug only and 
refer to the principal offence.   
                                                




261 NICHE is a specialist records management system software for law enforcement agencies 
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11.2.4 Drug driving data collection 
Police data on drug driving is not collected separately from data on driving while 
under the influence of alcohol.  A review of road traffic offence statistics concluded 
that, while there is a desire for better recording of drug driving offence data, the issue 
needs to be addressed from a legal aspect not a statistical one (Home Office 2001).  
Until the law distinguishes between the two causes of impairment, it will not be 
possible to provide these data and changes in the law are dependent on 
technological advances in the ability to prove drug impairment.  At court level there is 
some breakdown of data by type of drink/drug driving offence. 
11.3 Results available 
11.3.1 Recorded crime 
In the United Kingdom in 2006/07 there were 200,270 drug possession offences (see 
Chapter 8, Table 8.3) and 37,913 drug trafficking offences recorded by the police.  In 
the same period crime statistics show that there were 90,926 arrests for drug 
offences (arrest data is not available for Scotland).262 
11.3.2 Stop and search 
Data on searches of persons or vehicles under PACE and other legislation in 
England and Wales show that, in 2006/07, 42 per cent of all searches by the police 
were carried out on suspicion of a drug offence.  Of the 406,451 searches carried out 
for drugs, eight per cent (33,030) resulted in an arrest for drugs.  Of the 65 intimate 
searches made for drugs, six per cent (n=4) resulted in a Class A drug being found 
(Ministry of Justice 2008a).  
11.3.3 Outcomes for drug possession offences 
It is not possible to provide data on a United Kingdom basis due to differences in law, 
available disposals and recording systems.  These differences are discussed in 11.1 
and 11.2. 
 
England and Wales 
Data on offenders found guilty of, or cautioned for, drug offences are published in the 
annual Crime Statistics publication by drug class and offence type.  The figures 
contained in the 2006 publication (Ministry of Justice 2007b) are slightly different 
from those presented here as they refer to those found guilty not those sentenced 
and it is possible for somebody to be found guilty in one year and sentenced in 
another.  Supplementary tables to this publication can be found on the Ministry of 
Justice website and data there are available on sentence outcome by offence type 
and drug class.  Data by individual drug presented here have been provided by the 
Ministry of Justice and extracted from the same dataset as the published drug 
offence data. 
 
Data provided are for offenders who have been sentenced after a finding of guilt at 
court or issued a caution for drug offences.  The latest year of complete data is 2006, 
presented on a principal offence basis. The sentence shown is the most severe 
sentence or order given; data on secondary sentences are not included.  Data refer 
to the year in which the offence was dealt with not when the offence was committed.  
                                                
262 Scotland accounted for 17.7 per cent of all drug offences recorded by police in the United 
Kingdom.  The differences between recorded crime and arrests may be due to the fact that 
cannabis warnings do not result in an arrest. 
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For this reason, and reasons discussed in 11.2, it is not possible to link recorded 
crime or arrests with outcomes.  
 
In England and Wales in 2006 there were 62,561 persons sentenced or cautioned for 
drug offences263 and 80,500 cannabis warnings were issued.  Just over half of drug 
possession offences dealt with by the police were for cannabis (52.5%).  Cocaine 
powder possession offences (14.6%) and heroin possession offences (8.9 per cent) 
were the next most common (Table 11.2).  
Table 11.2: Number and proportion of all possession offences by individual drug in England 
and Wales, 2006 
Drug Number % 
Amphetamines 4,058 6.5 
Cannabis* 32,822 52.5 
Cocaine powder 9,140 14.6 
Crack cocaine 1,431 2.3 
Ecstasy 3,481 5.6 
Heroin  5,570 8.9 
LSD 91 0.1 
Other drugs** 5,968 9.5 
All drugs 62,561 100 
*excludes 80,500 formal warnings for cannabis 
**all other drugs classified under the Misuse of Drugs Act 1971 
Source: Ministry of Justice 
 
In 2006, 34,626 offenders were cautioned for drug possession offences, the majority 
of which (59%) were for cannabis possession.  There were 1,090 offenders 
sentenced to immediate custody for possession, around a third of which (n=370) 
were for heroin possession (Table 11.3). 
Table 11.3: Number of offenders receiving each disposal for drug possession offences by 
individual drug in England and Wales, 2006 




sentence Discharge Other Total 
Cannabis*  20,370 6,368 2,527 141 66 3,069 281 32,822 
Heroin 1,631 1,159 1,208 370 98 978 126 5,570 
Cocaine powder 5,159 2,055 984 187 93 578 84 9,140 
Crack cocaine 458 392 292 86 32 156 15 1,431 
Amphetamines 1,899 940 429 85 38 601 66 4,058 
Ecstasy 1,957 672 478 62 38 256 18 3,481 
LSD 43 22 15 2 3 5 1 91 
Other drugs** 3,109 1,024 763 157 68 748 99 5,968 
All drugs 34,626 12,632 6,696 1,090 436 6,391 690 62,561 
*excludes 80,500 formal warnings issued for cannabis possession 
**all other drugs classified under the Misuse of Drugs Act 1971 
Source: Ministry of Justice 
 
Seventy-one per cent of cannabis possession offences were dealt with by issuing a 
cannabis warning.  Overall, for possession offences, excluding those where a 
cannabis warning was issued, the most common disposal was a police caution (55 
%).  The most common disposal for drug possession offences used by a court was a 
fine (45.2% of court actions), followed by a community sentence (24% of court 
actions) and no further action/discharge (22.9% of court actions).   
 
                                                
263  Data refer to offenders on a principal offence basis and are drawn from the cautions 
database and court proceedings database. These cannot be compared with figures provided 
in Chapter 8 or Standard Table 11 as they are calculated on a different basis. 
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Overall, two per cent of drug possession offences resulted in immediate custody 
(Figure 11.2).  However, possession offences involving heroin and crack cocaine, 
were more likely to receive immediate custody, seven per cent and six per cent 
respectively, or a community sentence, 22 per cent and 20 per cent respectively 
(compared to 11% of all drug offences).  Conversely, those found guilty of heroin or 
crack cocaine possession were less likely to receive a police caution, 29 per cent of 
heroin offences and 32 per cent of crack cocaine offences received a police caution 
(compared to 55% of all drug offences264). 
 
The difference between methods of disposal for possession of cocaine powder and 
possession of crack cocaine is shown clearly in Figure 11.2; 78 per cent of cocaine 
powder offences were dealt with by a caution or fine compared to 59 per cent of 
crack cocaine offences. 






















































*excludes formal warnings for cannabis possession 
Source: Ministry of Justice 
Scotland 
Data for Scotland does not include out-of- court disposals.  Although the police and 
PF office collect data, this is as part of a management system and resources are not 
available to extract the requested information from administrative systems.  Data 
provided are on a principal offence basis and are provided by the Scottish 
Government.  Data on penalties handed down by courts for drug offences are 
published in an annual statistical bulletin, the latest is for 2006/07 (Scottish 
Government 2008i).  However, this is published at an aggregated level only and does 
not provide information by drug offence type or by drug type. 
    
In Scotland, in 2006/07, there were 7,001 offenders found guilty at court for drug 
possession offences (Table 11.4).  Of these, three-quarters received a fine and four 
per cent were sentenced to immediate custody.  Where a drug was recorded, 
cannabis and heroin were the most common drugs, 19 per cent for each drug.  
However, in 38 per cent of reports, no drug type was recorded.  It is therefore difficult 
to comment on the use of different disposals by individual drug.  
                                                
264 Excluding cannabis warnings 
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Table 11.4: Number of offenders receiving each disposal for drug possession offences by 
individual drug in Scotland, 2006/07 
Drug Fine Community Sentence 
Immediate 
custody Discharge Other Total 
Cannabis 947 29 22 4 308 1,310 
Heroin 738 79 121 - 368 1,306 
Cocaine powder 648 15 19 3 72 757 
Amphetamines 181 8 6 - 40 235 
Ecstasy 390 6 5 3 62 466 
Other drugs* 2,378 53 82 3 411 2,927 
All drugs 5,282 190 255 13 1,261 7,001 
  *includes 2,669 offenders where no drug was recorded 
Source: Scottish Government 
Northern Ireland 
Data for Northern Ireland are available by class of drug only (see 11.3).  In 2006, 
1,354 offenders were either cautioned or found guilty at court of drug possession 
offences, the majority (81%) for Class C offences (Table 11.5). 
Table 11.5: Number of offenders receiving each disposal for drug possession offences by 
class of drug in Northern Ireland, 2006 




sentence Discharge Total 
Class A 59 90 23 9 29 2 216 
Class B 21 19 6 2 5 2 55 
Class C 712 292 43 8 6 27 1,093 
All drugs 782 401 72 19 40 31 1,354 
Source: Northern Ireland Office; Police Services Northern Ireland 
 
Fifty-eight per cent of all drug possession offenders were dealt with by a caution in 
2006.  Only one per cent of offenders were sentenced to immediate custody.  
Penalties were proportionately harsher for drugs in higher drug classes, with only 27 
per cent of Class A offences given a caution compared to 65 per cent of Class C 
offences.  Class A offenders were six times more likely to receive an immediate 
custodial sentence than Class C offenders (Figure 11.3). 





























UNITED KINGDOM FOCAL POINT REPORT 2008  
 176
11.3.4 Outcomes for drug trafficking offences  
England and Wales 
In 2006 there were 12,764 offenders cautioned or sentenced at court for drug 
trafficking offences265, just over a third of whom (35%) were guilty of cannabis 
trafficking.  The next most common trafficking offence involved heroin, 2,331 
offenders (18% of offenders) were cautioned or found guilty of heroin trafficking in 
2006 (Table 11.6).   
Table 11.6: Number of offenders receiving each disposal for drug trafficking offences by 
individual drug in England and Wales, 2006 




sentence Discharge Other Total 
Cannabis 1,877 378 961 566 411 275 33 4,501 
Heroin 57 8 366 1,659 207 12 22 2,331 
Cocaine powder 147 23 168 1,139 144 17 15 1,653 
Crack cocaine 30 7 82 435 41 4 4 603 
Amphetamines 43 4 89 163 77 13 7 396 
Ecstasy 92 24 124 337 89 3 6 675 
LSD 11 0 1 4 4 0 1 21 
Other 
substances* 256 70 529 1,231 398 62 38 2,584 
All drugs 2,513 514 2,320 5,534 1,371 386 126 12,764 
*all other drugs classified under the Misuse of Drugs Act 1971 
Source: Ministry of Justice 
 
The most common disposal for drug trafficking offences was immediate custody 
(45%) followed by a caution (20%) and community sentence (19%).  Cannabis and 
LSD offences were the only trafficking offences where immediate custody was not 
the most common disposal (Figure 11.4).  
 
The difference between disposals used for cocaine powder and crack cocaine is less 
pronounced when looking at drug trafficking offences.  In 2006, 69 per cent of 
offences involving cocaine powder trafficking were given immediate custodial 
sentences compared to 72 per cent of crack cocaine offences and 71 per cent of 
heroin offences.  The use of fines was low with only four per cent of all drug 
trafficking offences receiving a fine as the main sentence. 
                                                
265 Excludes offences of importation and exportation of drugs 
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Source: Ministry of Justice 
 
The trafficking offences above do not include the offence of unlawful importation or 
exportation of drugs as they can only be broken down by drug class not by individual 
drug type.  In 2006, there were 856 offenders sentenced at court or cautioned for 
importation of drugs; 92 per cent received immediate custody and one per cent were 
cautioned by police. In the same year there were 55 offenders sentenced at court or 
cautioned by police for exportation of drugs; 53 per cent received immediate custody 
and 44 per cent received a caution. 
 
There were a further 668 offenders sentenced or cautioned for ‘other drug offences’; 
38 per cent received a caution, 16 per cent a fine, 14 per cent immediate custody 
and 12 per cent a conditional discharge. 
Scotland 
In Scotland in 2006/07 there were 1,817 persons found guilty of drug trafficking 
offences at court.  Of these, 465 (27%) were for heroin offences, 391 (22%) for 
cannabis offences and 120 (7%) were for cocaine powder offences (Table 11.7).  
Almost half of all offenders (48%) found guilty of trafficking offences were sentenced 
to immediate custody with a further 19 per cent given a community sentence and 16 
per cent receiving a fine.  As Scotland data refers to court actions only and includes a 
large number of cases where the individual drug is not known, it is difficult to 
comment on the use of available disposals by individual drug. 
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Table 11.7: Number of offenders receiving each disposal for drug trafficking offences by 
individual drug in Scotland, 2006/07 
Drug Fine Community Sentence 
Immediate 
custody Discharge Other Total 
Cannabis 133 104 83 1 70 391 
Heroin 27 50 297 - 91 465 
Cocaine powder 9 24 77 - 10 120 
Amphetamines 5 12 38 - 5 60 
Ecstasy 18 32 25 1 8 84 
Other substances* 97 127 347 1 121 693 
All drugs 289 349 867 3 305 1,813 
*includes 575 cases where drug is not known 
Source: Scottish Government 
Northern Ireland 
In 2006 there were 178 offenders cautioned or found guilty at court of drug trafficking.  
Over half of these (54%) were guilty of a Class C drug offence, 28 per cent of a Class 
A offence and 17 per cent of a Class B offence (Table 11.8). 
Table 11.8: Number of offenders receiving each disposal for drug trafficking offences by class 
of drug in Northern Ireland, 2006 




sentence Discharge Total 
Class A 1 1 3 30  11 1 49 
Class B 2 0 1 22  5 0 30 
Class C 14 20 7 28  23 4 97 
All drugs 19 21 11 80  39 5 178 
Source: Northern Ireland Office; Police Services Northern Ireland 
 
Similar to elsewhere in the United Kingdom, immediate custody was the most 
common disposal for drug trafficking offences, 45 per cent of offenders were 
sentenced to immediate custody in 2006.  However, those convicted of Class A and 
Class B offences were more likely to receive a custodial sentence, 61 and 73 per 
cent respectively, compared to 29 per cent of those convicted of a Class C offence.  
The use of cautions decreased with the severity of the offence and fines were used 
almost exclusively for Class C offences (Figure 11.5).  

























Source: Northern Ireland Office; Police Services Northern Ireland 
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11.3.4 Average sentence length 
England and Wales 
The average sentence handed down for trafficking offences is much larger than the 
sentence for possession offences, around three years compared to less than one 
year (Table 11.9).  In 2006, the average length of a prison sentence for trafficking 
was highest for those drugs categorised as Class A while amphetamines (Class B) 
and cannabis (Class C) received lower sentences.   
Table 11.9: Average custodial sentence length in months for drug offences in England and 
Wales, 2006 by offence and individual drug 
Drug Possession Trafficking 
Amphetamines 2.9 24.5 
Cannabis 2.8 14.8 
Cocaine powder 5.2 38.3 
Crack cocaine 5.1 36.2 
Ecstasy 7.4 29.0 
Heroin  9.7 36.6 
LSD 1.5 44.8 
Other drugs 6.6 35.0 
Source: Ministry of Justice 
 
In 2006, seven people were sentenced under the Power of Criminal Courts 
(Sentencing) Act (2000), which imposes a minimum seven year prison sentence for 
those found guilty of a third Class A trafficking offence (House of Commons Written 
Answers 8/7/08). 
 
However, there were no offenders sentenced to the maximum penalty for supplying 
drugs in 2006 (House of Commons Written Answers 28/4/08).  
Northern Ireland 
In Northern Ireland, average sentence lengths were similar to England and Wales; 
the average sentence length was longer for Class A drugs and for those found guilty 
of trafficking (Table 11.10). 
Table 11.10: Average custodial sentence length in months for drug offences in Northern 
Ireland, 2006 by offence and drug class 
Drug Possession Trafficking 
Class A 7 31 
Class B 2 26 
Class C 3 22 
All drugs 5 26 
Source: Northern Ireland Office 
Scotland  
No data on average sentence length by individual drug type are available for 
Scotland. 
11.3.5 Outcomes for drug driving offences  
As discussed in 11.2, driving while under the influence of drugs is recorded  
alongside alcohol related driving offences.  The vast majority of these offences will be 
for the consumption of alcohol not drugs.  In the 2006 ACPO Christmas Drink/Drug 
Driving Campaign only 2.5 per cent of those found to be impaired were believed to 
be under the influence of drugs.266   
                                                
266 See: http://www.acpo.police.uk/pressrelease.asp?PR_GUID=%7BAB561A46-787C-471D-
BB44-4A92E487B272%7D  
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Court statistics show that, in 2006, there were 88,700 offenders (principal offence 
basis) proceeded against at a Magistrates Court and 101,400 offences of driving 
after consuming drink or taking drugs (Ministry of Justice 2008c).  Courts returned 
guilty verdicts for 92,671 offences and five per cent (4,400) of these were sentenced 
to immediate custody.  Supplementary tables on motoring offences break the offence 
type down further and show that, in 2006, there were findings of guilt for 414 offences 
of being ‘unfit to drive through drugs’ and 26 offences of being ‘in charge of a motor 
vehicle while unfit through drugs’; no information on outcomes is available (Ministry 










































ACMD (Advisory Council on the Misuse of Drugs) (2008a). Cannabis: Classification and 
Public Health. Advisory Council on the Misuse of Drugs. Home Office, London. Available: 
http://drugs.homeoffice.gov.uk/publication-search/acmd/acmd-cannabis-report-
2008?view=Binary [accessed 09.05.08] 
 
ACMD (Advisory Council on the Misuse of Drugs) (2008b). GBL & 1,4-BD: Assessment of 
Risk to the Individual and Communities in the UK. Advisory Council on the Misuse of 




ACMD (Advisory Council on the Misuse of Drugs) (2008c). Advice on the classification of 
24 steroidal and 2 non-steroidal substances. Letter to the Home Secretary.  Advisory 




ACPO (Association of Chief Police Officers) (2007). Guidance on policing cannabis; Use 
of cannabis warnings. Association of Chief Police Officers of England , 
London.Available:www.acpo.police.uk/asp/policies/Data/Cannabis_Use_of%20_Warnings
_website_17x01x2007.doc [accessed 07.10.08]  
 
The Anti-Social Behaviour Act 2003. The Stationery Office, London. 
http://www.opsi.gov.uk/acts/acts2003/ukpga_20030038_en_1 [accessed 07.10.08] 
 
APPHG (All-Party Parliamentary Hepatology Group) (2006). A Matter of Chance, All-Party 
Parliamentary Hepatology Group, London. Available: 
http://www.hepctrust.org.uk/NR/rdonlyres/92D12999-0D64-4028-8E15-
1931A7368B21/0/AMatterOfChancePCTAuditofHepatitisCHealthcare.pdf   [accessed 
28.08.08] 
 
APPHG (All-Party Parliamentary Hepatology Group) (2008). Location, Location, Location 
An Audit of Hepatitis C Healthcare in England. An All- All-Party Parliamentary Hepatology 
Group report, APPHG, London. Available: 
http://www.hepctrust.org.uk/NR/rdonlyres/8571A7BF-760A-48C2-8148-
17EF61D30DCB/0/Locationlocationlocation.pdf  [accessed 28.08.08] 
 
The Armed Forces Act 1996. Her Majesty’s Stationary Office. Available: 
http://www.opsi.gov.uk/acts/acts1996/ukpga_19960046_en_1 [accessed 30.10.08] 
 
Audit Commission (2004). Reducing the local impact. Audit Commission, London. 
 
Baldacchino, A., Iqbal, S., Walls, S. and Cameron, K. (2008). Drug Deaths in Fife Scotland 
2005-2007: A report on the findings of the Fife Drug Deaths Monitoring and Prevention 
Group. Fife Drug and Alcohol Action Team. Available: 
http://www.nhsfife.scot.nhs.uk/publications/Fife%20DD_report_compiled%20Final%20with
%20foreword.pdf. [accessed 16.06.08] 
 
UNITED KINGDOM FOCAL POINT REPORT 2008  
  
 184
Barrett, D., Lines, R., Schleifer, R., Elliott, R. and Bewley-Taylor, D. (2008). Recalibrating 
the Regime: The Need for a Human Rights-Based Approach to International Drug Policy. 




Bell, J. and Harvey-Dodds, L. (2008). Pregnancy and injecting drug use. British Medical 
Journal 336 1303 - 1305. 
 
Best, D., Man, L, Zador, D., Darke, S., Strang, J. and Ashton, M. (2007). Overdosing on 
opiates. Part 1. Causes. Drug and Alcohol Findings. 
 
Best, D., Day, E., Homayoun, S., Lenton, H., Moverley, R. and Openshaw, M. (2008). Do 
primary drug users fare better than primary offenders? Drugs: education, prevention and 
policy 15 (2) 201-209. Available: 
http://dx.doi.org/10.1080/09687630701198165 [accessed 29.05.08] 
 
Beynon, C. M, McVeigh, J. and Roe, B. (2007a). Problematic drug use, ageing and older 
people: trends in the age of drug users in northwest England. Ageing and Society 27 799-
810. 
 
Beynon, C.M., McVeigh, J., Chandler, M., Wareing, M. and Bellis, M.A. (2007b). The 
impact of citrate introduction at UK syringe exchange programmes: a retrospective cohort 
study in Cheshire and Merseyside, UK Harm Reduction Journal 4 1.  Available: 
http://www.harmreductionjournal.com/content/4/1/21 [accessed 13.08.08] 
 
Bird, S. (2007). Compulsory Drugs Testing in the British Army: Assessing the data. RUSI 
Journal. December 2007.  Available: 
http://www.rusi.org/downloads/assets/RUSIJOURNALFEATURE_DEC07.pdf  
 
Blakeborough, L. and Pierpoint. H. (2007). Conditional cautions: An examination of the 
early implementation of the scheme. Ministry of Justice, London. Available:  
http://www.justice.gov.uk/publications/research171207.htm [accessed 17.04.08] 
 
Blakey, D. (2008). Disrupting the supply of illicit drugs. A report to the Director General of 




Bloor, M., Gannon, M., Hay, G., Jackson, G., Leyland, A.H. and McKeganey, N. (2008). 
Contribution of problem drug users’ deaths to excess mortality in Scotland: secondary 
analysis of cohort study. British Medical Journal 22 337-478. 
 
Bloor, M., Mckintosh, J., McKeganey, N. and Robertson, M. (2008). ‘Topping up’ 
methadone: An analysis of patterns of heroin use amongst a treatment sample of Scottish 
drug users. Public Health 122 1013-1019. 
 
Boreham, R., Cronberg, A., Dollin, L. and Pudney, S. (2007). The ArresteeS Survey 2003 
– 2006. 2nd Edition. Home Office Statistical Bulletin12/07. Home Office, London. 
Available: http://www.homeoffice.gov.uk/rds/pdfs07/hosb1207.pdf [accessed 02.12.07] 
 
UNITED KINGDOM FOCAL POINT REPORT 2008  
  
 185
Brown, M. and Bolling, K. (2007). 2006 Scottish Crime And Victimisation Survey: Main 
Findings. Scottish Government Social Research. Scottish Government, Edinburgh. 
Available: http://www.scotland.gov.uk/Publications/2007/09/26163243/0 [accessed 
07.10.08] 
 
Brown, R. and Payne, S. (2007). Process Evaluation of the Salford Community Justice 
Initiative. Ministry of Justice Research Series 14/07. Ministry of Justice, London. Available: 
http://www.communityjustice.gov.uk/docs/Salford_ELS_evaluation_report_FINAL_publicati
on.pdf [accessed 23.03.08] 
 
Campbell, A., Finch, E., Brotchie, J. and Davis, P. (2007). The International Treatment 
Effectiveness Project Implementing psychosocial interventions for adult drug misusers. 
National Treatment Agency for Substance Misuse, London. Available:  
http://www.nta.nhs.uk/publications/documents/nta_itep_implementing_psychosocial_interv
entions_for_adult_drug_misusers_rb34.pdf [accessed 21.12.07] 
 
CSIP (Care Services Improvement Partnership) (2007). What's the Score? Housing 
Learning and Improvement Network. Care Services Improvement Partnership. 
 
Case, S. and Haines, K. (2008). Factors shaping substance use by young people in 




CIPD (Chartered Institute of Personnel and Development) (2007). Managing drug and 
alcohol misuse at work. Survey report September 2007. Chartered Institute of Personnel 




CLG (Communities and Local Government) (2007). The New Performance Framework for 
Local Authorities and Local Authority Partnerships: Single Set of National Indicators. 
Communities and Local Government, London. Available: 
http://www.communities.gov.uk/documents/localgovernment/pdf/505713.pdf  [accessed 
04.04.08] 
 
COI (The Central Office of Information) and GfK-NOP (2007). Audit of Prescribing 
Practitioners. Summary Report. The Central Office of Information, London. 
 
Coles. E. and Pates, R. The Economic and Social Costs of Class A drug and alcohol 
abuse in Wales. Unpublished, reported in Welsh Assembly Government) (2008), Working 
Together to Reduce Harm. The Substance Misuse Strategy for Wales 2008–2018. Welsh 
Assembly Government, Cardiff. Available: 
http://wales.gov.uk/consultation/dsjlg/2008/workingtogether/finaldocumente.pdf?lang=en  
[accessed 03.04.08]  
 
Corkery, J. (2008). UK drug-related mortality – issues in definition and classification. Drugs 
and Alcohol Today 8 (2) 17-25. 
 
The Crime (Sentences) Act 1997. The Stationery Office, London. 
 
The Criminal Justice Act 2003. The Stationery Office, London. Available: 
http://www.opsi.gov.uk/acts/acts2003/ukpga_20030044_en_1 [accessed 27.10.08] 
 
UNITED KINGDOM FOCAL POINT REPORT 2008  
  
 186
CSP (Centre for Suicide Prevention). (2008). The National Confidential Inquiry into Suicide 
and Homicide by People with Mental Illness: Lessons for mental health care in Scotland. 
Centre for Suicide Prevention, University of Manchester, Manchester. Available:  
http://www.medicine.manchester.ac.uk/suicideprevention/nci/Useful/scotland_full_report.p
df [accessed 07.10.08] 
 
Currie, C., Levin, K. and Todd, J. (2008). HBSC Scotland National Report. Child and 




DAIRU (Drug and Alcohol Research Unit) / DHSSPSNI (Department of Health, Social 
Services and Public Safety Northern Ireland) (2003). Statistics from the Northern Ireland 
Drug Misuse Database: 1 April 2002 - 31 March 2003. Department of Health, Social 
Services and Public Safety Northern Ireland, Belfast. Available: 
http://www.dhsspsni.gov.uk/needle_exchange_mar03.pdf [accessed 02.09.08] 
 
DAIRU (Drug and Alcohol Research Unit) / DHSSPSNI (Department of Health, Social 
Services and Public Safety Northern Ireland) (2005). Statistics from the Northern Ireland 
Drug Misuse Database: 1 April 2004 - 31 March 2005. Department of Health, Social 
Services and Public Safety Northern Ireland, Belfast. Available: 
http://www.dhsspsni.gov.uk/needle_exchange_mar05.pdf [accessed 02.09.08] 
 
DAIRU (Drug and Alcohol Research Unit) / DHSSPSNI (Department of Health, Social 
Services and Public Safety Northern Ireland) (2006). Statistics from the Northern Ireland 
Drug Misuse Database: 1 April 2005 - 31 March 2006. Department of Health, Social 
Services and Public Safety Northern Ireland, Belfast. Available: 
http://www.dhsspsni.gov.uk/needle_exchange_mar06.pdf [accessed 02.09.08] 
 
Day, E., Best, D., Copello, A., Young, H., Khoosal, N. and Modern, N. (2007). 
Characteristics of drug-using patients and treatment provided in primary and secondary 
settings. Journal of Substance Use 13 (1) 27-35. Available: 
http://dx.doi.org/10.1080/14659890701639816 [accessed 24.05.08] 
 
DCSF (Department for Children, Schools and Families) (2007). The Children’s Plan 
Building brighter futures. Department for Children, Schools and Families, London.   
Available: http://www.dcsf.gov.uk/publications/childrensplan/index.shtml [accessed 
02.09.08] 
 
DCSF (Department for Children, Schools and Families) (2008). Outcome indicators for 
looked after children: Twelve months to 30 September 2007, England. Department for 
Children, Schools and Families, London. 
 
DH (Department of Health) (2001). The Government Response to the Advisory Council on 
the Misuse of Drugs Report into Drug Related Deaths. Department of Health, London. 
Available: 
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuid
ance/DH_4015217 [accessed 13.05.08]  
 
DH (Department of Health) (2002a). Mental Health policy implementation: dual diagnosis 
and good practice. Department of Health, London. Available: 
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuid
ance/DH_4009058 [accessed 07.10.08]  
 
UNITED KINGDOM FOCAL POINT REPORT 2008  
  
 187
DH (Department of Health) (2002b). Models of care for substance misuse treatment: 
promoting quality, efficiency and effectiveness in drug misuse treatment services. 
Department of Health, London. Available: 
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuid
ance/DH_4008118 [accessed 07.10.08]  
 
DH (Department of Health) (2004). Hepatitis C Action Plan for England. Department of 
Health, London. Available: 
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuid
ance/Browsable/DH_4103274 [accessed 07.10.08]  
 
DH (Department of Health) (England) and the devolved administrations (2007). Drug 
Misuse and Dependence: UK Guidelines on Clinical Management. Department of Health 
(England), the Scottish Government, Welsh Assembly Government and Northern Ireland 




DH (Department of Health) and National Treatment Agency for Substance Misuse (NTA) 
(2007). Reducing Drug-related Harm: An Action Plan. Department of Health, London. 
Available: 
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuid
ance/DH_074850 [accessed 13.05.08] 
 
DH (Department of Health), The Scottish Office Department of Health, Welsh Office, 
Department of Health and Social Services, Northern Ireland (1999). Drug misuse and 
dependence – guidelines on clinical management. The Stationery Office. London. 
Available: http://www.dh.gov.uk/assetRoot/04/07/81/98/04078198.pdf  [accessed 28. 
07.08].  
 
DHSSPSNI (Department of Health, Social Services and Public Safety Northern Ireland) 
(2006). New Strategic Direction for Alcohol and Drugs (2006 – 2011). Department of 
Health, Social Services and Public Safety Northern Ireland, Belfast. Available: 
http://www.dhsspsni.gov.uk/nsdad-finalversion-may06.pdf [accessed 07.10.08] 
 
DHSSPSNI (Department of Health, Social Services and Public Safety Northern Ireland) 
(2007a). Statistics from the Northern Ireland Substitute Prescribing Database: 31 March 




DHSSPSNI (Department of Health, Social Services and Public Safety Northern Ireland) 
(2007b). The Action Plan for the Prevention, Management and Control of Hepatitis C in 
Northern Ireland. Department of Health, Social Services and Public Safety, Belfast. 
Available: www.dhsspsni.gov.uk/hepatitisc-actionplan-2007.pdf [accessed 19.09.08] 
 
The Drugs Act 2005. The Stationery Office, London. Available: 
http://www.opsi.gov.uk/acts/acts2005/ukpga_20050017_en_1 [accessed 08.10.08] 
 
DrugScope (2007). Bash street kids: Street Drug Trends Survey 2007 Druglink Sept/Oct 
2007. 
 
DrugScope (2008). Peaking valleys: Street Drug Trends Survey 2008. Druglink Sept/Oct 
2008. 
 
UNITED KINGDOM FOCAL POINT REPORT 2008  
  
 188
Duffy, M., Schafer, N., Coomber, R., O'Connell, L. and Turnbull, P. (2008). Cannabis 
supply and young people. "It's a social thing". Joseph Rowntree Foundation, York. 
Available: http://www.jrf.org.uk/bookshop/details.asp?pubID=940 [accessed 08.10.08] 
 
Duffy, P. and Beynon, C.M. (2008). Younger drug users assessed by DIP teams in non-
intensive areas; characteristics and implications for service delivery. Drug Interventions 
Programme Monitoring and Research Team. Centre for Public Health. Liverpool John 
Moores University, Liverpool. 
 
DWP (Department for Work and Pensions ) (2008). No one written off: reforming welfare 
to reward responsibility. Public consultation. Department for Work and Pensions, London. 
Available: http://www.dwp.gov.uk/welfarereform/noonewrittenoff/ [accessed 12.08.08] 
 
Elliott, S. and Smith, C. (2008). Investigation of the first deaths in the United Kingdom 
involving the detection and quantitation of the piperazines BZP and 3-TFMPP. Journal 
Anal Toxicol 32 (2)172-7. 
 
Farrell, M. and Marsden, J. (2008). Acute risk of drug-related death among newly released 
prisoners in England and Wales. Addiction 103 (2) 251-5. 
 
Field-Smith, M. E., Butland, B. K., Ramsey, J. D. and Anderson, H. R. (2008). Trends in 
deaths associated with Volatile Substance Abuse, 1971 to 2006. Report 21. Division of 




Fischer, J. and Neale, J. (2008). Involving drug users in treatment decisions: An 
exploration of potential problems. Drugs: education, prevention and policy 15 (2) 161-175. 
Available: http://dx.doi.org/10.1080/09687630701391604 [accessed 28.05.08] 
 
Fisk, J.E., and Montgomery, C. (2008). Real world memory and executive processes in 
cannabis users and nonusers. Journal of Psychopharmacology 22 727-736. Available: 
http://jop.sagepub.com/cgi/content/abstract/22/7/727 [accessed 06.10.08] 
 
Forrester, D., Pokhrel, S., McDonald, L., Copello, A., Binne, C., Jensch, G,. Waissbein, C 
& Giannou, D (2007). Final Report on the evaluation of ‘Option 2’. Welsh Assembly 




Francis, B. and Crosland, P. (2002). The police national computer and the offenders index: 
Can they be combined for research purposes? Home Office, London. Available: 
www.homeoffice.gov.uk/rds/pdfs2/r170.pdf [accessed 07.10.08]  
 
Fraser, C., McIntyre, A. and Manby, M. (2008). Exploring the Impact of Parental 
Drug/Alcohol Problems on Children and Parents in a Midlands County in 2005/06. British 
Journal of Social Work 1 1093. 
 
Frischer, M., Heatlie, H. and Hickman, M. (2004). Estimating the prevalence of problematic 
and injecting drug use for Drug Action Team areas in England: a feasibility study using the 
Multiple Indicator Method. Home Office online report 34/04. Home Office, London. 
Available: http://www.homeoffice.gov.uk/rds/pdfs04/rdsolr3404.pdf [accessed 11.08.08] 
 
UNITED KINGDOM FOCAL POINT REPORT 2008  
  
 189
Fuller, E. (Ed.) (2008). Drug use, smoking and drinking among young people in England in 
2007. The Health and Social Care Information Centre, London. 
 
Galvani, S. and Humphreys, C. (2007). The impact of violence and abuse on engagement 
and retention rates for  women in substance use treatment. National Treatment Agency for 
Substance Misuse, London. Available: 
http://www.nta.nhs.uk/publications/documents/nta_the_impact_of_violence_and_abuse_w
omen.pdf [accessed 23.05.08] 
 
Ghodse, H., Corkery, J., Oyefeso, A. and Schifano, F. (2008). Drug-related deaths in the 
UK. Annual Report 2008. National Programme on Substance Abuse Deaths (np-SAD). 
International Centre for Drug Policy (ICDP). St. George’s, University of London.  
 
Goodwin, A. (2007). Measuring the harm from illegal drugs: the Drug Harm Index 2005. 
Home Office Online Report 22/07. Crime and Drugs Analysis and Research, Home Office, 
London. Available: http://www.homeoffice.gov.uk/rds/pdfs07/rdsolr2207.pdf [accessed 
22.11.07] 
 
Gordon L, Tinsley L, Godfrey C, Parrott S. (2006). The economic and social costs of Class 
A drug use in England and Wales, 2003/04. In Singleton, N., Murray, R. and Tinsley, L 
(eds). Measuring different aspects of problem drug use: methodological developments. 
Home Office Online Report. Home Office, London. Available: 
http://www.homeoffice.gov.uk/rds/pdfs06/rdsolr1606.pdf [accessed 30.05.08] 
 
Graham, J., Mitchell, M., Day, N. and Lewis, J. (2007). Young people's views and 
experiences of specialist substance misuse services. National Centre for Social Research. 
London. Available: 
http://www.natcen.ac.uk/natcen/pages/op_crimeandjustice.htm [accessed 10.10.08] 
 
Griffiths, C., Romeri, E., Brock, A. and Morgan, O. (2008). Geographical variations in 
deaths related to drug misuse in England and Wales, 1993-2006. Health Statistics 
Quarterly Autumn 39 14-21. Available: 
http://www.statistics.gov.uk/downloads/theme_health/HSQ39.pdf [accessed 28.06.08] 
 
GROS (General Register Office for Scotland) (2008). Drug-Related Deaths in Scotland in 
2007. General Register Office for Scotland, Edinburgh. Available: 
http://www.gro-scotland.gov.uk/files1/stats/drug-related-deaths-in-scotland-2007/drug-
related-deaths-in-scotland-2007.pdf [accessed 03.09.08] 
 
Hardwick, S. and King L. (2008). Home Office Cannabis Potency Study 2008. Scientific 
Development Branch, Home Office, London. Available: 
http://drugs.homeoffice.gov.uk/publication-search/cannabis/potency [accessed 10.08.08] 
 
HAS (Health Advisory Service) (2001).  Substance misuse and mental health co-morbidity 
(dual diagnosis). Standards for Mental Health Services, Health Advisory Service, London. 
 
Hay, G., McKeganey, N. and Hutchinson, S. (2001). Estimating the national and local 
prevalence of problem drug misuse in Scotland. Centre for Drug Misuse, University of 
Glasgow. Available: www.drugmisuse.isdscotland.org/publications/local/Prevalence.pdf 
[accessed 11.08.08] 
 
UNITED KINGDOM FOCAL POINT REPORT 2008  
  
 190
Hay, G., Gannon, M., McKeganey, N., Hutchinson, S. and Goldberg, D. (2004). Estimating 
the national and local prevalence of problem drug misuse in Scotland. Centre for Drug 
Misuse Research, University of Glasgow and Scottish Centre for Infection and 




Hay, G., Gannon, G. MacDougall, J., Millar, T., Eastwood, C. and McKeganey, N. (2006a). 
Local and national estimates of the prevalence of opiate use and/or crack cocaine cocaine 
use (2004/05) in Singleton, N., Murray, R. and Tinsley L. Measuring different aspects of 
problem drug use: methodological developments. Home Office Online Report 16/06. 
Home Office, London. Available: 
http://www.homeoffice.gov.uk/rds/pdfs06/rdsolr1606.pdf [accessed 11.08.08] 
 
Hay, G., Higgins. K., Gannon, M. and Carroll, C. (2006b). Estimating the Prevalence of 
Problem Opiate and problem Cocaine Use in Northern Ireland. Drug and Alcohol 
Information and Research Unit, Department of Health, Social Services and Public Safety 
Northern Ireland, Belfast. Available: http://www.dhsspsni.gov.uk/opiate_cocaine.pdf  
[accessed 17.10.07] 
 
Hay. G., Gannon, M., MacDougall, J., Millar, T., Eastwood, C. and McKeganey, N. (2007). 
National and regional estimates of the prevalence of opiate use and/or crack cocaine use 
2005/06: a summary of key findings. Home Office Online Report 21/07. Home Office. 
London. Available:  
http://www.homeoffice.gov.uk/rds/pdfs07/rdsolr2107.pdf [accessed 22.11.07] 
 
Hay, G. and Bauld, L. (2008). Population estimates of problematic drug users in England 
who access DWP benefits: A feasibility study. Working Paper No. 46. Department for 




Healthcare Commission and NTA (National Treatment Agency for Substance Misuse) 






Healthcare Commission and NTA (National Treatment Agency for Substance Misuse) 
(2008a). Service review. Assessment framework for substance misuse services 2007/8. 
Theme A – Diversity. Theme B – Tier 4 services. National Treatment Agency for 
Substance Misuse. Available: 
http://www.nta.nhs.uk/areas/standards_and_inspections/2007-
08_review/docs/assessment_framework_0708_diversity_tier4.pdf   [accessed 28.05.08] 
 
Healthcare Commission and NTA (National Treatment Agency for Substance 
Misuse) (2008b). Improving services for substance misuse. Commissioning drug treatment 






UNITED KINGDOM FOCAL POINT REPORT 2008  
  
 191
Health Protection Agency (HPA) (2007). Hepatitis C in England, the Health Protection 
Agency Annual Report 2007. Health Protection Agency, London. 
Available: http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1204100441645  
[accessed 07.10.08]  
 
Health Protection Scotland (HPS) (2007). Scotland’s Action Plan for Hepatitis C Phase 1 
September 2006 – August 2008: First Year Progress Report. Health Protection Scotland, 
Glasgow. Available: http://www.hepcscotland.co.uk/pdfs/scot-act-plan-hepc-p1-sep-2006-
aug2008.pdf [accessed 13.05.08] 
 
Hickman, M., Vickerman, p., Macleod, J., Kirkbride, J. and Jones, P.B. (2007). Cannabis 
and schizophrenia: Model projections of the impact of the rise in cannabis use on historical 
and future trends in schizophrenia in England and Wales. Addiction 102 597-606. 
 
Hickman, M., Lingford-Hughes, A., Bailey, C., Macleod, J., Nutt, D. and Henderson, G. 
(2008a). Does alcohol increase the risk of overdose death: the need for a translational 
approach. Addiction 103 (7) 1060-2. 
 
Hickman, M., McDonald, T., Judd, A., Nichols, T., Hope, V., Skidmore, S. and Parry, J.V. 
(2008b). Increasing the uptake of hepatitis C virus testing among injecting drug users in 
specialist drug treatment and prison settings by using dried blood spots for diagnostic 
testing: a cluster randomized controlled trial. Journal of Viral Hepatitis 15 250–254 
 
HM (Her Majesty’s) Government (2007). National Community Safety Plan. Home Office, 
London. Available: 
http://www.crimereduction.homeoffice.gov.uk/activecommunities/activecommunities088.pd
f [accessed 08.10.08] 
 
HM (Her Majesty’s) Government (2008a). Drugs: protecting families and communities. The 
2008 drug strategy. Home Office, London. Available: 
http://drugs.homeoffice.gov.uk/publication-search/drug-strategy/drug-strategy-2008 
 [accessed 07.10.08] 
 
HM (Her Majesty’s) Government (2008b). Drugs: protecting families and communities. 
Action Plan 2008–2011. Home Office, London. Available: 
http://drugs.homeoffice.gov.uk/publication-search/drug-strategy/drug-action-plan-2008-
2011?view=Binary [accessed 14.03.08] 
 
HM (Her Majesty’s) Prison Service, Department of Health and Welsh Assembly 
Government (2007). Disinfectant Tablets. Offender Health Newsletter. Issue 28. Her 
Majesty’s Prison Service, London. Available: 
http://www.phrn.nhs.uk/Policy/OffHealth28.pdf [accessed 17.04.08] 
 
HM (Her Majesty’s) Treasury (2007a). 2007 Pre-Budget Report and Comprehensive 
Spending Review. Her Majesty’s Treasury, London. Available: http://www.hm-
treasury.gov.uk/pre_budget_report_2007.htm [accessed 08.10.08]  
 
HM (Her Majesty’s) Treasury (2007b). Aiming High for Young People: A Ten Year Strategy 
for Positive Activities concludes the Government’s Policy Review undertaken to inform the 
2007 Comprehensive Spending Review (CSR). Her Majesty’s Treasury, London.  
Available: http://62.164.176.164/d/cyp_tenyearstrategy_260707.pdf  [accessed 07.10.08] 
 
UNITED KINGDOM FOCAL POINT REPORT 2008  
  
 192
Hoare, J. and Flatley, J. Drug Misuse Declared: Findings from the 2007/08 British Crime 




Home Office (2001). Statistics of road traffic offences: A review of coverage, collection and 
publication.  Home Office, London. Available: 
http://www.statistics.gov.uk/about/data/methodology/quality/reviews/downloads/motoring.p
df [accessed 07.10.08]  
 
Home Office (2004). Review of drug seizure and offender statistics. National Statistics. 
Home Office, London. 
Available:http://www.statistics.gov.uk/methods_quality/quality_review/downloads/Final_Re
port.doc [accessed 08.10.08] 
 
Home Office (2007a). Cutting Crime: A New Partnership 2008-11. Home Office, London. 
Available: http://www.homeoffice.gov.uk/documents/crime-strategy-07/crime-strategy-
07?view=Binary [accessed 30.09.08] 
 
Home Office (2007b). FRANK – Advertising Tracker Wave 6, Findings on the ‘Brain 





Home Office (2007c). Around arrest, beyond release: The experiences and needs of 
families in relation to the arrest and release of drug using offenders.  Home Office, 
London. Available: http://drugs.homeoffice.gov.uk/publication-
search/dip/AC_DIP_FAMILIES_around_arrest [accessed 27.10.08] 
 
Home Office (2007d). Managing Drug Misusers Under Probation Supervision: Guidance 
for Probation, Criminal Justice Integrated Teams (CJITS) and Counselling Assessment 





Home Office (2007e). Good Practice Guidance to Increasing the Engagement of Adults 
Involved in Prostitution within the Drug Interventions Programme. Drug Interventions 




Home Office (2008a). Home Secretary: Cannabis should be reclassified. News 7 May 
2008. Home Office, London. Available: http://www.homeoffice.gov.uk/about-
us/news/cannabis-reclassified [accessed 09.05.08] 
 
Home Office (2008b). Conditional cautioning and the DIP condition. Operational 
Guidelines for Criminal Justice Intervention Teams and Partners. Drug Interventions 




UNITED KINGDOM FOCAL POINT REPORT 2008  
  
 193
Home Office and Communities and Local Government (2006).The Respect Standard for 
Housing Management.  Home Office and Communities and Local Government, London.  
 
Homeless Link (2007). Clean Break – Development of Integrated housing and care 
pathways for drug users. Research Report. Homeless Link. 
 
Hope, V., Kimber, J., Vickerman, P., Hickman, M. and Ncube, F. (2008). Frequency, 
factors and costs associated with injection site infections: findings from a national multi-
site survey of injecting drug users in England. Infectious Diseases 8 120. Available: 
http://www.biomedcentral.com/1471-2334/8/120/abstract [accessed 19.09.08]  
 
HPA (Health Protection Agency), Department of Health, Social Services and Public Safety 
Northern Ireland, National Public Health Services for Wales and Health Protection 
Scotland (2008). Shooting Up. Infections among injecting drug users in the United 
Kingdom 2007. An update: 2008. Health Protection Agency, London.  
 
Hurst, A., Beynon, C., Hughes, S., Marr, A. and McVeigh, J. (2007). NDTMS themed 
report: Patterns of mortality amongst injecting and non-injecting drug users in contact with 
treatment services in the North West of England, 2003/04 – 2005/06. Liverpool John 
Moores University, Liverpool. 
 





ISD (Information Services Division) (2007). Drug misuse statistics Scotland 2007. 




Jones, A., Weston, S., Moody, A., Millar, T., Dollin, L., Anderson, T. and Donmall. M. 
(2007). The drug treatment outcomes research study (DTORS): baseline report. Research 
Report 3. Home Office, London. Available: 
http://www.homeoffice.gov.uk/rds/pdfs07/horr03c.pdf [accessed 01.12.07] 
 
Joseph Rowntree Foundation (2008). What are today’s social evils? Joseph Rowntree 
Foundation, York. Available: http://www.socialevils.org.uk/ [accessed 28.04.08] 
 
Kapadia, N., Fox, D., Rowlands, G. and Ashworth, M. (2007). Developing primary care 
services for high-dose benzodiazepine-dependent patients: A consultation survey. Drugs: 
education, prevention and policy 14 (5) 429-442. 
 
Keene, J., Stenner, K., Connor, M. and Fenley, S. (2007). A case-study of substitute 
opiate prescribing for drug-using offenders. Drugs: education, prevention and policy 14 (5) 
443-456. 
Available: http://dx.doi.org/10.1080/09687630601138675 [accessed 11.03.08] 
 
Kershaw, C., Nicholas, S. and Walker, A. (2008). Crime in England and Wales 2007/08. 
Findings from the British Crime Survey and police recorded crime. Statistical Bulletin 
07/08. Home Office, London. Available: 
http://www.homeoffice.gov.uk/rds/pdfs08/hosb0708.pdf [accessed 15.07.08] 
 
UNITED KINGDOM FOCAL POINT REPORT 2008  
  
 194
Kirkbride, J., Croudace, T., Brewin, J., Donoghue, K., Mason, P. et al. (2008). Is the 
incidence of psychotic disorder in decline? Epidemiological evidence from two decades of 
research. International Journal of Epidemiology. Online early access. 
 
Ley, A., Jeffrey, D., Shaw, S. & Weaver, T. (2007). A brief screening instrument to detect 
the possibility of substance misuse problems in community patients with severe mental 
illness. Journal of Mental Health 16 (5) 679-690 
 
Life Education Centres (2008). Life Education National Children’s Survey: Report of initial 
findings. Life Education Centres: London. 
 
Lister, S., Wincup, E., Seddon, T., Barrett, S. and Traynor, P. (2008). Street policing of 
problem drug users.7 Joseph Rowntree Foundation, York. Available: 
http://www.jrf.org.uk/bookshop/eBooks/2170-policing-drugs-crime.pdf [accessed 30.10.08] 
 
London Drug Policy Forum and Home Office (2008) Safer Nightlife. Home Office, London. 
Available: 
http://www.cityoflondon.gov.uk/Corporation/LGNL_Services/Community_and_living/Comm
unity_advice/London_Drug_Policy_Forum/ldpf_resources.htm [accessed 27.08.08] 
 
Lord Carter (2007). Securing the future. Proposals for the efficient and sustainable use of 
custody in England and Wales. Lord Carter’s Review of Prisons. Ministry of Justice, 
London. Available: http://www.justice.gov.uk/publications/securing-the-future.htm 
[accessed 18.03.08] 
 
Macdivitt, K. (2008). An Evaluation of the Structured Deferred Sentence Pilots. Justice 
Analytical Services. Scottish Government, Edinburgh. Available: 
http://www.scotland.gov.uk/Publications/2008/04/09134401/0 [accessed 07.05.08] 
 
McElrath, K. (2002). Prevalence of problem opiate use in Northern Ireland. Department of 
Health, Social Services and Public Safety Northern Ireland, Belfast. Available: 
http://www.dhsspsni.gov.uk/heroin_use_ni.pdf [accessed 08.08.08] 
 
McKenna, A. (2007). Qualitative evaluation of the key components of the Community 
Justice Centre, North Liverpool. Ministry of Justice Research Series No.12/07. Ministry of 
Justice, London. Available: 
http://www.communityjustice.gov.uk/docs/Liverpool_Ecotech_NL_evaluation_report_FINA
L_publication.pdf [accessed 23.03.08] 
 
McIntosh, J., Bloor, M. and Robertson, M. (2008). Drug treatment and the achievement of 
paid employment. Addiction Research and Theory 16 (1) 37-45. Available: 
http://dx.doi.org/10.1080/16066350701699197 [accessed 27.04.08] 
 
McKeown, S. (2006). Safe as Houses: An Inclusive Approach for Housing Drug Users. 
Shelter, London.  
 
McNaughton, C.C. (2008).Transitions through homelessness, substance use, and the 
effect of material marginalization and psychological trauma. Drugs: education, prevention 
and policy 15 (2) 177-188. Available: 
http://dx.doi.org/10.1080/09687630701377587  [accessed 29.05.08] 
 
UNITED KINGDOM FOCAL POINT REPORT 2008  
  
 195
McSweeney, T., Turnbull, P.J. and Hough, M. (2008a). The treatment and supervision of 
drug-dependent offenders.  A review of the literature prepared for the UK Drug Policy 
Commission. United Kingdom Drug Policy Commission, London. Available: 
http://www.ukdpc.org.uk/reports.shtml [accessed 17.03.08] 
 
McSweeney, T., Turnbull, P. and Hough, M. (2008b). Tackling drug markets and 
distribution networks in the UK: A review of the recent literature. Available: 
www.ukdpc.org.uk/resources/Drug_Markets_Full_Report.pdf [accessed 01.09.08] 
 
McWhirter, J. (2008). Grandparents Project - ‘Mind the Gap’ Impact evaluation report. The 
Mentor Foundation, London. Available: 
http://www.mentorfoundation.org/uploads/UK_Mind_the_Gap_Impact_Evaluation_Report.
pdf [accessed 02.06.08] 
 
Manning, V., Strathdee, G., Best, D., Keaney, F., Bhui, K. and Gossop, M. (2008). 
Differences in mental health, substance use and other problems among dual diagnosis 
patients attending psychiatric or substance misuse treatment services. Mental Health and 
Substance Use: Dual diagnosis. Online early access. 
 
Markit Training and Consultancy Ltd. (2007). The National Evaluation of the All Wales 
School Liaison Core Programme: The Impact of the All Wales School Liaison Core 
Programme on Children and Young People. Final Report. Welsh Assembly Government, 
Cardiff. 
 
Marsden, J., Farrell, M., Bradbury, C., Dale-Perera, A., Eastwood, B., Roxburgh, M. and 
Taylor, s. (2008). Development of the treatment outcomes profile. Addiction  
103 (9) 1450–1460. 
 
Matrix Knowledge Group (2007). The illicit drug trade in the United Kingdom. London: 
Home Office. Available: www.homeoffice.gov.uk/rds/pdfs07/rdsolr2007.pdf [accessed 
01.09.08] 
 
Matrix Knowledge Group (2008). Dedicated Drug Court Pilots A Process Report. Ministry 
of Justice Research Series 7/08. Ministry of Justice, London. Available: 
http://www.justice.gov.uk/publications/research010408.htm [accessed 02.04.08] 
 
Meier, P., Best, D. and Day, E. (2007). Detoxification in Rehabilitation in England: 
Effective continuity of care or unhappy bedfellows? Journal of Substance Use 12 (4), 293-
300. Available: http://dx.doi.org/10.1080/14659890701269473 [accessed 21.11.07] 
 
Ministry of Justice (2007a). A Survey of Buprenorphine Misuse in Prisons. Prisons Drug 
Strategy Team Interventions and Substance Abuse Unit. Ministry of Justice, London. 
Available: http://www.justice.gov.uk/docs/survey-buprenorphine.pdf [accessed 02.04.08] 
 
Ministry of Justice (2007b). Criminal Statistics 2006. Ministry of Justice, London. Available: 
http://www.justice.gov.uk/publications/criminalannual.htm [accessed 27.10.08] 
 
Ministry of Justice (MOJ) (2008a). Arrests for recorded crime (notifiable offences) and the 
operation of certain police powers under PACE, England and Wales, 2006/07. 
quality review series. Report No.29. Ministry of Justice, London. Available: 
http://www.justice.gov.uk/publications/arrestsfornotibleoffences.htm [accessed 08.10.08] 
 
UNITED KINGDOM FOCAL POINT REPORT 2008  
  
 196
Ministry of Justice (2008b). Prison policy update briefing paper. Ministry of Justice, 
London. Available: http://www.justice.gov.uk/publications/prison-policy-update.htm 
[accessed 04.03.08] 
 
Ministry of Justice. (2008c). Motoring offences and breath test statistics: England and 




Ministry of Justice. (2008d). Offences relating to motor vehicles England and Wales 2006: 










Mitcheson, L., McCambridge, J., Byrne, A., Hunt, N. and Winstock, A. (2008). Sexual 
health risk among dance drug users: Cross-sectional comparisons with nationally 
representative data. International Journal of Drug Policy. Online early access. 
 
Morgan, C. J. A. and Curran, H. V. (2008). Effects of cannabidiol on schizophrenia-like 
symptoms in people who use cannabis. British Journal of Psychiatry 192 (4) 306-07. 
 
Murphy, R. and Roe, S. (2007). Drug Misuse Declared: Findings from the 2006/07 British 




8&ie=UTF-8&proxystylesheet=rds&site=RDS [accessed 30.10.08] 
 
NACD (National Advisory Committee on Drugs) and PHIRB (Public Health Information and 
Research Branch) (2008a). Drug use in Ireland and Northern Ireland: First results from the 
2006/07 Drug Prevalence Survey. Department of Health, Social Services and Public 
Safety Northern Ireland, Belfast. Available: http://www.dhsspsni.gov.uk/first-results-
200607-drug-prevalence-survey.pdf [accessed 08.10.08] 
 
NACD (National Advisory Committee on Drugs) and PHIRB (Public Health Information and 
Research Branch) (2008b). Drug use in Ireland and Northern Ireland. 2006/07 Drug 
Prevalence Survey: Cocaine results. Department of Health, Social Services and Public 
Safety Northern Ireland, Belfast. Available: 
http://www.dhsspsni.gov.uk/index/stats_research/public_health/statistics_and_research-
drugs_alcohol-2.htm [accessed 21.10.08] 
 
National Assembly for Wales (2000). Tackling substance misuse in Wales: a partnership 
approach. National Assembly for Wales. Cardiff. Available: 
http://wales.gov.uk/topics/housingandcommunity/safety/publications/substancemisusestrat
egy?lang=en [accessed 08.10.08] 
 
UNITED KINGDOM FOCAL POINT REPORT 2008  
  
 197
Neale, J. (2007). Homelessness, drug use and Hepatitis C: A complex problem explored 
within the context of social exclusion. International Journal of Drug Policy. Online early 
access. 
 
Neale, J., Sheard, L., Tompkins, C. (2007). Factors that help injecting drug users to 
access and benefit from services: a qualitative study. Substance Abuse Treatment, 
Prevention and Policy 2 31. 
 
NICE (National Institute for Health and Clinical Excellence) (2007a). Community-based 
interventions to reduce substance misuse among vulnerable and disadvantaged children 
and young people. National Institute for Health and Clinical Excellence, London.  
 
NICE (National Institute for Health and Clinical Excellence) (2007b). Methadone and 
Buprenorphine for the Management of Opioid Dependence. NICE technology appraisal 
114. National Institute for Health and Clinical Excellence. London. Available: 
http://www.nice.org.uk/Guidance/TA114/NiceGuidance/pdf/English [accessed 01.10.08] 
 
NICE (National Institute for Health and Clinical Excellence) (2007c). Drug misuse. 
psychosocial interventions. NICE clinical guideline 51. National Institute for Health and 
Clinical Excellence, London. Available: 
http://www.nice.org.uk/nicemedia/pdf/CG051NICEguideline2.pdf [accessed 13.05.08] 
 
NIO (Northern Ireland Office) (1999). Drug strategy for Northern Ireland. Northern Ireland 




NIPS (Northern Ireland Prison Service) (2008). Report in Minimising the Supply of Drugs 
in Northern Ireland Prisons. Northern Ireland Prison Service, Belfast. 
Available: 
http://www.niprisonservice.gov.uk/module.cfm/opt/1/area/News/page/news/caid/5/marea/H
eadquarters/nid/483 [accessed 13.08.08] 
 
NISRA (Northern Ireland Statistics and Research Agency). (2008a) Young Person’s 





NISRA (Northern Ireland Statistics and Research Agency). (2008b). Young Person’s 




Northern Ireland Executive (2007). Northern Ireland Executive Programme for 
Government 2008-2011. Annex One. PSA Framework. Northern Ireland Executive, 
Belfast. Available: www.pfgbudgetni.gov.uk/psaframework241007.pdf [accessed 11.08.08] 
 
Northern Ireland Prison Service (2008). Report in Minimising the Supply of Drugs in 
Northern Ireland Prisons. Northern Ireland Prison Service, Belfast. 
Available: 
http://www.niprisonservice.gov.uk/module.cfm/opt/1/area/News/page/news/caid/5/marea/H
eadquarters/nid/483 [accessed 13.08.08] 
 
UNITED KINGDOM FOCAL POINT REPORT 2008  
  
 198
NTA (National Treatment Agency for Substance Misuse) (2006). Models of residential 
rehabilitation for drug and alcohol misusers National Treatment Agency for Substance 
Misuse, London. Available: 
http://www.nta.nhs.uk/publications/documents/nta_models_of_residential_rehab_drg_and
_alc.pdf [accessed 08.08.08] 
 
NTA (National Treatment Agency for Substance Misuse) (2007a). Harm reduction findings 
from the NTA’s 2006 survey of user satisfaction in England. National Treatment Agency 




NTA (National Treatment Agency for Substance Misuse) (2007b). Statement on 
medication choice and dosing in drug misuse treatment. National Treatment Agency for 





NTA (National Treatment Agency for Substance Misuse) (2007c). NTA Briefing on 
Naltrexone implants. National Treatment Agency for Substance Misuse, London.  
 
NTA (National Treatment Agency for Substance Misuse) (2007d). “Nothing about us, 
without us”: The English user representatives’ report from the 2007 
International Harm Reduction Association Conference. National Treatment Agency for 
Substance Misuse, London. Available: 
http://www.nta.nhs.uk/publications/documents/nta_nothing_about_us_without_us_irha200
7.pdf [accessed 01.10.08] 
 
NTA (National Treatment Agency for Substance Misuse) (2008a). Release of statistics and 
analysis of drug activity in England 2007/08. National Treatment Agency for Substance 
Misuse, London. (online) Available: 
http://www.nta.nhs.uk/news_events/newsarticle.aspx?NewsarticleID=101 
 
NTA (National Treatment Agency for Substance Misuse) (2008b). Improving the Value of 
Drug Treatment Systems: Draft assumptions. National Treatment Agency for Substance 
Misuse, London. Available: 
http://www.nta.nhs.uk/areas/value_improvement/docs/improving_value_drug_treatment_s
ystems_consultation_document_final.pdf [accessed 14.10.08] 
 
NTA (National Treatment Agency for Substance Misuse) (2008c). Young people’s 
specialist substance misuse treatment. Needs assessment good practice guidance. 




NTA (National Treatment Agency for Substance Misuse) (2008d). Improving the quality 
and provision of Tier 4 interventions as part of client treatment journeys. A best practice 
guide. National Treatment Agency for Substance Misuse, London. Available: 
http://www.nta.nhs.uk/areas/tier_4/default.aspx [accessed 14.10.08] 
 
NTA (National Treatment Agency for Substance Misuse) (2008e). Supporting and 
involving carers. A guide for commissioners and providers. National Treatment Agency for 
Substance Misuse, London. Available: http://www.nta.nhs.uk/ [accessed 14.10.08] 
 
UNITED KINGDOM FOCAL POINT REPORT 2008  
  
 199
NTA (National Treatment Agency for Substance Misuse) (2008f). Clinical governance in 
drug treatment: A draft good practice guide for providers and commissioners. National 




NTA (National Treatment Agency for Substance Misuse) (2008g). Needle exchange 
monitoring system Guidance notes for implementation version 1.1. National Treatment 
Agency for Substance Misuse, London. Available: 
http://www.nta.nhs.uk/areas/drug_related_deaths/docs/nexm_guidance.pdf  [accessed 
13.05.08] 
 
Office for Criminal Justice Reform (2007). Out-of-court disposals for adults. Home Office, 
London. Available: http://police.homeoffice.gov.uk/publications/operational-
policing/Out_Of_Court_Disposals.pdf [accessed 08.10.08] 
 
OFMDFMNI (Office of the First Minister and Deputy First Minister for Northern Ireland) 
(2006). Our Children and Young People – Our Pledge: A 10 year strategy for children and 
young people in Northern Ireland, 2006-2016. Office of the First Minister and Deputy First 
Minister for Northern Ireland, Belfast. Available: http://www.allchildrenni.gov.uk/ten-year-
strategy.pdf [accessed 02.06.08] 
 
Ofsted (Office for Standards in Education) (2007). TellUs2 Questionnaire summary sheet. 
Ofsted, London. 
 
ONS (Office for National Statistics) (2008). Deaths related to drug poisoning in England 





Palmateer, N., Hutchinson, S., Taylor, A., Allen, E., Cameron, S. and Goldberg, D. (2008). 
The Needle Exchange Surveillance Initiative (NESI): Prevalence of HCV, HIV and injecting 
risk behaviours among injecting drug users attending needle exchanges in Scotland, 2007. 
Health Protection Scotland, Glasgow. Available: 
http://www.documents.hps.scot.nhs.uk/bbvsti/idu/needle-exchange-surveillance-initiative-
2007-2008-05.pdf [accessed 17.09.08] 
 
Patterson, S., Crawford, M., Weaver, T., Rutter, D., Agath, K. et al. (2007). User 
involvement in efforts to improve the quality of drug misuse services: factors that promote 
and hinder successful working. Online. Available: 
http://www.lshtm.ac.uk/research/dmri/exec_summs.htm 
 
Pizzey, R., Hunt, N. (2008). Distributing foil from needle and syringe programmes (NSPs) 
to promote transitions from heroin injecting to chasing: an evaluation. Harm Reduction 
Journal 5 24. Available: http://www.harmreductionjournal.com/content/5/1/24 [accessed 
13.05.08] 
 
Pleace, N. (2008). Effective Services for Substance Misuse and Homelessness in 
Scotland: Evidence from an International Review. Scottish Government Social Research. 
Scottish Government, Edinburgh. Available: 
http://www.scotland.gov.uk/Publications/2008/07/24143449/13 [accessed 18.08.08] 
 
UNITED KINGDOM FOCAL POINT REPORT 2008  
  
 200
The Police and Criminal Evidence Act 1984. The Stationery Office London. Available: 
http://www.opsi.gov.uk/si/si1988/Uksi_19881200_en_1.htm [accessed 08.10.08] 
 
Potter, D., Clark, P. and Brown, M. B. (2008). Potency of Delta 9 THC and other 
cannabinoids in cannabis in England: Implications for psychoactivity and pharmacology. 
Journal of Forensic Science 53(1) 90-94. 
 
PricewaterhouseCoopers (2007). Report to the Department of Health and Ministry of 
Justice. Executive Summary: Review of Prison-Based Drug Treatment Funding. Final 
Report. PricewaterhouseCoopers LLP. Available: 
http://www.justice.gov.uk/news/announcement170308a.htm [accessed 04.04.08] 
 
PHIRB (Public Health Information and Research Branch) / DHSSPSNI (Department of 
Health, Social Services and Public Safety) (2008). Statistics from the Northern Ireland 
drug addicts index 2007. Department of Health, Social Services and Public Safety, Belfast. 
Available: 
http://www.dhsspsni.gov.uk/index/stats_research/public_health/statistics_and_research-
drugs_alcohol-2.htm [accessed 28.03.08]  
 
PSNI (Police Service Northern Ireland) (2004). Drug Seizures and Arrests 2002/03. Police 
Service Northern Ireland, Belfast. Available: 
http://www.psni.police.uk/index/statistics_branch/pg_drugs_stats/drug_statistics_-
_archive_.htm [accessed 07.08.08] 
 
PSNI (Police Service Northern Ireland) (2006a). Drug Seizures and Arrests 2004/05. 
Police Service Northern Ireland, Belfast. Available: 
http://www.psni.police.uk/index/statistics_branch/pg_drugs_stats/drug_statistics_-
_archive_.htm [accessed 07.08.08] 
 
PSNI (Police Service Northern Ireland) (2006b). Recorded Crimes and Clearances. 1st 
April 2005 – 31st March 2006. Statistical Report No. 1. Police Service Northern Ireland, 
Belfast. Available: http://www.psni.police.uk/index/statistics_branch/crime_statistics_-
_archive_.htm [accessed 07.08.08] 
 
PSNI (Police Service Northern Ireland) (2008a). Recorded Crimes and Clearances. 1st 
April 2007 – 31st March 2008. PSNI Statistics: Annual Statistical Report. Statistical Report 
No. 1Police Service Northern Ireland, Belfast. Available: 
http://www.psni.police.uk/1._recorded_crime-2.pdf [accessed 07.08.08] 
 
PSNI (Police Service Northern Ireland) (2008b). Drug Seizures and Arrests. 1st April 2007 
– 31st March 2008. PSNI Statistics: Annual Statistical Report.  Statistical Report No. 4. 
Police Service Northern Ireland, Belfast. Available: 
http://www.psni.police.uk/index/statistics_branch/pg_drugs_stats.htm [accessed 07.08.08] 
 
Raistrick, D., Russell, D., Tober, G. and Tindale, A. (2007). A survey of substance use by 
health care professionals and their attitudes to substance misuse patients. Journal of 
Substance Use 13 (1) 57-69. 
 
Raistrick, D., Tober, G., Godfrey, C., Parrott, S., Lui, S. et al. (2008). Cost and Cost 
Effectiveness of Treatment as Usual in Drug Misuse Services. Online . Available: 
http://www.lshtm.ac.uk/research/dmri/exec_summs.htm [accessed 24.10.08] 
 
Rethink (2008). Educating reefer: Effective health education and warnings on cannabis. 
Rethink. Available: http://www.rethink.org/document.rm?id=5839 [accessed 01.09.08] 
 
UNITED KINGDOM FOCAL POINT REPORT 2008  
  
 201
Rhodes, T., Briggs, D., Kimber, J., Jones, S. and Holloway, G. (2007). Crack–heroin 
speedball injection and its implications for vein care: qualitative study. Addiction 102 
1782–1790. 
 
Roberts, A.J., Hayes, A.J., Carlisle, J. and Shaw, J. (2007). Review of Drug and Alcohol 
Treatments in Prison and Community Settings. A Systematic Review. University of 
Manchester, Manchester. Available: 
http://www.phrn.nhs.uk/prison/SMreview.pdf [accessed 26.04.08] 
 
Ruddy, D. and Brown, A. (2008). Experience of drug misuse: Findings from the 2006/07 
Northern Ireland Crime Survey. Northern Ireland Office, Belfast. 
 
Sandilands, E.A. and Bateman, D.N. (2008). Co-proxamol withdrawal has reduced suicide 
from drugs in Scotland. British Journal Clinical Pharmacolology 66 (2) 290-3. 
 
SACDM (Scottish Advisory Committee on Drug Misuse) (2005). Scottish Advisory 
Committee on Drugs Misuse (SACDM) Working Group on Drug Related Deaths: Report 
and Recommendations. Scottish Government, Edinburgh. Available: 
http://www.scotland.gov.uk/Publications/2005/08/04154654/46563 [accessed 13.05.08] 
 
SACDM (Scottish Advisory Committee on Drug Misuse) (2008). Essential Care: a report 
on the approach required to maximise opportunity for recovery from problem substance 
use in Scotland. Scottish Government, Edinburgh. Available: 
http://www.scotland.gov.uk/Publications/2008/03/20144059/0 [accessed 18.04.08] 
 
Scotland’s Futures Forum (2008a). Approaches to Alcohol and Drugs in Scotland. A 
Question of Architecture. Scotland’s Futures Forum. The Scottish Parliament, Edinburgh. 
Available:  http://www.scotlandfutureforum.org/assets/files/report.pdf [accessed 11.07.08] 
 
Scotland’s Futures Forum (2008b). 12 Dimensions of a manageable problem: A collection 
of views. Scotland’s Futures Forum. The Scottish Parliament, Edinburgh. Available: 
http://www.scotlandfutureforum.org/assets/files/12_Dimensions.pdf  [accessed 09.10.08] 
 
Scott, J., Davy, C., Dodridge, E., Khan, K. and Milligan, Z. (2007). South West England 
needle exchange pharmacist's knowledge of the updated UK 'paraphernalia laws'. Journal 
of Substance Use 12 (5) 359 – 364. Available: 
http://dx.doi.org/10.1080/14659890701406893 [accessed 04.09.08] 
 
Scottish Executive (2006a). Getting it Right for Every Child: Implementation Plan, Scottish 
Executive, Edinburgh. Available: 
http://www.scotland.gov.uk/Publications/2006/06/22092413/2 [accessed 02.06.08] 
 
Scottish Executive (2006b). Hepatitis C Action Plan for Scotland Phase I: September 2006 
– August 2008. Scottish Executive, Edinburgh. Available: 
http://www.scotland.gov.uk/Publications/2006/09/15093626/0 [accessed 30.08.08] 
 
Scottish Executive (2007a). Delivering a Healthy Future An Action Framework for Children 
and Young People’s Health in Scotland. Scottish Executive, Edinburgh. Available: 
http://www.scotland.gov.uk/Publications/2007/02/14154246/0 [accessed 02.06.08] 
 
Scottish Government (2007a). Scottish Budget Spending Review 2007. Scottish 
Government, Edinburgh. Available: 
http://www.scotland.gov.uk/Publications/2007/11/13092240/0 [accessed 30.05.08] 
 
UNITED KINGDOM FOCAL POINT REPORT 2008  
  
 202
Scottish Government (2007b). National Quality Standards for Substance Misuse Services. 
Good Practice Guide to Service User Involvement. Web Only Publication. Available:  
http://www.scotland.gov.uk/Publications/2007/11/08092322/0 [accessed 01.02.08] 
 
Scottish Government (2007c). National Forum on Drug-related Deaths in Scotland Annual 
Report  2007. Scottish Government, Edinburgh. Available: 
 http://www.scotland.gov.uk/Publications/2007/12/17095935/14  [accessed 26.03.08] 
 
Scottish Government (2007d). Mental Health in Scotland Closing the Gaps – Making a 
Difference. Scottish Government, Edinburgh. Available: 
http://www.scotland.gov.uk/Publications/2007/12/10141643/0 [accessed 26.08.08] 
 
Scottish Government (2007e). Criminal Justice Social Work Statistics, 2006-07. Statistical 
Bulletin. Criminal Justice Series. CrJ/2007/12. Scottish Government. Available: 
http://www.scotland.gov.uk/Resource/Doc/209079/0055387.pdf [accessed 23.04.08] 
 
Scottish Government (2008a). The Road to Recovery. A New Approach to Tackling 
Scotland’s Drug Problem. Scottish Government, Edinburgh. Available: 
http://www.scotland.gov.uk/Publications/2008/05/22161610/0 [accessed 20.05.08] 
 
Scottish Government (2008b). The Government Economic Strategy. Scottish Government, 
Edinburgh. Available: http://www.scotland.gov.uk/Publications/2007/11/12115041/0 
[accessed 09.10.08] 
 
Scottish Government (2008c). Drug Death Matters, Issue 5, July 2008, Scottish 
Government, Edinburgh. Available: 
http://www.drugmisuse.isdscotland.org/publications/local/drugs_deaths_newsletter_ed5.pd
f [accessed 09.10.08] 
 
Scottish Government (2008d). The National Forum on Drug-related Deaths Annual report 
2007. The Scottish Government’s Response. Scottish Government, Edinburgh. Available: 
http://www.scotland.gov.uk/Publications/2008/05/27154627/0 [accessed 09.10.08]  
 
Scottish Government (2008e). Hepatitis C Action Plan for Scotland Phase II: May 2008 - 
March 2011. Scottish Government, Edinburgh. Available: 
http://www.scotland.gov.uk/Publications/2008/05/13103055/17 [accessed 13.05.08] 
 
Scottish Government (2008f). Safety, Risks and Outcomes from the Use of Injecting 
Paraphernalia. Scottish Government, Edinburgh. Available: 
http://www.scotland.gov.uk/Resource/Doc/127313/0057758.pdf [accessed 13.05.08] 
 
Scottish Government (2008g). Recorded Crime in Scotland, 2007/08. Statistical Bulletin, 
Crime and Justice Series, Scottish Government. Available:  
http://www.scotland.gov.uk/Publications/2008/09/29155946/27 [accessed 02.10.08] 
 
Scottish Government (2008h). Drug treatment pilot announced. News Release 
03/01/2008. The Scottish Government, Edinburgh. Available: 
http://www.scotland.gov.uk/News/Releases/2007/12/31112929 [accessed 05.01.08] 
 
Scottish Government (2008i). Criminal proceedings in Scottish Courts, 2006/07. Statistical 
Bulletin, Crime and Justice Series, Scottish Government.  Available: 
http://www.scotland.gov.uk/Publications/2008/06/02124526/0 [accessed 27.10.08] 
 
UNITED KINGDOM FOCAL POINT REPORT 2008  
  
 203
Scottish Government and COSLA (Convention of Scottish Local Authorities) (2008). Early 
Years and Early Intervention: A Joint Scottish Government and COSLA Policy Statement. 
Scottish Government, Edinburgh. Available: 
http://www.scotland.gov.uk/Publications/2008/03/14121428/0 [accessed 09.10.08] 
 
Scottish Office (1999). Tackling drugs in Scotland: Action in partnership. The Scottish 
Office, Edinburgh. Available: http://www.scotland.gov.uk/library/documents-w7/tdis-00.htm 
[accessed 05.05.08] 
 
Scottish Prison Service (2008). 10th Annual Prisoner Survey. Scottish Prison Service, 
Edinburgh. Available: http://www.sps.gov.uk/default.aspx?documentid=21190703-e7b4-
4abc-bc83-44b5d0f06f69 [accessed 13.08.08] 
 
Seymour. L. and Rutherford, M. (2008). The Community Order and the Mental Health 




SGC (Sentencing Guidelines Council) (2008). Causing Death By Driving, Definitive 
Guideline. Sentencing Guidelines Council, London. Available: 
http://www.sentencing-
guidelines.gov.uk/docs/causing_death_by_driving_definitive_guideline.pdf  [accessed 
20.08.08] 
 
Sheridan, J., Strang, J., Barber, N. and Glanz, A. (1996). Role of community pharmacies 
in relation to HIV prevention and drug misuse: findings from the 1995 national survey in 
England and Wales. British Medical Journal 313 272–274. 
 
Sheridan, J., Manning, V., Ridge, G., Mayet. S and Strang. J. (2007). Community 
pharmacies and the provision of opioid substitution services for drug misusers: changes in 
activity and attitudes of community pharmacists across England 1995–2005. Addiction 102 
1824–1830. 
 
Simmonds, L. and Coomber, R. (2007). Injecting drug users: A stigmatised and 
stigmatising population. International Journal of Drug Policy. Online publication. Available: 
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VJX-4R2GX08-
1&_user=777686&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_version=1&_urlVersi
on=0&_userid=777686&md5=d6c26243065199f6093c4c895c18f526 [accessed 07.10.08] 
 
Simpson, M. and McNulty, J. (2008). Different needs: Women’s drug use and treatment in 
the UK. International Journal of Drug Policy 19 169–175. 
 
Sinclair, J., Latifi, A. H. and Latifi, A. W. (2008). Co-morbid substance misuse in 
psychiatric patients: prevalence and association with length of stay. Journal of 
Psychopharmacology 22 (1) 92-99. 
 
Skodbo, S., Brown, G., Deacon, S., Cooper, A., Hall, A., Millar, T. et al. (2007). The Drug 
Interventions Programme (DIP): addressing drug use and offending through ‘Tough 
Choices’. Home Office Research Report 2. Home Office, London. Available: 
http://www.homeoffice.gov.uk/rds/pdfs07/horr02c.pdf [accessed 22.11.07] 
 
Smith, I. and Crome, I.B. (2007). In the coroner's chair - substance misuse and suicide in 
young people: have we got the focus right? Criminal Behaviour and Mental Health17 (4) 
197-203. 
 
UNITED KINGDOM FOCAL POINT REPORT 2008  
  
 204
Smith, K. (2008). Seizures of drugs in England and Wales 2006/07. Home Office 




SOCA (The Serious Organised Crime Agency) (2008). The United Kingdom Threat 
Assessment of Serious Organised Crime 2008/09. The Serious Organised Crime Agency. 
Available: http://www.soca.gov.uk/assessPublications/UKTA0809.html [accessed 
01.09.08] 
 
Stead, M., Stradling, R., MacKintosh, A.M., Macneil, M., Minty, S. and Eadie, D. (2007). 
Delivery of the Blueprint Programme. Home Office, London. Available: 
http://drugs.homeoffice.gov.uk/publication-
search/blueprint/dpreports/blueprintdelivery.pdf?view=Binary [accessed 02.06.08]  
 
Stephenson, M. (2006). Aftercare Three Years On. Addaction, London. 
 
Stevens, A., Radcliffe, P., Sanders, M. and Hunt, N. (2008). Early exit: estimating and 
explaining early exit from drug treatment. Harm Reduction Journal 5 (13). Online version. 
Available: http://www.harmreductionjournal.com/content/5/1/13 [accessed 28.05.08] 
 
Stonewall (2008). Prescription for Change: Lesbian and bisexual women’s health check 
2008. Available: http://www.sigmaresearch.org.uk/files/report2008.pdf  
 
Stradling, R., Macneil, M., Cheyne, B., Scott, J. and Minty, S. (2007). Delivering drug 
education in the classroom – lessons from the Blueprint programme. Home Office, 
London. Available:  http://drugs.homeoffice.gov.uk/publication-
search/blueprint/dpreports/blueprintpractioners?view=Binary  [accessed 02.06.08]  
 
Strang, J., Manning, V., Mayet, S., Titherington, E., Offor, L., Semmler, C. and Williams, A. 
(2008). Family carers and the prevention of heroin overdose deaths: Unmet training need 
and overlooked intervention opportunity of resuscitation training and supply of naloxone. 
Drugs: education, prevention and policy 15 (2) 211-218. 
 
Sweeting, H. and West, P. (2008).  Drug use over the youth-adult transition in a west of 
Scotland cohort: Prevalence, pathways and socio-demographic correlates. Addiction 
Research and Theory. Online early access. 
 
Taylor, A., Hutchinson, S.J., Gilchrist, G., Cameron, S., Carr, S. and Goldberg, D.J. 
(2008). Prevalence and determinants of hepatitis C virus infection among female drug 
injecting sex workers in Glasgow. Harm Reduction Journal 5 (11) 
 
Tompkins, C. N. E., Ghoneim, S., Wright, N. M. J., Sheard, L. and Jones, L. (2007). 
Needle fear among women injecting drug users: a qualitative study. Journal of Substance 
Use 12(4) 281 – 291. Available: 
http://www.informaworld.com/smpp/content~db=all?content=10.1080/1465989070123710
8 [accessed 07.10.08] 
 
Tompkins, C.N.E. Neale, J., Sheard, L. and Wright, N.M.J. (2007). Experiences of prison 
among injecting drug users in England: a qualitative study. International Journal of 
Prisoner Health 3 (3) 189-203 
 
UNITED KINGDOM FOCAL POINT REPORT 2008  
  
 205
Toner, P., Hardy, E., and Mistral, W. (2008). A specialized maternity drug service: 
Examples of good practice. Drugs: education, prevention and policy15 (1) 93–105. 
Available: 
http://www.informaworld.com/smpp/content~db=all?content=10.1080/0968763060115781
6 [accessed 07.10.08] 
 
UKADCU (United Kingdom Anti-Drugs Co-ordination Unit) (1998). Tackling drugs to build 
a better Britain. The Stationery Office, London. Available: http://www.archive.official-
documents.co.uk/document/cm39/3945/3945.htm [accessed 05.05.08] 
 
UKDPC (United Kingdom Drug Policy Commission) (2008a). Recovery Consensus 
Statement. United Kingdom Drug Policy Commission, London. Available: 
http://www.ukdpc.org.uk/Recovery_Consensus_Statement.shtml [accessed 08.07.08] 
 
UKDPC (United Kingdom Drug Policy Commission) (2008b). A response to the 
consultation paper ‘Working Together to Reduce Harm: The Substance Misuse Strategy 
for Wales 2008-2018’. United Kingdom Drug Policy Commission, London. Available: 
http://www.ukdpc.org.uk/Publications.shtml [accessed 14.10.09] 
 
UKDPC (United Kingdom Drug Policy Commission) (2008c). Reducing Drug Use, 
Reducing Reoffending. Are programmes for problem drug-using offenders in the UK 
supported by the evidence? United Kingdom Drug Policy Commission, London.  Available: 
http://www.ukdpc.org.uk/reports.shtml [accessed 17.03.08] 
 
UKDPC (United Kingdom Drug Policy Commission) (2008d). Prison risks doing more harm 
than good for the rehabilitation of drug users, says UK Drug Policy Commission. United 
Kingdom Drug Policy Commission, London. Available:  
http://www.ukdpc.org.uk/resources/RDURR_Press_Release.pdf  [accessed 09.10.08] 
 
Welsh Assembly Government (2004). Children and Young People: Rights to Action. Welsh 




Welsh Assembly Government (2008a) Working Together to Reduce Harm The Substance 
Misuse Strategy for Wales 2008-2018. Welsh Assembly Government, Cardiff. Available:  
http://new.wales.gov.uk/topics/housingandcommunity/safety/publications/strategy0818/?la
ng=en [accessed 061008] 
 
Welsh Assembly Government (2008b) Working Together to Reduce Harm. The Substance 
Misuse Strategy. Three-year Implementation Plan 2008-11. Welsh Assembly Government, 
Cardiff. Available:  
http://new.wales.gov.uk/topics/housingandcommunity/safety/publications/strategy0818/?la
ng=en [accessed 061008] 
 




Wilson, G. Wallace, J., Currie, J. and Schofield, J. (2008). Hepatitis C Patient Journey 
Evaluation. Findings from a Scoping Exercise. Scottish Drug Forum., Edinburgh.  
 
UNITED KINGDOM FOCAL POINT REPORT 2008  
  
 206
Wilson, M. and Campbell, P. (2008). Court prosecutions and sentencing 2006. Northern 
Ireland Office, Belfast. Available: 
http://www.nio.gov.uk/2008_court_prosecutions_and_sentencing_2006.pdf 
 
Wood, M.D., Greene, S., Alldus, G., Huggett, D., Nicoloau, M. et al. (2008). Improvement 
in the pre-hospital care recreational users through the development of club specific 
ambulance referral guidelines. Substance Abuse Treatment, Prevention, and Policy 3 (14). 
Available: http://www.substanceabusepolicy.com/content/pdf/1747-597X-3-14.pdf  
[accessed 17.09.08] 
 
Zammit, S., Spurlock, G., Williams, H., Norton, N., Williams, N. et al. (2007). Genotype 
effects of CHRNA7,CNR1 and COMT in schizophrenia: interactions with tobacco and 
cannabis use. British Journal of Psychiatry 191 402-407. 
 
UNITED KINGDOM FOCAL POINT REPORT 2008  
  
 207
List of tables used in text 
 
Table 1.1: Public expenditure by COFOG in England, 2006/07 and 2007/08 .......... 29 
 
Table 1.2: Public expenditure in Northern Ireland, 2007/08 ..................................... 30 
 
Table 2.1: Percentage of 16-59 year olds reporting having used individual drugs in 
lifetime, last year and last month in England and Wales, 2007/08 ........................... 36 
 
Table 2.2: Percentage of 15-64 year olds reporting having used individual drugs in 
lifetime, last year and last month in Northern Ireland, 2006/07 (DPS) ..................... 37 
 
Table 2.3: Percentage of 16 to 59 year olds reporting lifetime, last year and last 
month use of any drug in Northern Ireland, 2003/04 to 2006/07(NICS) ................... 38 
 
Table 2.4: Percentage of 16-24 year olds and 16-34 year olds reporting last year use 
of individual drugs in England and Wales, 2007/08 by gender ................................ 39 
 
Table 2.5: Frequent use: percentage of 16 to 24 year olds (all respondents) who 
have used any drug more than once a month in the past year in England and Wales, 
2002/03 to 2007/08 ..................................................................................................  41 
 
Table 2.6: Percentage of 15-24 year olds and 15-34 year olds reporting last year use 
of individual drugs in Northern Ireland, 2006/07 by gender (DPS) ........................... 42 
 
Table 2.7: Percentage of 16-24 year olds and 16-34 year olds reporting last year use 
of individual drugs in Northern Ireland, 2006/07 by gender (NICS) ......................... 43 
 
Table 2.8: Percentage of pupils reporting use of individual drugs in the last month, in 
the last year and in lifetime, by gender in England, 2007 ........................................ 44 
 
Table 2.9: Percentage of pupils reporting use of individual drugs in the last year, by 
age in England, 2007 ............................................................................................... 44 
 
Table 2.10: Percentage of pupils reporting last year use of individual drugs in 
England, 2001 to 2007 ............................................................................................. 45 
 
Table 2.11: Percentage of pupils reporting use of individual drugs in the last month, 
in the last year and in lifetime, by gender in Northern Ireland, 2007 ........................ 47 
 
Table 2.12: Drug tests and percentage positive in the British Armed Forces, 2000 to 
2007 ......................................................................................................................... 49 
 
Table 4.1: Problem drug user estimates and rates per 1,000 population aged 15 to 64 
in England, 2005/06 ................................................................................................. 60 
 
Table 4.2: Prevalence rate per 1,000 population of opiate and/or crack cocaine users 
by gender in England, 2005/06 ................................................................................ 60 
 
Table 4.3: Prevalence rate per 1,000 population of opiate and/or crack cocaine users 
by age group in England, 2005/06 ........................................................................... 61 
 
Table 4.4: Estimates of problem drug use in the United Kingdom: number and rate 
per 1,000 population            61 




Table 4.5: Estimates of injecting drug use in the United Kingdom: number and rate 
per 1,000 population ................................................................................................ 62 
 
Table 4.6: Estimates of problem drug use: number and rate per 1,000 population, 
aged 15 to 64 in the United Kingdom ....................................................................... 62 
 
Table 4.7: Estimates of number of injecting drug users and rate per 1,000 population, 
aged 15 to 64, United Kingdom ................................................................................ 62 
 
Table 4.8: Presentations by centre type in the United Kingdom, 2003/04 to 2006/07 
.................................................................................................................................. 64 
 
Table 4.9: Number of units covered by centre type in the United Kingdom, 2006/07 
.................................................................................................................................. 64 
 
Table 4.10: Number and percentage of drug treatment presentations by primary drug 
of use in the United Kingdom, 2006/07 .................................................................... 65 
 
Table 4.11: Primary drug by centre type in the United Kingdome, 2006/07 ............. 65 
 
Table 4.12: Number and percentage of first drug treatment demands by primary drug 
of use in the United Kingdom, 2006/07 .................................................................... 66 
 
Table 4.13: Primary drug by centre type, first drug treatment, 2006/07 ................... 66 
 
Table 4.14: Age of drug users identified through TDI in the United Kingdom, 2006/07 
.................................................................................................................................. 66 
 
Table 4.15: Age of individuals reporting cannabis as main drug, 2003/04 to 2006/07 
.................................................................................................................................. 67 
 
Table 4.16: Injecting status by gender in the United Kingdom, 2006/07, all treatments 
.................................................................................................................................. 67 
 
Table 4.17: Injecting status by gender in the United Kingdom 2006/07, first 
treatments ................................................................................................................ 67 
 
Table 4.18: Number and percentage of drug treatment presentations by primary drug 
in the United Kingdom, 2003/04 to 2006/07 ............................................................. 68 
 
Table 4.19: Number and percentage of first drug treatment presentations by primary 
drug, in the United Kingdom, 2003/04 to 2006/07 .................................................... 69 
 
Table 4.20: PDU estimates: PDUs identified through English treatment monitoring 
system (NDTMS) ...................................................................................................... 71 
 
Table 6.1: Drug mentions on death certificates in the United Kingdom, 2002 to 2007 
.................................................................................................................................. 92 
 
Table 6.2: Hospital Episode Statistics: Inpatient episodes due to poisoning by 
cocaine in England, 2000/01 to 2006/07 ................................................................ 105 
 
Table 6.3: Effect of maternal drugs of addiction in England, 2003/04 to 2006/07 .. 107 
 
UNITED KINGDOM FOCAL POINT REPORT 2008  
  
 209
Table 7.1: Syringe provision: number of visits, syringes issued and proportion 
involving return of used equipment in Northern Ireland, 2001/02 to 2007/08 ........ 114 
 
Table 8.1: Gender of all persons receiving benefit and of problem drug users 
estimated to be receiving benefits in England, 2006 .............................................. 123 
 
Table 8.2: Age of all persons receiving benefit and of problem drug users estimated 
to be receiving benefits in England, 2006 .............................................................. 123 
 
Table 8.3: Recorded crime: Drug offences in the United Kingdom by offence type and 
country, 2002/03 to 2007/08 .................................................................................. 126 
 
Table 8.4: Number of persons arrested for drug offences in England and Wales, and 
Northern Ireland, 2002/03 to 2007/08 .................................................................... 126 
 
Table 8.5: Persons found guilty or cautioned for drug offences in the United Kingdom 
2000 to 2006 by individual drug ............................................................................. 127 
 
Table 10.1: Percentage of pupils who reported ever being offered individual drugs in 
England, 2001 to 2007 ........................................................................................... 153 
 
Table 10.2: Estimated market share of different cannabis types ........................... 155 
 
Table 10.3: Number of seizures of drugs by law enforcement agencies in the United 
Kingdom, 2003 to 2006 .......................................................................................... 156 
 
Table 10.4: Quantity of seizures of drugs by law enforcement agencies in the United 
Kingdom 2004 to 2006 ........................................................................................... 157 
 
Table 10.5: Law enforcement agencies: Mean price of illegal drugs in the United 
Kingdom, 2003 to 2007 .......................................................................................... 158 
 
Table 10.6: Independent Drug Monitoring Unit: Mean price of drugs at street level in 
the United Kingdom, 2004 to 2007 ......................................................................... 158 
 
Table 10.7: DrugScope: Mean price of drugs at street level in the United Kingdom, 
2006 to 2008 .......................................................................................................... 159 
 
Table 10.8: Street level mean percentage purity of certain drugs in the United 
Kingdom, 2003 to 2007 .......................................................................................... 160 
 
Table 10.9: Mean THC content (%) of different types of cannabis in England and 
Wales, 1995-2007 .................................................................................................. 161 
 
Table 10.10: Proportion of arrestees reporting that the price and purity of individual 
drugs had increased, stayed the same or decreased in the past six months and the 
net decrease in England and Wales 2005/06      162 
 
Table 11.1: Measures which can be used by police for drug offences in England and 
Wales ..................................................................................................................... 166 
 
Table 11.2: Number and proportion of all possession offences by individual drug in 
England and Wales, 2006 ...................................................................................... 173 
 
UNITED KINGDOM FOCAL POINT REPORT 2008  
  
 210
Table 11.3: Number of offenders receiving each disposal for drug possession 
offences by individual drug in England and Wales, 2006 ....................................... 173 
 
Table 11.4: Number of offenders receiving each disposal for drug possession 
offences by individual drug in Scotland, 2006/07 ................................................... 175 
 
Table 11.5: Number of offenders receiving each disposal for drug possession 
offences by class of drug in Northern Ireland, 2006 ............................................... 175 
 
Table 11.6: Number of offenders receiving each disposal for drug trafficking offences 
by individual drug in England and Wales, 2006 ..................................................... 176 
 
Table 11.7: Number of offenders receiving each disposal for drug trafficking offences 
by individual drug in Scotland, 2006/07 ................................................................. 178 
 
Table 11.8: Number of offenders receiving each disposal for drug trafficking offences 
by class of drug in Northern Ireland, 2006 ............................................................. 178 
 
Table 11.9: Average custodial sentence length in months for drug offences in 
England and Wales, 2006 by offence and individual drug ..................................... 179 
 
Table 11.10: Average custodial sentence length in months for drug offences in 
Northern Ireland, 2006 by offence and drug class ................................................. 179 
 
Table A.1: Percentage prevalence of illegal drugs amongst adults in the United 
Kingdom by drug and country ................................................................................ 215 
 
Table A.2: Percentage of 16-34 year olds reporting having used individual drugs in 
lifetime, last year and last month in the United Kingdom, 2006/07 ........................ 216 
 
Table A.3: Percentage of 16-24 year olds reporting having used individual drugs in 
lifetime, last year and last month in the United Kingdom, 2006/07 ........................ 217 
 
UNITED KINGDOM FOCAL POINT REPORT 2008  
  
 211
List of figures used in text  
 
Figure 2.1: Percentage of 16 to 59 year olds reporting having used drugs in the last 
year in England and Wales, 1996 to 2007/08 .......................................................... 36 
 
Figure 2.2: Percentage of 16 to 34 year olds reporting having used drugs in the last 
year in England and Wales, 2002/03 to 2007/08 ..................................................... 40 
 
Figure 2.3: Percentage of 16 to 24 year olds reporting having used drugs in the last 
year in England and Wales, 1996 to 2007/08 .......................................................... 41 
 
Figure 2.4: Drug use amongst school children in England, 2001 to 2007 ................ 45 
 
Figure 4.2: Presentations for cocaine powder and crack cocaine in the United 
Kingdom, 2003/4 to 2006/07 .................................................................................... 68 
 
Figure 5.1: Numbers in treatment monitored through NDTMS and new of 
presentations to treatment measured by the TDI, 2003/04 to 2007/08, England ..... 77 
 
Figure 6.1: Deaths in the United Kingdom 1996-2006: EMCDDA definition ............ 90 
 
Figure 6.2: Comparison of total number of deaths using three definitions in the United 
Kingdom, 1996 – 2006 ............................................................................................. 91 
 
Figure 6.3: Deaths by age and gender United Kingdom, 2006: EMCDDA definition 91 
 
Figure 6.4: Psychiatric inpatient discharges with a diagnosis of drug misuse in 
Scotland, 2001/02 to 2005/06; rate per 100,000 population .................................. 102 
 
Figure 11.1: Measures available to prosecution services other than prosecution at 
court in the United Kingdom ................................................................................... 166 
 
Figure 11.2: Outcomes of drug possession offences by individual drug in England 
and Wales,2006 ..................................................................................................... 174 
 
Figure 11.3: Outcomes of drug possession offences by class of drug in Northern 
Ireland, 2006 .......................................................................................................... 175 
 
Figure 11.4: Outcomes of drug trafficking offences by type of drug in England and 
Wales, 2006 ........................................................................................................... 177 
 
Figure 11.5: Outcomes of drug trafficking offences by class of drug in Northern 
Ireland, 2006 .......................................................................................................... 178 
UNITED KINGDOM FOCAL POINT REPORT 2008  
  
 212
List of abbreviations used in the text 
 
A&E Accident and Emergency 
ACMD  Advisory Council on the Misuse of Drugs 
ACPO  Association of Chief Police Officers 
ADATs  Alcohol and Drug Action Teams  
ADHD Attention Deficit Hyperactivity Disorder 
ADR Annual Data Requirement  
AIDS  Acquired Immunodeficiency Syndrome  
APPHG All-Party Parliamentary Hepatology Group 
ASB Anti-Social Behaviour 
ASBO Anti-Social Behaviour Order 
ATM Addictions Testing Measure 
AUDIT Alcohol Use Disorders Identification Test 
BCS  British Crime Survey  
BMA British Medical Association 
BMJ British Medical Journal 
BOSS Body Orifice Security Scanners 
BZP Benzylpiperazine 
CAPI Computer Assisted Personal Interviewing 
CARATS  Counselling, Assessment, Referral, Advice and Through-care Services 
CASI Computer-Aided Self-administered Interviewing 
CBD Cannabidiol 
CCTV  Closed Circuit Television  
CDSC Communicable Disease Surveillance Centre 
CHS Criminal History System 
CI  Confidence Interval 
CIPD Chartered Institute of Personnel and Development 
CISS Christo Inventory for Substance-misuse Services 
CJITs Criminal Justice Interventions Teams  
CLG Communities and Local Government 
CMR Circumstances, Motivation and Readiness scale 
SCOFOG Classification of the Functions of Government 
COI  The Central Office of Information 
COMT Catechol-O-methyltransferase 
COPFS Crown Office and Procurator Fiscal Service  
CPP Community Planning Partnership 
CPP Chlorophenylpiperazine 
CPR Cardio-Pulmonary Resuscitation 
CPS Crown Prosecution Service  
CSPs Community Safety Partnerships 
CSP Centre for Suicide Prevention 
CSR Comprehensive Spending Review 
DAATs Drug (and Alcohol) Action Teams  
DACTs Drug and Alcohol Coordination Teams  
DAIRU  Drug and Alcohol Information and Research Unit 
DATs Drug Action Teams  
DCSF Department for Children, Schools and Families 
DDC Dedicated Drug Court 
DfES  Department for Education and Skills 
DH  Department of Health 
DHI Drug Harm Index 
DHSSPSNI  Department of Health, Social Services and Public Safety Northern Ireland 
DIP Drug Interventions Programme 
DIR Drug Interventions Record 
DORIS  Drug Outcome Research in Scotland  
DRD Drug-Related Deaths 
DRR  Drug Rehabilitation Requirement 
DTORS Drug Treatment Outcomes Research Study 
DTTO Drug Treatment and Testing Order 
UNITED KINGDOM FOCAL POINT REPORT 2008  
  
 213
DVLA Driver and Vehicle Licensing Agency 
DWP Department for Work and Pensions 
EACS Enhanced Addiction Casework Service  
EDDRA Exchange on Drug Demand Reduction Action 
EMCDDA  European Monitoring Centre for Drugs and Drug Addiction 
ESPAD European School Survey Project on Alcohol and Other Drugs 
EU European Union 
FCE Finished Consultant Episodes 
FSS  Forensic Science Service 
GAE Grant Aided Expenditure 
GBL Gamma-butyrolactone 
GCSE General Certificate of Secondary Education 
GDP Gross Domestic Product 
GHB  Gamma hydroxybutyrate  
GLADA Greater London Alcohol and Drug Alliance 
GMR  General Mortality Register  
GP  General Practitioner 
GRO  General Register Offices for England and Wales 
GRONI  General Register Office for Northern Ireland 
GROS  General Register Office for Scotland 
HAS  Health Advisory Service  
HBSC  Health Behaviour in School Aged Children 
HBV  Hepatitis B Virus 
HCV  Hepatitis C Virus 
HES Hospital Episode Statistics 
HFA High Focus Area 
HIV  Human Immunodeficiency Virus  
HMRC HM Revenue and Customs  
HOCR Home Office Counting Rules  
HPA  Health Protection Agency 
HPS Health Protection Scotland 
HSSB Health and Social Service Boards 
ICD-10 International Statistical Classification of Diseases and Related Health 
Problems – tenth edition 
ICIS Integrated Crime Information System  
IDMU Independent Drug Monitoring Unit 
IDTS  Integrated Drug Treatment System 
IDUs Injecting Drug Users 
ISCJIS Integration of Scottish Criminal Justice Information Systems 
ISD Information Services Division 
ISO Individual Support Order 
ITEP International Treatment Effectiveness Project 
LAA Local Area Agreement 
LSD  Lysergic Dyethylamide acid  
MDMA  3,4-Methylenedioxy-n-methylamphetamine 
MDT  Mandatory Drug Testing 
MHRA  Medicines and Health Care Products Regulation Agency  
MHTR Mental Health Treatment Requirement 
NACD National Advisory Committee on Drugs 
NatCen  National Centre for Social Research 
NATSAL National Survey of Sexual Attitudes and Lifestyles 
NCRS National Crime Recording Standard  
NDEC  National Drug Evidence Centre 
NDTMS National Drug Treatment Monitoring System 
NESI Needle Exchange Surveillance Initiative 
NHS  National Health Service 
NI National Indicator 
NICE  National Institute for Clinical and Health Excellence 
NICS Northern Ireland Crime Survey 
NIDPS Northern Ireland Drug Prevalence Survey 
UNITED KINGDOM FOCAL POINT REPORT 2008  
  
 214
NIO Northern Ireland Office 
NIPS  Northern Ireland Prison Service 
NISRA Northern Ireland Statistics and Research Agency 
NOMS  National Offender Management Service 
np-SAD  National Programme on Substance Abuse Deaths 
NTA  National Treatment Agency 
NTORS  National Treatment Outcome Research Study 
OBTJ Offenders Brought to Justice  
Ofsted  Office for Standards in Education 
OLIFE Oxford Liverpool Inventory of Life Experiences 
ONS  Office for National Statistics  
OTC Over The Counter (medicines) 
p2w  Progress2Work 
PACE Police and Criminal Evidence act 1984  
PCTs  Primary Care Trusts 
PDI Partnership Drugs Initiative 
PDU Problem Drug Users 
PHIRB Public Health Information and Research Branch 
PNC Police National Computer  
POM Prescription Only Medicine 
PPO  Prolific and other Priority Offender 
PPS Public Prosecution Service 
PSA  Public Service Agreement  
PSHE Personal, Social and Health Education 
PSNI Prison Service Northern Ireland 
PTB Pooled Treatment Budget 
QIS Quality Improvement Scotland 
RSA Royal Society for the encouragement of Arts, manufactures and commerce 
SACDM Scottish Advisory Committee on Drugs Misuse 
SALSUS  Scottish Schools Adolescent Lifestyle and Substance Use Survey 
SCIEH  Scottish Centre for Infection and Environmental Health  
SCRS Scottish Crime Recording Standard 
SCVS Scottish Crime and Victimisation Survey 
SD Standard Deviation 
SHA Strategic Health Authority 
SMACAP Scottish Ministerial Advisory Committee on Alcohol Problems 
SMR  Special Mortality Register  
SOA Single Outcome Agreements 
SOCA Serious Organised Crime Agency 
SPS  Scottish Prison Service 
SPSA Scottish Police Services Authority 
STI  Sexually Transmitted Infection 
TAS Throughcare Addiction Services 
TDI Treatment Demand Indicator 
TFMPP 3-Trifluoromethylphenylpiperazine monohydrochloride  
THC Tetrahydrocannabinol 
TOP Treatment Outcomes Profile 
UAPMP  Unlinked Anonymous Prevalence Monitoring Programme 
UK United Kingdom 
UKADCU United Kingdom Anti Drugs Co ordination Unit 
UKDPC United Kingdom Drug Policy Commission 
UV Ultraviolet  
VDT  Voluntary Drug Testing 
VSA  Volatile Substance Abuse 
WAG Welsh Assembly Government 
YOT Youth Offending Team 
YPBAS Young Person’s Behaviour and Attitude Survey 
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Appendix A: United Kingdom prevalence estimates from 
population surveys 
 
By combining data from the British Crime Survey (BCS) 2006/07, the 2006 Scottish 
Crime and Victimisation Survey (SCVS) (Brown and Bolling 2007) and the 2006/07 
Drug Prevalence Survey in Northern Ireland, estimates of drug use have been 
produced for the United Kingdom 
Table A.1: Percentage prevalence of illegal drugs amongst adults in the United 






















16 to 59 year 
olds 
16 to 59 year 
olds 
15 to 64 year 
olds 
16 to 59 year 
olds  
16 to 59 year 
olds 
Lifetime prevalence 
Any illicit drug  35.5 27.3 28.0 36.6 35.4 
Amphetamines 11.9 6.3 5.8 14.1 11.9 
Cannabis  30.1 20.1 24.7 32.9 30.2 
Cocaine  7.7 3.4 5.2 8.9 7.7 
Ecstasy  7.3 5.6 7.7 9.9 7.5 
LSD 5.4 3.6 6.6 7.7 5.6 
Magic mushrooms 7.1 4.6 6.7 7.2 7.1 
Last year prevalence 
Any illicit drug 10.0 8.4 9.4 12.6 10.2 
Amphetamines 1.3 0.5 1.0 2.2 1.4 
Cannabis  8.2 6.3 7.2 11.0 8.4 
Cocaine  2.6 0.9 1.9 3.8 2.7 
Ecstasy 1.8 0.9 1.8 3.2 1.9 
LSD 0.2 0.1 0.2 0.6 0.2 
Magic mushrooms 0.6 0.2 0.2 0.9 0.6 
Last month prevalence 
Any illicit drug 5.9 4.3 3.6 8.0 6.0 
Amphetamines 0.5 0.3 0.3 0.9 0.5 
Cannabis 4.8 3.0 2.6 6.8 4.9 
Cocaine 1.3 0.5 0.3 1.8 1.3 
Ecstasy  0.8 0.4 0.8 1.6 0.9 
LSD 0.1 0.1 0.0 0.2 0.1 
Magic mushrooms 0.1 0.1 0.0 0.3 0.1 
Total sample size 31,054 2,390 2,002 3,158 N/A 
Source: Standard Tables provided for the United Kingdom Focal Point 
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Table A.2: Percentage of 16-34 year olds reporting having used individual drugs in 
























16 to 34 year 
olds 
16 to 34 year 
olds 
15 to 34 year 
olds 
16 to 34 year 
olds  
16 to 34 year 
olds 
Lifetime prevalence 
Any illicit drug  46.4 38.6 40.2 54.3 46.9 
Amphetamines 16.5 10.4 9.1 22.1 16.8 
Cannabis  41.4 30.9 35.0 49.6 41.9 
Cocaine  12.7 5.7 9.1 15.5 12.8 
Ecstasy  13.0 10.9 14.3 19.4 13.5 
LSD 7.1 5.6 9.4 11.6 7.5 
Magic mushrooms 9.3 5.3 8.3 9.1 9.2 
Last year prevalence 
Any illicit drug 18.6 16.0 17.3 23.7 19.0 
Amphetamines 2.7 1.1 1.7 4.1 2.8 
Cannabis  15.6 13.0 12.4 20.4 15.9 
Cocaine  5.4 2.1 3.5 8.0 5.6 
Ecstasy 3.9 2.0 3.4 6.9 4.1 
LSD 0.5 0.2 0.0 1.2 0.6 
Magic mushrooms 1.4 0.4 0.5 1.8 1.4 
Last month prevalence 
Any illicit drug 11.2 8.0 5.9 14.9 11.3 
Amphetamines 1.0 0.7 0.3 1.5 1.0 
Cannabis 9.2 6.0 3.7 12.6 9.3 
Cocaine  2.7 1.2 0.6 4.1 2.7 
Ecstasy  1.8 0.7 1.4 3.3 1.9 
LSD 0.2 0.2 0.0 0.4 0.2 
Magic mushrooms 0.3 0.2 0.1 0.4 0.3 
Total sample size 11,973 920 714 1115 N/A 
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Table A.3: Percentage of 16-24 year olds reporting having used individual drugs in 
lifetime, last year and last month in the United Kingdom, 2006/07 

























16 to 24 
year olds 
16 to 24 
year olds 
15 to 24 
year olds 
16 to 24 
year olds  
16 to 24 
year olds 
Lifetime prevalence 
Any illicit drug  44.7 38.7 38.4 52.9 45.2 
Amphetamines 11.2 7.6 5.7 15.6 11.4 
Cannabis  39.5 29.8 33.0 48.9 41.9 
Cocaine (including 
crack) 
11.2 5.8 7.7 15.6 11.5 
Ecstasy  7.8 6.7 12.0 14.8 10.7 
LSD 3.2 2.4 4.6 5.0 3.4 
Magic mushrooms 7.0 4.2 4.4 5.0 6.8 
Last year prevalence 
Any illicit drug 24.1 22.0 19.0 31.0 24.5 
Amphetamines 3.5 1.4 1.9 5.6 3.6 
Cannabis  20.9 17.8 13.7 27.1 21.2 
Cocaine (including 
crack) 
6.1 2.0 2.3 11.0 6.4 
Ecstasy 4.8 3.0 3.7 9.2 5.1 
LSD 0.8 0.2 0.0 2.0 0.9 
Magic mushrooms 1.8 0.8 0.6 2.6 1.8 
Last month prevalence 
Any illicit drug 14.3 9.5 6.3 20.4 14.6 
Amphetamines 1.2 0.8 0.3 2.3 1.3 
Cannabis 12.0 6.7 3.5 16.6 12.1 
Cocaine (including 
crack) 
3.2 1.2 0.0 6.3 3.4 
Ecstasy  2.5 0.8 2.2 5.0 2.7 
LSD 0.3 0.2 0.0 0.5 0.3 
Magic mushrooms 0.4 0.4 0.0 0.5 0.4 
Total sample size 5,749 342 299 426 N/A 
